3-(1h-indol-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof

ABSTRACT

6-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 6-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No. 62/200,468, filed Aug. 3, 2015, which is incorporated herein by reference in its entirety.

BACKGROUND Technical Field

This disclosure relates to inhibitors of one or more proteins in the Wnt pathway, including inhibitors of one or more Wnt proteins, and compositions comprising the same. More particularly, it concerns the use of a 6-azaindazole compound or salts or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

Background

The Wnt growth factor family includes more than 10 genes identified in the mouse and at least 19 genes identified in the human. Members of the Wnt family of signaling molecules mediate many short- and long-range patterning processes during invertebrate and vertebrate development. The Wnt signaling pathway is known for its role in the inductive interactions that regulate growth and differentiation, and it also plays roles in the homeostatic maintenance of post-embryonic tissue integrity. Wnt stabilizes cytoplasmic β-catenin, which stimulates the expression of genes including c-myc, c jun, fra-1, and cyclin D1. In addition, misregulation of Wnt signaling can cause developmental defects and is implicated in the genesis of several human cancers. The Wnt pathway has also been implicated in the maintenance of stem or progenitor cells in a growing list of adult tissues including skin, blood, gut, prostate, muscle, and the nervous system.

SUMMARY

The present disclosure provides methods and reagents, involving contacting a cell with an agent, such as a 6-azaindazole compound, in a sufficient amount to antagonize a Wnt activity, e.g., to reverse or control an aberrant growth state or correct a genetic disorder due to mutations in Wnt signaling components.

Some embodiments disclosed herein include Wnt inhibitors containing a 6-azaindazole core. Other embodiments disclosed herein include pharmaceutical compositions and methods of treatment using these compounds.

One embodiment disclosed herein includes a compound having the structure of Formula I:

as well as prodrugs and pharmaceutically acceptable salts thereof.

In some embodiments of Formula (I):

R¹ and R⁴ are independently selected from the group consisting of H and halide;

R³ is selected from the group consisting of -heteroaryl optionally substituted with 1-4 R⁶ and -heterocyclyl optionally substituted with 1-10 R⁷;

X is CR⁵ or N;

R⁵ is selected from the group consisting of H, -heteroaryl optionally substituted with 1-4 R⁸, -heterocyclyl optionally substituted with 1-10 R⁹, and -aryl optionally substituted with 1-5 R¹⁰;

each R⁶ is independently selected from the group consisting of halide, —(C₁₋₆ alkyl), —(C₂₋₆ alkenyl), —(C₂₋₆ alkynyl), —(C₁₋₄ alkylene)_(p)heterocyclyl optionally substituted with 1-10 R¹¹, —(C₂₋₄ alkenylene)_(p)heterocyclyl optionally substituted with 1-10 R¹¹, —(C₂₋₄ alkynylene)_(p)heterocyclyl optionally substituted with 1-10 R¹¹, —(C₁₋₄ alkylene)_(p)carbocyclyl optionally substituted with 1-12 R¹², —(C₂₋₄ alkenylene)_(p)carbocyclyl optionally substituted with 1-12 R¹², —(C₂₋₄ alkynylene)_(p)carbocyclyl optionally substituted with 1-12 R¹², —(C₁₋₄ alkylene)_(p)aryl optionally substituted with 1-5 R¹³, —(C₂₋₄ alkenylene)_(p)aryl optionally substituted with 1-5 R¹³, —(C₂₋₄ alkynylene)_(p)aryl optionally substituted with 1-5 R¹³, —NHC(═O)R¹⁴, —NR¹⁵R¹⁶, —(C₁₋₆ alkylene)NR¹⁷R¹⁸, —(C₂₋₆ alkenylene)NR¹⁷R¹⁸, —(C₂₋₆ alkynylene)NR¹⁷R¹⁸, and —(C₁₋₄ alkylene)_(p)OR²⁴;

each R⁷ is independently selected from the group consisting of —(C₁₋₄ alkyl), —(C₂₋₄ alkenyl), —(C₂₋₄ alkynyl), halide, —CF₃, and —CN;

-   -   each R⁸ is independently selected from the group consisting of         —(C₁₋₆ alkyl), —(C₂₋₆ alkenyl), —(C₂₋₆ alkynyl), halide, —CF₃,         —OCH₃, —CN, and —C(═O)R¹⁹;     -   each R⁹ is independently selected from the group consisting of         —(C₁₋₆ alkyl), —(C₂₋₆ alkenyl), —(C₂₋₆ alkynyl), halide, —CF₃,         —CN, and —OCH₃;     -   each R¹⁰ is independently selected from the group consisting of         —(C₁₋₆ alkyl), —(C₂₋₆ alkenyl), —(C₂₋₆ alkynyl), halide, —CF₃,         —CN, —(C₁₋₆ alkylene)_(p)NHSO₂R¹⁹, —(C₂₋₆         alkenylene)_(p)NHSO₂R¹⁹, —(C₂₋₆ alkynylene)NHSO₂R¹⁹, —NR¹⁵(C₁₋₆         alkylene)NR¹⁵R¹⁶, —NR¹⁵(C₂₋₆ alkenylene)NR¹⁵R¹⁶, —NR¹⁵(C₂₋₆         alkynylene)NR¹⁵R¹⁶, —(C₁₋₆ alkylene)_(p)NR¹⁵R¹⁶, —(C₂₋₆         alkenylene)_(p)NR¹⁵R¹⁶, —(C₂₋₆ alkynylene)_(p)NR¹⁵R¹⁶, and         —OR²⁷;     -   each R¹¹ is independently selected from the group consisting of         amino, —(C₁₋₄ alkyl), —(C₂₋₄ alkenyl), —(C₂₋₄ alkynyl), halide,         —CF₃, and —CN;     -   each R¹² is independently selected from the group consisting of         —(C₁₋₄ alkyl), —(C₂₋₄ alkenyl), —(C₂₋₄ alkynyl), halide, —CF₃,         and —CN;     -   each R¹³ is independently selected from the group consisting of         —(C₁₋₄ alkyl), —(C₂₋₄ alkenyl), —(C₂₋₄ alkynyl), halide, —CF₃,         and —CN;     -   each R¹⁴ is independently selected from the group consisting of         —(C₁₋₉ alkyl), —(C₁₋₄ haloalkyl), —(C₂₋₉ alkenyl), —(C₂₋₉         alkynyl), -heteroaryl optionally substituted with 1-4 R²⁰, -aryl         optionally substituted with 1-5 R²¹, —CH₂aryl optionally         substituted with 1-5 R²¹, -carbocyclyl optionally substituted         with 1-12 R²², —CH₂carbocyclyl optionally substituted with 1-12         R²², —(C₁₋₄ alkylene)_(p)NR²⁵R²⁶, —(C₂₋₄ alkenylene)_(p)NR²⁵R²⁶,         —(C₂₋₄ alkynylene)_(p)NR²⁵R²⁶, -heterocyclyl optionally         substituted with 1-10 R²³, and —CH₂heterocyclyl optionally         substituted with 1-10 R²³;

each R¹⁵ is independently selected from the group consisting of H, —(C₁₋₆ alkyl), —(C₂₋₆ alkenyl), and —(C₂₋₆ alkynyl);

each R¹⁶ is independently selected from the group consisting of H, —(C₁₋₆ alkyl), —(C₂₋₆ alkenyl), —(C₂₋₆ alkynyl), —CH₂aryl optionally substituted with 1-5 R²¹, and —CH₂carbocyclyl optionally substituted with 1-12 R²²;

each R¹⁷ is independently selected from the group consisting of H, —(C₁₋₆ alkyl), —(C₂₋₆ alkenyl), and —(C₂₋₆ alkynyl);

each R¹⁸ is independently selected from the group consisting of H, —(C₁₋₆ alkyl), —(C₂₋₆ alkenyl), —(C₂₋₆ alkynyl), —CH₂aryl optionally substituted with 1-5 R²¹ and —CH₂carbocyclyl optionally substituted with 1-12 R²²;

each R¹⁹ is independently selected from the group consisting of —(C₁₋₆ alkyl), —(C₂₋₆ alkenyl), and —(C₂₋₆ alkynyl);

each R²⁰ is independently selected from the group consisting of —(C₁₋₄ alkyl), —(C₂₋₄ alkenyl), —(C₂₋₄ alkynyl), halide, —CF₃, and —CN;

each R²¹ is independently selected from the group consisting of —(C₁₋₄ alkyl), —(C₂₋₄ alkenyl), —(C₂₋₄ alkynyl), halide, —CF₃, and —CN;

each R²² is independently selected from the group consisting of —(C₁₋₄ alkyl), —(C₂₋₄ alkenyl), —(C₂₋₄ alkynyl), halide, —CF₃, and —CN;

each R²³ is independently selected from the group consisting of —(C₁₋₄ alkyl), —(C₂₋₄ alkenyl), —(C₂₋₄ alkynyl), halide, —CF₃, and —CN;

R²⁴ is selected from the group consisting of H, —(C₁₋₆alkyl), —(C₂₋₆ alkenyl), —(C₂₋₆ alkynyl), —(C₁₋₄ alkylene)_(p)heterocyclyl optionally substituted with 1-10 R²³, —(C₂₋₄ alkenylene)_(p)heterocyclyl optionally substituted with 1-10 R²³, —(C₂₋₄ alkynylene)_(p)heterocyclyl optionally substituted with 1-10 R²³, —(C₁₋₄ alkylene)_(p)carbocyclyl optionally substituted with 1-12 R²², —(C₂₋₄ alkenylene)_(p)carbocyclyl optionally substituted with 1-12 R²², —(C₂₋₄ alkynylene)_(p)carbocyclyl optionally substituted with 1-12 R²², —(C₁₋₄ alkylene)_(p)aryl optionally substituted with 1-5 R²¹, —(C₂₋₄ alkenylene)_(p)aryl optionally substituted with 1-5 R²¹, —(C₂₋₄ alkynylene)_(p)aryl optionally substituted with 1-5 R²¹, —(C₁₋₆ alkylene)_(p)NR²⁵R²⁶, —(C₂₋₄ alkenylene)_(p)NR²⁵R²⁶, and —(C₂₋₄ alkynylene)_(p)NR²⁵R²⁶;

each R²⁵ is independently selected from the group consisting of H, —(C₁₋₆ alkyl), —(C₂₋₆ alkenyl), and —(C₂₋₆ alkynyl);

each R²⁶ is independently selected from the group consisting of H, —(C₁₋₆ alkyl), —(C₂₋₆ alkenyl), and —(C₂₋₆ alkynyl);

R²⁷ is selected from the group consisting of H, —(C₁₋₆ alkyl), —(C₂₋₆ alkenyl), —(C₂₋₆ alkynyl), —(C₁₋₄ alkylene)_(p)heterocyclyl optionally substituted with 1-10 R²³, —(C₂₋₄ alkenylene)_(p)heterocyclyl optionally substituted with 1-10 R²³, —(C₂₋₄ alkynylene)_(p)heterocyclyl optionally substituted with 1-10 R²³, —(C₁₋₆ alkylene)_(p)NR²⁵R²⁶, —(C₂₋₆ alkenylene)_(p)NR²⁵R²⁶, and —(C₂₋₆ alkynylene)_(p)NR²⁵R²⁶; and

each p is independently an integer of 0 or 1.

In some embodiments of Formula (I):

R¹ and R⁴ are independently selected from the group consisting of H and halide;

R³ is selected from the group consisting of -heteroaryl optionally substituted with 1-4 R⁶ and -heterocyclyl optionally substituted with 1-10 R⁷;

X is CR⁵ or N;

R⁵ is selected from the group consisting of H, -heteroaryl optionally substituted with 1-4 R⁸, -heterocyclyl optionally substituted with 1-10 R⁹, and -aryl optionally substituted with 1-5 R¹⁰;

each R⁶ is independently selected from the group consisting of halide, —(C₁₋₆ alkyl), —(C₂₋₆ alkenyl), —(C₂₋₆ alkynyl), —(C₁₋₄ alkylene)_(p)heterocyclyl optionally substituted with 1-10 R¹¹, —(C₂₋₄ alkenylene)_(p)heterocyclyl optionally substituted with 1-10 R¹¹, —(C₂₋₄ alkynylene)_(p)heterocyclyl optionally substituted with 1-10 R¹¹, —(C₁₋₄ alkylene)_(p)carbocyclyl optionally substituted with 1-12 R¹², —(C₂₋₄ alkenylene)_(p)carbocyclyl optionally substituted with 1-12 R¹², —(C₂₋₄ alkynylene)_(p)carbocyclyl optionally substituted with 1-12 R¹², —(C₁₋₄ alkylene)_(p)aryl optionally substituted with 1-5 R¹³, —(C₂₋₄ alkenylene)_(p)aryl optionally substituted with 1-5 R¹³, —(C₂₋₄ alkynylene)_(p)aryl optionally substituted with 1-5 R¹³, —NHC(═O)R¹⁴, —NR¹⁵R¹⁶, —(C₁₋₆ alkylene)NR¹⁷R¹⁸, —(C₂₋₆ alkenylene)NR¹⁷R¹⁸, and —(C₂₋₆ alkynylene)NR¹⁷R¹⁸, —OR²⁴;

each R⁷ is independently selected from the group consisting of —(C₁₋₄ alkyl), —(C₂₋₄ alkenyl), —(C₂₋₄ alkynyl), halide, —CF₃, and —CN;

each R⁸ is independently selected from the group consisting of —(C₁₋₆ alkyl), —(C₂₋₆ alkenyl), —(C₂₋₆ alkynyl), halide, —CF₃, —OCH₃, —CN, and —C(═O)R¹⁹;

each R⁹ is independently selected from the group consisting of —(C₁₋₆ alkyl), —(C₂₋₆alkenyl), —(C₂₋₆ alkynyl), halide, —CF₃, —CN, and —OCH₃;

each R¹⁰ is independently selected from the group consisting of —(C₁₋₆ alkyl), —(C₂₋₆ alkenyl), —(C₂₋₆ alkynyl), halide, —CF₃, —CN, —(C₁₋₆ alkylene)_(p)NHSO₂R¹⁹, —(C₂₋₆ alkenylene)_(p)NHSO₂R¹⁹, —(C₂₋₆ alkynylene)_(p)NHSO₂R¹⁹, —NR¹⁵(C₁₋₆ alkylene)NR¹⁵R¹⁶, —NR¹⁵(C₂₋₆ alkenylene)NR¹⁵R¹⁶, —NR¹⁵(C₂₋₆ alkynylene)NR¹⁵R¹⁶, —(C₁₋₆ alkylene)_(p)NR¹⁵R¹⁶, —(C₂₋₆ alkenylene)_(p)NR¹⁵R¹⁶, —(C₂₋₆ alkynylene)_(p)NR¹⁵R¹⁶, and —OR²⁷;

each R¹¹ is independently selected from the group consisting of amino, —(C₁₋₄ alkyl), —(C₂₋₄alkenyl), —(C₂₋₄ alkynyl), halide, —CF₃, and —CN;

each R¹² is independently selected from the group consisting of —(C₁₋₄ alkyl), —(C₂₋₄ alkenyl), —(C₂₋₄ alkynyl), halide, —CF₃, and —CN;

each R¹³ is independently selected from the group consisting of —(C₁₋₄ alkyl), —(C₂₋₄ alkenyl), —(C₂₋₄ alkynyl), halide, —CF₃, and —CN;

each R¹⁴ is independently selected from the group consisting of —(C₁₋₉ alkyl), —(C₂₋₉ alkenyl), —(C₂₋₉ alkynyl), -heteroaryl optionally substituted with 1-4 R²⁰, -aryl optionally substituted with 1-5 R²¹, —CH₂aryl optionally substituted with 1-5 R²¹, -carbocyclyl optionally substituted with 1-12 R²², —CH₂carbocyclyl optionally substituted with 1-12 R²², —(C₁₋₄ alkylene)_(p)NR²⁵R²⁶, —(C₂₋₄ alkenylene)_(p)NR²⁵R²⁶, —(C₂₋₄ alkynylene)_(p)NR²⁵R²⁶, -heterocyclyl optionally substituted with 1-10 R²³, and —CH₂heterocyclyl optionally substituted with 1-10 R²³;

each R¹⁵ is independently selected from the group consisting of H, —(C₁₋₆ alkyl), —(C₂₋₆ alkenyl), and —(C₂₋₆ alkynyl);

each R¹⁶ is independently selected from the group consisting of H, —(C₁₋₆ alkyl), —(C₂₋₆ alkenyl), —(C₂₋₆ alkynyl), —CH₂aryl optionally substituted with 1-5 R²¹, and —CH₂carbocyclyl optionally substituted with 1-12 R²²;

each R¹⁷ is independently selected from the group consisting of H, —(C₁₋₆ alkyl), —(C₂₋₆ alkenyl), and —(C₂₋₆ alkynyl);

each R¹⁸ is independently selected from the group consisting of H, —(C₁₋₆ alkyl), —(C₂₋₆ alkenyl), —(C₂₋₆ alkynyl), —CH₂aryl optionally substituted with 1-5 R²¹ and —CH₂carbocyclyl optionally substituted with 1-12 R²²;

each R¹⁹ is independently selected from the group consisting of —(C₁₋₆ alkyl), —(C₂₋₆ alkenyl), and —(C₂₋₆ alkynyl);

each R²⁰ is independently selected from the group consisting of —(C₁₋₄ alkyl), —(C₂₋₄ alkenyl), —(C₂₋₄ alkynyl), halide, —CF₃, and —CN;

each R²¹ is independently selected from the group consisting of —(C₁₋₄ alkyl), —(C₂₋₄ alkenyl), —(C₂₋₄ alkynyl), halide, —CF₃, and —CN;

each R²² is independently selected from the group consisting of —(C₁₋₄ alkyl), —(C₂₋₄ alkenyl), —(C₂₋₄ alkynyl), halide, —CF₃, and —CN;

each R²³ is independently selected from the group consisting of —(C₁₋₄ alkyl), —(C₂₋₄ alkenyl), —(C₂₋₄ alkynyl), halide, —CF₃, and —CN;

R²⁴ is selected from the group consisting of H, —(C₁₋₆ alkyl), —(C₂₋₆ alkenyl), —(C₂₋₆ alkynyl), —(C₁₋₄ alkylene)_(p)heterocyclyl optionally substituted with 1-10 R²³, —(C₂₋₄ alkenylene)_(p)heterocyclyl optionally substituted with 1-10 R²³, —(C₂₋₄ alkynylene)_(p)heterocyclyl optionally substituted with 1-10 R²³, —(C₁₋₄ alkylene)_(p)carbocyclyl optionally substituted with 1-12 R²², —(C₂₋₄ alkenylene)_(p)carbocyclyl optionally substituted with 1-12 R²², —(C₂₋₄ alkynylene)_(p)carbocyclyl optionally substituted with 1-12 R²², —(C₁₋₄ alkylene)_(p)aryl optionally substituted with 1-5 R²¹, —(C₂₋₄ alkenylene)_(p)aryl optionally substituted with 1- 5 R²¹, —(C₂₋₄ alkynylene)_(p)aryl optionally substituted with 1-5 R²¹, —(C₁₋₆ alkylene)_(p)NR²⁵R²⁶, —(C₂₋₄ alkenylene)_(p)NR²⁵R²⁶, and —(C₂₋₄ alkynylene)_(p)NR²⁵R²⁶;

each R²⁵ is independently selected from the group consisting of H, —(C₁₋₆ alkyl), —(C₂₋₆ alkenyl), and —(C₂₋₆ alkynyl);

each R²⁶ is independently selected from the group consisting of H, —(C₁₋₆ alkyl), —(C₂₋₆ alkenyl), and —(C₂₋₄ alkynyl);

R²⁷ is selected from the group consisting of H, —(C₁₋₆ alkyl), —(C₂₋₆ alkenyl), —(C₂₋₆ alkynyl), —(C₁₋₄ alkylene)_(p)heterocyclyl optionally substituted with 1-10 R²³, —(C₂₋₄ alkenylene)_(p)heterocyclyl optionally substituted with 1-10 R²³, —(C₂₋₄ alkynylene)_(p)heterocyclyl optionally substituted with 1-10 R²³, —(C₁₋₆ alkylene)_(p)NR²⁵R²⁶, —(C₂₋₆ alkenylene)_(p)NR²⁵R²⁶, and —(C₂₋₆ alkynylene)_(p)NR²⁵R²⁶; and

each p is independently an integer of 0 or 1.

Some embodiments include stereoisomers and pharmaceutically acceptable salts of a compound of Formula (I).

Some embodiments include pro-drugs of a compound of Formula (I).

Some embodiments of the present disclosure include pharmaceutical compositions comprising a compound of Formula (I) and a pharmaceutically acceptable carrier, diluent, or excipient.

Other embodiments disclosed herein include methods of inhibiting one or more members of the Wnt pathway, including one or more Wnt proteins by administering to a patient affected by a disorder or disease in which aberrant Wnt signaling is implicated, such as cancer and other diseases associated with abnormal angiogenesis, cellular proliferation, cell cycling and mutations in Wnt signaling components, a compound according to Formula (I). Accordingly, the compounds and compositions provided herein can be used to treat cancer, to reduce or inhibit angiogenesis, to reduce or inhibit cellular proliferation and correct a genetic disorder due to mutations in Wnt signaling components.

Non-limiting examples of diseases which can be treated with the compounds and compositions provided herein include a variety of cancers, diabetic retinopathy, pulmonary fibrosis, rheumatoid arthritis, sepsis, ankylosing spondylitis, psoriasis, scleroderma, mycotic and viral infections, osteochondrodysplasia, Alzheimer's disease, lung disease, bone/osteoporotic (wrist, spine, shoulder and hip) fractures, articular cartilage (chondral) defects, degenerative disc disease (or intervertebral disc degeneration), polyposis coli, osteoporosis-pseudoglioma syndrome, familial exudative vitreoretinopathy, retinal angiogenesis, early coronary disease, tetra-amelia syndrome, Müllerian-duct regression and virilization, SERKAL syndrome, diabetes mellitus type 2, Fuhrmann syndrome, Al-Awadi/Raas-Rothschild/Schinzel phocomelia syndrome, odonto-onycho-dermal dysplasia, obesity, split-hand/foot malformation, caudal duplication syndrome, tooth agenesis, Wilms tumor, skeletal dysplasia, focal dermal hypoplasia, autosomal recessive anonychia, neural tube defects, alpha-thalassemia (ATRX) syndrome, fragile X syndrome, ICF syndrome, Angelman syndrome, Prader-Willi syndrome, Beckwith-Wiedemann Syndrome, Norrie disease, and Rett syndrome.

Some embodiments of the present disclosure include methods to prepare compounds of Formula (I).

It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the disclosure, as claimed.

DETAILED DESCRIPTION

Provided herein are compositions and methods for inhibiting one or more members of the Wnt pathway, including one or more Wnt proteins. Other Wnt inhibitors and methods for using the same are disclosed in U.S. application Ser. Nos. 12/852,706; 12/968,505; 13/552,188; 13/800,963; 13/855,874; 13/887,177 13/938,691; 13/938,692; 14/019,103; 14/019,147; 14/019,940; 14/149,948; 14/178,749; 14/331,427; 14/334,005; and 14/664,517 and U.S. Provisional Application Ser. Nos. 61/232,603; 61/288,544; 61/305,459; 61/620,107; 61/642,915; 61/750,221; 61/968,350; 62/047,324; 62/047,371; 62/047,395; 62/047,401; 62/047,406; 62/047,438; 62/047,509; 62/047,575; 62/047,567, all of which are incorporated by reference in their entirety herein.

Some embodiments provided herein relate to a method for treating a disease or disorder including, but not limited to, cancers, diabetic retinopathy, pulmonary fibrosis, rheumatoid arthritis, sepsis, ankylosing spondylitis, psoriasis, scleroderma, mycotic and viral infections, bone and cartilage diseases, Alzheimer's disease, lung disease, osteoarthritis, bone/osteoporotic (wrist, spine, shoulder and hip) fractures, articular cartilage (chondral) defects, degenerative disc disease (or intervertebral disc degeneration), polyposis coli, bone density and vascular defects in the eye (Osteoporosis-pseudoglioma Syndrome, OPPG), familial exudative vitreoretinopathy, retinal angiogenesis, early coronary disease, tetra-amelia, Müllerian-duct regression and virilization, SERKAL syndrome, type II diabetes, Fuhrmann syndrome, Al-Awadi/Raas-Rothschild/Schinzel phocomelia syndrome, odonto-onycho-dermal dysplasia, obesity, split-hand/foot malformation, caudal duplication, tooth agenesis, Wilms tumor, skeletal dysplasia, focal dermal hypoplasia, autosomal recessive anonychia, neural tube defects, alpha-thalassemia (ATRX) syndrome, fragile X syndrome, ICF syndrome, Angelman syndrome, Prader-Willi syndrome, Beckwith-Wiedemann Syndrome, Norrie disease, and Rett syndrome.

In some embodiments, non-limiting examples of bone and cartilage diseases which can be treated with the compounds and compositions provided herein include bone spur (osteophytes), craniosynostosis, fibrodysplasia ossificans progressiva, fibrous dysplasia, giant cell tumor of bone, hip labral tear, meniscal tears, bone/osteoporotic (wrist, spine, shoulder and hip) fractures, articular cartilage (chondral) defects, degenerative disc disease (or intervertebral disc degeneration), osteochondritis dissecans, osteochondroma (bone tumor), osteopetrosis, relapsing polychondritis, and Salter-Harris fractures.

In some embodiments, pharmaceutical compositions are provided that are effective for treatment of a disease of an animal, e.g., a mammal, caused by the pathological activation or mutations of the Wnt pathway. The composition includes a pharmaceutically acceptable carrier and a compound as described herein.

Definitions

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of ordinary skill in the art to which this disclosure belongs. All patents, applications, published applications, and other publications are incorporated by reference in their entirety. In the event that there is a plurality of definitions for a term herein, those in this section prevail unless stated otherwise.

As used herein, “alkyl” means a branched, or straight chain chemical group containing only carbon and hydrogen, such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, n-pentyl, iso-pentyl, sec-pentyl and neo-pentyl. Alkyl groups can either be unsubstituted or substituted with one or more substituents. In some embodiments, alkyl groups include 1 to 9 carbon atoms (for example, 1 to 6 carbon atoms, 1 to 4 carbon atoms, or 1 to 2 carbon atoms).

As used herein, “alkenyl” means a straight or branched chain chemical group containing only carbon and hydrogen and containing at least one carbon-carbon double bond, such as ethenyl, 1-propenyl, 2-propenyl, 2-methyl-1-propenyl, 1-butenyl, 2-butenyl, and the like. In various embodiments, alkenyl groups can either be unsubstituted or substituted with one or more substituents. Typically, alkenyl groups will comprise 2 to 9 carbon atoms (for example, 2 to 6 carbon atoms, 2 to 4 carbon atoms, or 2 carbon atoms).

“Exocyclic double bond” means a carbon-carbon double bond connected to and hence external to, a ring structure.

As used herein, “alkynyl” means a straight or branched chain chemical group containing only carbon and hydrogen and containing at least one carbon-carbon triple bond, such as ethynyl, 1-propynyl, 1-butynyl, 2-butynyl, and the like. In various embodiments, alkynyl groups can either be unsubstituted or substituted with one or more substituents. Typically, alkynyl groups will comprise 2 to 9 carbon atoms (for example, 2 to 6 carbon atoms, 2 to 4 carbon atoms, or 2 carbon atoms).

As used herein, “alkylene” means a bivalent branched, or straight chain chemical group containing only carbon and hydrogen, such as methylene, ethylene, n-propylene, iso-propylene, n-butylene, iso-butylene, sec-butylene, tert-butylene, n-pentylene, iso-pentylene, sec-pentylene and neo-pentylene. Alkylene groups can either be unsubstituted or substituted with one or more substituents. Alkylene groups can be saturated or unsaturated (e.g., containing —C═C— or —C≡C— subunits), at one or several positions. In some embodiments, alkylene groups include 1 to 9 carbon atoms (for example, 1 to 6 carbon atoms, 1 to 4 carbon atoms, or 1 to 2 carbon atoms).

As used herein, “alkenylene” means a bivalent branched, or straight chain chemical group containing only carbon and hydrogen and containing at least one carbon-carbon double bond, such as ethenylene, 1-propenylene, 2-propenylene, 2-methyl-1-propenylene, 1-butenylene, 2-butenylene, and the like. In various embodiments, alkenylene groups can either be unsubstituted or substituted with one or more substituents. Typically, alkenylene groups will comprise 2 to 9 carbon atoms (for example, 2 to 6 carbon atoms, 2 to 4 carbon atoms, or 2 carbon atoms).

As used herein, “alkynylene” means a bivalent branched, or straight chain chemical group containing only carbon and hydrogen and containing at least one carbon-carbon triple bond, such as ethynylene, 1-propynylene, 1-butynylene, 2-butynylene, and the like. In various embodiments, alkynylene groups can either be unsubstituted or substituted with one or more substituents. Typically, alkynylene groups will comprise 2 to 9 carbon atoms (for example, 2 to 6 carbon atoms, 2 to 4 carbon atoms, or 2 carbon atoms).

As used herein, “carbocyclyl” means a cyclic ring system containing only carbon atoms in the ring system backbone, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cyclohexenyl. Carbocyclyls may include multiple fused rings. Carbocyclyls may have any degree of saturation provided that at least one ring in the ring system is not aromatic. Carbocyclyl groups can either be unsubstituted or substituted with one or more substituents. In some embodiments, carbocyclyl groups include 3 to 10 carbon atoms, for example, 3 to 6 carbon atoms.

As used herein, “aryl” means a mono-, bi-, tri- or polycyclic group with only carbon atoms present in the ring backbone having 5 to 14 ring atoms, alternatively 5, 6, 9, or 10 ring atoms; and having 6, 10, or 14 pi electrons shared in a cyclic array; wherein at least one ring in the system is aromatic. Aryl groups can either be unsubstituted or substituted with one or more substituents. Examples of aryl include phenyl, naphthyl, tetrahydronaphthyl, 2,3-dihydro-1H-indenyl, and others. In some embodiments, the aryl is phenyl.

As used herein, “arylalkylene” means an aryl-alkylene-group in which the aryl and alkylene moieties are as previously described. In some embodiments, arylalkylene groups contain a C₁₋₄alkylene moiety. Exemplary arylalkylene groups include benzyl and 2-phenethyl.

As used herein, the term “heteroaryl” means a mono-, bi-, tri- or polycyclic group having 5 to 14 ring atoms, alternatively 5, 6, 9, or 10 ring atoms; and having 6, 10, or 14 pi electrons shared in a cyclic array; wherein at least one ring in the system is aromatic, and at least one ring in the system contains one or more heteroatoms independently selected from the group consisting of N, O, and S. Heteroaryl groups can either be unsubstituted or substituted with one or more substituents. Examples of heteroaryl include thienyl, pyridinyl, furyl, oxazolyl, oxadiazolyl, pyrrolyl, imidazolyl, triazolyl, thiodiazolyl, pyrazolyl, isoxazolyl, thiadiazolyl, pyranyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, thiazolyl benzothienyl, benzoxadiazolyl, benzofuranyl, benzimidazolyl, benzotriazolyl, cinnolinyl, indazolyl, indolyl, isoquinolinyl, isothiazolyl, naphthyridinyl, purinyl, thienopyridinyl, pyrido[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyridinyl, quinazolinyl, quinolinyl, thieno[2,3-c]pyridinyl, pyrazolo[3,4-b]pyridinyl, pyrazolo[3,4-c]pyridinyl, pyrazolo[4,3-c]pyridine, pyrazolo[4,3-b]pyridinyl, tetrazolyl, chromane, 2,3-dihydrobenzo[b][1,4]dioxine, benzo[d][1,3]dioxole, 2,3-dihydrobenzofuran, tetrahydroquinoline, 2,3-dihydrobenzo[b][1,4]oxathiine, and others. In some embodiments, the heteroaryl is selected from thienyl, pyridinyl, furyl, pyrazolyl, imidazolyl, pyranyl, pyrazinyl, and pyrimidinyl.

As used herein, “halo”, “halide” or “halogen” is a chloro, bromo, fluoro, or iodo atom radical. In some embodiments, a halo is a chloro, bromo or fluoro. For example, a halide can be fluoro.

As used herein, “haloalkyl” means a hydrocarbon substituent, which is a linear or branched, alkyl, alkenyl or alkynyl substituted with one or more chloro, bromo, fluoro, and/or iodo atom(s). In some embodiments, a haloalkyl is a fluoroalkyls, wherein one or more of the hydrogen atoms have been substituted by fluoro. In some embodiments, haloalkyls are of 1 to about 3 carbons in length (e.g., 1 to about 2 carbons in length or 1 carbon in length). The term “haloalkylene” means a diradical variant of haloalkyl, and such diradicals may act as spacers between radicals, other atoms, or between a ring and another functional group.

As used herein, “heterocyclyl” means a nonaromatic cyclic ring system comprising at least one heteroatom in the ring system backbone. Heterocyclyls may include multiple fused rings. Heterocyclyls may be substituted or unsubstituted with one or more substituents. In some embodiments, heterocycles have 5-7 members. In six membered monocyclic heterocycles, the heteroatom(s) are selected from one to three of O, N or S, and wherein when the heterocycle is five membered, it can have one or two heteroatoms selected from O, N, or S. Examples of heterocyclyl include azirinyl, aziridinyl, azetidinyl, oxetanyl, thietanyl, 1,4,2-dithiazolyl, dihydropyridinyl, 1,3-dioxanyl, 1,4-dioxanyl, 1,3-dioxolanyl, morpholinyl, thiomorpholinyl, piperazinyl, pyranyl, pyrrolidinyl, tetrahydrofuryl, tetrahydropyridinyl, oxazinyl, thiazinyl, thiinyl, thiazolidinyl, isothiazolidinyl, oxazolidinyl, isoxazolidinyl, piperidinyl, pyrazolidinyl imidazolidinyl, thiomorpholinyl, and others. In some embodiments, the heterocyclyl is selected from azetidinyl, morpholinyl, piperazinyl, pyrrolidinyl, and tetrahydropyridinyl.

As used herein, “monocyclic heterocyclyl” means a single nonaromatic cyclic ring comprising at least one heteroatom in the ring system backbone. Heterocyclyls may be substituted or unsubstituted with one or more substituents. In some embodiments, heterocycles have 5-7 members. In six membered monocyclic heterocycles, the heteroatom(s) are selected from one to three of O, N or S, and wherein when the heterocycle is five membered, it can have one or two heteroatoms selected from O, N, or S. Examples of heterocyclyl include azirinyl, aziridinyl, azetidinyl, oxetanyl, thietanyl, 1,4,2-dithiazolyl, dihydropyridinyl, 1,3-dioxanyl, 1,4-dioxanyl, 1,3-dioxolanyl, morpholinyl, thiomorpholinyl, piperazinyl, pyranyl, pyrrolidinyl, tetrahydrofuryl, tetrahydropyridinyl, oxazinyl, thiazinyl, thiinyl, thiazolidinyl, isothiazolidinyl, oxazolidinyl, isoxazolidinyl, piperidinyl, pyrazolidinyl imidazolidinyl, thiomorpholinyl, and others.

The term “substituted” refers to moieties having substituents replacing a hydrogen on one or more non-hydrogen atoms of the molecule. It will be understood that “substitution” or “substituted with” includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g., which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc. Substituents can include, for example, —(C₁₋₉ alkyl) optionally substituted with one or more of hydroxyl, —NH₂, —NH(C₁₋₃ alkyl), and —N(C₁₋₃ alkyl)₂; —(C₁₋₉ haloalkyl); a halide; a hydroxyl; a carbonyl [such as —C(O)OR, and —C(O)R]; a thiocarbonyl [such as —C(S)OR, —C(O)SR, and —C(S)R]; —(C₁₋₉ alkoxyl) optionally substituted with one or more of halide, hydroxyl, —NH₂, —NH(C₁₋₃ alkyl), and —N(C₁₋₃ alkyl)₂; —OPO(OH)₂; a phosphonate [such as —PO(OH)₂ and —PO(OR′)₂]; —OPO(OR′)R″; —NRR′; —C(O)NRR′; —C(NR)NR′R″; —C(NR′)R″; a cyano; a nitro; an azido; —SH; —S—R; —OSO₂(OR); a sulfonate [such as —SO₂(OH) and —SO₂(OR)]; —SO₂NR′R″; and —SO₂R; in which each occurrence of R, R′ and R″ are independently selected from H; —(C₁₋₉ alkyl); C₆₋₁₀ aryl optionally substituted with from 1-3R″′; 5-10 membered heteroaryl having from 1-4 heteroatoms independently selected from N, O, and S and optionally substituted with from 1-3 R″′; C₃₋₇ carbocyclyl optionally substituted with from 1-3 R′″; and 3-8 membered heterocyclyl having from 1-4 heteroatoms independently selected from N, O, and S and optionally substituted with from 1-3 R′″; wherein each R′″ is independently selected from —(C₁₋₆ alkyl), —(C₁₋₆ haloalkyl), a halide (e.g., F), a hydroxyl, —C(O)OR, —C(O)R, —(C₁₋₆ alkoxyl), —NRR′, —C(O)NRR′, and a cyano, in which each occurrence of R and R′ is independently selected from H and —(C₁₋₆ alkyl). In some embodiments, the substituent is selected from —(C₁₋₆ alkyl), —(C₁₋₆ haloalkyl), a halide (e.g., F), a hydroxyl, —C(O)OR, —C(O)R, —(C₁₋₆ alkoxyl), —NRR′, —C(O)NRR′, and a cyano, in which each occurrence of R and R′ is independently selected from H and —(C₁₋₆ alkyl).

As used herein, when two groups are indicated to be “linked” or “bonded” to form a “ring”, it is to be understood that a bond is formed between the two groups and may involve replacement of a hydrogen atom on one or both groups with the bond, thereby forming a carbocyclyl, heterocyclyl, aryl, or heteroaryl ring. The skilled artisan will recognize that such rings can and are readily formed by routine chemical reactions. In some embodiments, such rings have from 3-7 members, for example, 5 or 6 members.

The skilled artisan will recognize that some structures described herein may be resonance forms or tautomers of compounds that may be fairly represented by other chemical structures, even when kinetically, the artisan recognizes that such structures are only a very small portion of a sample of such compound(s). Such compounds are clearly contemplated within the scope of this disclosure, though such resonance forms or tautomers are not represented herein.

The compounds provided herein may encompass various stereochemical forms. The compounds also encompass diastereomers as well as optical isomers, e.g., mixtures of enantiomers including racemic mixtures, as well as individual enantiomers and diastereomers, which arise as a consequence of structural asymmetry in certain compounds. Separation of the individual isomers or selective synthesis of the individual isomers is accomplished by application of various methods which are well known to practitioners in the art. Unless otherwise indicated, when a disclosed compound is named or depicted by a structure without specifying the stereochemistry and has one or more chiral centers, it is understood to represent all possible stereoisomers of the compound.

The term “administration” or “administering” refers to a method of providing a dosage of a compound or pharmaceutical composition to a vertebrate or invertebrate, including a mammal, a bird, a fish, or an amphibian, where the method is, e.g., orally, subcutaneously, intravenously, intralymphatic, intranasally, topically, transdermally, intraperitoneally, intramuscularly, intrapulmonarilly, vaginally, rectally, ontologically, neuro-otologically, intraocularly, subconjuctivally, via anterior eye chamber injection, intravitreally, intraperitoneally, intrathecally, intracystically, intrapleurally, via wound irrigation, intrabuccally, intra-abdominally, intra-articularly, intra-aurally, intrabronchially, intracapsularly, intrameningeally, via inhalation, via endotracheal or endobronchial instillation, via direct instillation into pulmonary cavities, intraspinally, intrasynovially, intrathoracically, via thoracostomy irrigation, epidurally, intratympanically, intracistemally, intravascularly, intraventricularly, intraosseously, via irrigation of infected bone, or via application as part of any admixture with a prosthetic device. The method of administration can vary depending on various factors, e.g., the components of the pharmaceutical composition, the site of the disease, the disease involved, and the severity of the disease.

A “diagnostic” as used herein is a compound, method, system, or device that assists in the identification or characterization of a health or disease state. The diagnostic can be used in standard assays as is known in the art.

The term “mammal” is used in its usual biological sense. Thus, it specifically includes humans, cattle, horses, monkeys, dogs, cats, mice, rats, cows, sheep, pigs, goats, and non-human primates, but also includes many other species.

The term “pharmaceutically acceptable carrier”, “pharmaceutically acceptable diluent” or “pharmaceutically acceptable excipient” includes any and all solvents, co-solvents, complexing agents, dispersion media, coatings, isotonic and absorption delaying agents and the like which are not biologically or otherwise undesirable. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions. In addition, various adjuvants such as are commonly used in the art may be included. These and other such compounds are described in the literature, e.g., in the Merck Index, Merck & Company, Rahway, N.J. Considerations for the inclusion of various components in pharmaceutical compositions are described, e.g., in Gilman et al. (Eds.) (2010); Goodman and Gilman's: The Pharmacological Basis of Therapeutics. 12th Ed., The McGraw-Hill Companies.

The term “pharmaceutically acceptable salt” refers to salts that retain the biological effectiveness and properties of the compounds provided herein and, which are not biologically or otherwise undesirable. In many cases, the compounds provided herein are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto. Many such salts are known in the art, for example, as described in WO 87/05297. Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids. Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like. Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases. Inorganic bases from which salts can be derived include, for example, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like; particularly preferred are the ammonium, potassium, sodium, calcium, and magnesium salts. Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like, specifically such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine.

“Solvate” refers to the compound formed by the interaction of a solvent and a compound as provided herein or a salt thereof. Suitable solvates are pharmaceutically acceptable solvates including hydrates.

“Patient” as used herein, means a human or a non-human mammal, e.g., a dog, a cat, a mouse, a rat, a cow, a sheep, a pig, a goat, a non-human primate, or a bird, e.g., a chicken, as well as any other vertebrate or invertebrate. In some embodiments, the patient is a human.

A “therapeutically effective amount” of a compound as provided herein is one which is sufficient to achieve the desired physiological effect and may vary according to the nature and severity of the disease condition, and the potency of the compound. “Therapeutically effective amount” is also intended to include one or more of the compounds of Formula I in combination with one or more other agents that are effective to treat the diseases and/or conditions described herein. The combination of compounds can be a synergistic combination. Synergy, as described, for example, by Chou and Talalay, Advances in Enzyme Regulation (1984), 22, 27-55, occurs when the effect of the compounds when administered in combination is greater than the additive effect of the compounds when administered alone as a single agent. In general, a synergistic effect is most clearly demonstrated at sub-optimal concentrations of the compounds. It will be appreciated that different concentrations may be employed for prophylaxis than for treatment of an active disease. This amount can further depend upon the patient's height, weight, sex, age and medical history.

A therapeutic effect relieves, to some extent, one or more of the symptoms of the disease.

“Treat,” “treatment,” or “treating,” as used herein refers to administering a compound or pharmaceutical composition as provided herein for therapeutic purposes. The term “therapeutic treatment” refers to administering treatment to a patient already suffering from a disease thus causing a therapeutically beneficial effect, such as ameliorating existing symptoms, ameliorating the underlying metabolic causes of symptoms, postponing or preventing the further development of a disorder, and/or reducing the severity of symptoms that will or are expected to develop.

“Drug-eluting” and/or controlled release as used herein refers to any and all mechanisms, e.g., diffusion, migration, permeation, and/or desorption by which the drug(s) incorporated in the drug-eluting material pass therefrom overtime into the surrounding body tissue.

“Drug-eluting material” and/or controlled release material as used herein refers to any natural, synthetic or semi-synthetic material capable of acquiring and retaining a desired shape or configuration and into which one or more drugs can be incorporated and from which incorporated drug(s) are capable of eluting over time.

“Elutable drug” as used herein refers to any drug or combination of drugs having the ability to pass over time from the drug-eluting material in which it is incorporated into the surrounding areas of the body.

Compounds

The compounds and compositions described herein can be used as anti-proliferative agents, e.g., anti-cancer and anti-angiogenesis agents, and/or as inhibitors of the Wnt signaling pathway, e.g., for treating diseases or disorders associated with aberrant Wnt signaling. In addition, the compounds can be used as inhibitors of one or more kinases, kinase receptors, or kinase complexes. Such compounds and compositions are also useful for controlling cellular proliferation, differentiation, and/or apoptosis.

Some embodiments of the present disclosure include compounds of Formula I:

or salts, pharmaceutically acceptable salts, or prodrugs thereof.

In some embodiments, R¹ and R⁴ are independently selected from the group consisting of H and halide (e.g., F, Cl, Br, I).

In some embodiments, R¹ is H, and R⁴ is F.

In some embodiments, R¹ is F, and R⁴ is H.

In some embodiments, R¹ and R⁴ are both H.

In some embodiments, R¹ and R⁴ are both F.

In some embodiments, R³ is selected from the group consisting of -heteroaryl optionally substituted with 1-4 (e.g., 1-3, 1-2, 1) R⁶ and -heterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R⁷.

In some embodiments, R³ is selected from the group consisting of -heteroaryl optionally substituted with 1-2 (e.g., 1) R⁶ and -heterocyclyl optionally substituted with 1-2 (e.g., 1) R⁷.

In some embodiments, the heteroaryl of R³ is selected from the group consisting of -pyridinyl, -pyrimidinyl, -pyrazolyl, -imidazolyl, -thiazolyl, and -oxazolyl.

In some embodiments, the heteroaryl of R³ is selected from the group consisting of -pyridin-3-yl, -pyrimidin-5-yl, -pyrazol-4-yl, -imidazol-5-yl, -thiazol-2-yl, -thiazol-5-yl, -oxazol-2-yl, and -oxazol-5-yl.

In some embodiments, the -heterocyclyl of R³ is selected from the group consisting of -tetrahydropyridinyl and -piperidinyl.

In some embodiments, the -heterocyclyl of R³ is selected from the group consisting of-1,2,3,6-tetrahydropyridinyl and -piperidin-4-yl.

In some embodiments, R³ is -pyridinyl optionally substituted with 1 R⁶.

In some embodiments, R³ is -pyridin-3-yl optionally substituted with 1 R⁶.

In some embodiments, R³ is -pyrimidinyl optionally substituted with 1 R⁶.

In some embodiments, R³ is -pyrimidin-5-yl optionally substituted with 1 R⁶.

In some embodiments, R³ is -pyrazolyl optionally substituted with 1 R⁶.

In some embodiments, R³ is -pyrazolyl substituted with 1 R⁶.

In some embodiments, R³ is -pyrazolyl substituted with 1 methyl.

In some embodiments, R³ is -pyrazolyl optionally substituted with 2 R⁶.

In some embodiments, R³ is -pyrazolyl substituted with 2 R⁶.

In some embodiments, R³ is -pyrazolyl substituted with 1 methyl and 1 —CH₂OH.

In some embodiments, R³ is -pyrazol-4-yl optionally substituted with 1 R⁶.

In some embodiments, R³ is -pyrazol-4-yl substituted with 1 R⁶.

In some embodiments, R³ is -pyrazol-4-yl substituted with 1 methyl.

In some embodiments, R³ is -pyrazol-4-yl optionally substituted with 2 R⁶.

In some embodiments, R³ is -pyrazol-4-yl substituted with 2 R⁶.

In some embodiments, R³ is -pyrazol-4-yl substituted with 1 methyl and 1 —CH₂OH.

In some embodiments, R³ is -imidazolyl optionally substituted with 1-2 R⁶.

In some embodiments, R³ is -imidazolyl substituted with 1-2 R⁶.

In some embodiments, R³ is -imidazolyl substituted with 1-2 methyls.

In some embodiments, R³ is -imidazolyl substituted with 1 methyl.

In some embodiments, R³ is -imidazolyl substituted with 2 methyls.

In some embodiments, R³ is -imidazol-5-yl optionally substituted with 1-2 R⁶.

In some embodiments, R³ is -imidazol-5-yl substituted with 1-2 R⁶.

In some embodiments, R³ is -imidazol-5-yl substituted with 1-2 methyls.

In some embodiments, R³ is -imidazol-5-yl substituted with 1 methyl.

In some embodiments, R³ is -imidazol-5-yl substituted with 2 methyls.

In some embodiments, R³ is -thiazolyl optionally substituted with 1 R⁶.

In some embodiments, R³ is -thiazol-2-yl optionally substituted with 1 R⁶.

In some embodiments, R³ is thiazol-5-yl optionally substituted with 1 R⁶.

In some embodiments, R³ is -oxazolyl optionally substituted with 1 R⁶.

In some embodiments, R³ is -oxazol-2-yl optionally substituted with 1 R⁶.

In some embodiments, R³ is -oxazol-5-yl optionally substituted with 1 R⁶.

In some embodiments, X is CR⁵ or N.

In some embodiments, X is N.

In some embodiments, X is CR⁵.

In some embodiments, X is CR⁵ and R⁵ is H.

In some embodiments, R⁵ is selected from the group consisting of H, -heteroaryl optionally substituted with 1-4 (e.g., 1-3, 1-2, 1) R⁸, -heterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R⁹, and -aryl optionally substituted with 1-5 (e.g., 1-4, 1-3, 1-2, 1) R¹⁰.

In some embodiments, R⁵ is selected from the group consisting of H, -heteroaryl optionally substituted with 1-2 (e.g., 1) R⁸, -heterocyclyl optionally substituted with 1-2 (e.g., 1) R⁹, and -phenyl optionally substituted with 1-2 (e.g., 1) R¹⁰.

In some embodiments, R⁵ is H.

In some embodiments, R⁵ is -heteroaryl optionally substituted with 1-2 (e.g., 1) R⁸.

In some embodiments, R⁵ is -heterocyclyl optionally substituted with 1-2 (e.g., 1) R⁹.

In some embodiments, R⁵ is -piperidinyl optionally substituted with 1-2 (e.g., 1) R⁹.

In some embodiments, R⁵ is -piperazinyl optionally substituted with 1-2 (e.g., 1) R⁹.

In some embodiments, R⁵ is -aryl optionally substituted with 1-2 (e.g., 1) R¹⁰.

In some embodiments, R⁵ is -phenyl optionally substituted with 1-2 (e.g., 1) R¹⁰.

In some embodiments, R⁵ is -pyridinyl optionally substituted with 1-2 (e.g., 1) R⁸.

In some embodiments, R⁵ is -pyridin-3-yl optionally substituted with 1-2 (e.g., 1) R⁸.

In some embodiments, R⁵ is -pyridin-4-yl optionally substituted with 1-2 (e.g., 1) R⁸.

In some embodiments, R⁵ is -pyridin-5-yl optionally substituted with 1-2 (e.g., 1) R⁸.

In some embodiments, R⁵ is -imidazolyl optionally substituted with 1-2 (e.g., 1) R⁸.

In some embodiments, R⁵ is -imidazolyl substituted with 1-2 (e.g., 1) R⁸.

In some embodiments, R⁵ is -imidazolyl substituted with 1 R⁸.

In some embodiments, R⁵ is -imidazolyl substituted with 1 methyl.

In some embodiments, R⁵ is -imidazol-1-yl optionally substituted with 1-2 (e.g., 1) R⁸.

In some embodiments, R⁵ is -imidazol-1-yl substituted with 1-2 (e.g., 1) R⁸.

In some embodiments, R⁵ is -imidazol-1-yl substituted with 1 R⁸.

In some embodiments, R⁵ is -imidazol-1-yl substituted with 1 methyl.

In some embodiments, R⁵ is -furanyl optionally substituted with 1-2 (e.g., 1) R⁸.

In some embodiments, R⁵ is -furan-2-yl optionally substituted with 1-2 (e.g., 1) R⁸.

In some embodiments, R⁵ is -furan-3-yl optionally substituted with 1-2 (e.g., 1) R⁸.

In some embodiments, R⁵ is -thiophenyl optionally substituted with 1-2 (e.g., 1) R⁸.

In some embodiments, R⁵ is -thiophen-2-yl optionally substituted with 1-2 (e.g., 1) R⁸.

In some embodiments, R⁵ is -thiophen-2-yl optionally substituted with 1-2 (e.g., 1) R⁸, and each R⁸ is independently halide.

In some embodiments, R⁵ is -thiophen-2-yl optionally substituted with 1-2 (e.g., 1) F.

In some embodiments, R⁵ is -thiophen-2-yl optionally substituted with 1-2 (e.g., 1) Cl.

In some embodiments, R⁵ is -thiophen-2-yl optionally substituted with 1-2 (e.g., 1) R⁸, and each R⁸ is independently —(C₁₋₆ alkyl).

In some embodiments, R⁵ is -thiophen-2-yl optionally substituted with 1-2 (e.g., 1) R⁸, and each R⁸ is independently —(C₁₋₂ alkyl).

In some embodiments, R⁵ is -thiophen-2-yl optionally substituted with 1-2 (e.g., 1) methyls.

In some embodiments, R⁵ is -thiophen-2-yl optionally substituted with 1-2 (e.g., 1) —CF₃.

In some embodiments, R⁵ is -thiophen-2-yl optionally substituted with 1-2 (e.g., 1) —CN.

In some embodiments, R⁵ is -thiophen-2-yl optionally substituted with 1 —C(═O)R¹⁹.

In some embodiments, R⁵ is -thiophen-2-yl optionally substituted with 1 —C(═O)R¹⁹, and R¹⁹ is —(C₁₋₆ alkyl).

In some embodiments, R⁵ is -thiophen-2-yl optionally substituted with 1 —C(═O)R¹⁹, and R¹⁹ is —(C₁₋₄ alkyl).

In some embodiments, R⁵ is -thiophen-2-yl optionally substituted with 1 —C(═O)R¹⁹, and R¹⁹ is —(C₁₋₂ alkyl).

In some embodiments, R⁵ is -thiophen-2-yl optionally substituted with 1 —C(═O)R¹⁹, and R¹⁹ is methyl.

In some embodiments, R⁵ is -thiophen-3-yl optionally substituted with 1-2 (e.g., 1) R⁸.

In some embodiments, R⁵ is -thiophen-3-yl optionally substituted with 1-2 (e.g., 1) R⁸ and each R⁸ is independently halide.

In some embodiments, R⁵ is -thiophen-3-yl optionally substituted with 1-2 (e.g., 1) F.

In some embodiments, R⁵ is -thiophen-3-yl optionally substituted with 1-2 (e.g., 1) Cl.

In some embodiments, R⁵ is -thiophen-3-yl optionally substituted with 1-2 (e.g., 1) R⁸, and each R⁸ is independently —(C₁₋₆ alkyl).

In some embodiments, R⁵ is -thiophen-3-yl optionally substituted with 1-2 (e.g., 1) R⁸, and each R⁸ is independently —(C₁₋₂ alkyl).

In some embodiments, R⁵ is -thiophen-3-yl optionally substituted with 1-2 (e.g., 1) methyls.

In some embodiments, R⁵ is -thiophen-3-yl optionally substituted with 1-2 (e.g., 1) —CF₃.

In some embodiments, R⁵ is -thiophen-3-yl optionally substituted with 1-2 (e.g., 1) —CN.

In some embodiments, R⁵ is -thiophen-3-yl optionally substituted with 1 —C(═O)R¹⁹.

In some embodiments, R⁵ is -thiophen-3-yl optionally substituted with 1 —C(═O)R¹⁹, and R¹⁹ is —(C₁₋₆ alkyl).

In some embodiments, R⁵ is -thiophen-3-yl optionally substituted with 1 —C(═O)R¹⁹, and R¹⁹ is —(C₁₋₄ alkyl).

In some embodiments, R⁵ is -thiophen-3-yl optionally substituted with 1 —C(═O)R¹⁹, and R¹⁹ is —(C₁₋₂ alkyl).

In some embodiments, R⁵ is -thiophen-3-yl optionally substituted with 1 —C(═O)R¹⁹, and R¹⁹ is methyl.

In some embodiments, R⁵ is selected from the group consisting of:

In some embodiments, R⁵ is -phenyl optionally substituted with 1-2 (e.g., 1) R¹⁰, and each R¹⁰ is independently halide.

In some embodiments, R⁵ is -phenyl optionally substituted with 1-2 (e.g., 1) F.

In some embodiments, R⁵ is -phenyl optionally substituted with 2 R¹⁰, one R¹⁰ is halide and the other R¹⁰ is —(C₁₋₆ alkylene)NHSO₂R¹⁹.

In some embodiments, R⁵ is -phenyl optionally substituted with 2 R¹⁰, one R¹⁰ is halide and the other R¹⁰ is —(C₁₋₄ alkylene)NHSO₂R¹⁹.

In some embodiments, R⁵ is -phenyl optionally substituted with 2 R¹⁰, one R¹⁰ is halide and the other R¹⁰ is —(C₁₋₂ alkylene)NHSO₂R¹⁹.

In some embodiments, R⁵ is -phenyl optionally substituted with 2 R¹⁰, one R¹⁰ is halide and the other R¹⁰ is —CH₂NHSO₂R¹⁹.

In some embodiments, R⁵ is -phenyl optionally substituted with 2 R¹⁰, one R¹⁰ is halide and the other R¹⁰ is —CH₂NHSO₂R¹⁹, R¹⁹ is —(C₁₋₄ alkyl).

In some embodiments, R⁵ is -phenyl optionally substituted with 2 R¹⁰, one R¹⁰ is halide and the other R¹⁰ is —CH₂NHSO₂R¹⁹, R¹⁹ is —(C₁₋₂ alkyl).

In some embodiments, R⁵ is -phenyl optionally substituted with 2 R¹⁰, one R¹⁰ is halide and the other R¹⁰ is —CH₂NHSO₂R¹⁹, R¹⁹ is methyl.

In some embodiments, R⁵ is -phenyl optionally substituted with 2 R¹⁰, one R¹⁰ is F and the other R¹⁰ is —CH₂NHSO₂R¹⁹, R¹⁹ is —(C₁₋₂ alkyl).

In some embodiments, R⁵ is -phenyl optionally substituted with 2 R¹⁰, one R¹⁰ is F and the other R¹⁰ is —CH₂NHSO₂R¹⁹, R¹⁹ is methyl.

In some embodiments, R⁵ is -phenyl optionally substituted with 2 R¹⁰, one R¹⁰ is halide and the other R¹⁰ is —NR¹⁵(C₁₋₆ alkylene)NR¹⁵R¹⁶.

In some embodiments, R⁵ is -phenyl optionally substituted with 2 R¹⁰, one R¹⁰ is halide and the other R¹⁰ is —NR¹⁵(C₁₋₅ alkylene)NR¹⁵R¹⁶.

In some embodiments, R⁵ is -phenyl optionally substituted with 2 R¹⁰, one R¹⁰ is halide and the other R¹⁰ is —NR¹⁵(C₁₋₄ alkylene)NR¹⁵R¹⁶.

In some embodiments, R⁵ is -phenyl optionally substituted with 2 R¹⁰, one R¹⁰ is halide and the other R¹⁰ is —NR⁵(C₁₋₃ alkylene)NR¹⁵R¹⁶.

In some embodiments, R⁵ is -phenyl optionally substituted with 2 R¹⁰, one R¹⁰ is halide and the other R¹⁰ is —NR¹⁵CH₂CH₂NR¹⁵R¹⁶.

In some embodiments, R⁵ is -phenyl optionally substituted with 2 R¹⁰, one R¹⁰ is halide and the other R¹⁰ is —NHCH₂CH₂NR¹⁵R¹⁶.

In some embodiments, R⁵ is -phenyl optionally substituted with 2 R¹⁰, one R¹⁰ is halide and the other R¹⁰ is —NHCH₂CH₂NR¹⁵R¹⁶, and R¹⁵ and R¹⁶ are independently selected from —(C₁₋₆ alkyl).

In some embodiments, R⁵ is -phenyl optionally substituted with 2 R¹⁰, one R¹⁰ is halide and the other R¹⁰ is —NHCH₂CH₂NR¹⁵R¹⁶, and R¹⁵ and R¹⁶ are independently selected from —(C₁₋₄ alkyl).

In some embodiments, R⁵ is -phenyl optionally substituted with 2 R¹⁰, one R¹⁰ is halide and the other R¹⁰ is —NHCH₂CH₂NR¹⁵R¹⁶, and R¹⁵ and R¹⁶ are independently selected from —(C₁₋₂ alkyl).

In some embodiments, R⁵ is -phenyl optionally substituted with 2 R¹⁰, one R¹⁰ is halide and the other R¹⁰ is —NHCH₂CH₂NR¹⁵R¹⁶, and both R¹⁵ and R¹⁶ are methyls.

In some embodiments, R⁵ is -phenyl optionally substituted with 2 R¹⁰, one R¹⁰ is F and the other R¹⁰ is —NHCH₂CH₂NR¹⁵R¹⁶, and R¹⁵ and R¹⁶ are independently selected from —(C₁₋₂ alkyl).

In some embodiments, R⁵ is -phenyl optionally substituted with 2 R¹⁰, one R¹⁰ is F and the other R¹⁰ is —NHCH₂CH₂NR¹⁵R¹⁶, and both R¹⁵ and R¹⁶ are methyls.

In some embodiments, R⁵ is -phenyl optionally substituted with 2 R¹⁰, one R¹⁰ is halide and the other R¹⁰ is —OR²⁷.

In some embodiments, R⁵ is -phenyl optionally substituted with 2 R¹⁰, one R¹⁰ is halide and the other R¹⁰ is —OCH₂CH₂NR²⁵R²⁶.

In some embodiments, R⁵ is -phenyl optionally substituted with 2 R¹⁰, one R¹⁰ is halide and the other R¹⁰ is —OCH₂CH₂NR²⁵R²⁶, and R²⁵ and R²⁶ are independently —(C₁₋₂ alkyl).

In some embodiments, R⁵ is -phenyl optionally substituted with 2 R¹⁰, one R¹⁰ is halide and the other R¹⁰ is —OCH₂CH₂NR²⁵R²⁶, and R²⁵ and R²⁶ are both methyl.

In some embodiments, R⁵ is -phenyl optionally substituted with 2 R¹⁰, one R¹⁰ is F and the other R¹⁰ is —OCH₂CH₂NR²⁵R²⁶, and R² and R²⁶ are both methyl.

In some embodiments, R⁵ is -phenyl optionally substituted with 2 R¹⁰, one R¹⁰ is halide and the other R¹⁰ is —OCH₂CH₂heterocyclyl optionally substituted with 1-2 (e.g., 1) R²³.

In some embodiments, R⁵ is -phenyl optionally substituted with 2 R¹⁰, one R¹⁰ is F and the other R¹⁰ is —OCH₂CH₂heterocyclyl optionally substituted with 1-2 (e.g., 1) R²³.

In some embodiments, R⁵ is -phenyl optionally substituted with 2 R¹⁰, one R¹⁰ is halide and the other R¹⁰ is —OH.

In some embodiments, R⁵ is -phenyl optionally substituted with 2 R¹⁰, one R¹⁰ is halide and the other R¹⁰ is —OMe.

In some embodiments, R⁵ is -phenyl optionally substituted with 1 —OMe.

In some embodiments, R⁵ is selected from the group consisting of:

In some embodiments, R⁵ is -piperidin-1-yl optionally substituted with 1-2 (e.g., 1) R⁹.

In some embodiments, R⁵ is -piperidin-1-yl optionally substituted with 1-2 (e.g., 1) R⁹, and each R⁹ is independently halide.

In some embodiments, R⁵ is -piperazin-1-yl optionally substituted with 1-2 (e.g., 1) R⁹.

In some embodiments, R⁵ is -piperazin-1-yl optionally substituted with 1 C₁₋₃ alkyl.

In some embodiments, R⁵ is -piperazin-1-yl optionally substituted with 1 methyl.

In some embodiments, R⁵ is -morpholinyl optionally substituted with 1-2 (e.g., 1) R⁹.

In some embodiments, R⁵ is -morpholin-1-yl optionally substituted with 1-2 (e.g., 1) R⁹.

In some embodiments, R⁵ is selected from the group consisting of:

In some embodiments, each R⁶ is independently selected from the group consisting of halide, —(C₁₋₆ alkyl), —(C₂₋₆ alkenyl), —(C₂₋₆ alkynyl), —(C₁₋₄ alkylene)_(p)heterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R¹¹, —(C₂₋₄ alkenylene)_(p)heterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R¹¹, —(C₂₋₄alkynylene)_(p)heterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R¹¹, —(C₁₋₄alkylene)_(p)carbocyclyl optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R¹², —(C₂₋₄ alkenylene)_(p)carbocyclyl optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R¹², —(C₂₋₄ alkynylene)_(p)carbocyclyl optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R¹², —(C₁₋₄alkylene)_(p)aryl optionally substituted with 1-5 (e.g., 1-4, 1-3, 1-2, 1) R¹³, —(C₂₋₄ alkenylene)_(p)aryl optionally substituted with 1-5 (e.g., 1-4, 1-3, 1-2, 1) R¹³, —(C₂₋₄ alkynylene)_(p)aryl optionally substituted with 1-5 (e.g., 1-4, 1-3, 1-2, 1) R¹³, —NHC(═O)R¹⁴, —NR¹⁵R¹⁶, —(C₁₋₆ alkylene)NR¹⁷R¹⁸, —(C₂₋₆ alkenylene)NR¹⁷R¹⁸, —(C₂₋₆ alkynylene)NR¹⁷R¹⁸, and —OR²⁴.

In some embodiments, each R⁶ is independently selected from the group consisting of halide, —(C₁₋₆ alkyl), —(C₂₋₆ alkenyl), —(C₂₋₆ alkynyl), —(C₁₋₄ alkylene)_(p)heterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R¹¹, —(C₂₋₄ alkenylene))heterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R¹¹, —(C₂₋₄alkynylene)_(p)heterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R¹¹, —(C₁₋₄alkylene)_(p)carbocyclyl optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R¹², —(C₂₋₄ alkenylene)_(p)carbocyclyl optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R¹², —(C₂₋₄ alkynylene)_(p)carbocyclyl optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R¹², —(C₁₋₄alkylene)_(p)aryl optionally substituted with 1-5 (e.g., 1-4, 1-3, 1-2, 1) R¹³, —(C₂₋₄ alkenylene)_(p)aryl optionally substituted with 1-5 (e.g., 1-4, 1-3, 1-2, 1) R¹³, —(C₂₋₄ alkynylene)_(p)aryl optionally substituted with 1-5 (e.g., 1-4, 1-3, 1-2, 1) R¹³, —NHC(═O)R¹⁴, —NR¹⁵R¹⁶, —(C₁₋₆ alkylene)NR¹⁷R¹⁸, —(C₂₋₆ alkenylene)NR¹⁷R¹⁸, —(C₂₋₆ alkynylene)NR¹⁷R¹⁸, and —(C₁₋₄ alkylene)_(p)OR²⁴.

In some embodiments, each R⁶ is independently selected from the group consisting of F, Cl, —(C₁₋₃ alkyl), -heterocyclyl optionally substituted with 1-2 (e.g., 1) R¹¹, —CH₂heterocyclyl optionally substituted with with 1-2 (e.g., 1) R¹¹, -carbocyclyl optionally substituted with 1-2 (e.g., 1) R¹², —CH₂carbocyclyl optionally substituted with 1-2 (e.g., 1) R¹², -aryl optionally substituted with 1-2 (e.g., 1) R¹³, —CH₂aryl optionally substituted with 1-2 (e.g., 1) R¹³, —NHC(═O)R¹⁴, —NR¹⁵R¹⁶, —CH₂NR¹⁷R¹⁸, and —OR²⁴.

In some embodiments, each R⁶ is independently selected from the group consisting of F, Cl, —(C₁₋₃ alkyl), -heterocyclyl optionally substituted with 1-2 (e.g., 1) R¹¹, —CH₂heterocyclyl optionally substituted with with 1-2 (e.g., 1) R¹¹, -carbocyclyl optionally substituted with 1-2 (e.g., 1) R¹², —CH₂carbocyclyl optionally substituted with 1-2 (e.g., 1) R¹², -aryl optionally substituted with 1-2 (e.g., 1) R¹³, —CH₂aryl optionally substituted with 1-2 (e.g., 1) R¹³, —NHC(═O)R¹⁴, —NR¹⁵R¹⁶, —CH₂NR¹⁷R¹⁸, —CH₂OR²⁴, and —OR²⁴.

In some embodiments, each R⁶ is independently selected from the group consisting of F, -Me, -heterocyclyl optionally substituted with 1-2 (e.g., 1) halides, -heterocyclyl optionally substituted with 1-2 (e.g., 1) methyls, —CH₂heterocyclyl optionally substituted with with 1-2 (e.g., 1) halides, —CH₂heterocyclyl optionally substituted with with 1-2 (e.g., 1) methyls, -carbocyclyl optionally substituted with 1-2 (e.g., 1) halides, —CH₂carbocyclyl optionally substituted with 1-2 (e.g., 1) halides, -aryl optionally substituted with 1-2 (e.g., 1) halides, —CH₂aryl optionally substituted with 1-2 (e.g., 1) halides, —NHC(═O)R¹⁴, —NH₂, —NHMe, —NHEt, —NHPr, —NMe₂, —CH₂NMe₂, —CH₂NHMe, —CH₂NHEt, —CH₂NHCH₂phenyl, —CH₂NHCH₂carbocylyl, —CH₂OH, and —OR²⁴.

In some embodiments, R⁶ is selected from the group consisting of —(C₁₋₃ alkyl), —CH₂heterocyclyl optionally substituted with 1-2 R¹¹, —NHC(═O)R¹⁴, —NR¹⁵R¹⁶, —CH₂NR¹⁷R¹⁸, —CH₂OH, and —OR²⁴.

In some embodiments, at least one R⁶ is —(C₁₋₃ alkyl).

In some embodiments, at least one R⁶ is —(C₁₋₂ alkyl).

In some embodiments, at least one R⁶ is -Me.

In some embodiments, at least one R⁶ is halide.

In some embodiments, at least one R⁶ is F.

In some embodiments, at least one R⁶ is —(C₁₋₄ alkylene)heterocyclyl optionally substituted with 1-2 R¹¹.

In some embodiments, at least one R⁶ is —(C₁₋₃ alkylene)heterocyclyl optionally substituted with 1-2 R¹¹.

In some embodiments, at least one R⁶ is —(C₁₋₂ alkylene)heterocyclyl optionally substituted with 1-2 R¹¹.

In some embodiments, at least one R⁶ is —CH₂pyrrolidinyl optionally substituted with 1-2 R¹¹.

In some embodiments, R⁶ is —CH₂pyrrolidinyl optionally substituted with 1-2 R¹¹.

In some embodiments, R⁶ is —CH₂pyrrolidinyl optionally substituted with 1-2 R¹¹, and each R¹¹ is independently halide.

In some embodiments, R⁶ is —CH₂pyrrolidinyl optionally substituted with 1-2 F.

In some embodiments, R⁶ is —CH₂pyrrolidinyl substituted with 1-2 F.

In some embodiments, R⁶ is —CH₂pyrrolidinyl substituted with 2 F.

In some embodiments, at least one R⁶ is —CH₂piperidinyl optionally substituted with 1-2 R¹¹.

In some embodiments, R⁶ is —CH₂piperidinyl optionally substituted with 1-2 R¹¹.

In some embodiments, R⁶ is —CH₂piperidinyl optionally substituted with 1-2 R¹¹, and each R¹¹ is independently halide.

In some embodiments, R⁶ is —CH₂piperidinyl optionally substituted with 1-2 F.

In some embodiments, R⁶ is

In some embodiments, at least one R⁶ is —(C₁₋₄ alkylene)carbocyclyl optionally substituted with 1-2 (e.g., 1) R¹².

In some embodiments, at least one R⁶ is —(C₁₋₃ alkylene)carbocyclyl optionally substituted with 1-2 (e.g., 1) R¹².

In some embodiments, at least one R⁶ is —(C₁₋₂ alkylene)carbocyclyl optionally substituted with 1-2 (e.g., 1) R¹².

In some embodiments, at least one R⁶ is —CH₂carbocyclyl optionally substituted with 1-2 (e.g., 1) R¹².

In some embodiments, R⁶ is —CH₂carbocyclyl optionally substituted with 1-2 (e.g., 1) R¹².

In some embodiments, at least one R⁶ is —CH₂aryl optionally substituted with 1-2 (e.g., 1) R¹³,

In some embodiments, at least one R⁶ is —CH₂phenyl optionally substituted with 1-2 (e.g., 1) R¹³,

In some embodiments, R⁶ is —CH₂phenyl optionally substituted with 1-2 (e.g., 1) R¹³,

In some embodiments, at least one R⁶ is —NHC(═O)R¹⁴.

In some embodiments, R⁶ is —NHC(═O)R¹⁴.

In some embodiments, at least one R⁶ is —NHC(═O)R¹⁴ and R¹⁴ is —(C₁₋₉ alkyl).

In some embodiments, at least one R⁶ is —NHC(═O)R¹⁴ and R¹⁴ is —(C₁₋₈ alkyl).

In some embodiments, at least one R⁶ is —NHC(═O)R¹⁴ and R¹⁴ is —(C₁₋₇ alkyl).

In some embodiments, at least one R⁶ is —NHC(═O)R¹⁴ and R¹⁴ is —(C₁₋₆ alkyl).

In some embodiments, at least one R⁶ is —NHC(═O)R¹⁴ and R¹⁴ is —(C₁₋₅ alkyl).

In some embodiments, R⁶ is —NHC(═O)R¹⁴ and R¹⁴ is —(C₁₋₅ alkyl).

In some embodiments, at least one R⁶ is —NHC(═O)R¹⁴ and R¹⁴ is —(C₁₋₄ alkyl).

In some embodiments, R⁶ is —NHC(═O)R¹⁴ and R¹⁴ is —(C₁₋₄ alkyl).

In some embodiments, at least one R⁶ is —NHC(═O)R¹⁴ and R¹⁴ is —(C₁₋₃ alkyl).

In some embodiments, R⁶ is —NHC(═O)R¹⁴ and R¹⁴ is —(C₁₋₃ alkyl).

In some embodiments, at least one R⁶ is —NHC(═O)R¹⁴ and R¹⁴ is —(C₁₋₂ alkyl).

In some embodiments, R⁶ is —NHC(═O)R¹⁴ and R¹⁴ is —(C₁₋₂ alkyl).

In some embodiments, R⁶ is —NHC(═O)R¹⁴ and R¹⁴ is —CF₃.

In some embodiments, at least one R⁶ is —NHC(═O)R¹⁴ and R¹⁴ is —(C₂₋₅ alkyl).

In some embodiments, R⁶ is —NHC(═O)R¹⁴ and R¹⁴ is —(C₂₋₅ alkyl).

In some embodiments, at least one R⁶ is —NHC(═O)R¹⁴ and R¹⁴ is —(C₃₋₄ alkyl).

In some embodiments, at least one R⁶ is —NHC(═O)R¹⁴, R¹⁴ is -aryl optionally substituted with 1-2 (e.g., 1) R²¹.

In some embodiments, at least one R⁶ is —NHC(═O)R¹⁴, R¹⁴ is -phenyl optionally substituted with 1-2 (e.g., 1) R²¹.

In some embodiments, at least one R⁶ is —NHC(═O)R¹⁴, R¹⁴ is —CH₂aryl optionally substituted with 1-2 (e.g., 1) R²¹.

In some embodiments, at least one R⁶ is —NHC(═O)R¹⁴, R¹⁴ is —CH₂phenyl optionally substituted with 1-2 (e.g., 1) R²¹.

In some embodiments, at least one R⁶ is —NHC(═O)R¹⁴, R¹⁴ is -heteroaryl optionally substituted with 1-2 (e.g., 1) R²⁰.

In some embodiments, at least one R⁶ is —NHC(═O)R¹⁴, R¹⁴ is -carbocyclyl optionally substituted with 1-2 (e.g., 1) R²².

In some embodiments, at least one R⁶ is —NHC(═O)R¹⁴, R¹⁴ is -cyclopropyl optionally substituted with 1-2 (e.g., 1) R²².

In some embodiments, at least one R⁶ is —NHC(═O)R¹⁴, R¹⁴ is -cyclobutyl optionally substituted with 1-2 (e.g., 1) R²².

In some embodiments, at least one R⁶ is —NHC(═O)R¹⁴, R¹⁴ is -cyclopentyl optionally substituted with 1-2 (e.g., 1) R²².

In some embodiments, at least one R⁶ is —NHC(═O)R¹⁴, R⁴ is -cyclohexyl optionally substituted with 1-2 (e.g., 1) R²².

In some embodiments, at least one R⁶ is —NHC(═O)R¹⁴, R¹⁴ is —CH₂carbocyclyl optionally substituted with 1-2 (e.g., 1) R²².

In some embodiments, at least one R⁶ is —NHC(═O)R¹⁴, R¹⁴ is —CH₂cyclopropyl optionally substituted with 1-2 (e.g., 1) R²².

In some embodiments, at least one R⁶ is —NR¹⁵R¹⁶.

In some embodiments, at least one R⁶ is —NR¹⁵R¹⁶, and R¹⁵ and R¹⁶ are independently selected from the group consisting of H and —(C₁₋₆ alkyl).

In some embodiments, at least one R⁶ is —NR¹⁵R¹⁶, and R¹⁵ and R¹⁶ are independently selected from the group consisting of H and —(C₁₋₅ alkyl).

In some embodiments, at least one R⁶ is —NR¹⁵R¹⁶, and R¹⁵ and R¹⁶ are independently selected from the group consisting of H and —(C₁₋₄ alkyl).

In some embodiments, at least one R⁶ is —NR¹⁵R¹⁶, and R¹⁵ and R¹⁶ are independently selected from the group consisting of H and —(C₁₋₃ alkyl).

In some embodiments, at least one R⁶ is —NR¹⁵R¹⁶, and R¹⁵ and R¹⁶ are independently selected from the group consisting of H and —(C₁₋₂ alkyl).

In some embodiments, at least one R⁶ is —NR¹⁵R¹⁶, and R¹⁵ and R¹⁶ are independently selected from the group consisting of H and methyl.

In some embodiments, at least one R⁶ is —NH₂.

In some embodiments, R⁶ is —NH₂.

In some embodiments, at least one R⁶ is —NHR¹⁶ and R¹⁶ is —(C₁₋₄ alkyl).

In some embodiments, at least one R⁶ is —NHR¹⁶ and R¹⁶ is —(C₁₋₃ alkyl).

In some embodiments, at least one R⁶ is —NHR¹⁶ and R¹⁶ is —(C₁₋₂ alkyl).

In some embodiments, R⁶ is —NHR¹⁶ and R¹⁶ is —(C₁₋₂ alkyl).

In some embodiments, at least one R⁶ is —NHR¹⁶ and R¹⁶ is —CH₂aryl optionally substituted with 1-2 (e.g., 1) R²¹.

In some embodiments, at least one R⁶ is —NHR¹⁶ and R¹⁶ is —CH₂phenyl optionally substituted with 1-2 (e.g., 1) R²¹.

In some embodiments, at least one R⁶ is —NHR⁶ and R¹⁶ is —CH₂carbocyclyl optionally substituted with 1-2 (e.g., 1) R²².

In some embodiments, at least one R⁶ is —NHR⁶ and R¹⁶ is —CH₂cyclopropyl optionally substituted with 1-2 (e.g., 1) R²².

In some embodiments, at least one R⁶ is —NHR¹⁶ and R¹⁶ is —CH₂cyclobutyl optionally substituted with 1-2 (e.g., 1) R²².

In some embodiments, at least one R⁶ is —NHR¹⁶ and R¹⁶ is —CH₂cyclopentyl optionally substituted with 1-2 (e.g., 1) R²².

In some embodiments, at least one R⁶ is —NHR¹⁶ and R¹⁶ is —CH₂cyclohexyl optionally substituted with 1-2 (e.g., 1) R²².

In some embodiments, at least one R⁶ is —(C₁₋₆ alkylene)NR¹⁷R¹⁸.

In some embodiments, at least one R⁶ is —(C₁₋₅ s alkylene)NR¹⁷R¹⁸.

In some embodiments, at least one R⁶ is —(C₁₋₄ alkylene)NR¹⁷R¹⁸.

In some embodiments, at least one R⁶ is —(C₁₋₃ alkylene)NR¹⁷R¹⁸.

In some embodiments, at least one R⁶ is —(C₁₋₂ alkylene)NR¹⁷R¹⁸.

In some embodiments, at least one R⁶ is —CH₂NR¹⁷R¹⁸.

In some embodiments, R⁶ is —CH₂NR¹⁷R¹⁸.

In some embodiments, at least one R⁶ is —CH₂NR¹⁷R¹⁸, and R¹⁷ and R¹⁸ are independently selected from the group consisting of H and —(C₁₋₆ alkyl).

In some embodiments, at least one R⁶ is —CH₂NR¹⁷R¹⁸, and R¹⁷ and R¹⁸ are independently selected from the group consisting of H and —(C₁₋₅ alkyl).

In some embodiments, at least one R⁶ is —CH₂NR¹⁷R¹⁸, and R¹⁷ and R¹⁸ are independently selected from the group consisting of H and —(C₁₋₄ alkyl).

In some embodiments, at least one R⁶ is —CH₂NR¹⁷R¹⁸, and R¹⁷ and R¹⁸ are independently selected from the group consisting of H and —(C₁₋₃ alkyl).

In some embodiments, at least one R⁶ is —CH₂NR¹⁷R¹⁸, and R¹⁷ and R¹⁸ are independently selected from the group consisting of H and —(C₁₋₂ alkyl).

In some embodiments, at least one R⁶ is —CH₂NR¹⁷R¹⁸, and R¹⁷ and R¹⁸ are independently selected from the group consisting of H and methyl.

In some embodiments, R⁶ is —CH₂NR¹⁷R¹⁸, and R¹⁷ and R¹⁸ are independently selected from the group consisting of H and methyl.

In some embodiments, at least one R⁶ is —CH₂NH₂.

In some embodiments, R⁶ is —CH₂NH₂.

In some embodiments, at least one R⁶ is —CH₂NMe₂.

In some embodiments, R⁶ is —CH₂NMe₂.

In some embodiments, at least one R⁶ is —CH₂NHR¹⁸ and R¹⁸ is —(C₁₋₄ alkyl).

In some embodiments, at least one R⁶ is —CH₂NHR¹⁸ and R¹⁸ is —(C₁₋₃ alkyl).

In some embodiments, at least one R⁶ is —CH₂NHR¹⁸ and R¹⁸ is —(C₁₋₂ alkyl).

In some embodiments, R⁶ is —CH₂NHR¹⁸ and R¹⁸ is —(C₁₋₂ alkyl).

In some embodiments, at least one R⁶ is —CH₂NHR¹⁸ and R¹⁸ is —CH₂aryl optionally substituted with 1-2 (e.g., 1) R²¹.

In some embodiments, at least one R⁶ is —CH₂NHR¹⁸ and R¹⁸ is —CH₂phenyl optionally substituted with 1-2 (e.g., 1) R²¹.

In some embodiments, R⁶ is —CH₂NHR¹⁸ and R¹⁸ is —CH₂phenyl optionally substituted with 1-2 (e.g., 1) R²².

In some embodiments, at least one R⁶ is —CH₂NHR¹⁸ and R¹⁸ is —CH₂carbocyclyl optionally substituted with 1-2 (e.g., 1) R²².

In some embodiments, at least one R⁶ is —CH₂NHR¹⁸ and R¹⁸ is —CH₂cyclopropyl optionally substituted with 1-2 (e.g., 1) R²².

In some embodiments, R⁶ is —CH₂NHR¹⁸ and R¹⁸ is —CH₂cyclopropyl optionally substituted with 1-2 (e.g., 1) R²².

In some embodiments, at least one R⁶ is —CH₂NHR¹⁸ and R¹⁸ is —CH₂cyclobutyl optionally substituted with 1-2 (e.g., 1) R²².

In some embodiments, R⁶ is —CH₂NHR¹⁸ and R¹⁸ is —CH₂cyclobutyl optionally substituted with 1-2 (e.g., 1) R²².

In some embodiments, at least one R⁶ is —CH₂NHR¹⁸ and R¹⁸ is —CH₂cyclopentyl optionally substituted with 1-2 (e.g., 1) R²².

In some embodiments, R⁶ is —CH₂NHR¹⁸ and R¹⁸ is —CH₂cyclopentyl optionally substituted with 1-2 (e.g., 1) R²².

In some embodiments, at least one R⁶ is —CH₂NHR¹⁸ and R¹⁸ is —CH₂cyclohexyl optionally substituted with 1-2 (e.g., 1) R²².

In some embodiments, R⁶ is —CH₂NHR¹⁸ and R¹⁸ is —CH₂cyclohexyl optionally substituted with 1-2 (e.g., 1) R²².

In some embodiments, at least one R⁶ is —OR²⁴.

In some embodiments, at least one R⁶ is —OH.

In some embodiments, R⁶ is —OH.

In some embodiments, at least one R⁶ is —(C₁₋₄ alkylene)OR²⁴.

In some embodiments, R⁶ is —(C₁₋₄ alkylene)OR²⁴.

In some embodiments, R⁶ is —(C₁₋₃ alkylene)OR²⁴.

In some embodiments, R⁶ is —(C₁₋₂ alkylene)OR²⁴.

In some embodiments, R⁶ is —CH₂OR²⁴.

In some embodiments, R⁶ is —CH₂OH.

In some embodiments, at least one R⁶ is —OR²⁴ and R²⁴ is —(C₁₋₃ alkyl).

In some embodiments, at least one R⁶ is —OR²⁴ and R²⁴ is —(C₁₋₂ alkyl).

In some embodiments, at least one R⁶ is —OMe.

In some embodiments, R⁶ is —OMe.

In some embodiments, at least one R⁶ is —OR²⁴ and R²⁴ is -heterocyclyl optionally substituted with 1-2 (e.g., 1) R²³.

In some embodiments, R⁶ is —OR²⁴ and R²⁴ is -heterocyclyl optionally substituted with 1-2 (e.g., 1) R²³.

In some embodiments, at least one R⁶ is —OR²⁴ and R²⁴ is -carbocyclyl optionally substituted with 1-2 (e.g., 1) R²².

In some embodiments, R⁶ is —OR²⁴ and R²⁴ is -carbocyclyl optionally substituted with 1-2 (e.g., 1) R²².

In some embodiments, at least one R⁶ is —OR²⁴ and R²⁴ is —(C₁₋₄ alkylene)heterocyclyl optionally substituted with 1-2 (e.g., 1) R²³.

In some embodiments, at least one R⁶ is —OR²⁴ and R²⁴ is —(CH₂CH₂)heterocyclyl optionally substituted with 1-2 (e.g., 1) R²³.

In some embodiments, R⁶ is —OR²⁴ and R²⁴ is —(CH₂CH₂)heterocyclyl optionally substituted with 1-2 (e.g., 1) R²³.

In some embodiments, at least one R⁶ is —OR²⁴ and R²⁴ is —(C₁₋₄ alkylene)NR²⁵R²⁶ and R²⁵ and R²⁶ are independently —(C₁₋₄ alkyl).

In some embodiments, at least one R⁶ is —OR²⁴ and R²⁴ is —(CH₂CH₂)NR²⁵R²⁶ and R²⁵ and R²⁶ are independently —(C₁₋₂ alkyl).

In some embodiments, at least one R⁶ is —OR²⁴ and R²⁴ is —(CH₂CH₂)NMe₂.

In some embodiments, R⁶ is —OR²⁴ and R²⁴ is —(CH₂CH₂)NMe₂.

In some embodiments, at least one R⁶ is —OR²⁴ and R²⁴ is —(C₁₋₄ alkylene)aryl optionally substituted with 1-2 (e.g., 1) R²¹, and each R²¹ is independently halide.

In some embodiments, at least one R⁶ is —OR²⁴ and R²⁴ is —(CH₂CH₂)phenyl optionally substituted with 1-2 (e.g., 1) R²¹, and each R²¹ is independently halide.

In some embodiments, R⁶ is —OR²⁴ and R²⁴ is —(CH₂CH₂)phenyl optionally substituted with 1-2 (e.g., 1) R²¹, and each R²¹ is independently halide.

In some embodiments, at least one R⁶ is —OR²⁴ and R²⁴ is —(CH₂)phenyl optionally substituted with 1-2 (e.g., 1) R²¹, and each R²¹ is independently halide.

In some embodiments, R⁶ is —OR²⁴ and R²⁴ is —(CH₂)phenyl optionally substituted with 1-2 (e.g., 1) R²¹, and each R²¹ is independently halide.

In some embodiments, each R⁷ is independently selected from the group consisting of —(C₁₋₄ alkyl), —(C₂₋₄ alkenyl), —(C₂₋₄ alkynyl), halide, —CF₃, and —CN.

In some embodiments, each R⁷ is independently selected from the group consisting of methyl, F, Cl, —CF₃, and —CN.

In some embodiments, at least one R⁷ is —(C₁₋₄ alkyl).

In some embodiments, at least one R⁷ is —(C₁₋₃ alkyl).

In some embodiments, at least one R⁷ is —(C₁₋₂ alkyl).

In some embodiments, at least one R⁷ is methyl.

In some embodiments, at least one R⁷ is halide.

In some embodiments, at least one R⁷ is F.

In some embodiments, each R⁸ is independently selected from the group consisting of —(C₁₋₆ alkyl), —(C₂₋₆ alkenyl), —(C₂₋₆ alkynyl), halide, —CF₃, —OCH₃, —CN, and —C(═O)R¹⁹.

In some embodiments, each R⁸ is independently selected from the group consisting of methyl, F, Cl, —CF₃, —OCH₃, —CN, and —C(═O)Me.

In some embodiments, at least one R⁸ is halide.

In some embodiments, at least one R⁸ is F.

In some embodiments, at least one R⁸ is —(C₁₋₄ alkyl).

In some embodiments, at least one R⁸ is —(C₁₋₃ alkyl).

In some embodiments, at least one R⁸ is —(C₁₋₂ alkyl).

In some embodiments, at least one R⁸ is methyl.

In some embodiments, R⁸ is methyl.

In some embodiments, at least one R⁸ is —C(O)(C₁₋₃ alkyl).

In some embodiments, at least one R⁸ is —C(═O)Me.

In some embodiments, R⁸ is —C(═O)Me.

In some embodiments, each R⁹ is independently selected from the group consisting of —(C₁₋₆ alkyl), —(C₂₋₆ alkenyl), —(C₂₋₆ alkynyl), halide, —CF₃, —CN, and —OCH₃.

In some embodiments, each R⁹ is independently selected from the group consisting of methyl, F, Cl, —CF₃, —CN, and —OCH₃.

In some embodiments, each R¹⁰ is independently selected from the group consisting of —(C₁₋₆ alkyl), —(C₂₋₆ alkenyl), —(C₂₋₆ alkynyl), halide, —CF₃, —CN, —(C₁₋₆ alkylene)_(p)NHSO₂R¹⁹, —(C₂₋₆ alkenylene)NHSO₂R¹⁹, —(C₂₋₆ alkynylene)NHSO₂R¹⁹, —NR¹⁵(C₁₋₆alkylene)NR¹⁵R¹⁶, —NR¹⁵ (C₂₋₆ alkenylene)NR¹⁵R¹⁶, —NR¹⁵ (C₂₋₆ alkynylene)NR¹⁵R¹⁶, —(C₁₋₆ alkylene)_(p)NR¹⁵R¹⁶, —(C₂₋₆ alkenylene)_(p)NR¹⁵R¹⁶, —(C₂₋₆ alkynylene)_(p)NR¹⁵R¹⁶, and —OR²⁷.

In some embodiments, each R¹¹ is independently selected from the group consisting of amino, —(C₁₋₄ alkyl), —(C₂₋₄ alkenyl), —(C₂₋₄ alkynyl), halide, —CF₃, and —CN.

In some embodiments, each R¹¹ is independently selected from the group consisting of amino, methyl, F, Cl, —CF₃, and —CN.

In some embodiments, each R¹² is independently selected from the group consisting of —(C₁₋₄ alkyl), —(C₂₋₄ alkenyl), —(C₂₋₄ alkynyl), halide, —CF₃, and —CN.

In some embodiments, each R¹² is independently selected from the group consisting of methyl, F, Cl, —CF₃, and —CN.

In some embodiments, each R¹³ is independently selected from the group consisting of —(C₁₋₄ alkyl), —(C₂₋₄ alkenyl), —(C₂₋₄ alkynyl), halide, —CF₃, and —CN.

In some embodiments, each R¹³ is independently selected from the group consisting of methyl, F, Cl, —CF₃, and —CN.

In some embodiments, each R¹⁴ is independently selected from the group consisting of —(C₁₋₉ alkyl), —(C₁₋₄ haloalkyl), —(C₂₋₉ alkenyl), —(C₂₋₉ alkynyl), -heteroaryl optionally substituted with 1-4 (e.g., 1-3, 1-2, 1) R²⁰, -aryl optionally substituted with 1-5 (e.g., 1-4, 1-3, 1-2, 1) R²¹, —CH₂aryl optionally substituted with 1-5 (e.g., 1-4, 1-3, 1-2, 1) R²¹, -carbocyclyl optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R²², —CH₂carbocyclyl optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R², —(C₁₋₄ alkylene)_(p)NR²⁵R²⁶, —(C₂₋₄ alkenylene)_(p)NR²⁵R²⁶, —(C₂₋₄ alkynylene)_(p)NR²⁵R²⁶, -heterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R²³, and —CH₂heterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R²³.

In some embodiments, each R¹⁵ is independently selected from the group consisting of H, —(C₁₋₆ alkyl), —(C₂₋₆ alkenyl), and —(C₂₋₆ alkynyl).

In some embodiments, each R¹⁶ is independently selected from the group consisting of H, —(C₁₋₆ alkyl), —(C₂₋₆ alkenyl), —(C₂₋₆ alkynyl), —CH₂aryl optionally substituted with 1-5 (e.g., 1-4, 1-3, 1-2, 1) R²¹, and —CH₂carbocyclyl optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R²².

In some embodiments, each R¹⁷ is independently selected from the group consisting of H, —(C₁₋₆ alkyl), —(C₂₋₆ alkenyl), and —(C₂₋₆ alkynyl).

In some embodiments, each R¹⁸ is independently selected from the group consisting of H, —(C₁₋₆ alkyl), —(C₂₋₆ alkenyl), —(C₂₋₆ alkynyl), —CH₂aryl optionally substituted with 1-5 (e.g., 1-4, 1-3, 1-2, 1) R²¹ and —CH₂carbocyclyl optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R²².

In some embodiments, each R¹⁹ is independently selected from the group consisting of —(C₁₋₆ alkyl), —(C₂₋₆ alkenyl), and —(C₂₋₆ alkynyl).

In some embodiments, each R²⁰ is independently selected from the group consisting of —(C₁₋₄ alkyl), —(C₂₋₄ alkenyl), —(C₂₋₄ alkynyl), halide, —CF₃, and —CN.

In some embodiments, each R²⁰ is independently selected from the group consisting of methyl, F, Cl, —CF₃, and —CN.

In some embodiments, each R²¹ is independently selected from the group consisting of —(C₁₋₄ alkyl), —(C₂₋₄ alkenyl), —(C₂₋₄ alkynyl), halide, —CF₃, and —CN.

In some embodiments, each R²¹ is independently selected from the group consisting of methyl, F, Cl, —CF₃, and —CN.

In some embodiments, each R²² is independently selected from the group consisting of —(C₁₋₄ alkyl), —(C₂₋₄ alkenyl), —(C₂₋₄ alkynyl), halide, —CF₃, and —CN.

In some embodiments, each R²² is independently selected from the group consisting of methyl, F, Cl, —CF₃, and —CN.

In some embodiments, each R²³ is independently selected from the group consisting of —(C₁₋₄ alkyl), —(C₂₋₄ alkenyl), —(C₂₋₄ alkynyl), halide, —CF₃, and —CN.

In some embodiments, each R²³ is independently selected from the group consisting of methyl, F, Cl, —CF₃, and —CN.

In some embodiments, R²⁴ is selected from the group consisting of H, —(C₁₋₆ alkyl), —(C₂₋₆ alkenyl), —(C₂₋₆ alkynyl), —(C₁₋₄ alkylene)_(p)heterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R²³, —(C₂₋₄ alkenylene)_(p)heterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R²³, —(C₂₋₄ alkynylene)_(p)heterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R²³, —(C₁₋₄ alkylene)_(p)carbocyclyl optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R²², —(C₂₋₄ alkenylene)_(p)carbocyclyl optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R²², —(C₂₋₄ alkynylene)_(p)carbocyclyl optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R², —(C₁₋₄ alkylene)_(p)aryl optionally substituted with 1-5 (e.g., 1-4, 1-3, 1-2, 1) R²¹, —(C₂₋₄ alkenylene)_(p)aryl optionally substituted with 1-5 (e.g., 1-4, 1-3, 1-2, 1) R²¹, —(C₂₋₄ alkynylene)_(p)aryl optionally substituted with 1-5 (e.g., 1-4, 1-3, 1-2, 1) R²¹, —(C₁₋₆ alkylene)_(p)NR²⁵R²⁶, —(C₂₋₄ alkenylene)_(p)NR²⁵R²⁶, and —(C₂₋₄ alkynylene)_(p)NR²⁵R²⁶.

In some embodiments, each R²⁵ is independently selected from the group consisting of H, —(C₁₋₆ alkyl), —(C₂₋₆ alkenyl), and —(C₂₋₆ alkynyl).

In some embodiments, each R²⁶ is independently selected from the group consisting of H, —(C₁₋₆ alkyl), —(C₂₋₄ alkenyl), and —(C₂₋₄ alkynyl).

In some embodiments, R²⁷ is selected from the group consisting of H, —(C₁₋₆ alkyl), —(C₂₋₆ alkenyl), —(C₂₋₆ alkynyl), —(C₁₋₄ alkylene)_(p)heterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R²³, —(C₂₋₄ alkenylene)_(p)heterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R²³, —(C₂₋₄ alkynylene)_(p)heterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R²³, —(C₁₋₆ alkylene)_(p)NR²⁵R²⁶, —(C₂₋₆ alkenylene)_(p)NR²⁵R²⁶, and —(C₂₋₆ alkynylene)_(p)NR²⁵R²⁶.

In some embodiments, each p is independently an integer of 0 or 1.

In some embodiments, p is 0.

In some embodiments, p is 1.

Illustrative compounds of Formula (I) are shown in Table 1.

TABLE 1

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

273

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670

671

672

673

674

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692

693

694

695

696

697

698

699

700

701

702

703

704

705

706

707

708

709

710

711

712

713

714

715

716

717

718

719

720

721

722

723

724

725

726

727

728

729

730

731

732

733

734

735

736

737

738

739

740

741

742

743

744

745

746

747

748

749

750

751

752

753

754

755

756

757

758

759

760

761

762

763

764

765

766

767

768

769

770

771

772

773

774

775

776

777

778

779

780

781

782

783

784

785

786

787

788

789

790

791

792

793

794

795

796

797

798

799

800

801

802

803

804

805

806

807

808

809

810

811

812

813

814

815

816

817

818

819

820

821

822

823

824

825

826

827

828

829

830

831

832

833

834

835

836

837

838

839

840

841

842

843

844

845

846

847

848

849

850

851

852

853

854

855

856

857

858

859

860

861

862

863

864

865

866

867

868

869

870

871

872

873

874

875

876

877

878

879

880

881

882

883

884

885

886

887

888

889

890

891

892

893

894

895

896

897

898

899

900

901

902

903

904

905

906

907

908

909

910

911

912

913

914

915

916

917

918

919

920

921

922

923

924

925

926

927

928

929

930

931

932

933

934

935

936

937

938

939

940

941

942

943

944

945

946

947

948

949

950

951

952

953

954

955

956

957

958

959

960

961

962

963

964

965

966

967

968

969

970

971

972

973

974

975

976

977

978

979

980

981

982

983

984

985

986

987

988

989

990

991

992

993

994

995

996

997

998

999

1000

1001

1002

1003

1004

1005

1006

1007

1008

1009

1010

1011

1012

1013

1014

1015

1016

1017

1018

1019

1020

1021

1022

1023

1024

1025

1026

1027

1028

1029

1030

1031

1032

1033

1034

1035

1036

1037

Administration and Pharmaceutical Compositions

Some embodiments include pharmaceutical compositions comprising: (a) a therapeutically effective amount of a compound provided herein, or its corresponding enantiomer, diastereoisomer or tautomer, or pharmaceutically acceptable salt; and (b) a pharmaceutically acceptable carrier.

The compounds provided herein may also be useful in combination (administered together or sequentially) with other known agents.

Non-limiting examples of diseases which can be treated with a combination of a compound of Formula (I) and other known agents are colorectal cancer, ovarian cancer, retinitis pigmentosa, macular degeneration, diabetic retinopathy, idiopathic pulmonary fibrosis/pulmonary fibrosis, and osteoarthritis.

In some embodiments, colorectal cancer can be treated with a combination of a compound of Formula (I) and one or more of the following drugs: 5-Fluorouracil (5-FU), which can be administered with the vitamin-like drug leucovorin (also called folinic acid); capecitabine (XELODA®), irinotecan (CAMPOSTAR®), oxaliplatin (ELOXATIN®). Examples of combinations of these drugs which could be further combined with a compound of Formula (I) are FOLFOX (5-FU, leucovorin, and oxaliplatin), FOLFIRI (5-FU, leucovorin, and irinotecan), FOLFOXIRI (leucovorin, 5-FU, oxaliplatin, and irinotecan) and CapeOx (Capecitabine and oxaliplatin). For rectal cancer, chemo with 5-FU or capecitabine combined with radiation may be given before surgery (neoadjuvant treatment).

In some embodiments, ovarian cancer can be treated with a combination of a compound of Formula (I) and one or more of the following drugs: Topotecan, Liposomal doxorubicin (DOXIL®), Gemcitabine (GEMZAR®), Cyclophosphamide (CYTOXAN®), Vinorelbine (NAVELBINE®), Ifosfamide (IFEX®), Etoposide (VP-16), Altretamine (HEXALEN®), Capecitabine (XELODA®), Irinotecan (CPT-11, CAMPTOSAR®), Melphalan, Pemetrexed (ALIMTA®) and Albumin bound paclitaxel (nab-paclitaxel, ABRAXANE®). Examples of combinations of these drugs which could be further combined with a compound of Formula (I) are TIP (paclitaxel [Taxol], ifosfamide, and cisplatin), VeIP (vinblastine, ifosfamide, and cisplatin) and VIP (etoposide [VP-16], ifosfamide, and cisplatin).

In some embodiments, a compound of Formula (I) can be used to treat cancer in combination with any of the following methods: (a) Hormone therapy such as aromatase inhibitors, LHRH [luteinizing hormone-releasing hormone] analogs and inhibitors, and others; (b) Ablation or embolization procedures such as radiofrequency ablation (RFA), ethanol (alcohol) ablation, microwave thermotherapy and cryosurgery (cryotherapy); (c) Chemotherapy using alkylating agents such as cisplatin and carboplatin, oxaliplatin, mechlorethamine, cyclophosphamide, chlorambucil and ifosfamide; (d) Chemotherapy using anti-metabolites such as azathioprine and mercaptopurine; (e) Chemotherapy using plant alkaloids and terpenoids such as vinca alkaloids (i.e. Vincristine, Vinblastine, Vinorelbine and Vindesine) and taxanes; (f) Chemotherapy using podophyllotoxin, etoposide, teniposide and docetaxel; (g) Chemotherapy using topoisomerase inhibitors such as irinotecan, topotecan, amsacrine, etoposide, etoposide phosphate, and teniposide; (h) Chemotherapy using cytotoxic antibiotics such as actinomycin, anthracyclines, doxorubicin, daunorubicin, valrubicin, idarubicin, epirubicin, bleomycin, plicamycin and mitomycin; (i) Chemotherapy using tyrosine-kinase inhibitors such as Imatinib mesylate (GLEEVEC®, also known as STI-571), Gefitinib (Iressa, also known as ZD1839), Erlotinib (marketed as TARCEVA®), Bortezomib (VELCADE®), tamoxifen, tofacitinib, crizotinib, Bcl-2 inhibitors (e.g. obatoclax in clinical trials, ABT-263, and Gossypol), PARP inhibitors (e.g. Iniparib, Olaparib in clinical trials), PI3K inhibitors (e.g. perifosine in a phase III trial), VEGF Receptor 2 inhibitors (e.g. Apatinib), AN-152, (AEZS-108), Braf inhibitors (e.g. vemurafenib, dabrafenib and LGX818), MEK inhibitors (e.g. trametinib and MEK162), CDK inhibitors, (e.g. PD-0332991), salinomycin and Sorafenib; (j) Chemotherapy using monoclonal antibodies such as Rituximab (marketed as MABTHERA® or RITUXAN®), Trastuzumab (Herceptin also known as ErbB2), Cetuximab (marketed as ERBITUX®), and Bevacizumab (marketed as AVASTIN®); and (k) radiation therapy.

In some embodiments, diabetic retinopathy can be treated with a combination of a compound of Formula (I) and one or more of the following natural supplements: Bilberry, Butcher's broom, Ginkgo, Grape seed extract, and Pycnogenol (Pine bark).

In some embodiments, idiopathic pulmonary fibrosis/pulmonary fibrosis can be treated with a combination of a compound of Formula (I) and one or more of the following drugs: pirfenidone (pirfenidone was approved for use in 2011 in Europe under the brand name Esbriet®), prednisone, azathioprine, N-acetylcysteine, interferon-γ 1b, bosentan (bosentan is currently being studied in patients with IPF, [The American Journal of Respiratory and Critical Care Medicine (2011), 184(1), 92-9]), Nintedanib (BIBF 1120 and Vargatef), QAX576 [British Journal of Pharmacology (2011), 163(1), 141-172], and anti-inflammatory agents such as corticosteroids.

In some embodiments, a compound of Formula (I) can be used to treat idiopathic pulmonary fibrosis/pulmonary fibrosis in combination with any of the following methods: oxygen therapy, pulmonary rehabilitation and surgery.

In some embodiments, a compound of Formula (I) can be used to treat osteoarthritis in combination with any of the following methods: (a) Nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, naproxen, aspirin and acetaminophen; (b) physical therapy; (c) injections of corticosteroid medications; (d) injections of hyaluronic acid derivatives (e.g. Hyalgan, Synvisc); (e) narcotics, like codeine; (f) in combination with braces and/or shoe inserts or any device that can immobilize or support your joint to help you keep pressure off it (e.g., splints, braces, shoe inserts or other medical devices); (g) realigning bones (osteotomy); (h) joint replacement (arthroplasty); and (i) in combination with a chronic pain class.

In some embodiments, macular degeneration can be treated with a combination of a compound of Formula (I) and one or more of the following drugs: Bevacizumab (Avastin®), Ranibizumab (Lucentis®), Pegaptanib (Macugen), Aflibercept (Eylea®), verteporfin (Visudyne®) in combination with photodynamic therapy (PDT) or with any of the following methods: (a) in combination with laser to destroy abnormal blood vessels (photocoagulation); and (b) in combination with increased vitamin intake of antioxidant vitamins and zinc.

In some embodiments, retinitis pigmentosa can be treated with a combination of a compound of Formula (I) and one or more of the following drugs: UF-021 (Ocuseva™), vitamin A palmitate and pikachurin or with any of the following methods: (a) with the Argus® II retinal implant; and (b) with stem cell and/or gene therapy.

Administration of the compounds disclosed herein or the pharmaceutically acceptable salts thereof can be via any of the accepted modes of administration, including, but not limited to, orally, subcutaneously, intravenously, intranasally, topically, transdermally, intraperitoneally, intramuscularly, intrapulmonarilly, vaginally, rectally, ontologically, neuro-otologically, intraocularly, subconjuctivally, via anterior eye chamber injection, intravitreally, intraperitoneally, intrathecally, intracystically, intrapleurally, via wound irrigation, intrabuccally, intra-abdominally, intra-articularly, intra-aurally, intrabronchially, intracapsularly, intrameningeally, via inhalation, via endotracheal or endobronchial instillation, via direct instillation into pulmonary cavities, intraspinally, intrasynovially, intrathoracically, via thoracostomy irrigation, epidurally, intratympanically, intracisternally, intravascularly, intraventricularly, intraosseously, via irrigation of infected bone, or via application as part of any admixture with a prosthetic devices. In some embodiments, the administration method includes oral or parenteral administration.

Compounds provided herein intended for pharmaceutical use may be administered as crystalline or amorphous products. Pharmaceutically acceptable compositions may include solid, semi-solid, liquid, solutions, colloidal, liposomes, emulsions, suspensions, complexes, coacervates and aerosols. Dosage forms, such as, e.g., tablets, capsules, powders, liquids, suspensions, suppositories, aerosols, implants, controlled release or the like. They may be obtained, for example, as solid plugs, powders, or films by methods such as precipitation, crystallization, milling, grinding, supercritical fluid processing, coacervation, complex coacervation, encapsulation, emulsification, complexation, freeze drying, spray drying, or evaporative drying. Microwave or radio frequency drying may be used for this purpose. The compounds can also be administered in sustained or controlled release dosage forms, including depot injections, osmotic pumps, pills (tablets and or capsules), transdermal (including electrotransport) patches, implants and the like, for prolonged and/or timed, pulsed administration at a predetermined rate.

The compounds can be administered either alone or in combination with a conventional pharmaceutical carrier, excipient or the like. Pharmaceutically acceptable excipients include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery systems (SEDDS) such as d-α-tocopherol polyethylene glycol 1000 succinate, surfactants used in pharmaceutical dosage forms such as Tweens, poloxamers or other similar polymeric delivery matrices, serum proteins, such as human serum albumin, buffer substances such as phosphates, tris, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium-chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethyl cellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, and wool fat. Cyclodextrins such as α-, β, and γ-cyclodextrin, or chemically modified derivatives such as hydroxyalkylcyclodextrins, including 2- and 3-hydroxypropyl-β-cyclodextrins, or other solubilized derivatives can also be used to enhance delivery of compounds described herein. Dosage forms or compositions containing a compound as described herein in the range of 0.005% to 100% with the balance made up from non-toxic carrier may be prepared. The contemplated compositions may contain 0.001%-100% of a compound provided herein, in one embodiment 0.1-95%, in another embodiment 75-85%, in a further embodiment 20-80%. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington: The Science and Practice of Pharmacy, 22^(nd) Edition (Pharmaceutical Press, London, UK. 2012).

In one embodiment, the compositions will take the form of a unit dosage form such as a pill or tablet and thus the composition may contain, along with a compound provided herein, a diluent such as lactose, sucrose, dicalcium phosphate, or the like; a lubricant such as magnesium stearate or the like; and a binder such as starch, gum acacia, polyvinylpyrrolidine, gelatin, cellulose, cellulose derivatives or the like. In another solid dosage form, a powder, marume, solution or suspension (e.g., in propylene carbonate, vegetable oils, PEG's, poloxamer 124 or triglycerides) is encapsulated in a capsule (gelatin or cellulose base capsule). Unit dosage forms in which one or more compounds provided herein or additional active agents are physically separated are also contemplated; e.g., capsules with granules (or tablets in a capsule) of each drug; two-layer tablets; two-compartment gel caps, etc. Enteric coated or delayed release oral dosage forms are also contemplated.

Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, etc. a compound provided herein and optional pharmaceutical adjuvants in a carrier (e.g., water, saline, aqueous dextrose, glycerol, glycols, ethanol or the like) to form a solution, colloid, liposome, emulsion, complexes, coacervate or suspension. If desired, the pharmaceutical composition can also contain minor amounts of nontoxic auxiliary substances such as wetting agents, emulsifying agents, co-solvents, solubilizing agents, pH buffering agents and the like (e.g., sodium acetate, sodium citrate, cyclodextrin derivatives, sorbitan monolaurate, triethanolamine acetate, triethanolamine oleate, and the like).

In some embodiments, the unit dosage of compounds of Formula (I) is about 0.25 mg/Kg to about 50 mg/Kg in humans.

In some embodiments, the unit dosage of compounds of Formula (I) is about 0.25 mg/Kg to about 20 mg/Kg in humans.

In some embodiments, the unit dosage of compounds of Formula (I) is about 0.50 mg/Kg to about 19 mg/Kg in humans.

In some embodiments, the unit dosage of compounds of Formula (I) is about 0.75 mg/Kg to about 18 mg/Kg in humans.

In some embodiments, the unit dosage of compounds of Formula (I) is about 1.0 mg/Kg to about 17 mg/Kg in humans.

In some embodiments, the unit dosage of compounds of Formula (I) is about 1.25 mg/Kg to about 16 mg/Kg in humans.

In some embodiments, the unit dosage of compounds of Formula (I) is about 1.50 mg/Kg to about 15 mg/Kg in humans.

In some embodiments, the unit dosage of compounds of Formula (I) is about 1.75 mg/Kg to about 14 mg/Kg in humans.

In some embodiments, the unit dosage of compounds of Formula (I) is about 2.0 mg/Kg to about 13 mg/Kg in humans.

In some embodiments, the unit dosage of compounds of Formula (I) is about 3.0 mg/Kg to about 12 mg/Kg in humans.

In some embodiments, the unit dosage of compounds of Formula (I) is about 4.0 mg/Kg to about 11 mg/Kg in humans.

In some embodiments, the unit dosage of compounds of Formula (I) is about 5.0 mg/Kg to about 10 mg/Kg in humans.

In some embodiments, the compositions are provided in unit dosage forms suitable for single administration.

In some embodiments, the compositions are provided in unit dosage forms suitable for twice a day administration.

In some embodiments, the compositions are provided in unit dosage forms suitable for three times a day administration.

Injectables can be prepared in conventional forms, either as liquid solutions, colloid, liposomes, complexes, coacervate or suspensions, as emulsions, or in solid forms suitable for reconstitution in liquid prior to injection. The percentage of a compound provided herein contained in such parenteral compositions is highly dependent on the specific nature thereof, as well as the activity of the compound and the needs of the patient. However, percentages of active ingredient of 0.01% to 10% in solution are employable, and could be higher if the composition is a solid or suspension, which could be subsequently diluted to the above percentages.

In some embodiments, the composition will comprise about 0.1-10% of the active agent in solution.

In some embodiments, the composition will comprise about 0.1-5% of the active agent in solution.

In some embodiments, the composition will comprise about 0.1-4% of the active agent in solution.

In some embodiments, the composition will comprise about 0.15-3% of the active agent in solution.

In some embodiments, the composition will comprise about 0.2-2% of the active agent in solution.

In some embodiments, the compositions are provided in dosage forms suitable for continuous dosage by intravenous infusion over a period of about 1-96 hours.

In some embodiments, the compositions are provided in dosage forms suitable for continuous dosage by intravenous infusion over a period of about 1-72 hours.

In some embodiments, the compositions are provided in dosage forms suitable for continuous dosage by intravenous infusion over a period of about 1-48 hours.

In some embodiments, the compositions are provided in dosage forms suitable for continuous dosage by intravenous infusion over a period of about 1-24 hours.

In some embodiments, the compositions are provided in dosage forms suitable for continuous dosage by intravenous infusion over a period of about 1-12 hours.

In some embodiments, the compositions are provided in dosage forms suitable for continuous dosage by intravenous infusion over a period of about 1-6 hours.

In some embodiments, these compositions can be administered by intravenous infusion to humans at doses of about 5 mg/m² to about 300 mg/m².

In some embodiments, these compositions can be administered by intravenous infusion to humans at doses of about 5 mg/m² to about 200 mg/m².

In some embodiments, these compositions can be administered by intravenous infusion to humans at doses of about 5 mg/m² to about 100 mg/m².

In some embodiments, these compositions can be administered by intravenous infusion to humans at doses of about 10 mg/m² to about 50 mg/m².

In some embodiments, these compositions can be administered by intravenous infusion to humans at doses of about 50 mg/m² to about 200 mg/m².

In some embodiments, these compositions can be administered by intravenous infusion to humans at doses of about 75 mg/m² to about 175 mg/m².

In some embodiments, these compositions can be administered by intravenous infusion to humans at doses of about 100 mg/m² to about 150 mg/m².

It is to be noted that concentrations and dosage values may also vary depending on the specific compound and the severity of the condition to be alleviated. It is to be further understood that for any particular patient, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed compositions.

In one embodiment, the compositions can be administered to the respiratory tract (including nasal and pulmonary) e.g., through a nebulizer, metered-dose inhalers, atomizer, mister, aerosol, dry powder inhaler, insufflator, liquid instillation or other suitable device or technique.

In some embodiments, aerosols intended for delivery to the nasal mucosa are provided for inhalation through the nose. For optimal delivery to the nasal cavities, inhaled particle sizes of about 5 to about 100 microns are useful, with particle sizes of about 10 to about 60 microns being preferred. For nasal delivery, a larger inhaled particle size may be desired to maximize impaction on the nasal mucosa and to minimize or prevent pulmonary deposition of the administered formulation. In some embodiments, aerosols intended for delivery to the lung are provided for inhalation through the nose or the mouth. For delivery to the lung, inhaled aerodynamic particle sizes of about less than 10 μm are useful (e.g., about 1 to about 10 microns). Inhaled particles may be defined as liquid droplets containing dissolved drug, liquid droplets containing suspended drug particles (in cases where the drug is insoluble in the suspending medium), dry particles of pure drug substance, drug substance incorporated with excipients, liposomes, emulsions, colloidal systems, coacervates, aggregates of drug nanoparticles, or dry particles of a diluent which contain embedded drug nanoparticles.

In some embodiments, compounds of Formula (I) disclosed herein intended for respiratory delivery (either systemic or local) can be administered as aqueous formulations, as non-aqueous solutions or suspensions, as suspensions or solutions in halogenated hydrocarbon propellants with or without alcohol, as a colloidal system, as emulsions, coacervates, or as dry powders. Aqueous formulations may be aerosolized by liquid nebulizers employing either hydraulic or ultrasonic atomization or by modified micropump systems (like the soft mist inhalers, the Aerodose® or the AERx® systems). Propellant-based systems may use suitable pressurized metered-dose inhalers (pMDIs). Dry powders may use dry powder inhaler devices (DPIs), which are capable of dispersing the drug substance effectively. A desired particle size and distribution may be obtained by choosing an appropriate device.

In some embodiments, the compositions of Formula (I) disclosed herein can be administered to the ear by various methods. For example, a round window catheter (e.g., U.S. Pat. Nos. 6,440,102 and 6,648,873) can be used.

Alternatively, formulations can be incorporated into a wick for use between the outer and middle ear (e.g., U.S. Pat. No. 6,120,484) or absorbed to collagen sponge or other solid support (e.g., U.S. Pat. No. 4,164,559).

If desired, formulations of the disclosure can be incorporated into a gel formulation (e.g., U.S. Pat. Nos. 4,474,752 and 6,911,211).

In some embodiments, compounds of Formula (I) disclosed herein intended for delivery to the ear can be administered via an implanted pump and delivery system through a needle directly into the middle or inner ear (cochlea) or through a cochlear implant stylet electrode channel or alternative prepared drug delivery channel such as but not limited to a needle through temporal bone into the cochlea.

Other options include delivery via a pump through a thin film coated onto a multichannel electrode or electrode with a specially imbedded drug delivery channel (pathways) carved into the thin film for this purpose. In other embodiments the acidic or basic solid compound of Formula (I) can be delivered from the reservoir of an external or internal implanted pumping system.

Formulations of the disclosure also can be administered to the ear by intratympanic injection into the middle ear, inner ear, or cochlea (e.g., U.S. Pat. No. 6,377,849 and Ser. No. 11/337,815).

Intratympanic injection of therapeutic agents is the technique of injecting a therapeutic agent behind the tympanic membrane into the middle and/or inner ear. In one embodiment, the formulations described herein are administered directly onto the round window membrane via transtympanic injection. In another embodiment, the ion channel modulating agent auris-acceptable formulations described herein are administered onto the round window membrane via a non-transtympanic approach to the inner ear. In additional embodiments, the formulation described herein is administered onto the round window membrane via a surgical approach to the round window membrane comprising modification of the crista fenestrae cochleae.

In some embodiments, the compounds of Formula (I) are formulated in rectal compositions such as enemas, rectal gels, rectal foams, rectal aerosols, suppositories, jelly suppositories, or retention enemas, containing conventional suppository bases such as cocoa butter or other glycerides, as well as synthetic polymers such as polyvinylpyrrolidone, PEG (like PEG ointments), and the like.

Suppositories for rectal administration of the drug (either as a solution, colloid, suspension or a complex) can be prepared by mixing a compound provided herein with a suitable non-irritating excipient that is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt or erode/dissolve in the rectum and release the compound. Such materials include cocoa butter, glycerinated gelatin, hydrogenated vegetable oils, poloxamers, mixtures of polyethylene glycols of various molecular weights and fatty acid esters of polyethylene glycol. In suppository forms of the compositions, a low-melting wax such as, but not limited to, a mixture of fatty acid glycerides, optionally in combination with cocoa butter, is first melted.

Solid compositions can be provided in various different types of dosage forms, depending on the physicochemical properties of the compound provided herein, the desired dissolution rate, cost considerations, and other criteria. In one of the embodiments, the solid composition is a single unit. This implies that one unit dose of the compound is comprised in a single, physically shaped solid form or article. In other words, the solid composition is coherent, which is in contrast to a multiple unit dosage form, in which the units are incoherent.

Examples of single units which may be used as dosage forms for the solid composition include tablets, such as compressed tablets, film-like units, foil-like units, wafers, lyophilized matrix units, and the like. In one embodiment, the solid composition is a highly porous lyophilized form. Such lyophilizates, sometimes also called wafers or lyophilized tablets, are particularly useful for their rapid disintegration, which also enables the rapid dissolution of the compound.

On the other hand, for some applications the solid composition may also be formed as a multiple unit dosage form as defined above. Examples of multiple units are powders, granules, microparticles, pellets, mini-tablets, beads, lyophilized powders, and the like. In one embodiment, the solid composition is a lyophilized powder. Such a dispersed lyophilized system comprises a multitude of powder particles, and due to the lyophilization process used in the formation of the powder, each particle has an irregular, porous microstructure through which the powder is capable of absorbing water very rapidly, resulting in quick dissolution. Effervescent compositions are also contemplated to aid the quick dispersion and absorption of the compound.

Another type of multiparticulate system which is also capable of achieving rapid drug dissolution is that of powders, granules, or pellets from water-soluble excipients which are coated with a compound provided herein so that the compound is located at the outer surface of the individual particles. In this type of system, the water-soluble low molecular weight excipient may be useful for preparing the cores of such coated particles, which can be subsequently coated with a coating composition comprising the compound and, for example, one or more additional excipients, such as a binder, a pore former, a saccharide, a sugar alcohol, a film-forming polymer, a plasticizer, or other excipients used in pharmaceutical coating compositions.

Also provided herein are kits. Typically, a kit includes one or more compounds or compositions as described herein. In certain embodiments, a kit can include one or more delivery systems, e.g., for delivering or administering a compound as provided herein, and directions for use of the kit (e.g., instructions for treating a patient). In another embodiment, the kit can include a compound or composition as described herein and a label that indicates that the contents are to be administered to a patient with cancer. In another embodiment, the kit can include a compound or composition as described herein and a label that indicates that the contents are to be administered to a patient with one or more of hepatocellular carcinoma, colon cancer, leukemia, lymphoma, sarcoma, ovarian cancer, diabetic retinopathy, pulmonary fibrosis, rheumatoid arthritis, sepsis, ankylosing spondylitis, psoriasis, scleroderma, mycotic and viral infections, bone and cartilage diseases, Alzheimer's disease, lung disease, bone/osteoporotic (wrist, spine, shoulder and hip) fractures, articular cartilage (chondral) defects, degenerative disc disease (or intervertebral disc degeneration), polyposis coli, bone density and vascular defects in the eye (Osteoporosis-pseudoglioma Syndrome, OPPG), familial exudative vitreoretinopathy, retinal angiogenesis, early coronary disease, tetra-amelia, Müllerian-duct regression and virilization, SERKAL syndrome, type II diabetes, Fuhrmann syndrome, Al-Awadi/Raas-Rothschild/Schinzel phocomelia syndrome, odonto-onycho-dermal dysplasia, obesity, split-hand/foot malformation, caudal duplication, tooth agenesis, Wilms tumor, skeletal dysplasia, focal dermal hypoplasia, autosomal recessive anonychia, neural tube defects, alpha-thalassemia (ATRX) syndrome, fragile X syndrome, ICF syndrome, Angelman syndrome, Prader-Willi syndrome, Beckwith-Wiedemann Syndrome, Norrie disease, and Rett syndrome.

Methods of Treatment

The compounds and compositions provided herein can be used as inhibitors and/or modulators of one or more components of the Wnt pathway, which may include one or more Wnt proteins, and thus can be used to treat a variety of disorders and diseases in which aberrant Wnt signaling is implicated, such as cancer and other diseases associated with abnormal angiogenesis, cellular proliferation, and cell cycling. Accordingly, the compounds and compositions provided herein can be used to treat cancer, to reduce or inhibit angiogenesis, to reduce or inhibit cellular proliferation, to correct a genetic disorder, and/or to treat a neurological condition/disorder/disease due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Non-limiting examples of diseases which can be treated with the compounds and compositions provided herein include a variety of cancers, diabetic retinopathy, pulmonary fibrosis, rheumatoid arthritis, scleroderma, mycotic and viral infections, bone and cartilage diseases, neurological conditions/diseases such as Alzheimer's disease, amyotrophic lateral sclerosis (ALS), motor neuron disease, multiple sclerosis or autism, lung disease, bone/osteoporotic (wrist, spine, shoulder and hip) fractures, polyposis coli, bone density and vascular defects in the eye (Osteoporosis-pseudoglioma Syndrome, OPPG), familial exudative vitreoretinopathy, retinal angiogenesis, early coronary disease, tetra-amelia, Müllerian-duct regression and virilization, SERKAL syndrome, type II diabetes, Fuhrmann syndrome, Al-Awadi/Raas-Rothschild/Schinzel phocomelia syndrome, odonto-onycho-dermal dysplasia, obesity, split-hand/foot malformation, caudal duplication, tooth agenesis, Wilms tumor, skeletal dysplasia, focal dermal hypoplasia, autosomal recessive anonychia, neural tube defects, alpha-thalassemia (ATRX) syndrome, fragile X syndrome, ICF syndrome, Angelman syndrome, Prader-Willi syndrome, Beckwith-Wiedemann Syndrome, Norrie disease and Rett syndrome.

The compounds and compositions described herein can be used to treat tendinopathy includes all tendon pathologies (tendinitis, tendinosis and paratenonitis) localized in and around the tendons and is characterized by pain, swelling and impaired performance due to the degeneration of the tendon's collagen in response tendon overuse, often referred to as tendinosis. Tendinopathy may be categorized into two histopathologic entities—tendonitis, which results from acute injury to the tendon accompanied by intratendinous inflammation, and more commonly, tendinosis, which is a degenerative response to repetitive microtrauma resulting from overuse. Tendinosis may be accompanied by paratenonitis, an inflammatory condition of the lining of the tendon.

With respect to cancer, the Wnt pathway is known to be constitutively activated in a variety of cancers including, for example, colon cancer, hepatocellular carcinoma, lung cancer, ovarian cancer, prostate cancer, pancreatic cancer and leukemias such as CML, CLL and T-ALL. Accordingly, the compounds and compositions described herein may be used to treat these cancers in which the Wnt pathway is constitutively activated. In certain embodiments, the cancer is chosen from hepatocellular carcinoma, colon cancer, leukemia, lymphoma, sarcoma and ovarian cancer.

Other cancers can also be treated with the compounds and compositions described herein.

More particularly, cancers that may be treated by the compounds, compositions and methods described herein include, but are not limited to, the following:

1) Breast cancers, including, for example ER⁺ breast cancer, ER breast cancer, her2⁻ breast cancer, her2⁺ breast cancer, stromal tumors such as fibroadenomas, phyllodes tumors, and sarcomas, and epithelial tumors such as large duct papillomas; carcinomas of the breast including in situ (noninvasive) carcinoma that includes ductal carcinoma in situ (including Paget's disease) and lobular carcinoma in situ, and invasive (infiltrating) carcinoma including, but not limited to, invasive ductal carcinoma, invasive lobular carcinoma, medullary carcinoma, colloid (mucinous) carcinoma, tubular carcinoma, and invasive papillary carcinoma; and miscellaneous malignant neoplasms. Further examples of breast cancers can include luminal A, luminal B, basal A, basal B, and triple negative breast cancer, which is estrogen receptor negative (ER⁻), progesterone receptor negative, and her2 negative (her2⁻). In some embodiments, the breast cancer may have a high risk Oncotype score.

2) Cardiac cancers, including, for example sarcoma, e.g., angiosarcoma, fibrosarcoma, rhabdomyosarcoma, and liposarcoma myxoma; rhabdomyoma; fibroma lipoma and teratoma.

3) Lung cancers, including, for example, bronchogenic carcinoma, e.g., squamous cell, undifferentiated small cell, undifferentiated large cell, and adenocarcinoma alveolar and bronchiolar carcinoma; bronchial adenoma; sarcoma; lymphoma; chondromatous hamartoma and mesothelioma.

4) Gastrointestinal cancer, including, for example, cancers of the esophagus, e.g., squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, and lymphoma; cancers of the stomach, e.g., carcinoma, lymphoma, and leiomyosarcoma cancers of the pancreas, e.g., ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, and vipoma; cancers of the small bowel, e.g., adenocarcinoma, lymphoma, carcinoid tumors, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, and fibroma; cancers of the large bowel, e.g., adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, and leiomyoma.

5) Genitourinary tract cancers, including, for example, cancers of the kidney, e.g., adenocarcinoma, Wilm's tumor (nephroblastoma), lymphoma, and leukemia; cancers of the bladder and urethra, e.g., squamous cell carcinoma, transitional cell carcinoma, and adenocarcinoma; cancers of the prostate, e.g., adenocarcinoma, and sarcoma; cancer of the testis, e.g., seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, and lipoma.

6) Liver cancers, including, for example, hepatoma, e.g., hepatocellular carcinoma; cholangiocarcinoma; hepatoblastoma; angiosarcoma; hepatocellular adenoma; and hemangioma.

7) Bone cancers, including, for example, osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochrondroma (osteocartilaginous exostoses), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma and giant cell tumors.

8) Nervous system cancers, including, for example, cancers of the skull, e.g., osteoma, hemangioma, granuloma, xanthoma, and osteitis deformans; cancers of the meninges, e.g., meningioma, meningiosarcoma, and gliomatosis; cancers of the brain, e.g., astrocytoma, medulloblastoma, glioma, ependymoma, germinoma (pinealoma), glioblastoma multiform, oligodendroglioma, schwannoma, retinoblastoma, and congenital tumors; and cancers of the spinal cord, e.g., neurofibroma, meningioma, glioma, and sarcoma.

9) Gynecological cancers, including, for example, cancers of the uterus, e.g., endometrial carcinoma; cancers of the cervix, e.g., cervical carcinoma, and pre tumor cervical dysplasia; cancers of the ovaries, e.g., ovarian carcinoma, including serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma, granulosa theca cell tumors, Sertoli Leydig cell tumors, dysgerminoma, and malignant teratoma; cancers of the vulva, e.g., squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, and melanoma; cancers of the vagina, e.g., clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma, and embryonal rhabdomyosarcoma; and cancers of the fallopian tubes, e.g., carcinoma.

10) Hematologic cancers, including, for example, cancers of the blood, e.g., acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple myeloma, and myelodysplastic syndrome, Hodgkin's lymphoma, non-Hodgkin's lymphoma (malignant lymphoma) and Waldenstrbm's macroglobulinemia.

11) Skin cancers and skin disorders, including, for example, malignant melanoma and metastatic melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, keloids, and scleroderma.

12) Adrenal gland cancers, including, for example, neuroblastoma.

Cancers may be solid tumors that may or may not be metastatic. Cancers may also occur, as in leukemia, as a diffuse tissue. Thus, the term “tumor cell,” as provided herein, includes a cell afflicted by any one of the above identified disorders.

A method of treating cancer using a compound or composition as described herein may be combined with existing methods of treating cancers, for example by chemotherapy, irradiation, or surgery (e.g., oophorectomy). In some embodiments, a compound or composition can be administered before, during, or after another anticancer agent or treatment.

The compounds and compositions described herein can be used as anti-angiogenesis agents and as agents for modulating and/or inhibiting the activity of protein kinases, thus providing treatments for cancer and other diseases associated with cellular proliferation mediated by protein kinases. For example, the compounds described herein can inhibit the activity of one or more kinases. Accordingly, provided herein is a method of treating cancer or preventing or reducing angiogenesis through kinase inhibition.

In addition, and including treatment of cancer, the compounds and compositions described herein can function as cell-cycle control agents for treating proliferative disorders in a patient. Disorders associated with excessive proliferation include, for example, cancers, scleroderma, immunological disorders involving undesired proliferation of leukocytes, and restenosis and other smooth muscle disorders. Furthermore, such compounds may be used to prevent de-differentiation of post-mitotic tissue and/or cells.

Diseases or disorders associated with uncontrolled or abnormal cellular proliferation include, but are not limited to, the following:

-   -   a variety of cancers, including, but not limited to, carcinoma,         hematopoietic tumors of lymphoid lineage, hematopoietic tumors         of myeloid lineage, tumors of mesenchymal origin, tumors of the         central and peripheral nervous system and other tumors including         melanoma, seminoma and Kaposi's sarcoma.     -   a disease process which features abnormal cellular         proliferation, e.g., benign prostatic hyperplasia, familial         adenomatosis polyposis, neurofibromatosis, atherosclerosis,         arthritis, glomerulonephritis, restenosis following angioplasty         or vascular surgery, inflammatory bowel disease, transplantation         rejection, endotoxic shock, and fungal infections. Fibrotic         disorders such as skin fibrosis; scleroderma; progressive         systemic fibrosis; lung fibrosis; muscle fibrosis; kidney         fibrosis; glomerulosclerosis; glomerulonephritis; hypertrophic         scar formation; uterine fibrosis; renal fibrosis; cirrhosis of         the liver, liver fibrosis; fatty liver disease (FLD); adhesions,         such as those occurring in the abdomen, pelvis, spine or         tendons; chronic obstructive pulmonary disease; fibrosis         following myocardial infarction; pulmonary fibrosis; fibrosis         and scarring associated with diffuse/interstitial lung disease;         central nervous system fibrosis, such as fibrosis following         stroke; fibrosis associated with neuro-degenerative disorders         such as Alzheimer's Disease or multiple sclerosis; fibrosis         associated with proliferative vitreoretinopathy (PVR);         restenosis; endometriosis; ischemic disease and radiation         fibrosis.     -   defective apoptosis-associated conditions, such as cancers         (including but not limited to those types mentioned herein),         viral infections (including but not limited to herpesvirus,         poxvirus, Epstein-Barr virus, Sindbis virus and adenovirus),         prevention of AIDS development in HIV-infected individuals,         autoimmune diseases (including but not limited to systemic lupus         erythematosus, rheumatoid arthritis, sepsis, ankylosing         spondylitis, psoriasis, scleroderma, autoimmune mediated         glomerulonephritis, inflammatory bowel disease and autoimmune         diabetes mellitus), neuro-degenerative disorders (including but         not limited to Alzheimer's disease, lung disease, amyotrophic         lateral sclerosis, retinitis pigmentosa, Parkinson's disease,         AIDS-related dementia, spinal muscular atrophy and cerebellar         degeneration), myelodysplastic syndromes, aplastic anemia,         ischemic injury associated with myocardial infarctions, stroke         and reperfusion injury, arrhythmia, atherosclerosis,         toxin-induced or alcohol related liver diseases, hematological         diseases (including but not limited to chronic anemia and         aplastic anemia), degenerative diseases of the musculoskeletal         system (including but not limited to osteoporosis and         arthritis), tendinopathies such as tendinitis and tendinosis,         aspirin-sensitive rhinosinusitis, cystic fibrosis, multiple         sclerosis, kidney diseases and cancer pain.     -   genetic diseases due to mutations in Wnt signaling components,         such as polyposis coli, bone density and vascular defects in the         eye (Osteoporosis-pseudoglioma Syndrome, OPPG), familial         exudative vitreoretinopathy, retinal angiogenesis, early         coronary disease, tetra-amelia, Müllerian-duct regression and         virilization, SERKAL syndrome, type II diabetes, Fuhrmann         syndrome, Al-Awadi/Raas-Rothschild/Schinzel phocomelia syndrome,         odonto-onycho-dermal dysplasia, obesity, split-hand/foot         malformation, caudal duplication, tooth agenesis, Wilms tumor,         skeletal dysplasia, focal dermal hypoplasia, autosomal recessive         anonychia, neural tube defects, alpha-thalassemia (ATRX)         syndrome, fragile X syndrome, ICF syndrome, Angelman syndrome,         Prader-Willi syndrome, Beckwith-Wiedemann Syndrome, Norrie         disease and Rett syndrome.

The compounds and compositions described herein can be used to treat neurological conditions, disorders and/or diseases caused by dysfunction in the Wnt signaling pathway. Non-limiting examples of neurological conditions/disorders/diseases which can be treated with the compounds and compositions provided herein include Alzheimer's disease, aphasia, apraxia, arachnoiditis, ataxia telangiectasia, attention deficit hyperactivity disorder, auditory processing disorder, autism, alcoholism, Bell's palsy, bipolar disorder, brachial plexus injury, Canavan disease, carpal tunnel syndrome, causalgia, central pain syndrome, central pontine myelinolysis, centronuclear myopathy, cephalic disorder, cerebral aneurysm, cerebral arteriosclerosis, cerebral atrophy, cerebral gigantism, cerebral palsy, cerebral vasculitis, cervical spinal stenosis, Charcot-Marie-Tooth disease, Chiari malformation, chronic fatigue syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), chronic pain, Coffin-Lowry syndrome, complex regional pain syndrome, compression neuropathy, congenital facial diplegia, corticobasal degeneration, cranial arteritis, craniosynostosis, Creutzfeldt-Jakob disease, cumulative trauma disorder, Cushing's syndrome, cytomegalic inclusion body disease (CIBD), Dandy-Walker syndrome, Dawson disease, de Morsier's syndrome, Dejerine-Klumpke palsy, Dejerine-Sottas disease, delayed sleep phase syndrome, dementia, dermatomyositis, developmental dyspraxia, diabetic neuropathy, diffuse sclerosis, Dravet syndrome, dysautonomia, dyscalculia, dysgraphia, dyslexia, dystonia, empty sella syndrome, encephalitis, encephalocele, encephalotrigeminal angiomatosis, encopresis, epilepsy, Erb's palsy, erythromelalgia, essential tremor, Fabry's disease, Fahr's syndrome, familial spastic paralysis, febrile seizure, Fisher syndrome, Friedreich's ataxia, fibromyalgia, Foville's syndrome, Gaucher's disease, Gerstmann's syndrome, giant cell arteritis, giant cell inclusion disease, globoid cell leukodystrophy, gray matter heterotopia, Guillain-Barré syndrome, HTLV-1 associated myelopathy, Hallervorden-Spatz disease, hemifacial spasm, hereditary spastic paraplegia, heredopathia atactica polyneuritiformis, herpes zoster oticus, herpes zoster, Hirayama syndrome, holoprosencephaly, Huntington's disease, hydranencephaly, hydrocephalus, hypercortisolism, hypoxia, immune-mediated encephalomyelitis, inclusion body myositis, incontinentia pigmenti, infantile phytanic acid storage disease, infantile Refsum disease, infantile spasms, inflammatory myopathy, intracranial cyst, intracranial hypertension, Joubert syndrome, Karak syndrome, Kearns-Sayre syndrome, Kennedy disease, Kinsbourne syndrome, Klippel Feil syndrome, Krabbe disease, Kugelberg-Welander disease, kuru, Lafora disease, Lambert-Eaton myasthenic syndrome, Landau-Kleffner syndrome, lateral medullary (Wallenberg) syndrome, Leigh's disease, Lennox-Gastaut syndrome, Lesch-Nyhan syndrome, leukodystrophy, Lewy body dementia, lissencephaly, locked-in syndrome, Lou Gehrig's disease, lumbar disc disease, lumbar spinal stenosis, Lyme disease, Machado-Joseph disease (Spinocerebellar ataxia type 3), macrencephaly, macropsia, megalencephaly, Melkersson-Rosenthal syndrome, Meniere's disease, meningitis, Menkes disease, metachromatic leukodystrophy, microcephaly, micropsia, Miller Fisher syndrome, misophonia, mitochondrial myopathy, Mobius syndrome, monomelic amyotrophy, motor neuron disease, motor skills disorder, Moyamoya disease, mucopolysaccharidoses, multi-infarct dementia, multifocal motor neuropathy, multiple sclerosis, multiple system atrophy, muscular dystrophy, myalgic encephalomyelitis, myasthenia gravis, myelinoclastic diffuse sclerosis, myoclonic Encephalopathy of infants, myoclonus, myopathy, myotubular myopathy, myotonia congenital, narcolepsy, neurofibromatosis, neuroleptic malignant syndrome, lupus erythematosus, neuromyotonia, neuronal ceroid lipofuscinosis, Niemann-Pick disease, O'Sullivan-McLeod syndrome, occipital Neuralgia, occult Spinal Dysraphism Sequence, Ohtahara syndrome, olivopontocerebellar atrophy, opsoclonus myoclonus syndrome, optic neuritis, orthostatic hypotension, palinopsia, paresthesia, Parkinson's disease, paramyotonia congenita, paraneoplastic diseases, paroxysmal attacks, Parry-Romberg syndrome, Pelizaeus-Merzbacher disease, periodic paralyses, peripheral neuropathy, photic sneeze reflex, phytanic acid storage disease, Pick's disease, polymicrogyria (PMG), polymyositis, porencephaly, post-polio syndrome, postherpetic neuralgia (PHN), postural hypotension, Prader-Willi syndrome, primary lateral sclerosis, prion diseases, progressive hemifacial atrophy, progressive multifocal leukoencephalopathy, progressive supranuclear palsy, pseudotumor cerebri, Ramsay Hunt syndrome type I, Ramsay Hunt syndrome type II, Ramsay Hunt syndrome type III, Rasmussen's encephalitis, reflex neurovascular dystrophy, Refsum disease, restless legs syndrome, retrovirus-associated myelopathy, Rett syndrome, Reye's syndrome, rhythmic movement disorder, Romberg syndrome, Saint Vitus dance, Sandhoffdisease, schizophrenia, Schilder's disease, schizencephaly, sensory integration dysfunction, septo-optic dysplasia, Shy-Drager syndrome, Sjögren's syndrome, snatiation, Sotos syndrome, spasticity, spina bifida, spinal cord tumors, spinal muscular atrophy, spinocerebellar ataxia, Steele-Richardson-Olszewski syndrome, Stiff-person syndrome, stroke, Sturge-Weber syndrome, subacute sclerosing panencephalitis, subcortical arteriosclerotic encephalopathy, superficial siderosis, Sydenham's chorea, syncope, synesthesia, syringomyelia, tarsal tunnel syndrome, tardive dyskinesia, tardive dysphrenia, Tarlov cyst, Tay-Sachs disease, temporal arteritis, tetanus, tethered spinal cord syndrome, Thomsen disease, thoracic outlet syndrome, tic douloureux, Todd's paralysis, Tourette syndrome, toxic encephalopathy, transient ischemic attack, transmissible spongiform encephalopathies, transverse myelitis, tremor, trigeminal neuralgia, tropical spastic paraparesis, trypanosomiasis, tuberous sclerosis, ubisiosis, Von Hippel-Lindau disease (VHL), Viliuisk Encephalomyelitis (VE), Wallenberg's syndrome, Werdnig, Hoffman disease, west syndrome, Williams syndrome, Wilson's disease and Zellweger syndrome.

The compounds and compositions may also be useful in the inhibition of the development of invasive cancer, tumor angiogenesis and metastasis.

In some embodiments, the disclosure provides a method for treating a disease or disorder associated with aberrant cellular proliferation by administering to a patient in need of such treatment an effective amount of one or more of the compounds of Formula (I), in combination (simultaneously or sequentially) with at least one other agent.

In some embodiments, the disclosure provides a method of treating or ameliorating in a patient a disorder or disease selected from the group consisting of: cancer, pulmonary fibrosis, idiopathic pulmonary fibrosis (IPF), degenerative disc disease, bone/osteoporotic fractures, bone or cartilage disease, and osteoarthritis, the method comprising administering to the patient a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof.

In some embodiments, the pharmaceutical composition comprises a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

In some embodiments, the method of treats a disorder or disease in which aberrant Wnt signaling is implicated in a patient, the method comprises administering to the patient a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

In some embodiments, the disorder or disease is cancer.

In some embodiments, the disorder or disease is systemic inflammation.

In some embodiments, the disorder or disease is metastatic melanoma.

In some embodiments, the disorder or disease is fatty liver disease.

In some embodiments, the disorder or disease is liver fibrosis.

In some embodiments, the disorder or disease is tendon regeneration.

In some embodiments, the disorder or disease is diabetes.

In some embodiments, the disorder or disease is degenerative disc disease.

In some embodiments, the disorder or disease is osteoarthritis.

In some embodiments, the disorder or disease is diabetic retinopathy.

In some embodiments, the disorder or disease is pulmonary fibrosis.

In some embodiments, the disorder or disease is idiopathic pulmonary fibrosis (IPF).

In some embodiments, the disorder or disease is degenerative disc disease.

In some embodiments, the disorder or disease is rheumatoid arthritis.

In some embodiments, the disorder or disease is scleroderma.

In some embodiments, the disorder or disease is a mycotic or viral infection.

In some embodiments, the disorder or disease is a bone or cartilage disease.

In some embodiments, the disorder or disease is Alzheimer's disease.

In some embodiments, the disorder or disease is osteoarthritis.

In some embodiments, the disorder or disease is lung disease.

In some embodiments, the disorder or disease is tendinitis.

In some embodiments, the disorder or disease is tendinosis.

In some embodiments, the disorder or disease is paratenonitis.

In some embodiments, the disorder or disease is degeneration of the tendon's collagen.

In some embodiments, the disorder or disease is tendinopathy.

In some embodiments, the disorder or disease is a genetic disease caused by mutations in Wnt signaling components, wherein the genetic disease is selected from: polyposis coli, osteoporosis-pseudoglioma syndrome, familial exudative vitreoretinopathy, retinal angiogenesis, early coronary disease, tetra-amelia syndrome, Müllerian-duct regression and virilization, SERKAL syndrome, diabetes mellitus type 2, Fuhrmann syndrome, Al-Awadi/Raas-Rothschild/Schinzel phocomelia syndrome, odonto-onycho-dermal dysplasia, obesity, split-hand/foot malformation, caudal duplication syndrome, tooth agenesis, Wilms tumor, skeletal dysplasia, focal dermal hypoplasia, autosomal recessive anonychia, neural tube defects, alpha-thalassemia (ATRX) syndrome, fragile X syndrome, ICF syndrome, Angelman syndrome, Prader-Willi syndrome, Beckwith-Wiedemann Syndrome, Norrie disease and Rett syndrome.

In some embodiments, the patient is a human.

In some embodiments, the cancer is chosen from: hepatocellular carcinoma, colon cancer, breast cancer, pancreatic cancer, chronic myeloid leukemia (CML), chronic myelomonocytic leukemia, chronic lymphocytic leukemia (CLL), acute myeloid leukemia, acute lymphocytic leukemia, Hodgkin lymphoma, lymphoma, sarcoma and ovarian cancer.

In some embodiments, the cancer is chosen from: lung cancer—non-small cell, lung cancer—small cell, multiple myeloma, nasopharyngeal cancer, neuroblastoma, osteosarcoma, penile cancer, pituitary tumors, prostate cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, skin cancer—basal and squamous cell, skin cancer—melanoma, small intestine cancer, stomach (gastric) cancers, testicular cancer, thymus cancer, thyroid cancer, uterine sarcoma, vaginal cancer, vulvar cancer, laryngeal or hypopharyngeal cancer, kidney cancer, Kaposi sarcoma, gestational trophoblastic disease, gastrointestinal stromal tumor, gastrointestinal carcinoid tumor, gallbladder cancer, eye cancer (melanoma and lymphoma), Ewing tumor, esophagus cancer, endometrial cancer, colorectal cancer, cervical cancer, brain or spinal cord tumor, bone metastasis, bone cancer, bladder cancer, bile duct cancer, anal cancer and adrenal cortical cancer.

In some embodiments, the cancer is hepatocellular carcinoma.

In some embodiments, the cancer is colon cancer.

In some embodiments, the cancer is colorectal cancer.

In some embodiments, the cancer is breast cancer.

In some embodiments, the cancer is pancreatic cancer.

In some embodiments, the cancer is chronic myeloid leukemia (CML).

In some embodiments, the cancer is chronic myelomonocytic leukemia.

In some embodiments, the cancer is chronic lymphocytic leukemia (CLL).

In some embodiments, the cancer is acute myeloid leukemia.

In some embodiments, the cancer is acute lymphocytic leukemia.

In some embodiments, the cancer is Hodgkin lymphoma.

In some embodiments, the cancer is lymphoma.

In some embodiments, the cancer is sarcoma.

In some embodiments, the cancer is ovarian cancer.

In some embodiments, the cancer is lung cancer—non-small cell.

In some embodiments, the cancer is lung cancer—small cell.

In some embodiments, the cancer is multiple myeloma.

In some embodiments, the cancer is nasopharyngeal cancer.

In some embodiments, the cancer is neuroblastoma.

In some embodiments, the cancer is osteosarcoma.

In some embodiments, the cancer is penile cancer.

In some embodiments, the cancer is pituitary tumors.

In some embodiments, the cancer is prostate cancer.

In some embodiments, the cancer is retinoblastoma.

In some embodiments, the cancer is rhabdomyosarcoma.

In some embodiments, the cancer is salivary gland cancer.

In some embodiments, the cancer is skin cancer—basal and squamous cell.

In some embodiments, the cancer is skin cancer—melanoma.

In some embodiments, the cancer is small intestine cancer.

In some embodiments, the cancer is stomach (gastric) cancers.

In some embodiments, the cancer is testicular cancer.

In some embodiments, the cancer is thymus cancer.

In some embodiments, the cancer is thyroid cancer.

In some embodiments, the cancer is uterine sarcoma.

In some embodiments, the cancer is vaginal cancer.

In some embodiments, the cancer is vulvar cancer.

In some embodiments, the cancer is Wilms tumor.

In some embodiments, the cancer is laryngeal or hypopharyngeal cancer.

In some embodiments, the cancer is kidney cancer.

In some embodiments, the cancer is Kaposi sarcoma.

In some embodiments, the cancer is gestational trophoblastic disease.

In some embodiments, the cancer is gastrointestinal stromal tumor.

In some embodiments, the cancer is gastrointestinal carcinoid tumor.

In some embodiments, the cancer is gallbladder cancer.

In some embodiments, the cancer is eye cancer (melanoma and lymphoma).

In some embodiments, the cancer is Ewing tumor.

In some embodiments, the cancer is esophagus cancer.

In some embodiments, the cancer is endometrial cancer.

In some embodiments, the cancer is colorectal cancer.

In some embodiments, the cancer is cervical cancer.

In some embodiments, the cancer is brain or spinal cord tumor.

In some embodiments, the cancer is bone metastasis.

In some embodiments, the cancer is bone cancer.

In some embodiments, the cancer is bladder cancer.

In some embodiments, the cancer is bile duct cancer.

In some embodiments, the cancer is anal cancer.

In some embodiments, the cancer is adrenal cortical cancer.

In some embodiments, the disorder or disease is a neurological condition, disorder or disease, wherein the neurological condition/disorder/disease is selected from: Alzheimer's disease, frontotemporal dementias, dementia with lewy bodies, prion diseases, Parkinson's disease, Huntington's disease, progressive supranuclear palsy, corticobasal degeneration, multiple system atrophy, amyotrophic lateral sclerosis (ALS), inclusion body myositis, autism, degenerative myopathies, diabetic neuropathy, other metabolic neuropathies, endocrine neuropathies, orthostatic hypotension, multiple sclerosis and Charcot-Marie-Tooth disease.

In some embodiments, the compound of Formula (I) inhibits one or more proteins in the Wnt pathway.

In some embodiments, the compound of Formula (I) inhibits signaling induced by one or more Wnt proteins.

In some embodiments, the Wnt proteins are chosen from: WNT1, WNT2, WNT2B, WNT3, WNT3A, WNT4. WNT5A, WNT5B, WNT6, WNT7A, WNT7B, WNT8A, WNT8B, WNT9A, WNT9B, WNT10A, WNT10B, WNT11, and WNT16.

In some embodiments, the compound of Formula (I) inhibits a kinase activity.

In some embodiments, the method treats a disease or disorder mediated by the Wnt pathway in a patient, the method comprises administering to the patient a therapeutically effective amount of a compound (or compounds) of Formula (I), or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound of Formula (I) inhibits one or more Wnt proteins.

In some embodiments, the method treats a disease or disorder mediated by kinase activity in a patient, the method comprises administering to the patient a therapeutically effective amount of a compound (or compounds) of Formula (I), or a pharmaceutically acceptable salt thereof.

In some embodiments, the disease or disorder comprises tumor growth, cell proliferation, or angiogenesis.

In some embodiments, the method inhibits the activity of a protein kinase receptor, the method comprises contacting the receptor with an effective amount of a compound (or compounds) of Formula (I), or a pharmaceutically acceptable salt thereof.

In some embodiments, the method treats a disease or disorder associated with aberrant cellular proliferation in a patient; the method comprises administering to the patient a therapeutically effective amount of a compound (or compounds) of Formula (I), or a pharmaceutically acceptable salt thereof.

In some embodiments, the method prevents or reduces angiogenesis in a patient; the method comprises administering to the patient a therapeutically effective amount of a compound (or compounds) of Formula (I), or a pharmaceutically acceptable salt thereof.

In some embodiments, the method prevents or reduces abnormal cellular proliferation in a patient; the method comprises administering to the patient a therapeutically effective amount of a compound (or compounds) of Formula (I), or a pharmaceutically acceptable salt thereof.

In some embodiments, the method treats a disease or disorder associated with aberrant cellular proliferation in a patient, the method comprises administering to the patient a pharmaceutical composition comprising one or more of the compounds of claim 1 in combination with a pharmaceutically acceptable carrier and one or more other agents.

Moreover, the compounds and compositions, for example, as inhibitors of the cyclin-dependent kinases (CDKs), can modulate the level of cellular RNA and DNA synthesis and therefore are expected to be useful in the treatment of viral infections such as HIV, human papilloma virus, herpes virus, Epstein-Barr virus, adenovirus, Sindbis virus, pox virus and the like.

Compounds and compositions described herein can inhibit the kinase activity of, for example, CDK/cyclin complexes, such as those active in the G₀. or G.₁ stage of the cell cycle, e.g., CDK2, CDK4, and/or CDK6 complexes.

Evaluation of Biological Activity

The biological activity of the compounds described herein can be tested using any suitable assay known to those of skill in the art, see, e.g., WO 2001/053268 and WO 2005/009997. For example, the activity of a compound may be tested using one or more of the test methods outlined below.

In one example, tumor cells may be screened for Wnt independent growth. In such a method, tumor cells of interest are contacted with a compound (i.e. inhibitor) of interest, and the proliferation of the cells, e.g. by uptake of tritiated thymidine, is monitored. In some embodiments, tumor cells may be isolated from a candidate patient who has been screened for the presence of a cancer that is associated with a mutation in the Wnt signaling pathway. Candidate cancers include, without limitation, those listed above.

In another example, one may utilize in vitro assays for Wnt biological activity, e.g. stabilization of β-catenin and promoting growth of stem cells. Assays for biological activity of Wnt include stabilization of β-catenin, which can be measured, for example, by serial dilutions of a candidate inhibitor composition. An exemplary assay for Wnt biological activity contacts a candidate inhibitor with cells containing constitutively active Wnt/β-catenin signaling. The cells are cultured for a period of time sufficient to stabilize β-catenin, usually at least about 1 hour, and lysed. The cell lysate is resolved by SDS PAGE, then transferred to nitrocellulose and probed with antibodies specific for β-catenin.

In a further example, the activity of a candidate compound can be measured in a Xenopus secondary axis bioassay (Leyns, L. et al. Cell (1997), 88(6), 747-756).

To further illustrate this disclosure, the following examples are included. The examples should not, of course, be construed as specifically limiting the disclosure. Variations of these examples within the scope of the claims are within the purview of one skilled in the art and are considered to fall within the scope of the disclosure as described, and claimed herein. The reader will recognize that the skilled artisan, armed with the present disclosure, and skill in the art is able to prepare and use the disclosure without exhaustive examples.

EXAMPLES Compound Preparation

The starting materials used in preparing the compounds of the disclosure are known, made by known methods, or are commercially available. It will be apparent to the skilled artisan that methods for preparing precursors and functionality related to the compounds claimed herein are generally described in the literature. The skilled artisan given the literature and this disclosure is well equipped to prepare any of the compounds.

It is recognized that the skilled artisan in the art of organic chemistry can readily carry out manipulations without further direction, that is, it is well within the scope and practice of the skilled artisan to carry out these manipulations. These include reduction of carbonyl compounds to their corresponding alcohols, oxidations, acylations, aromatic substitutions, both electrophilic and nucleophilic, etherifications, esterification and saponification and the like. These manipulations are discussed in standard texts such as March's Advanced Organic Chemistry: Reactions. Mechanisms, and Structure 7^(th) Ed., John Wiley & Sons (2013), Carey and Sundberg, Advanced Organic Chemistry 5^(th) Ed., Springer (2007), Comprehensive Organic Transformations: A Guide to Functional Group Transformations, 2^(nd) Ed., John Wiley & Sons (1999) (incorporated herein by reference in its entirety) and the like.

The skilled artisan will readily appreciate that certain reactions are best carried out when other functionality is masked or protected in the molecule, thus avoiding any undesirable side reactions and/or increasing the yield of the reaction. Often the skilled artisan utilizes protecting groups to accomplish such increased yields or to avoid the undesired reactions. These reactions are found in the literature and are also well within the scope of the skilled artisan. Examples of many of these manipulations can be found for example in T. Greene and P. Wuts Protective Groups in Organic Synthesis, 4th Ed., John Wiley & Sons (2007), incorporated herein by reference in its entirety.

Trademarks used herein are examples only and reflect illustrative materials used at the time of the disclosure. The skilled artisan will recognize that variations in lot, manufacturing processes, and the like, are expected. Hence the examples, and the trademarks used in them are non-limiting, and they are not intended to be limiting, but are merely an illustration of how a skilled artisan may choose to perform one or more of the embodiments of the disclosure.

(¹H) nuclear magnetic resonance spectra (NMR) were measured in the indicated solvents on a Bruker NMR spectrometer (Avance™ DRX300, 300 MHz for ¹H or Avance™ DRX500, 500 MHz for ¹H) or Varian NMR spectrometer (Mercury 400 BB, 400 MHz for ¹H). Peak positions are expressed in parts per million (ppm) downfield from tetramethylsilane. The peak multiplicities are denoted as follows, s, singlet; d, doublet; t, triplet; q, quartet; ABq, AB quartet; quin, quintet; sex, sextet; sep, septet; non, nonet; dd, doublet of doublets; ddd, doublet of doublets of doublets; d/ABq, doublet of AB quartet; dt, doublet of triplets; td, triplet of doublets; dq, doublet of quartets; m, multiplet.

The following abbreviations have the indicated meanings:

-   -   Ac₂O=acetic anhydride     -   BH₃-Me₂S=borane dimethyl sulfide complex     -   B(i-PrO)₃=triisopropyl borate     -   (Boc)₂O=di-tert-butyl dicarbonate     -   brine=saturated aqueous sodium chloride     -   CDCl₃=deuterated chloroform     -   CD₃OD=deuterated methanol     -   Cy₃P=tricyclohexylphosphine     -   DCAD=di-(4-chlorobenzyl)azodicarboxylate     -   DCE=dichloroethane     -   DCM=dichloromethane     -   DEAD=diethyl azodicarboxylate     -   DHP=dihydropyran     -   DIPEA—diisopropylethylamine     -   DMAP=4-dimethylaminopyridine     -   DMF=N,N-dimethylformamide     -   DMSO-d₆=deuterated dimethylsulfoxide     -   ESIMS=electron spray mass spectrometry     -   EtOAc=ethyl acetate     -   EtOH=ethanol     -   HCl=hydrochloric acid     -   HOAc=acetic acid     -   K₂CO₃=potassium carbonate     -   KOAc=potassium acetate     -   LC/MS=liquid chromatography-mass spectrometry     -   LDA=lithium diisopropylamide     -   MeOH=methanol     -   MgSO₄=magnesium sulfate     -   MPLC=Medium pressure liquid chromatography     -   MsCl=methanesulfonyl chloride or mesyl chloride     -   MTBE=methyl tert-butyl ether     -   NaBH₄=sodium borohydride     -   NaBH(OAc)₃=sodium triacetoxyborohydride     -   NaCNBH₃=sodium cyanoborohydride     -   NaHCO₃=sodium bicarbonate     -   NaH₂PO₄=monosodium phosphate     -   Na₂HPO₄=disodium phosphate     -   NaIO₄=sodium periodate     -   NaOH=sodium hydroxide     -   Na₂SO₄=sodium sulfate     -   NMR=nuclear magnetic resonance     -   ON=overnight     -   Pd₂(dba)₃=tris(dibenzylideneacetone)dipalladium(0)     -   Pd(dppf)Cl₂=1,1′-bis(diphenylphosphino)ferrocene]palladium(II)         chloride     -   Pd(PPh₃)₄=tetrakis(triphenylphosphine)palladium(0)     -   PE=petroleum ether     -   Pin₂B₂=bis(pinacolato)diboron     -   PPh₃=triphenylphosphine     -   prep-HPLC=preparative High-performance liquid chromatography     -   r.t=room temperature     -   SEM-Cl=2-(trimethylsilyl)ethoxymethyl chloride     -   TEA=triethylamine     -   TFA=trifluoroacetic acid     -   THF=tetrahydrofuran     -   THP=tetrahydropyran     -   TLC=thin layer chromatography     -   p-TsOH=p-toluenesulfonic acid     -   XPhos=2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl

The following example schemes are provided for the guidance of the reader, and collectively represent an example method for making the compounds provided herein. Furthermore, other methods for preparing compounds of the disclosure will be readily apparent to the person of ordinary skill in the art in light of the following reaction schemes and examples. The skilled artisan is thoroughly equipped to prepare these compounds by those methods given the literature and this disclosure. The compound numberings used in the synthetic schemes depicted below are meant for those specific schemes only, and should not be construed as or confused with same numberings in other sections of the application. Unless otherwise indicated, all variables are as defined above.

General Procedure

Compounds of Formula (I) of the present disclosure can be prepared as depicted in Scheme 1a.

Compound I, wherein PG is a protecting group such as THP, undergoes Suzuki coupling with Compound II to provide Compound III. In certain embodiments, Compound I (X═Br) undergoes Suzuki coupling with Compound II (Y═—B(OH)₂ or boronate ester) to provide Compound III after removal of the protecting group. In other embodiments, Compound I (X═Br) is first converted to the corresponding boronic acid or boronate ester (not shown), which in turn undergoes Suzuki coupling with Compound II (Y═Br) to provide Compound III after removal of the protecting group. Treatment of Compound III with KOH and I₂ followed by Boc₂O affords the protected iodide IV.

In certain embodiments, when R* is R⁵ (e.g., a six-membered ring), Suzuki coupling between iodide (IV) and boronic acid (V) followed by removal of the protecting groups affords the desired bi-heteroaryl product VI (see, for example, conditions A above).

In other embodiments, when R* is Br or Cl, the resultant Suzuki product can further undergo a second Suzuki coupling to install the R⁵ substituent. In some cases, this procedure is useful when the R⁵ substituent is a five-membered ring. In these embodiments, removal of the protecting groups affords the desired bi-heteroaryl product VI. See, for example, conditions B above.

Compounds of Formula (I) of the present disclosure can be prepared as depicted in Scheme 1.

Scheme 1 describes a method for preparation of 3-(1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine and 3-(1H-pyrrolo[3,2-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridine compounds (IX) by either converting the 1H-pyrazolo[4,3-b]pyridine (I) to the tributylstannane (II) followed by Migita-Kosugi-Stille coupling to with various bromo compounds to form (III) analogs or by reacting (I) directly with various boronic acids using Suzuki coupling to produce compound (III) analogs. (III) is then deprotected before iodination of (IV) with iodine and potassium hydroxide to produce compound (V) analogs. The 3-iodo-1H-pyrazolo[3,4-c]pyridine (V) nitrogen is then protected with Boc followed by Suzuki coupling with the Boc/SEM protected (1H-indol-2-yl)boronic acid or (1H-pyrrolo[3,2-b]pyridin-2-yl)boronic acid (VII) to form the protected 3-(1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine and 3-(1H-pyrrolo[3,2-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridine compounds (VIII). Final deprotection of the pyrazole nitrogen yields the desired substituted 3-(1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine and 3-(1H-pyrrolo[3,2-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridine compounds (IX).

Alternatively, compounds of Formula (I) of the present disclosure can be prepared as depicted in Scheme 2.

Scheme 2 describes an alternative method for preparation of 3-(1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine compounds (XIII) by reacting Boc protected 3-iodo-1H-pyrazolo[3,4-c]pyridine (VI) with the Boc/SEM protected (4-bromo-1H-indol-2-yl)boronic acid (X) by Suzuki coupling. A second Suzuki coupling with various boronic acids yields the protected 3-(1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine (XII). Final deprotection of the pyrazole nitrogen yields the desired substituted 3-(1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine (XIII).

Illustrative Compound Examples

Preparation of intermediates (XVII) and (XVIII) are depicted below in Scheme 3.

Step 1

A suspension of 2-bromo-4-methyl-5-nitropyridine (XIV) (200 g, 921 mmol, 1.00 eq) and NH₄Cl (240 g, 4.49 mol, 4.87 eq) in EtOH (3.50 L) and water (150 mL) was heated with stirring to 50° C. To this mixture was added Fe (120 g, 2.15 mol, 2.33 eq) and HCl (10.2 g, 279 mmol, 0.30 eq). The suspension was then heated to 80° C. for another 3 h. The reaction was cooled to 25° C. and filtered through a plug of Celite. The filtrate was concentrated under reduced pressure to yield a residue that was taken up in EtOAc (1 L×3) and washed with brine. The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure to give 6-bromo-4-methylpyridin-3-amine (XV) as brown solid (167.9 g, 898 mmol, 97.4% yield) which was used for the next step without any purification. ¹H NMR (CDCl₃, 400 MHz) δ ppm 2.15 (s, 3H), 3.44 (br s, 2H), 7.14 (s, 1H), 7.78 (s, 1H); ESIMS found for C₆H₇BrN₂ m/z 186.8 (M+H).

Step 2

To a suspension 6-bromo-4-methylpyridin-3-amine (XV) (186 g, 994 mmol, 1.00 eq) and KOAc (115 g, 1.17 mol, 1.18 eq) in CHCl₃ (3.50 L) was added Ac₂O (405 g, 3.97 mol, 3.99 eq) and the suspension was stirred at 25° C. for 1 h and then heated at 60-70° C. to reflux for an additional 2 h. After cooling the suspension to 25° C., isopentyl nitrate (233 g, 1.99 mol, 2.00 eq) and 18-crown-6 (21 g, 79.5 mmol, 0.08 eq) was added and the suspension heated to reflux for 12 h. After cooling to 25° C., the suspension was filtered and the filtrate was concentrated under reduced pressure to yield a residue that was treated with a suspension of potassium carbonate (450 g) in a solution of methanol and water (450 mL) at 0° C. for 3 h. The suspension was concentrated under reduced pressure to yield a residue that was extracted with EtOAc (1000 mL×3) and washed with brine. The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure to give 5-bromo-1H-pyrazolo[3,4-c]pyridine (XVI) (200 g, crude) as yellow solid. The crude product was used for the next step without any purification. ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 7.96 (s, 1H), 8.15 (s, 1H), 8.86 (s, 1H); ESIMS found for C₆H₄BrN₃ m/z 198.3 (M+H).

Step 3

To a solution of 5-bromo-1H-pyrazolo[3,4-c]pyridine (XVI) (200 g, 1.01 mol, 1.00 eq) in DCM (1.60 L), THF (1.60 L) and DMF (100 mL) at 25° C. was added 3,4-dihydro-2H-pyran (169 g, 2.02 mol, 2.00 eq) and p-TsOH (17.4 g, 101 mmol, 0.10 eq). The reaction solution was stirred at 25° C. for 12 h. The solvent was removed under vacuum. 10% NaHCO₃ (2 L) and EtOAc (2 L) was added to the residue. The layers were separated and the organic layer washed with brine (500 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure to give 5-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-c]pyridine (XVII) (280 g, crude) as yellow solid. The crude product was used for the next step without any purification. ESIMS found for C₁₁H₁₂BrN₃O m/z 283.9 (M+H).

Step 4

To a solution of 5-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-c]pyridine (XVII) (178 g, 630 mmol, 1.00 eq) in 1,4-dioxane (1.8 L) was added LiCl (160 g, 3.79 mol, 6.0 eq), Cy₃P (17.6 g, 63 mmol, 0.10 eq), bis(tributyltin) (439 g, 757 mmol, 1.2 eq) and Pd₂(dba)₃ (28.8 g, 31.5 mmol, 0.05 eq) under Nitrogen. The resulting suspension was stirred at 100° C. for 12 h. The suspension was filtered through Celite. The filter cake was washed with EtOAc (200 mL×3). The crude product was purified by column chromatography (PE/EtOAc=4/1) to obtain the 1-(tetrahydro-2H-pyran-2-yl)-5-(tributylstannyl)-1H-pyrazolo[3,4-c]pyridine (XVIII) (185 g, 375.8 mmol, 59.6% yield) as a brown oil. ¹H NMR (CDCl₃, 400 MHz) δ ppm 0.82-0.97 (m, 9H), 1.04-1.25 (m, 6H), 1.25-1.44 (m, 6H), 1.45-1.90 (m, 12H), 3.81 (t, J=9.6 Hz, 1H), 4.13 (d, J=11.2 Hz, 1H), 5.74 (dd, J=3.2 Hz, J=8.8 Hz, 1H), 7.65 (s, 1H), 8.14 (s, 1H), 9.43 (s, 1H); ESIMS found for C₂₃H₃₉N₃OSn m/z 494.1 (M+H).

Preparation of intermediate N-(5-bromopyridin-3-yl)pivalamide (XXI) is depicted below in Scheme 4.

Step 1

To a solution of 3-amino-5-bromo pyridine (XIX) (1.0 g, 5.78 mmol) in dry pyridine (10 mL) was added pivaloyl chloride (XX) (769 mg, 6.38 mmol). The reaction mixture was stirred at room temperature for 3 h. The reaction was poured into an ice water/saturated aqueous NaHCO₃ mixture and stirred for 30 min. The precipitate was filtered, washed with cold water and dried at room temperature to yield N-(5-bromopyridin-3-yl)pivalamide (XXI) as an off-white solid (1.082 g, 4.22 mmol, 73.1% yield). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 1.23 (s, 9H), 8.37 (d, J=2 Hz, 1H), 8.39 (t, J=2 Hz, 1H), 8.80 (d, J=2 Hz, 1H), 9.58 (brs, 1H); ESIMS found C₁₀H₁₃BrN₂O m/z 258.9 (Br⁸¹M+H).

The following intermediates were prepared in accordance with the procedure described in the above Scheme 4.

N-(5-Bromopyridin-3-yl)isobutyramide (XXII): Off-white solid, (71% yield). ¹H NMR (CDCl₃) δ ppm 8.55-8.35 (m, 3H), 7.32 (s, 1H), 2.59-2.48 (m, 1H), 1.28-1.27 (d, 6H); ESIMS found C₉H₁₁BrN₂O m/z 242.9 (Br⁷⁹M+H).

N-(5-Bromopyridin-3-yl)propionamide (XXIII): Off white solid (92% yield). ¹H NMR (DMSO-d₆) δ ppm 1.09 (t, J=7.54 Hz, 3H), 2.36 (q, J=7.54 Hz, 2H), 8.36 (m, 2H), 8.65 (d, J=2.07 Hz, 1H), 10.26 (s, 1H); ESIMS found C₈H₉BrN₂O m/z 231.1 (Br⁸¹M+H).

N-(5-Bromopyridin-3-yl)butyramide (XXIV): Yellow solid (2.1 g, 8.64 mmol, 88.8% yield). ¹H NMR (CD₃OD, 400 MHz) δ ppm 1.02 (t, J=7.2 Hz, 3H), 1.74 (sxt, J=7.2 Hz, 2H), 2.40 (t, J=7.2 Hz, 2H), 8.35 (d, J=2 Hz, 1H), 8.46 (t, J=2 Hz, 1H), 8.63 (d, J=2 Hz, 1H); ESIMS found C₉H₁₁BrN₂O m/z 243.1 (Br⁷⁹M+H).

N-(5-Bromopyridin-3-yl)pentanamide (XXV): Yellow solid (2.0 g, 7.78 mmol, 85.3% yield). ¹H NMR (CD₃OD, 400 MHz) δ ppm 0.98 (t, J=7.4 Hz, 3H), 1.43 (sxt, J=7.4 Hz, 2H), 1.70 (quin, J=7.4 Hz, 2H), 2.43 (t, J=7.6 Hz, 2H), 8.35 (s, 1H), 8.45 (d, J=2 Hz, 1H), 8.64 (d, J=2 Hz, 1H); ESIMS found C₁₀H₁₃BrN₂O m/z 256.9 (Br⁷⁹M+H).

N-(5-Bromopyridin-3-yl)-3-methylbutanamide (XXVI): Off white solid, (67% yield), ¹H NMR (CDCl₃, 500 MHz) δ ppm 8.55-8.42 (m, 3H), 7.62 (s, 1H), 2.31-2.18 (m, 3H), 1.02-1.01 (d, J=6 Hz, 6H); ESIMS found C₁₀H₁₃BrN₂O m/z 258.9 (Br⁸¹M+H).

N-(5-Bromopyridin-3-yl)-3,3-dimethylbutanamide (XXVII): Yellow solid (1.7 g, 6.27 mmol, 78.6% yield). ¹H NMR (CD₃OD, 400 MHz) δ ppm 1.10 (s, 9H), 2.29 (s, 2H), 8.36 (d, J=1.6 Hz, 1H), 8.46 (d, J=2.0 Hz, 1H), 8.64 (d, J=2.0 Hz, 1H); ESIMS found C₁₁H₁₅BrN₂O m/z 273.1 ((Br⁸¹M+H).

N-(5-Bromopyridin-3-yl)-2-phenylacetamide (XXVIII): White solid (2.5 g, 8.59 mmol, 77.9% yield). ¹H NMR (CDCl₃, 400 MHz) δ ppm 3.76 (s, 2H), 7.26-7.45 (m, 5H), 7.57 (brs, 1H), 8.33 (s, 1H), 8.37 (s, 2H); ESIMS found C₁₃H₁₁BrN₂O m/z 292.8 (Br⁸¹M+H).

N-(5-Bromopyridin-3-yl)benzamide (XXIX): White solid (2.7 g, 9.74 mmol, 60% yield). ¹H NMR (CDCl₃, 400 MHz) δ ppm 7.40-7.52 (m, 2H), 7.52-7.62 (m, 1H), 7.86 (d, J=7.2 Hz, 2H), 8.39 (d, J=1.6 Hz, 1H), 8.46 (s, 1H), 8.55 (d, J=1.6 Hz, 1H), 8.57 (d, J=2.0 Hz, 1H); ESIMS found C₁₂H₉BrN₂O m/z 278.8 (Br⁸¹M+H).

N-(5-Bromopyridin-3-yl)cyclopropanecarboxamide (XXX): Off-white solid, (83% yield), ¹H NMR (CDCl₃, 500 MHz) δ ppm 8.46-8.39 (m, 3H), 7.54 (bs, 1H), 1.56-1.50 (m, 1H), 1.13-1.07 (m, 2H), 0.96-0.90 (m, 2H); ESIMS found for C₉H₉BrN₂O m/z 240.9 (Br⁷⁹M+H).

N-(5-Bromopyridin-3-yl)cyclobutanecarboxamide (XXXI): Yellow solid (2.1 g, 6.27 mmol, 86.6% yield). ¹H NMR (CD₃OD, 400 MHz) δ ppm 1.80-1.99 (m, 1H), 1.99-2.15 (m, 1H), 2.16-2.30 (m, 2H), 2.30-2.45 (m, 2H), 3.25-3.35 (m, 1H), 8.34 (d, J=2.0 Hz, 1H), 8.47 (s, 1H), 8.64 (d, J=2.0 Hz, 1H); ESIMS found C₁₀H₁₁BrN₂O m/z 257.1 (Br⁸¹M+H).

N-(5-Bromopyridin-3-yl)cyclopentanecarboxamide (XXXII): Yellow solid (1.9 g, 7.06 mmol, 80.2% yield). ¹H NMR (CD₃OD, 400 MHz) δ ppm 1.57-1.74 (m, 2H), 1.74-1.91 (m, 4H), 1.91-2.07 (m, 2H), 2.77-2.92 (m, 1H), 8.34 (d, J=1.6 Hz, 1H), 8.45 (s, 1H), 8.65 (d, J=2.0 Hz, 1H); ESIMS found C₁₁H₁₃BrN₂O m/z 271.1 (Br⁸¹M+H).

N-(5-Bromopyridin-3-yl)cyclohexanecarboxamide (XXXIII): Yellow solid (2.0 g, 7.06 mmol, 84.3% yield). ¹H NMR (CD₃OD, 400 MHz) δ ppm 1.19-1.46 (m, 3H), 1.46-1.63 (m, 2H), 1.74 (d, J=1.6 Hz, 1H), 1.88 (t, J=14.0 Hz, 4H), 2.40 (tt, J=1.6 Hz, J=3.6 Hz, 1H), 8.34 (d, J=2.0 Hz, 1H), 8.44 (t, J=2.0 Hz, 1H), 8.64 (d, J=2.0 Hz, 1H); ESIMS found C₁₂H₁₅BrN₂O m/z 285.1 (Br⁸¹M+H).

N-(5-Bromopyridin-3-yl)-2-cyclohexylacetamide (XXXIV): Yellow solid (261 mg, 0.878 mmol, 84.4% yield). ESIMS found C₁₃H₁₇BrN₂O m/z 297.1 (Br⁸¹M+H).

Preparation of intermediate 5-bromo-N,N-dimethylpyridin-3-amine (XXXVI) is depicted below in Scheme 5.

Step 1

To a solution of 3,5-dibromopyridine (XXXV) (2.37 g, 10.0 mmol) in dry DMF (20.0 mL) was added K₂CO₃ (4.5 g, 33 mmol) and dimethylamino hydrochloride (1.79 g, 22 mmol). The mixture was heated overnight at 200° C. in a sealed tube. The solution was cooled to room temperature and excess DMF was removed under vacuum. The residue was partitioned between EtOAc and water. The organic phase was separated. The aqueous phase was washed with EtOAc and the combined organic phases were dried over MgSO₄, and concentrated to afford 5-bromo-N,N-dimethylpyridin-3-amine (XXXVI) as an off-white solid (1.78 g, 8.85 mmol, 88% yield). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 2.94 (s, 6H), 7.25 (t, J=2 Hz, 1H), 7.91 (d, J=2 Hz, 1H), 8.07 (d, J=2 Hz, 1H); ESIMS found C₇H₉BrN₂ m/z 201.1 (M+H).

Preparation of intermediate 5-bromo-N-isopropylpyridin-3-amine (XXXVII) is depicted below in Scheme 6.

Steps 1

To a solution of 5-bromopyridin-3-amine (XIX) (535 mg, 3.09 mmol) in MeOH (62 mL) was added acetone (296 μL, 4.02 mL). The pH was adjusted to 4 using HOAc and stirred for 30 min. NaCNBH₃ (272 mg, 4.33 mmol) was added and stirred at room temperature overnight. The MeOH was removed under vacuum and the residue was partitioned between EtOAc and saturated aqueous NaHCO₃. The organic layer was dried over MgSO₄ and evaporated under vacuum. The crude product was purified on a silica gel column (100% hexanes→90:10 hexanes:EtOAc) to produce 5-bromo-N-isopropylpyridin-3-amine (XXXVII) as an oil which slowly solidified into an off-white solid (309 mg, 1.44 mmol, 47% yield). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 1.12 (d, J=6.3 Hz, 6H), 3.55-3.59 (m, 1H), 6.03 (d, J=7.9 Hz, 1H), 7.05-7.06 (m, 1H), 7.75 (d, J=2 Hz, 1H), 7.90 (d, J=2 Hz, 1H); ESIMS found C₈H₁₁BrN₂ m/z 215.1 (M+H).

Preparation of intermediate 1-(5-bromopyridin-3-yl)-N,N-dimethylmethanamine (XXXIX) is depicted below in Scheme 7.

Steps 1

Preparation of 1-(5-bromopyridin-3-yl)-N,N-dimethylmethanamine (XXXIX) was performed following the procedure listed in Scheme 6, Step 1. Brown oil (1.20 g, 5.59 mmol, 45% yield). ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 2.15 (s, 6H), 3.43 (s, 2H), 7.94 (s, 1H), 8.47 (d, J=1.1 Hz, 1H), 8.59 (d, J=2.2 Hz, 1H); ESIMS found C₈H₁₁BrN₂ m/z 215 (M^(Br79)+H) and 217 (M^(Br81)+H).

Preparation of intermediate 3-bromo-5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridine (XL) is depicted below in Scheme 8.

Steps 1

To a mixture of 5-bromopyridine-3-carbaldehyde (XXXVIII) (6.00 g, 32.26 mmol, 1.0 eq), 3,3-difluoropyrrolidine (5.56 g, 38.71 mmol, 1.20 eq) and TEA (5.39 mL, 38.71 mmol, 1.2 eq) in DCE (200 mL) was stirred at room temperature for 30 min, then added sodium triacetoxyborohydride (10.25 g, 48.38 mmol, 1.50 eq) in one portion at room temperature under N₂. The mixture was stirred at room temperature for 6 h. TLC showed the reaction was complete. The reaction was quenched with 1N NaOH (100 mL), extracted with DCE (100 mL×2). The combined organic layers were washed with brine (100 mL), dried and concentrated. The residue was purified by silica gel chromatography (column height: 50 mm, diameter: 50 mm, 300-400 mesh silica gel, DCM/MeOH=30/1→20/1) to give 3-bromo-5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridine (XL): Yellow oil (8.00 g, 28.9 mmol, 89.5% yield). ¹H NMR (CDCl₃, 400 MHz) δ ppm 2.30 (spt, J=7.2 Hz, 2H), 2.75 (t, J=6.8 Hz, 2H), 2.91 (t, J=13.2 Hz, 2H), 7.85 (s, 1H), 8.45 (s, 1H), 8.59 (d, J=2 Hz, 1H); ESIMS found for C₁₀H₁₁BrF₂N₂ m/z 277.0 (M+H).

The following intermediates were prepared in accordance with the procedure described in the above Schemes 6-8.

3-Bromo-5-(pyrrolidin-1-ylmethyl)pyridine (XLI): Golden liquid (1.35 g, 97% yield). ¹H NMR (DMSO-d₆) δ ppm 1.68-1.71 (m, 4H), 2.42-2.44 (m, 4H), 3.60 (s, 2H), 7.96 (s, 1H), 8.48 (d, J=2 Hz, 1H), 8.58 (d, J=3 Hz, 1H); ESIMS found for C₁₀H₃BrN₂ m/z 242.2 (M+H).

3-Bromo-5-(piperidin-1-ylmethyl)pyridine (XLII): Brown liquid (13.1 g, 94% yield). ¹H NMR (DMSO-d₆) δ ppm 1.36-1.39 (m, 2H), 1.46-1.51 (m, 4H), 2.31-2.32 (m, 4H), 3.46 (s, 2H), 7.94 (s, 1H), 8.47 (d, J=2 Hz, 1H), 8.58 (d, J=3 Hz, 1H); ESIMS found for C₁₁H₁₅BrN₂ m/z 257.0 (M+H).

N-((5-Bromopyridin-3-yl)methyl)ethanamine (XLIII): Golden liquid (1.29 g, 6.00 mmol, 60% yield). ¹H NMR (CDCl₃, 400 MHz) δ ppm 1.14 (t, J=7.2 Hz, 3H), 2.67 (q, J=F7.2 Hz, 2H), 3.79 (s, 2H), 7.85 (t, J=2 Hz, 1H), 8.46 (d, J=1.6 Hz, 1H), 8.56 (d, J=2.4 Hz, 1H); ESIMS found for C₈H₁₁BrN₂ m/z 215.1 (M+H).

N-Benzyl-1-(5-bromopyridin-3-yl)methanamine (XLIV): Yellow oil (8.0 g, 28.9 mmol, 89.5% yield). ¹H NMR (DMSO-d₆, 400 MHz) δ ppm 3.71 (s, 2H), 3.74 (s, 2H), 7.18-7.28 (m, 1H), 7.28-7.40 (m, 4H), 8.04 (s, 1H), 8.52 (s, 1H), 8.58 (s, 1H); ESIMS found for C₁₃H₁₃BrN₂ m/z 277.1 (M+H).

Preparation of intermediate tert-butyl (5-bromopyridin-3-yl)methyl (cyclopentylmethyl)carbamate (XLIX) is depicted below in Scheme 9.

Step 1

To a solution of 5-bromonicotinaldehyde (XXXVIII) (2.0 g, 10.8 mmol, 1 eq) in MeOH (20 mL) was added NaBH₄ (2.4 g, 64.9 mmol, 6 eq) and the reaction mixture was stirred at room temperature for 3 h. The mixture was concentrated in vacuo and the residue was diluted in water (15 mL), the aqueous phase was extracted with DCM (10 mL×3). The combined organic layers were dried over MgSO₄, filtered and concentrated in vacuo to afford (5-bromopyridin-3-yl)methanol (XLV) (1.8 g, 9.57 mmol, 90.0% yield) as a colorless oil. ¹H NMR (CDCl₃, 500 MHz) δ ppm 4.73 (s, 2H), 7.90 (s, 1H), 8.47 (s, 1H), 8.57 (s, 1H). ESIMS found for C₆H₆BrNO m/z 188.0 (M+H).

Step 2

To a stirred solution of (5-bromopyridin-3-yl)methanol (XLV) (1.60 g, 8.5 mmol, 1 eq), phthalimide (1.24 g, 8.5 mmol, 1 eq) and PPh₃ (3.33 g, 12.75 mmol, 1.5 eq) in anhydrous THF (15 mL) was added DEAD (2.21 g, 12.75 mmol, 1.5 eq) dropwise at 0° C. under N₂. Then the reaction mixture was stirred at room temperature for 6 h. The mixture was washed with saturated NaHCO₃ solution (15 mL), water (15 mL) and brine (15 mL) subsequently. The organic layers were dried over MgSO₄, concentrated under reduced pressure, the resultant residue was purified by flash chromatography on silica gel (PE:EtOAc=4:1) to give 2-((5-bromopyridin-3-yl)methyl)isoindoline-1,3-dione (XLVI) (2.5 g, 7.88 mmol, 82.3% yield) as a white solid. ESIMS found for C₁₄H₉BrN₂O₂ m/z 317.1 (M+H).

Step 3

A solution of 2-((5-bromopyridin-3-yl)methyl)isoindoline-1,3-dione (XLVI) (1.9 g, 6.0 mmol, 1 eq) and hydrazine hydrate (2.0 g, 40 mmol, 6 eq) in EtOH (20 mL) was heated at 70° C. for 3 h. The mixture was filtered through a Celite® pad and the filtrate was concentrated in vacuo, the crude product was dissolved in 1N HCl solution (15 mL) and concentrated to dryness, then it was washed with acetone (10 mL×3), the precipitate was collected by filtration, dried in vacuo to give (5-bromopyridin-3-yl)methanamine (XLVII) (1.3 g, 6.95 mmol, 97.7% yield) as a white solid. ¹H NMR (D₂O, 500 MHz) δ ppm 4.34 (s, 2H), 8.56 (s, 1H), 8.75 (d, J=1.2 Hz, 1H), 8.91 (d, J=1.6 Hz, 1H). ESIMS found for C₆H₇BrN₂ m/z 187.0 (M+H).

Step 4

A solution of (5-bromopyridin-3-yl)methanamine (XLVII) (1.30 g, 5.8 mmol, 1.0 eq), cyclopentanecarbaldehyde (0.57 g, 5.8 mmol, 1.0 eq) and TEA (0.60 g, 5.8 mmol, 1.0 eq) in MeOH (15 mL) was stirred at room temperature for 2 h. Then NaBH₃CN (1.98 g, 34.6 mmol, 6.0 eq) was added and the mixture was stirred at the same temperature for another 3 h. The solvent was removed under reduced pressure and the residue was diluted in water (20 mL) and extracted with DCM (10 mL×3), combined organic layers were dried over MgSO₄ and concentrated in vacuo to give 1-(5-bromopyridin-3-yl)-N-(cyclopentylmethyl)methanamine (XLVIII) (1.23 g, 4.57 mmol, 79.3% yield) as a yellow oil. ¹H NMR (CDCl₃, 400 MHz) δ ppm 1.07-1.23 (m, 2H), 1.47-1.67 (m, 4H), 1.70-1.84 (m, 2H), 2.02 (spt, J=7.6 Hz, 1H), 2.53 (d, J=7.2 Hz, 2H), 3.80 (s, 2H), 7.86 (s, 1H), 8.47 (s, 1H), 8.56 (d, J=2.0 Hz, 1H); ESIMS found for C₁₂H₁₇BrN₂ m/z 269.1 (M+H).

To a solution of 1-(5-bromopyridin-3-yl)-N-(cyclopentylmethyl)methanamine (XLVIII) (1.00 g, 3.7 mmol, 1 eq) and TEA (0.93 g, 9.2 mmol, 2.5 eq) in DCM (20 mL) was added portion wise Boc₂O (0.85 g, 4.0 mmol, 1.1 eq) at 0° C., the reaction mixture was stirred at room temperature for 1 h. The mixture was washed with water (10 mL), brine (10 mL), the organic layer was separated, dried over MgSO₄ and concentrated in vacuo to give tert-butyl (5-bromopyridin-3-yl)methyl(cyclopentylmethyl) carbamate (XLIX) (1.25 g, 3.38 mmol, 91.9% yield) as a white solid. ESIMS found for C₁₇H₂₅BrN₂O₂ m/z 369.1 (M+H).

Preparation of intermediate 3-bromo-5-(cyclohexyloxy)pyridine (LII) is depicted below in Scheme 10.

Step 1

To a solution of 5-bromopyridin-3-ol (L) (523 mg, 3.01 mmol) in THF (30 mL) cooled to 0° C. were added triphenylphosphine (867 mg, 3.31 mmol) and cyclohexanol (LI) (331 mg, 3.31 mmol) followed by (E)-bis(4-chlorobenzyl) diazene-1,2-dicarboxylate (1.21 g, 3.31 mmol), added portion wise. The reaction mixture was then stirred at 25° C. overnight. The reaction was worked-up with an EtOAc—NaHCO₃ extraction and the solid filtered off. The solvent was removed and the residue was purified by ISCO (20% EtOAc-hexanes) to give 3-bromo-5-(cyclohexyloxy)pyridine (LII) (209 mg, 0.82 mmol, 27.2% yield) as a yellow oil. ¹H NMR (DMSO-d₆, 500 MHz) δ ppm 1.21-1.31 (m, 1H) 1.34-1.48 (m, 4H) 1.49-1.57 (m, 1H) 1.70 (br dd, J=9.74, 4.25 Hz, 2H) 1.88-1.96 (m, 2H) 2.50 (dt, J=3.70, 1.72 Hz, 5H) 4.46-4.54 (m, 1H) 7.72 (t, J=2.20 Hz, 1H) 8.24 (d, J=1.92 Hz, 1H) 8.27 (d, J=2.47 Hz, 1H).

The following intermediate was prepared in accordance with the procedure described in the above Scheme 10.

tert-Butyl 4-((5-bromopyridin-3-yl)oxy)piperidine-1-carboxylate (LIII): Yellow oil (244 mg, 0.683 mmol, 23.2% yield). ESIMS found for C₁₅H₂₁BrN₂O₃ m/358.3 (M+H).

Preparation of intermediate 3-(benzyloxy)-5-bromopyridine (LV) is depicted below in Scheme 11.

Step 1

To a solution of 5-bromopyridin-3-ol (L) (174 mg, 1.0 mmol) in DMF (3 mL) was added potassium carbonate (415 mg, 3.0 mmol). The slurry was heated at 90° C. for 1 h and then cooled to 25° C. The (bromomethyl)benzene (LIV) (171 mg, 1.0 mmol) was added and the mixture was stirred at 25° C. overnight. The reaction was worked-up using a saturated sodium bicarbonate and EtOAc extraction. The product was purified by ISCO column (40-100% EtOAc-hexanes). The 3-(benzyloxy)-5-bromopyridine (LV) (105 mg, 0.398 mmol, 39.8% yield) was obtained as yellow oil. ESIMS found for C₁₂H₁₀BrNO m/z 266.1 (M+H).

The following intermediates were prepared in accordance with the procedure described in the above Scheme 11.

3-Bromo-5-(2-(pyrrolidin-1-yl)ethoxy)pyridine (LVI): Yellow oil (97 mg, 0.358 mmol, 15.56% yield). ESIMS found for C₁₁H₁₅BrN₂O m/z 272.2 (M+H).

2-((5-Bromopyridin-3-yl)oxy)-N,N-dimethylethan-1-amine (LVII): Yellow oil (97 mg, 0.396 mmol, 28.9% yield). ESIMS found for C₉H₁₃BrN₂O m/z 245.1 (M+H).

1-(2-(3-Bromo-5-fluorophenoxy)ethyl)pyrrolidine (LVIII): Yellow oil (370 mg, 1.284 mmol, 85.8% yield). ESIMS found for C₁₂H₁₅BrFNO m/z 289.0 (M+H).

2-(3-Bromo-5-fluorophenoxy)-N,N-dimethylethan-1-amine (LIX): Yellow oil (364 mg, 1.389 mmol, 50.2% yield). ESIMS found for C₁₀H₁₃BrFNO m/z 263.9 (M+H).

Preparation of intermediate tert-butyl 4-(2-((5-bromopyridin-3-yl)amino)-2-oxoethyl)piperidine-1-carboxylate (LXI) is depicted below in Scheme 12.

Step 1

To a solution of 2-(1-(tert-butoxycarbonyl)piperidin-4-yl)acetic acid (LX) (3.4 g, 13.97 mmol) in DCM (10 mL) was added DMF (1 mL). The solution was cooled in ice-water to 0° C. Oxalyl chloride (1.835 mL, 20.96 mmol) was then added dropwise. The mixture was stirred for 1 h at 25° C. The organic volatile was then removed under vacuum. The residue was dissolved in DCM (10 mL). DMAP (0.171 g, 1.397 mmol) and 5-bromopyridin-3-amine (XIX) (2.418 g, 13.97 mmol) were added to the solution and cooled to 0° C. DIPEA (4.88 ml, 27.9 mmol) was then added dropwise and the mixture was stirred for 2 h at 25° C. The reaction was worked-up with DCM and saturated NaHCO₃. The product was purified by ISCO (0-100% EtOAc-hexanes). The tert-butyl 4-(2-((5-bromopyridin-3-yl)amino)-2-oxoethyl)piperidine-1-carboxylate (LXI) (2.82 g, 7.08 mmol, 50.7% yield) was obtained as a yellow oil. ESIMS found for C₁₇H₂₄BrN₃O₃ m/z 343.1 (M−56).

The following intermediate was prepared in accordance with the procedure described in the above Scheme 12.

N-(5-Bromopyridin-3-yl)-2-(dimethylamino)acetamide (LXII): Yellow oil (528 mg, 2.05 mmol, 19.0% yield). ESIMS found for C₉H₁₂BrN₃O m/z 259.3 (M+H).

Preparation of intermediate tert-butyl (1-(6-chloropyrazin-2-yl)azetidin-3-yl)carbamate (LXV) is depicted below in Scheme 13.

Step 1

To a solution of tert-butyl azetidin-3-ylcarbamate hydrochloride (LXIII) (2 g, 9.58 mmol) in dry DMF (19.2 mL) was added DIPEA (8.37 ml, 47.9 mmol). To this mixture was added 2,6-dichloropyrazine (LXIV) (1.428 g, 9.58 mmol) and the reaction was stirred at 95° C. for 3 h. The reaction was quenched with water (20 mL) and extracted with EtOAc. The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by silica gel column chromatography (40 g) (100% hexanes→hexanes:EtOAc 1:1) to yield tert-butyl (1-(6-chloropyrazin-2-yl)azetidin-3-yl)carbamate (LXV) (2.2882 g, 8.04 mmol, 84% yield) as a white solid. ESIMS found for C₁₂H₁₇ClN₄O₂ m/z 285.1 (M+H).

Preparation of intermediate N-(3-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl) methanesulfonamide (LXIX) is depicted below in Scheme 14.

Step 1

A solution of 3-bromo-5-fluorobenzonitrile (LXVI) (44.0 g, 220.0 mmol, 1.0 eq) was dissolved in THF (30 mL). BH₃-Me₂S (33.43 g, 440.0 mmol, 2.0 eq) was added to the solution at 20° C. Then it was stirred at 80° C. for 2 h, HCl (6 N, 100 mL) was added to the mixture slowly at 20° C. The mixture was stirred at 80° C. for 1 h, then it was washed with EtOAc (300 mL). The water phase was basified with 50% aqueous NaOH and it was extracted with EtOAc (300 mL×3). The combined organic layers were dried over anhydrous Na₂SO₄ and concentrated in vacuo to produce (3-bromo-5-fluoro-phenyl)methanamine (LXVII) (24.0 g, 117.62 mmol, 53.5% yield). ¹H NMR (CDCl₃, 300 MHz) ppm 3.86 (s, 2H), 7.01 (d, J=8 Hz, 1H), 7.12 (d, J=8 Hz, 1H), 7.28 (s, 1H); ESIMS found C₇H₇BrFN m/z 203.9 (Br⁷⁹M+H).

Step 2

A solution of (3-bromo-5-fluoro-phenyl)methanamine (LXVII) (23.0 g, 112.7 mmol, 1.0 eq) was dissolved in DCM (15 mL), TEA (34.22 g, 338.2 mmol, 3.0 eq) was added to the mixture. Then MsCl (13.44 g, 117.3 mmol, 1.04 eq) was added slowly to the solution at 0° C. It was stirred at 0-30° C. for 2 h. The reaction was washed with water and extracted with EtOAc. The combined organic layers were dried over anhydrous Na₂SO₄ and concentrated to give N-(3-bromo-5-fluorobenzyl)methanesulfonamide (LXVIII) (34.0 g, 102.44 mmol, 90.9% yield, 85% purity) as an oil. ¹H NMR (CDCl₃, 300 MHz) ppm 2.88 (s, 3H), 4.24 (d, J=4.5 Hz, 2H), 6.99 (d, J=9 Hz, 1H), 7.13 (dt, J=8.1 Hz, J=2 Hz, 1H), 7.25 (s, 1H); ESIMS found C₈H₉BrFNO₂S m/z 282.0 (Br⁷⁹M+H).

Step 3

A solution of N-(3-bromo-5-fluorobenzyl)methanesulfonamide (LXVIII) (34.0 g, 102.4 mmol, 1.0 eq) and 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (52.02 g, 204.9 mmol, 2.0 eq), KOAc (20.11 g, 204.9 mmol, 2.0 eq) was dissolved in dioxane (20 mL). Then Pd(dppf)Cl₂ (7.60 g, 10.2 mmol, 0.1 eq) was added to the mixture. It was stirred at 90° C. for 2 h. Then the solvent was removed to get the residue which was purified by silica gel column (PE:EtOAc=10:1→100% EtOAc) to get N-(3-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)methanesulfonamide (LXIX) (30.0 g, crude). ¹H NMR (CDCl₃, 400 MHz) δ ppm 1.37 (s, 12H), 2.92 (s, 3H), 4.34 (d, J=6.3 Hz, 2H), 7.19 (dt, J=9.3 Hz, J=2.1 Hz, 1H), 7.44 (dd, J=8.7 Hz, J=2.4 Hz, 1H), 7.54 (s, 1H); ESIMS found C₁₄H₂₁BFNO₄S m/z 330.1 (M+H).

Preparation of intermediate (1-(tert-butoxycarbonyl)-4-(furan-3-yl)-1H-indol-2-yl)boronic acid (LXXIV) is depicted below in Scheme 15.

Step 1

To a solution of 4-bromo-1H-indole (LXX) (10 g, 50.8 mmol, 1 eq), DMAP (622 mg, 5.1 mmol, 0.1 eq) and TEA (10.6 ml, 76.1 mmol, 3 eq) in DCM (200 mL) was added Boc₂O (14.4 mL, 61 mmol, 1.2 eq) at 0° C. The reaction was warmed to room temperature and stirred for 2 h. Water (200 mL) was added and the mixture was extracted with DCM twice. The solvent was evaporated under vacuum to give tert-butyl 4-bromo-1H-indole-1-carboxylate (LXXI) as white solid (11.4 g, 38.5 mmol, 76% yield). ¹H NMR (CDCl₃, 400 MHz) δ ppm 1.68 (s, 9H), 6.64 (d, J=4 Hz, 1H), 7.17 (t, J=8.4 Hz, 1H), 7.39 (d, J=7.6 Hz, 1H), 7.64 (d, J=3.2 Hz, 1H), 8.11 (d, J=8.0 Hz, 1H); ESIMS found for C₁₃H₁₄BrNO₂ m/z 297.1 (M+H).

Step 2

A solution of tert-butyl 4-bromo-1H-indole-1-carboxylate (LXXI) (10 g, 33.8 mmol), 3-furylboronic acid (LXXII) (5.29 g, 47.3 mmol), K₃PO₄ (14.3 g, 67.5 mmol) and Pd(dppf)Cl₂ (1.24 g, 1.69 mmol) in dioxane (150 mL) was heated to 80° C. for 6 h under N₂. The mixture was filtered and the filtrate was concentrated, the residue was purified by MPLC (PE:EtOAc=10:1) to give tert-butyl 4-(furan-3-yl)-1H-indole-1-carboxylate (LXXIII) (8.4 g, 29.6 mmol, 87.8% yield) as yellow oil. ¹H NMR (CDCl₃, 400 MHz) δ ppm 1.70 (s, 9H), 6.7-6.81 (m, 2H), 7.28-7.38 (m, 2H), 7.56 (d, J=1.6 Hz, 1H), 7.66 (d, J=4 Hz, 1H), 7.79 (s, 1H), 8.13 (d, J=8 Hz, 1H); ESIMS found for C₁₇H₁₇NO₃ m/z 284.1 (M+H).

Step 3

To a solution of tert-butyl 4-(furan-3-yl)-1H-indole-1-carboxylate (LXXIII) (4.5 g, 15.9 mmol) in THF (100 mL) was added LDA (2 M, 8.73 mL) dropwise at −70° C. and stirred for 10 min, then triisopropyl borate (4.48 g, 23.8 mmol) was added and the resulting mixture was stirred at −70° C. for 2 h. The mixture was quenched with phosphate buffer (pH=7, 30 mL) at −70° C. followed by EtOAc (100 mL), the mixture was filtered and the organic filtrate was concentrated, the residue was dissolved in EtOAc (20 mL), mixed with petroleum ether (50 mL) and stirred for 30 min, the solid was filtered and dried to give (1-(tert-butoxycarbonyl)-4-(furan-3-yl)-1H-indol-2-yl)boronic acid (LXXIV) (4.2 g, 80.8% yield) as yellow solid. ESIMS found for C₁₇H₁₈BNO₅ m/z 350.0 (M+Na).

The following intermediates were prepared in accordance with the procedure described in the above Scheme 15.

(1-(tert-Butoxycarbonyl)-4-(thiophen-2-yl)-1H-indol-2-yl)boronic acid (LXXV): Yellow solid (0.7 g, 2.04 mmol, crude). ¹H NMR (CDCl₃, 400 MHz) δ ppm 1.69 (s, 9H), 7.02-7.05 (m, 1H), 7.30-7.38 (m, 4H), 7.65-7.67 (m, 1H), 8.17 (d, J=6.8 Hz, 1H); ESIMS found C₁₇H₁₈BNO₄S m/z 366.0 (M+Na).

(1-(tert-Butoxycarbonyl)-4-(3-fluorophenyl)-1H-indol-2-yl)boronic acid (LXXVI): Off-white solid (3.7 g, 10.9 mmol, 85.2% yield). ¹H NMR (CDCl₃, 400 MHz) δ ppm 1.77 (s, 9H), 7.05-7.15 (m, 1H), 7.29-7.32 (m, 2H), 7.38 (s, 1H), 7.40-7.46 (m, 2H), 7.59 (s, 1H), 8.07 (d, J=8.8 Hz, 1H); ESIMS found C₁₉H₁₉BFNO₄ m/z 378.1 (M+Na).

(1-(tert-Butoxycarbonyl)-4-(4-fluorophenyl)-1H-indol-2-yl)boronic acid (LXXVII): Off-white solid (3.0 g, 8.87 mmol, 64.2% yield). ¹H NMR (CDCl₃, 400 MHz) δ ppm 1.69 (s, 9H), 6.93 (s, 1H), 7.25-7.31 (m, 3H), 7.37 (t, J=8.4 Hz, 1H), 7.48 (s, 1H), 7.61-7.66 (m, 2H), 8.18 (d, J=8.4 Hz, 1H); ESIMS found C₁₉H₁₉BFNO₄ m/z 378.0 (M+Na).

(1-(tert-Butoxycarbonyl)-4-(2-fluorophenyl)-1H-indol-2-yl)boronic acid (LXXVIII): Off-white solid (4.2 g, 12.4 mmol, 75.8% yield). ¹H NMR (CDCl₃, 400 MHz) δ ppm 1.69 (s, 9H), 6.69 (s, 1H), 7.24-7.29 (m, 1H), 7.33 (t, J=7.6 Hz, 1H), 7.40 (t, J=7.6 Hz, 1H), 7.45-7.54 (m, 3H), 8.21 (d, J=8.4 Hz, 1H); ESIMS found C₁₉H₁₉BFNO₄ m/z 3578.1 (M+Na).

(1-(tert-Butoxycarbonyl)-4-(pyridin-3-yl)-1H-indol-2-yl)boronic acid (LXXIX): Off-white solid (3.7 g, 10.9 mmol, 60.8% yield). ¹H NMR (DMSO-d6, 400 MHz) δ ppm 1.58 (s, 9H), 6.65 (s, 1H), 7.26-7.46 (m, 2H), 7.52 (dd, J=7.2 Hz, J=4.8 Hz, 1H), 7.98 (d, J=7.6 Hz, 1H), 8.15 (d, J=8 Hz, 1H), 8.59 (d, J=3.6 Hz, 1H), 8.77 (d, J=6 Hz, 1H); ESIMS found C₁₈H₁₉BN₂O₄ m/z 339.1 (M+H).

(1-(tert-Butoxycarbonyl)-4-(pyridin-4-yl)-1H-indol-2-yl)boronic acid (LXXX): Off-white solid (8.1 g, 24.0 mmol, 84.1% yield). ¹H NMR (acetone-d6, 400 MHz) δ ppm 1.69 (s, 9H), 6.98 (s, 1H), 7.38 (d, J=7.2 Hz, 1H), 7.44 (t, J=7.8 Hz, 1H), 7.60 (d, J=6 Hz, 2H), 8.26 (d, J=8.4 Hz, 1H), 8.68 (d, J=5.6 Hz, 2H); ESIMS found C₁₈H₁₉BN₂O₄ m/z 339.1 (M+H).

Preparation of intermediate (1-(tert-butoxycarbonyl)-4-(pyridin-2-yl)-1H-indol-2-yl)boronic acid (LXXXIV) is depicted below in Scheme 16.

Step 1

To a solution of tert-butyl 4-bromo-1H-indole-1-carboxylate (LXX) (9 g, 30 mmol) and bis(pinacolato)diboron (8.45 g, 33 mmol) in DMSO (180 mL) was added KOAc (9 g, 91 mmol). The suspension was purged with nitrogen (3×) before adding Pd(dppf)Cl₂ (744 mg, 912 μmol). The reaction was stirred at 80° C. for 12 h. The suspension was poured into water (400 mL) and extracted with EtOAc (300 mL×2). The combined organic layer was washed with brine (200 mL), dried over Na₂SO₄ and concentrated under reduced pressure. Then the crude product was purified by silica gel (PE:EtOAc=40:1) to give tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-1-carboxylate (LXXXI) (7.8 g, 22.7 mmol, 75.8% yield) as a white solid. ¹H NMR (CDCl₃, 400 MHz) δ ppm 1.38 (s, 12H), 1.68 (s, 9H), 7.09 (d, J=3.6 Hz, 1H), 7.30 (t, J=7.6 Hz, 1H), 7.61 (d, J=3.2 Hz, 1H), 7.70 (d, J=7.2 Hz, 1H), 8.24 (d, J=8 Hz, 1H); ESIMS found for C₁₉H₂₆BNO₄ m/z 344.1 (M+H).

Step 2

A solution of tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-1-carboxylate (LXXXI) (4.8 g, 14 mmol) and 2-bromopyridine (LXXXII) (2.6 g, 17 mmol) in THF (70 mL) was added aqueous NaOH (2.24 g, 56 mmol) in water (30 mL). The suspension was purged with nitrogen (3×) before adding Pd(PPh₃)₄ (485 mg, 420 μmol). The reaction was heated to 70° C. and stirred for 6 h. The suspension was poured into water (80 mL) and extracted with EtOAc (250 mL×2). The combined organic layer was washed with brine (100 mL), dried over Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by silica gel (PE:EtOAc=30:1) to give tert-butyl 4-(pyridin-2-yl)-1H-indole-1-carboxylate (LXXXIII) (3.5 g, 11.9 mmol, 84.9% yield) as a yellow oil. ¹H NMR (CDCl₃, 400 MHz) δ ppm 1.69 (s, 9H), 7.29 (d, J=7.6 Hz, 2H), 7.42 (t, J=7.6 Hz, 1H), 7.62 (d, J=7.2 Hz, 1H), 7.67 (d, J=3.6 Hz, 1H), 7.74 (d, J=8 Hz, 1H), 7.82 (t, J=8 Hz, 1H), 8.26 (d, J=8.4 Hz, 1H), 8.78 (d, J=4.8 Hz, 1H); ESIMS found for C₁₈H₁₈N₂O₂ m/z 295.1 (M+H).

To a solution of tert-butyl 4-(pyridin-2-yl)-1H-indole-1-carboxylate (LXXXIII) (3.5 g, 11.9 mmol, 1 eq) and triisopropyl borate (4.5 g, 23.8 mmol, 2 eq) in THF (78 mL) was added LDA (2 M, 15.0 mL, 30.0 mmol, 2.5 eq) dropwise at −60 to 70° C. The reaction was stirred at −60° C. for 1 h. The reaction was quenched with buffer (NaH₂PO₄/Na₂HPO₄) solution (pH=7, 30 mL) at −60 to 70° C. and then warmed to 25° C. and stirred for 10 min. The suspension was then poured into water (80 mL) and extracted with EtOAc (150 mL). The organic layer was concentrated to give a crude product. To the crude product was added petroleum ether (200 mL) and stirred for 1 h. The solid was collected by filtration and dried under reduced pressure to give (1-(tert-butoxycarbonyl)-4-(pyridin-2-yl)-1H-indol-2-yl)boronic acid (LXXXIV) as an off-white solid (2.7 g, 7.98 mmol, 67.1% yield). ¹H NMR (acetone-d6, 400 MHz) δ ppm 1.69 (s, 9H), 7.30-7.37 (m, 1H), 7.38-7.46 (m, 2H), 7.67 (d, J=7.6 Hz, 1H), 7.82-7.94 (m, 2H), 8.25 (d, J=8 Hz, 1H), 8.74 (d, J=4.4 Hz, 1H); ESIMS found for C₁₈H₁₉BN₂O₄ m/z 339.1 (M+H).

Preparation of intermediate (1-(tert-butoxycarbonyl)-4-(3-((tert-butoxycarbonyl)(2-(dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-indol-2-yl)boronic acid (XC) is depicted below in Scheme 17.

Step 1

To mixture of 1,3-dibromo-5-fluorobenzene (LXXXV) (100 g, 393 mmol) and N′,N′-dimethylethane-1,2-diamine (173 g, 1.97 mol, 214 mL) was added t-BuOK (88 g, 787 mmol) in one portion at 25° C. under N₂. The mixture was stirred at 25° C. for 30 min, then heated to 110° C. and stirred for 11.5 h. The mixture was cooled to 25° C. and concentrated in reduced pressure at 45° C. The residue was purified by silica gel chromatography (column height: 250 mm, diameter: 100 mm, 100-200 mesh silica gel, PE/EtOAc=2:1, Rf=0.6) to give N¹-(3-bromo-5-fluorophenyl)-N²,N²-dimethylethane-1,2-diamine (LXXXVI) (30 g, 114.9 mmol, 29.2% yield) as a yellow oil. ESIMS found for C₁₀H₁₄BrFN₂ m/z 261.1 (M+H).

Step 1

To a mixture of N¹-(3-bromo-5-fluorophenyl)-N²,N²-dimethylethane-1,2-diamine (LXXXVI) (30 g, 114 mmol) in DCM (200 mL) was added (Boc)₂O (37.6 g, 172 mmol), TEA (34.8 g, 344 mmol) and DMAP (7 g, 57.4 mmol) in one portion at 25° C. under N₂. The mixture was stirred at 25° C. for 12 h. The mixture was concentrated in reduced pressure at 45° C. The residue was purified by silica gel chromatography (column height: 250 mm, diameter: 100 mm, 100-200 mesh silica gel, PE/EtOAc=2:1, R_(f)=0.43) to give tert-butyl (3-bromo-5-fluorophenyl)(2-(dimethylamino)ethyl)carbamate (LXXXVII) (20 g, 55.4 mmol, 48.2% yield) as yellow oil. ¹H NMR (CDCl₃, 400 MHz) δ ppm 1.43 (s, 9H), 2.21 (s, 6H), 2.41 (t, J=7 Hz, 2H), 3.67 (t, J=7.2 Hz, 2H), 6.96 (d, J=9.6 Hz, 1H), 7.06 (d, J=6 Hz, 1H), 7.22 (s, 1H); ESIMS found for C₁₅H₂₂BrFN₂O₂ m/z 361.0 (M+H).

Step 3

To a mixture of tert-butyl (3-bromo-5-fluorophenyl)(2-(dimethylamino)ethyl) carbamate (LXXXVII) (19 g, 52.6 mmol) and bis(pinacolato)diboron (20 g, 78.9 mmol) in dioxane (60 mL) was added Pd(dppf)Cl₂ (3.8 g, 5.26 mmol) and KOAc (30.9 g, 315.6 mmol) in one portion at 25° C. under N₂. The mixture was stirred at 25° C. for 30 min, then heated to 110° C. and stirred for 11.5 h. The mixture was cooled to 25° C. and concentrated in reduced pressure at 45° C. The residue was purified by silica gel chromatography (column height: 250 mm, diameter: 100 mm, 100-200 mesh silica gel, PE/EtOAc=1:1, Rf=0.24) to give tert-butyl (2-(dimethylamino)ethyl)(3-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)carbamate (LXXXVIII) (15 g, 36.7 mmol, 69.8% yield) as yellow oil. ESIMS found for C₂₁H₃₄BFN₂O₄ m/z 327.2 (M+H as the boronic acid).

Step 4

To a mixture of tert-butyl (2-(dimethylamino)ethyl)(3-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)carbamate (LXXXVIII) (20 g, 48.9 mmol) and tert-butyl 4-bromo-1H-indole-1-carboxylate (LXXI) (21.7 g, 73.4 mmol) in dioxane (100 mL) and water (10 mL) was added Pd(dppf)Cl₂ (3.58 g, 4.9 mmol) and K₂CO₃ (20 g, 146 mmol) in one portion at 25° C. under N₂. The mixture was stirred at 25° C. for 30 min, then heated to 110° C. and stirred for 5.5 h. The mixture was cooled to 25° C. and concentrated in reduced pressure at 45° C. The residue was purified by prep-HPLC (acid conditions) to produce tert-butyl 4-(3-((tert-butoxycarbonyl)(2-(dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-indole-1-carboxylate (LXXXIX) (6 g, 12.1 mmol, 24.7% yield) as yellow oil. ESIMS found for C₂₈H₃₆FN₃O₄ m/z 498.2 (M+H of the boronic acid).

To a solution of tert-butyl 4-(3-((tert-butoxycarbonyl)(2-(dimethylamino) ethyl)amino)-5-fluorophenyl)-1H-indole-1-carboxylate (LXXXIX) (3 g, 6.03 mmol, 1 eq) and triisopropyl borate (2.28 g, 12.1 mmol, 2 eq) in THF (78 mL) was added LDA (2 M, 7.5 mL, 15.1 mmol, 2.5 eq) dropwise at −60 to 70° C. The reaction was stirred at −60° C. for 1 h. The reaction was quenched with buffer (NaH₂PO₄Na₂HPO₄) solution (pH=7, 30 mL) at −60 to 70° C. Then warmed to 25° C. and stirred for 10 min. The suspension was then poured into water (80 mL) and extracted with EtOAc (150 mL). The organic layer was concentrated to give a crude product. The crude product was mixed with petroleum ether (200 mL) and stirred for 1 h. The solid was collected by filtration and dried under reduced pressure to give (1-(tert-butoxycarbonyl)-4-(3-((tert-butoxycarbonyl)(2-(dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-indol-2-yl)boronic acid (XC) (2 g, 3.69 mmol, 61.3% yield) as yellow oil. ESIMS found for C₂₈H₃₇BFN₃O₆ m/z 542.3 (M+H).

The following intermediate was prepared in accordance with the procedure described in the above Scheme 17.

(1-(tert-Butoxycarbonyl)-4-(3-fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-indol-2-yl)boronic acid (XCI): Yellow solid. ¹H NMR (MeOD, 400 MHz) δ ppm 1.13 (s, 9H), 2.90 (s, 3H), 4.32 (s, 2H), 7.04-7.13 (m, 3H), 7.13-7.21 (m, 1H), 7.25-7.33 (m, 2H), 7.40 (t, J=8.4 Hz, 1H); ESIMS found C₂₁H₂₄BFN₂O₆S m/z 485.1 (M+Na).

Preparation of intermediate (1-(tert-butoxycarbonyl)-4-(piperidin-1-yl)-1H-indol-2-yl)boronic acid (XCIV) is depicted below in Scheme 18.

Step 1

To a solution of tert-butyl 4-bromo-1H-indole-1-carboxylate (LXXI) (8.0 g, 27.0 mmol) in toluene (150 mL) was added piperidine (XCII) (6.9 g, 81 mmol), Cs₂CO₃ (17.6 g, 54 mmol), XPhos (1.29 g, 2.7 mmol) and Pd₂(dba)₃ (1.24 g, 1.35 mmol). The mixture was de-gassed and then heated to 100° C. for 12 h under N₂. The mixture was filtered and the filtrate was concentrated, the residue was purified by MPLC (PE:EtOAc=50:1 to 20:1) to yield tert-butyl 4-(piperidin-1-yl)-1H-indole-1-carboxylate (XCIII) (3.6 g, 12.0 mmol, 44.4% yield) as yellow oil. ¹H NMR (CDCl₃, 400 MHz) δ ppm 1.60-1.66 (m, 2H), 1.68 (s, 9H), 1.75-1.88 (m, 4H), 3.13 (t, J=5.2 Hz, 4H), 6.62 (d, J=3.6 Hz, 1H), 6.75 (d, J=7.6 Hz, 1H), 7.22 (t, J=8 Hz, 1H), 7.53 (d, J=3.6 Hz, 1H), 7.79 (d, J=8 Hz, 1H); ESIMS found for C₁₈H₂₄N₂O₂ m/z 301.0 (M+H).

Step 2

To a solution of tert-butyl 4-(piperidin-1-yl)-1H-indole-1-carboxylate (XCIII) (3.6 g, 12.0 mmol, 1.0 eq) in THF (100 mL) was added LDA (2 M, 9.0 mL, 18.0 mmol, 1.5 eq) dropwise at −70° C., then triisopropyl borate (4.5 g, 24.0 mmol, 2.00 eq) was added at −70° C., and the resulting mixture was stirred at −70° C. for 1 hr. The mixture was quenched with buffer (pH=7, 30 mL) at −70° C. followed by water (50 mL) and extraction with EtOAc (50 mL×2). The organic phases were dried and concentrated, the residue was mixed with petroleum ether (40 mL) and stirred for 30 min, the mixture was filtered, the cake was washed with petroleum ether (10 mL×2) and dried to give (1-(tert-butoxycarbonyl)-4-(piperidin-1-yl)-1H-indol-2-yl)boronic acid (XCIV). (2.8 g, 8.13 mmol, 67.9% yield) as a white solid. ¹H NMR (CDCl₃, 400 MHz) δ ppm 1.60-1.68 (m, 2H), 1.74 (s, 9H), 1.76-1.87 (m, 4H), 3.14 (t, J=5.6 Hz, 4H), 6.75 (d, J=7.6 Hz, 1H), 6.85 (s, 2H), 7.24 (d, J=8.4 Hz, 1H), 7.53 (s, 1H), 7.65 (d, J=9.2 Hz, 1H); ESIMS found for C₁₈H₂₅BN₂O₄ m/z 345.1 (M+H).

The following intermediate was prepared in accordance with the procedure described in the above Scheme 18.

(1-(tert-Butoxycarbonyl)-4-(4-methylpiperazin-1-yl)-1H-indol-2-yl)boronic acid (XCV): White solid (2.3 g, 6.4 mmol, 44.9% yield). ¹H NMR (DMSO-d6, 400 MHz) δ ppm 1.55 (s, 9H), 2.22 (s, 3H), 2.46-2.55 (m, 4H), 3.04 (brs, 4H), 6.54 (s, 1H), 6.64 (d, J=8 Hz, 1H), 7.12 (t, J=8 Hz, 1H), 7.68 (d, J=7.6 Hz, 1H), 8.13 (s, 2H); ESIMS found C₁₈H₂₆BN₃O₄ m/z 360.1 (M+H).

Example 1

Preparation of 3-methyl-N-(5-(3-(4-(pyridin-4-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)butanamide (114) is depicted below in Scheme 19.

Steps 1

To a solution of N-(5-bromopyridin-3-yl)-3-methylbutanamide (XXVI) (5.22 g, 20.3 mmol, 1.0 eq) in toluene (100 mL) was added 1-(tetrahydro-2H-pyran-2-yl)-5-(tributylstannyl)-1H-pyrazolo[3,4-c]pyridine (XVIII) (10 g, 20.3 mmol, 1.0 eq), and Pd(PPh₃)₄ (1.17 g, 1.0 mmol, 0.05 eq) under N₂. The suspension was stirred at 120° C. for 6 h. The suspension was concentrated under reduced pressure. The residue was purified by silica gel chromatography (DCM:MeOH=10:1) to give 3-methyl-N-(5-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)butanamide (XCVI) as a brown solid (7.0 g, 18.4 mmol, 90.6% yield). ESIMS found for C₂₁H₂₅N₅O₂ m/z 380.1 (M+H).

Step 21

To a stirred solution of 3-methyl-N-(5-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)butanamide (XCVI) (7.0 g, 18.4 mmol) in MeOH (21 mL) was added HCl/MeOH (4 M, 70 mL) at 20-25° C. The reaction suspension was stirred at this temperature for 3 h. The reaction suspension was concentrated under reduced pressure and triturated with MTBE (20 mL). The resulted slurry was filtered and dried in vacuum to give crude N-(5-(1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-3-methylbutanamide (XCVII) as a yellow solid (6.8 g, crude). ESIMS found for C₁₆H₁₇N₅O m/z 296.1 (M+H).

Steps 1

To a solution of N-(5-(1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-3-methylbutanamide (XCVII) (6.8 g, 23 mmol, 2 HCl) in DMF (50 mL) was added KOH (3.9 g, 69.1 mmol, 3 eq) and I₂ (4.4 g, 34.5 mmol, 1.5 eq). The mixture was stirred at 25° C. for 3 h. The mixture was poured into H₂O (100 mL) and EtOAc (100 mL) was added. The layers were separated and the aqueous layer was again extracted with EtOAc (50 mL×2). The combined organic layer was washed with saturated Na₂SO₃ solution, brine (100 mL), dried over anhydrous sodium sulfate and concentrated to give crude N-(5-(3-iodo-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-3-methylbutanamide (XCVIII) (8.2 g, 19.5 mmol, 84.5% yield) as a yellow solid which was used into the next step without further purification. ESIMS found for C₁₆H₁₆IN₅O m/z 422.1 (M+H).

Steps 4

To a solution of N-(5-(3-iodo-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-3-methylbutanamide (XCVIII) (4.0 g, 9.5 mmol, 1.0 eq) in DCM (40 mL), was added dropwise TEA (2.65 mL, 19.0 mmol, 2 eq), (Boc)₂O (3.1 g, 14.2 mmol, 1.5 eq) in turn. The solution was stirred for 12 h at 25° C. The reaction mixture was concentrated under reduced pressure and then diluted with water (60 mL). The aqueous phase was extracted with EtOAc (30 mL×3). The combined organic phase was washed with brine (50 mL×2), dried with anhydrous Na₂SO₄, filtered and concentrated in vacuum. The crude product was washed with MTBE to give tert-butyl 5-(5-(N-(tert-butoxycarbonyl)-3-methylbutanamido)pyridin-3-yl)-3-iodo-1H-pyrazolo[3,4-c]pyridine-1-carboxylate (XCIX) (2.2 g, 3.54 mmol, 37.3% yield) as a white solid. ¹H NMR (DMSO-d6, 400 MHz) δ ppm 0.97 (d, J=6.8 Hz, 6H), 1.36 (s, 9H), 1.69 (s, 9H), 2.07-2.17 (m, 1H), 2.90 (d, J=6.8 Hz, 2H), 8.25 (s, 1H), 8.44 (d, J=2.0 Hz, 1H), 8.49 (d, J=4 Hz, 1H), 9.38 (s, 1H), 9.44 (s, 1H); ESIMS found for C₂₆H₃₂IN₅O₅ m/z 622.8 (M+H).

Steps 5

A mixture of tert-butyl 5-(5-(N-(tert-butoxycarbonyl)-3-methylbutanamido) pyridin-3-yl)-3-iodo-1H-pyrazolo[3,4-c]pyridine-1-carboxylate (XCIX) (80 mg, 0.129 mmol, 1.0 eq), (1-(tert-butoxycarbonyl)-4-(pyridin-4-yl)-1H-indol-2-yl)boronic acid (LXXX) (43.5 mg, 0.129 mmol, 1.0 eq), Pd(PPh₃)₄ (14.9 mg, 0.013 mmol, 0.1 eq) and K₃PO₄ (54.6 mg, 0.257 mmol, 2.0 eq) in H₂O (4.0 mL) and dioxane (4.0 mL) was stirred at 85° C. for 16 h under N₂. The mixture was filtered and the filtrate was concentrated to give the crude tert-butyl 5-(5-(N-(tert-butoxycarbonyl)-3-methylbutanamido) pyridin-3-yl)-3-(1-(tert-butoxycarbonyl)-4-(pyridin-4-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine-1-carboxylate (C) (100 mg, 0.127 mmol, 98.6% yield) which was used in the next step directly. ESIMS found for C₄₄H₄₉N₇O₇ m/z 788.5 (M+1).

Step 6

A mixture of tert-butyl 5-(5-(N-(tert-butoxycarbonyl)-3-methylbutanamido) pyridin-3-yl)-3-(1-(tert-butoxycarbonyl)-4-(pyridin-4-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine-1-carboxylate (C) (100 mg, ˜0.127 mmol) in HCl/EtOAc (4 M, 50 mL) was stirred at 20° C. for 16 h. The mixture was filtered and the filtrate was concentrated. The residue was purified by acid prep-HPLC to give 3-methyl-N-(5-(3-(4-(pyridin-4-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)butanamide (114) as an off-white solid (22 mg, 0.045 mmol, 35.5% yield). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.99 (d, J=6.62 Hz, 6H), 2.16 (dt, J=13.56, 6.67 Hz, 1H), 2.37 (br d, J=7.28 Hz, 2H), 7.41 (br t, J=7.83 Hz, 1H), 7.55 (br d, J=7.28 Hz, 1H), 7.64 (s, 1H), 7.80 (br d, J=8.16 Hz, 1H), 8.55 (br d, J=6.39 Hz, 2H), 8.96 (s, 1H), 9.03 (br d, J=6.40 Hz, 2H), 9.15 (s, 1H), 9.31 (s, 1H), 9.33 (br s, 1H), 9.48 (s, 1H), 11.10 (br s, 1H), 12.41 (s, 1H), 14.42 (br s, 1H); ESIMS found for C₂₉H₂₅N₇O m/z 488.2 (M+1).

Preparation of N,N-dimethyl-5-(3-(4-(thiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-amine (343) is depicted below in Scheme 20.

Steps 1-2

A mixture of 5-bromo-N,N-dimethylpyridin-3-amine (XXXVI) (6.17 g, 30.7 mmol, 1.0 eq), bis(pinacolato)diboron (10.1 g, 39.9 mmol, 1.3 eq), Pd(dppf)Cl₂ (2.2 g, 3.07 mmol, 0.1 eq) and KOAc (16.3 g, 76.7 mmol, 2.5 eq) in dioxane (50 mL) was stirred at 85° C. for 16 h. The mixture was filtered and the filtrate was concentrated to give the crude N,N-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-amine as a brown oil. A mixture of 5-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-c]pyridine (XVII) (8.7 g, 30.7 mmol, 1.0 eq), the above obtained N,N-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-amine, Pd(dppf)Cl₂ (2.2 g, 3.07 mmol, 0.1 eq) and Na₂CO₃ (6.5 g, 61.4 mmol, 2.0 eq) in dioxane (50 mL) and H₂O (10 mL) was stirred at 85° C. for 16 h. The mixture was concentrated and the residue was purified by silica gel column chromatography to give N,N-dimethyl-5-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-amine (CI) as a yellow solid (4.4 g, 13.6 mmol, 44.3% yield). ¹H NMR (CDCl₃, 400 MHz) δ ppm 1.65-1.90 (m, 3H), 2.17 (d, J=12.4 Hz, 2H), 2.47-2.61 (m, 1H), 3.08 (s, 6H), 3.75-3.86 (m, 1H), 3.99-4.10 (m, 1H), 5.87 (dd, F=2 Hz, J=8.4 Hz, 1H), 7.70 (s, 1H), 8.05 (s, 1H), 8.12 (s, 1H), 8.17 (d, J=2.8 Hz, 1H), 8.56 (s, 1H), 9.26 (s, 1H); ESIMS found for C₁₈H₂₁N₅O m/z 324.1 (M+H).

Steps 3-5

Intermediates, CII, CIII, and CIV were prepared using the procedures listed in Scheme 19, Steps 2-4.

Steps 6

A mixture of tert-butyl 5-(5-(dimethylamino)pyridin-3-yl)-3-iodo-1H-pyrazolo[3,4-c]pyridine-1-carboxylate (CIV) (80 mg, 0.172 mmol, 1.0 eq), (1-(tert-butoxycarbonyl)-4-(thiophen-2-yl)-1H-indol-2-yl)boronic acid (LXXV) (65.0 mg, 0.189 mmol, 1.1 eq), Pd(dppf)Cl₂ (12.6 mg, 0.02 mmol, 0.1 eq), and K₃PO₄ (73.0 mg, 0.344 mmol, 2.0 eq) in dioxane (10 mL) and water (1 mL) was stirred at 90° C. for 16 h. The mixture was filtered and the filtrate was concentrated to give the crude tert-butyl 3-(1-(tert-butoxycarbonyl)-4-(thiophen-2-yl)-1H-indol-2-yl)-5-(5-(dimethylamino)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine-1-carboxylate (CV) as a yellow solid (50 mg, 0.079 mmol, 45.7% yield) which was used in the next step directly. ESIMS found for C₃₅H₃₆N₆O₄S m/z 637.0 (M+H).

Step 7

A mixture of tert-butyl 3-(1-(tert-butoxycarbonyl)-4-(thiophen-2-yl)-1H-indol-2-yl)-5-(5-(dimethylamino)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine-1-carboxylate (CV) (50 mg, ˜0.079 mmol) in HCl/EtOAc (4 M, 50 mL) was stirred at 20° C. for 16 h. The mixture was filtered and the filtrate was concentrated. The residue was purified by acid prep-HPLC to give N,N-dimethyl-5-(3-(4-(thiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl) pyridin-3-amine (343) as an off-white solid (5 mg, 0.011 mmol, 14.6% yield). ¹H NMR (400 MHz, METHANOL-d₄) δ ppm 3.12 (s, 6H), 6.91-6.99 (m, 1H), 7.14-7.24 (m, 1H), 7.31-7.39 (m, 2H), 7.42 (d, J=8.38 Hz, 1H), 7.60 (d, J=3.97 Hz, 1H), 7.86-7.90 (m, 1H), 7.92 (d, J=3.75 Hz, 1H), 8.09 (d, J=3.09 Hz, 1H), 8.53 (d, J=1.10 Hz, 1H), 8.55 (d, J=1.76 Hz, 1H), 9.12 (s, 1H); ESIMS found for C₂₅H₂₀N₆S m/z 437.0 (M+1).

The following compounds were prepared in accordance with the procedures described herein. See, for example, Schemes 1a and 1-20.

N-(5-(3-(4-(3-Fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl) pyridin-3-yl)propionamide 1

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.14 (t, J=7.42 Hz, 4H), 2.39-2.48 (m, 2H), 7.19 (d, J=6.26 Hz, 1H), 7.22-7.32 (m, 2H), 7.40 (d, J=2.35 Hz, 1H), 7.52-7.72 (m, 4H), 8.74 (s, 1H), 8.95 (br d, J=2.35 Hz, 1H), 8.97-9.03 (m, 1H), 9.23 (d, J=1.57 Hz, 1H), 9.27 (d, J=1.17 Hz, 1H), 10.52 (br s, 1H), 12.01 (d, J=1.57 Hz, 1H); ESIMS found for C₂₈H₂₁FN₆O m/z 477.1 (M+1).

3-(4-(3-Fluorophenyl)-1H-indol-2-yl)-5-(4-methylpyridin-3-yl)-1H-pyrazolo [3,4-c]pyridine 5

¹H NMR (400 MHz, DMSO-d₆) δ ppm 2.41 (s, 3H), 7.16 (d, J=7.06 Hz, 1H), 7.18-7.32 (m, 3H), 7.38 (br d, J=5.07 Hz, 1H), 7.48-7.60 (m, 3H), 7.60-7.68 (m, 1H), 8.32 (s, 1H), 8.48 (d, J=4.85 Hz, 1H), 8.68 (s, 1H), 9.22 (s, 1H), 11.95 (s, 1H), 14.07 (s, 1H); ESIMS found for C₂₆H₁₈FN₅ m/z 420.1 (M+1).

N-(5-(3-(4-(3-Fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl) pyridin-3-yl)benzamide 11

¹H NMR (400 MHz, DMSO-d₆) δ ppm 7.16-7.24 (m, 2H), 7.27 (t, J=7.60 Hz, 1H), 7.39 (d, J=1.54 Hz, 1H), 7.53-7.71 (m, 7H), 8.02-8.09 (m, 2H), 8.69 (s, 1H), 9.01 (s, 2H), 9.17 (d, J=1.32 Hz, 1H), 9.26 (d, J=1.10 Hz, 1H), 10.60 (s, 1H), 11.99 (d, J=1.76 Hz, 1H), 14.09 (s, 1H); ESIMS found for C₃₂H₂₁FN₆O m/z 525.1 (M+1).

1-(5-(3-(4-(3-Fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl) pyridin-3-yl)-N,N-dimethylmethanamine 13

¹H NMR (400 MHz, DMSO-d₆) δ ppm 2.82 (d, J=4.70 Hz, 6H), 4.48 (d, J=5.09 Hz, 2H), 7.19 (dd, J=7.24, 0.98 Hz, 1H), 7.23-7.33 (m, 2H), 7.42 (d, J=1.17 Hz, 1H), 7.54-7.64 (m, 3H), 7.67-7.73 (m, 1H), 8.79 (d, J=1.96 Hz, 1H), 8.82 (d, J=1.17 Hz, 1H), 8.89 (s, 1H), 9.27 (d, J=1.17 Hz, 1H), 9.54 (d, J=1.96 Hz, 1H), 10.39 (s, 1H), 12.02 (s, 1H); ESIMS found for C₂₈H₂₃FN₆ m/z 463.2 (M+1).

N-(5-(3-(4-(3-Fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl) pyridin-3-yl)-3,3-dimethylbutanamide 16

ESIMS found for C₃₁H₂₇FN₆O m/z 519.2 (M+1).

N-(5-(3-(4-(3-Fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl) pyridin-3-yl)cyclobutanecarboxamide 21

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.77-1.91 (m, 1H), 1.93-2.04 (m, 1H), 2.11-2.23 (m, 2H), 2.23-2.32 (m, 2H), 7.19 (d, J=7.06 Hz, 1H), 7.21-7.33 (m, 2H), 7.39 (br d, J=1.54 Hz, 1H), 7.47-7.72 (m, 4H), 8.71 (s, 1H), 8.91 (s, 1H), 8.97 (br s, 1H), 9.19 (br d, J=0.10 Hz, 1H), 9.25 (s, 1H), 10.31 (br s, 1H), 12.00 (s, 1H), 14.15 (br s, 1H); ESIMS found for C₃₀H₂₃FN₆O m/z 503.1 (M+1).

5-(5-((3,3-Difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-3-(4-(3-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine 26

¹H NMR (400 MHz, METHANOL-d₄) δ ppm 2.35-2.49 (m, 2H), 3.08 (t, J=7.18 Hz, 2H), 3.24 (br t, J=12.57 Hz, 2H), 7.08-7.14 (m, 1H), 7.16 (d, J=7.28 Hz, 1H), 7.28 (t, J=7.72 Hz, 1H), 7.32 (s, 1H), 7.46-7.55 (m, 3H), 7.56-7.63 (m, 1H), 8.63 (s, 1H), 8.68 (s, 1H), 8.87 (s, 1H), 9.17 (s, 1H), 9.34 (s, 1H); ESIMS found for C₃₀H₂₃F₃N₆ m/z 525.1 (M+1).

3-(4-(3-Fluorophenyl)-1H-indol-2-yl)-5-(pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridine 28

¹H NMR (400 MHz, DMSO-d₆) δ ppm 7.19 (br d, J=6.61 Hz, 1H), 7.23-7.36 (m, 3H), 7.50-7.72 (m, 5H), 8.14-8.24 (m, 1H), 8.59-8.68 (m, 1H), 8.76 (br d, J=4.63 Hz, 1H), 9.09 (s, 1H), 9.27 (s, 1H), 12.08 (br d, J=2.21 Hz, 1H), 14.25 (br s, 1H); ESIMS found for C₂₅H₁₆FN₅ m/z 406.1 (M+1).

N-(5-(3-(4-(4-Fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-3-methylbutanamide 30

¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.99 (d, J=6.62 Hz, 6H), 2.12-2.23 (m, 1H), 2.52 (d, J=1.98 Hz, 2H), 7.14 (br d, J=6.61 Hz, 1H), 7.20-7.31 (m, 2H), 7.35-7.45 (m, 2H), 7.52 (br d, J=7.94 Hz, 1H), 7.85 (br dd, J=8.60, 5.51 Hz, 2H), 8.72 (s, 1H), 8.95 (br d, J=1.54 Hz, 1H), 9.01-9.08 (m, 1H), 9.20-9.30 (m, 2H), 10.55 (br s, 1H), 11.98 (br d, J=2.43 Hz, 1H), 14.14 (br s, 1H); ESIMS found for C₃₀H₂₅FN₆O m/z 50.2 (M+1).

N-((5-(3-(4-(4-Fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methyl)ethanamine 34

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.28 (t, J=7.28 Hz, 3H), 3.02-3.15 (m, 2H), 4.31-4.40 (m, 2H), 7.14 (dd, J=7.28, 0.88 Hz, 1H), 7.23-7.30 (m, 1H), 7.33-7.44 (m, 3H), 7.56 (d, J=8.16 Hz, 1H), 7.81-7.91 (m, 2H), 8.80 (dd, J=8.05, 1.43 Hz, 2H), 8.96 (br s, 1H), 9.27 (d, J=1.10 Hz, 1H), 9.51 (d, J=1.98 Hz, 1H), 11.97 (br d, J=1.98 Hz, 1H), 14.19 (br s, 1H); ESIMS found for C₂₈H₂₃FN₆ m/z 463.1 (M+1).

N-(5-(3-(4-(4-Fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)pivalamide 36

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.32 (s, 9H), 7.14 (dd, J=7.28, 0.88 Hz, 1H), 7.23-7.31 (m, 1H), 7.31-7.47 (m, 3H), 7.54 (d, J=8.16 Hz, 1H), 7.79-7.91 (m, 2H), 8.90 (s, 1H), 9.23-9.35 (m, 2H), 9.43-9.53 (m, 2H), 10.36 (s, 1H), 12.05 (d, J=1.54 Hz, 1H), 14.31 (br s, 1H); ESIMS found for C₃₀H₂₅FN₆O m/z 505.2 (M+1).

N-(5-(3-(4-(4-Fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl) pyridin-3-yl)-2-phenylacetamide 38

¹H NMR (400 MHz, DMSO-d₆) δ ppm 3.74 (s, 2H), 7.13 (dd, J=7.28, 0.66 Hz, 1H), 7.21-7.30 (m, 3H), 7.31-7.44 (m, 6H), 7.52 (d, J=8.16 Hz, 1H), 7.78-7.88 (m, 2H), 8.65 (s, 1H), 8.83 (d, J=2.21 Hz, 1H), 8.89 (br t, J=1.98 Hz, 1H), 9.15 (d, J=1.98 Hz, 1H), 9.23 (d, J=1.10 Hz, 1H), 10.63 (s, 1H), 11.95 (d, J=1.98 Hz, 1H), 14.09 (s, 1H); ESIMS found for C₃₃H₂₃FN₆O m/z 539.0 (M+1).

3-(4-(4-Fluorophenyl)-1H-indol-2-yl)-5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine 42

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.87-2.01 (m, 2H), 2.03-2.16 (m, 2H), 3.13-3.25 (m, 2H), 3.43-3.56 (m, 2H), 4.65 (br d, J=5.73 Hz, 2H), 7.14 (dd, J=7.28, 0.88 Hz, 1H), 7.21-7.31 (m, 1H), 7.33-7.46 (m, 3H), 7.58 (d, J=7.94 Hz, 1H), 7.88 (dd, J=8.82, 5.73 Hz, 2H), 8.99 (d, J=0.88 Hz, 1H), 9.01 (d, J=1.54 Hz, 1H), 9.29 (d, J=1.10 Hz, 1H), 9.37 (s, 1H), 9.62 (d, J=1.98 Hz, 1H), 11.51 (br s, 1H), 12.01 (d, J=1.76 Hz, 1H), 14.31 (br s, 1H); ESIMS found for C₃₀H₂₅FN₆ m/z 489.1 (M+1).

N-(5-(3-(4-(4-Fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl) pyridin-3-yl)cyclohexanecarboxamide 51

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.21-1.39 (m, 3H), 1.42-1.57 (m, 2H), 1.65-1.72 (m, 1H), 1.75-1.84 (m, 2H), 1.84-1.95 (m, 2H), 2.39-2.45 (m, 1H), 7.14 (d, J=7.50 Hz, 1H), 7.20-7.29 (m, 1H), 7.34 (d, J=2.21 Hz, 1H), 7.38-7.47 (m, 2H), 7.49-7.56 (m, 1H), 7.77-7.90 (m, 2H), 8.59 (d, J=1.10 Hz, 1H), 8.72 (d, J=2.21 Hz, 1H), 8.92 (d, J=1.98 Hz, 1H), 9.09 (d, J=1.76 Hz, 1H), 9.23 (s, 1H), 10.19 (s, 1H), 11.96 (s, 1H), 14.07 (s, 1H); ESIMS found for C₃₂H₂₇FN₆O m/z 531.0 (M+1).

3-(4-(4-Fluorophenyl)-1H-indol-2-yl)-5-(pyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridine 55

¹H NMR (400 MHz, DMSO-d₆) δ ppm 7.12 (d, J=7.28 Hz, 1H), 7.25 (t, J=7.72 Hz, 1H), 7.37 (t, J=8.82 Hz, 2H), 7.42 (s, 1H), 7.52 (d, J=7.94 Hz, 1H), 7.83 (dd, J=8.38, 5.73 Hz, 2H), 8.82 (s, 1H), 9.23 (s, 1H), 9.27 (s, 1H), 9.58 (s, 2H), 11.94 (s, 1H), 14.16 (brs, 1H); ESIMS found for C₂₄H₁₅FN₆ m/z 407.1 (M+1).

5-(3-(4-(2-Fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl) pyridin-3-amine 59

¹H NMR (400 MHz, DMSO-d₆) δ ppm 6.64 (br s, 2H), 7.10 (d, J=7.50 Hz, 1H), 7.15 (s, 1H), 7.27 (t, J=7.83 Hz, 1H), 7.35-7.43 (m, 2H), 7.44-7.54 (m, 1H), 7.57 (d, J=8.16 Hz, 1H), 7.65-7.73 (m, 1H), 8.00 (d, J=2.20 Hz, 1H), 8.42 (d, J=1.32 Hz, 1H), 8.73 (s, 1H), 8.85 (s, 1H), 9.25 (d, J=1.10 Hz, 1H), 11.98 (d, J=1.98 Hz, 1H), 14.24 (br s, 1H); ESIMS found for C₂₅H₁₇FN₆ m/z 421.0 (M+1).

3-(4-(2-Fluorophenyl)-1H-indol-2-yl)-5-(pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine 60

¹H NMR (400 MHz, DMSO-d₆) δ ppm 7.10 (d, J=7.28 Hz, 1H), 7.18 (s, 1H), 7.27 (t, J=7.72 Hz, 1H), 7.35-7.44 (m, 2H), 7.45-7.54 (m, 1H), 7.58 (d, J=8.16 Hz, 1H), 7.68 (td, J=7.66, 1.43 Hz, 1H), 8.05 (dd, J=7.94, 5.29 Hz, 1H), 8.85 (d, J=4.85 Hz, 1H), 8.88 (s, 1H), 9.17 (br d, J=7.94 Hz, 1H), 9.29 (s, 1H), 9.63 (s, 1H), 12.00 (s, 1H), 14.27 (br s, 1H); ESIMS found for C₂₅H₁₆FN₅ m/z 406.0 (M+1).

N-(5-(3-(4-(2-Fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)isobutyramide 65

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.17 (d, J=6.84 Hz, 6H), 2.52-2.58 (m, 1H), 7.08 (br s, 1H), 7.11 (br d, J=7.28 Hz, 1H), 7.23-7.31 (m, 1H), 7.34-7.44 (m, 2H), 7.44-7.52 (m, 1H), 7.56 (br d, J=8.16 Hz, 1H), 7.70 (td, J=7.61, 1.76 Hz, 1H), 8.56 (s, 1H), 8.78 (br d, J=2.21 Hz, 1H), 8.83 (br t, J=2.20 Hz, 1H), 9.05 (d, J=1.76 Hz, 1H), 9.22 (br d, J=0.88 Hz, 1H), 10.17 (s, 1H), 11.90 (br d, J=1.54 Hz, 1H), 14.03 (br s, 1H); ESIMS found for C₂₉H₂₃FN₆O m/z 491.2 (M+1).

5-(3-(4-(2-Fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)-N-isopropylpyridin-3-amine 68

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.22 (d, J=6.17 Hz, 6H), 3.80-3.91 (m, 1H), 7.10 (d, J=7.06 Hz, 1H), 7.17 (s, 1H), 7.23-7.30 (m, 1H), 7.33-7.42 (m, 2H), 7.45-7.55 (m, 1H), 7.60 (d, J=8.16 Hz, 1H), 7.69 (td, J=7.72, 1.54 Hz, 1H), 8.05 (d, J=2.43 Hz, 1H), 8.34-8.45 (m, 1H), 8.83 (d, J=1.10 Hz, 2H), 9.25 (d, J=1.10 Hz, 1H), 12.07 (br d, J=1.76 Hz, 1H), 14.35 (br s, 1H); ESIMS found for C₂₈H₂₃FN₆ m/z 463.1 (M+1).

3-(4-(2-Fluorophenyl)-1H-indol-2-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine 71

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.65-1.90 (m, 6H), 2.86-3.03 (m, 2H), 3.35-3.44 (m, 2H), 4.46 (br d, J=4.39 Hz, 2H), 7.11 (d, J=6.14 Hz, 1H), 7.14 (s, 1H), 7.23-7.30 (m, 1H), 7.33-7.42 (m, 2H), 7.45-7.54 (m, 1H), 7.60 (d, J=8.77 Hz, 1H), 7.67-7.77 (m, 1H), 8.78 (br d, J=8.77 Hz, 2H), 8.88 (br s, 1H), 9.26 (s, 1H), 9.50 (s, 1H), 11.95 (s, 1H), 14.19 (br s, 1H); ESIMS found for C₃₁H₂₇FN₆ m/z 503.1 (M+1).

N-(5-(3-(4-(2-Fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-3,3-dimethylbutanamide 72

ESIMS found for C₃₁H₂₇FN₆O m/z 519.2 (M+1).

N-(5-(3-(4-(2-Fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl) pyridin-3-yl)pentanamide 75

¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.93 (t, J=7.39 Hz, 3H), 1.37 (dq, J=14.99, 7.28 Hz, 2H), 1.58-1.71 (m, 2H), 2.39 (t, J=7.50 Hz, 2H), 7.06-7.15 (m, 2H), 7.23-7.29 (m, 1H), 7.36-7.44 (m, 2H), 7.44-7.53 (m, 1H), 7.56 (d, J=8.16 Hz, 1H), 7.69 (td, J=7.72, 1.54 Hz, 1H), 8.57 (s, 1H), 8.76 (d, J=2.20 Hz, 1H), 8.82 (t, J=2.09 Hz, 1H), 9.05 (d, J=1.98 Hz, 1H), 9.23 (d, J=1.10 Hz, 1H), 10.23 (s, 1H), 11.92 (d, J=1.54 Hz, 1H), 14.06 (s, 1H); ESIMS found for C₃₀H₂₅FN₆O m/z 505.1 (M+1).

N-(5-(3-(4-(2-Fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl) pyridin-3-yl)cyclopropanecarboxamide 76

¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.78-1.08 (m, 4H), 1.88 (dt, J=12.18, 6.15 Hz, 1H), 7.05-7.16 (m, 2H), 7.27 (t, J=7.72 Hz, 1H), 7.35-7.44 (m, 2H), 7.45-7.53 (m, 1H), 7.57 (d, J=8.16 Hz, 1H), 7.69 (td, J=7.72, 1.54 Hz, 1H), 8.69 (s, 1H), 8.95 (br d, J=1.98 Hz, 1H), 9.01 (s, 1H), 9.22 (br d, J=0.66 Hz, 1H), 9.25 (s, 1H), 10.95 (br s, 1H), 11.96 (br d, J=1.54 Hz, 1H), 14.18 (br s, 1H); ESIMS found for C₂₉H₂₁FN₆O m/z 489.0 (M+1).

N-(5-(3-(4-(Pyridin-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl) pyridin-3-yl)propionamide 85

¹H NMR (400 MHz, DMSO-d₆) δ ppm; ESIMS found for C₂₇H₂₁N₇O m/z 460.1 (M+1).

5-(Pyridin-3-yl)-3-(4-(pyridin-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine 88

¹H NMR (400 MHz, DMSO-d₆) δ ppm 7.32-7.44 (m, 2H), 7.62 (d, J=1.32 Hz, 1H), 7.74 (dd, J=7.28, 0.88 Hz, 1H), 8.18 (dd, J=8.16, 5.51 Hz, 1H), 8.23 (dd, J=7.94, 5.73 Hz, 1H), 8.91 (d, J=5.29 Hz, 1H), 8.98 (d, J=5.29 Hz, 1H), 9.04 (br d, J=8.16 Hz, 1H), 9.16 (d, J=0.66 Hz, 1H), 9.29 (d, J=0.88 Hz, 1H), 9.39 (d, J=1.54 Hz, 1H), 9.46 (br d, J=8.38 Hz, 1H), 9.78 (d, J=1.54 Hz, 1H), 12.37 (s, 1H), 14.49 (br s, 1H); ESIMS found for C₂₄H₁₆N₆ m/z 389.1 (M+1).

N-(5-(3-(4-(Pyridin-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl) pyridin-3-yl)isobutyramide 93

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.18 (d, J=6.84 Hz, 6H), 2.70-2.81 (m, 1H), 7.32-7.41 (m, 2H), 7.56 (br d, J=0.10 Hz, 1H), 7.68 (br dd, J=6.73, 2.32 Hz, 1H), 8.12 (br dd, J=7.83, 5.62 Hz, 1H), 8.84-8.96 (m, 3H), 9.11 (br d, J=1.54 Hz, 1H), 9.21 (br s, 1H), 9.29 (br d, J=0.88 Hz, 2H), 9.38 (s, 1H), 10.82 (br s, 1H), 12.22 (s, 1H), 14.30 (br s, 1H); ESIMS found for C₂₈H₂₃N₇O m/z 474.2 (M+1).

N-(5-(3-(4-(Pyridin-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl) pyridin-3-yl)benzamide 95

¹H NMR (400 MHz, DMSO-d₆) δ ppm 7.33-7.42 (m, 2H), 7.55-7.66 (m, 3H), 7.66-7.77 (m, 2H), 8.18 (br d, J=7.50 Hz, 2H), 8.23 (br dd, J=7.83, 5.84 Hz, 1H), 8.94 (br d, J=5.51 Hz, 1H), 9.00-9.08 (m, 2H), 9.31 (br s, 1H), 9.35 (br s, 1H), 9.40 (br d, J=1.54 Hz, 1H), 9.56 (s, 1H), 9.71 (br s, 1H), 11.35 (s, 1H), 12.29 (s, 1H), 14.41 (s, 1H); ESIMS found for C₃₁H₂₁N₇O m/z 508.0 (M+1).

3-(4-(Pyridin-3-yl)-1H-indol-2-yl)-5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine 98

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.75 (br s, 4H), 2.60 (br s, 4H), 3.81 (s, 2H), 7.20 (br d, J=7.06 Hz, 1H), 7.30 (br t, J=7.72 Hz, 1H), 7.40 (s, 1H), 7.54-7.62 (m, 1H), 8.14 (s, 1H), 8.23 (br d, J=7.94 Hz, 1H), 8.49 (s, 1H), 8.54 (s, 1H), 8.63 (br d, J=4.85 Hz, 1H), 8.70 (s, 1H), 8.99 (s, 1H), 9.24 (s, 1H), 9.31 (s, 1H), 11.99 (s, 1H), 14.07 (br s, 1H); ESIMS found for C₂₉H₂₅N₇ m/z 472.1 (M+1).

N-(5-(3-(4-(Pyridin-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl) pyridin-3-yl)cyclopropanecarboxamide 104

¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.81-1.00 (m, 4H), 2.02-2.12 (m, 1H), 7.31-7.43 (m, 2H), 7.57 (s, 1H), 7.72 (br d, J=7.50 Hz, 1H), 8.28 (dd, J=7.83, 5.84 Hz, 1H), 8.96-9.05 (m, 2H), 9.08 (br d, J=8.16 Hz, 1H), 9.24 (d, J=1.54 Hz, 1H), 9.27 (s, 1H), 9.37 (s, 1H), 9.44 (s, 1H), 9.56 (s, 1H), 11.84 (s, 1H), 12.32 (s, 1H), 14.46 (br s, 1H); ESIMS found for C₂₈H₂₁N₇O m/z 472.1 (M+1).

5-(5-((3,3-Difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-3-(4-(pyridin-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine 110

¹H NMR (400 MHz, DMSO-d₆) δ ppm 2.60-2.77 (m, 2H), 3.75 (br d, J=6.62 Hz, 2H), 4.02 (br t, J=12.35 Hz, 2H), 4.92 (s, 2H), 7.31-7.41 (m, 2H), 7.65-7.77 (m, 2H), 8.27 (dd, J=8.05, 5.84 Hz, 1H), 8.95 (br d, J=5.51 Hz, 1H), 9.00-9.11 (m, 2H), 9.16 (s, 1H), 9.27 (s, 1H), 9.40 (s, 1H), 9.63 (s, 1H), 9.73 (s, 1H), 12.26 (s, 1H), 14.54 (br s, 2H); ESIMS found for C₂₉H₂₃F₂N₇ m/z 508.1 (M+1).

3-Methyl-N-(5-(3-(4-(pyridin-4-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)butanamide 114

¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.99 (d, J=6.62 Hz, 6H), 2.16 (dt, J=13.56, 6.67 Hz, 1H), 2.37 (br d, J=7.28 Hz, 2H), 7.41 (br t, J=7.83 Hz, 1H), 7.55 (br d, J=7.28 Hz, 1H), 7.64 (s, 1H), 7.80 (br d, J=8.16 Hz, 1H), 8.55 (br d, J=6.39 Hz, 2H), 8.96 (s, 1H), 9.03 (br d, J=6.40 Hz, 2H), 9.15 (s, 1H), 9.31 (s, 1H), 9.33 (br s, 1H), 9.48 (s, 1H), 11.10 (br s, 1H), 12.41 (s, 1H), 14.42 (br s, 1H); ESIMS found for C₂₉H₂₅N₇O m/z 488.2 (M+1).

5-(4-Methylpyridin-3-yl)-3-(4-(pyridin-4-yl)-1H-indol-2-yl)-1H-pyrazolo [3,4-c]pyridine 117

¹H NMR (400 MHz, DMSO-d₆) δ ppm 2.41 (s, 3H), 7.21-7.32 (m, 2H), 7.35-7.42 (m, 2H), 7.59 (d, J=7.72 Hz, 1H), 7.78 (d, J=5.95 Hz, 2H), 8.16 (s, 1H), 8.37 (s, 1H), 8.49 (d, J=4.85 Hz, 1H), 8.65-8.70 (m, 2H), 9.23 (s, 1H), 12.01 (s, 1H), 14.08 (br s, 1H); ESIMS found for C₂₅H₁₈N₆ m/z 403.1 (M+1).

N-(5-(3-(4-(Pyridin-4-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl) pyridin-3-yl)pivalamide 120

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.34 (s, 9H), 7.40 (br t, J=7.61 Hz, 1H), 7.55 (br d, J=7.28 Hz, 1H), 7.64 (br s, 1H), 7.81 (br d, J=7.94 Hz, 1H), 8.60 (br d, J=6.17 Hz, 2H), 8.97-9.13 (m, 3H), 9.29 (s, 1H), 9.36 (br d, J=1.10 Hz, 1H), 9.59 (br s, 1H), 9.80 (br s, 1H), 10.69 (br s, 1H), 12.44 (br s, 1H), 14.51 (br s, 1H); ESIMS found for C₂₉H₂₅N₇O m/z 488.1 (M+1).

N-Isopropyl-5-(3-(4-(pyridin-4-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-amine 124

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.21 (d, J=6.17 Hz, 6H), 3.70-3.81 (m, 1H), 5.89-5.99 (m, 1H), 7.25-7.34 (m, 2H), 7.46 (s, 1H), 7.61 (br d, J=7.28 Hz, 1H), 7.71 (br s, 1H), 7.85 (br d, J=5.51 Hz, 2H), 7.99 (br d, J=1.98 Hz, 1H), 8.13 (s, 1H), 8.59 (br d, J=5.95 Hz, 1H), 8.71 (br d, J=5.51 Hz, 2H), 9.22 (s, 1H), 12.04 (br s, 1H), 14.05 (br s, 1H); ESIMS found for C₂₇H₂₃N₇ m/z 446.1 (M+1).

3,3-Dimethyl-N-(5-(3-(4-(pyridin-4-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)butanamide 128

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.08 (s, 9H), 2.35 (s, 2H), 7.41 (br t, J=7.83 Hz, 1H), 7.54 (br d, J=7.28 Hz, 1H), 7.63 (s, 1H), 7.78 (br d, J=7.94 Hz, 1H), 8.51 (br d, J=5.95 Hz, 2H), 8.89 (s, 1H), 9.01 (br d, J=6.17 Hz, 2H), 9.06 (br s, 1H), 9.21 (br s, 1H), 9.30 (s, 1H), 9.38 (s, 1H), 10.78 (br s, 1H), 12.36 (br s, 1H), 14.34 (br s, 1H); ESIMS found for C₃₀H₂₇N₇O m/z 502.1 (M+1).

N-(5-(3-(4-(Pyridin-4-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl) pyridin-3-yl)cyclobutanecarboxamide 133

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.80-1.91 (m, 2H), 1.93-2.04 (m, 2H), 2.13-2.22 (m, 2H), 2.24-2.30 (m, 1H), 7.36-7.45 (m, 1H), 7.51 (br d, J=7.72 Hz, 1H), 7.60 (br s, 1H), 7.75 (br d, J=8.16 Hz, 1H), 8.43 (br d, J=4.63 Hz, 2H), 8.80 (br s, 1H), 8.97 (br d, J=6.39 Hz, 3H), 9.03 (br s, 1H), 9.24 (br s, 1H), 9.28 (br s, 1H), 10.37 (br s, 1H), 12.30 (br s, 1H), 14.26 (br s, 2H); ESIMS found for C₂₉H₂₃N₇O m/z 486.1 (M+1).

3-(4-(Pyridin-4-yl)-1H-indol-2-yl)-5-(pyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridine 139

¹H NMR (400 MHz, DMSO-d₆) δ ppm 7.41 (br t, J=7.72 Hz, 1H), 7.54 (br d, J=7.28 Hz, 1H), 7.66 (s, 1H), 7.78 (br d, J=8.38 Hz, 1H), 8.53 (br d, J=5.73 Hz, 2H), 8.91 (s, 1H), 9.00 (br d, J=5.51 Hz, 2H), 9.25 (br s, 1H), 9.31 (s, 1H), 9.63 (s, 2H), 12.35 (br s, 1H), 14.34 (br s, 1H); ESIMS found for C₂₃H₁₅N₇ m/z 390.0 (M+1).

5-(Pyridin-2-yl)-3-(4-(pyridin-4-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine 140

¹H NMR (400 MHz, DMSO-d₆) δ ppm 7.42 (t, J=7.63 Hz, 1H), 7.56 (d, J=7.43 Hz, 1H), 7.69 (s, 1H), 7.77-7.87 (m, 1H), 7.80 (d, J=8.22 Hz, 1H), 8.41-8.49 (m, 1H), 8.55 (d, J=7.04 Hz, 2H), 8.87 (br dd, J=6.65, 1.96 Hz, 1H), 8.84 (br d, J=5.87 Hz, 1H), 9.01 (d, J=7.04 Hz, 2H), 9.35 (s, 1H), 9.43 (br s, 1H), 12.46 (s, 1H); ESIMS found for C₂₄H₁₆N₆ m/z 389.1 (M+1).

5-(3-(4-(Pyridin-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl) pyridin-3-amine 143

¹H NMR (400 MHz, DMSO-d₆) δ ppm 7.43 (t, J=7.72 Hz, 1H), 7.62 (d, J=7.50 Hz, 1H), 7.66 (s, 1H), 7.85 (d, J=7.94 Hz, 1H), 8.00-8.10 (m, 2H), 8.56 (br d, J=8.16 Hz, 1H), 8.60 (s, 1H), 8.71 (br t, J=7.72 Hz, 1H), 9.02 (br s, 1H), 9.05 (br s, 2H), 9.27 (d, J=0.66 Hz, 1H), 12.48 (s, 1H), 14.50 (br s, 1H); ESIMS found for C₂₄H₁₇N₇ m/z 404.0 (M+1).

5-(4-Methylpyridin-3-yl)-3-(4-(pyridin-2-yl)-1H-indol-2-yl)-1H-pyrazolo [3,4-c]pyridine 145

¹H NMR (400 MHz, DMSO-d₆) δ ppm 2.43 (s, 3H), 7.22-7.31 (m, 1H), 7.32-7.37 (m, 1H), 7.39 (br d, J=4.85 Hz, 1H), 7.57 (d, J=7.72 Hz, 1H), 7.66 (s, 1H), 7.88-7.95 (m, 1H), 7.98-8.05 (m, 1H), 8.14 (s, 1H), 8.29 (s, 1H), 8.49 (d, J=5.07 Hz, 1H), 8.69 (s, 1H), 8.74 (br d, J=4.63 Hz, 1H), 9.23 (s, 1H), 11.90 (br s, 1H), 14.06 (br s, 1H); ESIMS found for C₂₅H₁₈N₆ m/z 403.0 (M+1).

2-Phenyl-N-(5-(3-(4-(pyridin-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)acetamide 150

¹H NMR (400 MHz, METHANOL-d₄) δ ppm 3.89 (s, 2H), 7.29-7.35 (m, 1H), 7.36-7.48 (m, 5H), 7.51-7.59 (m, 2H), 7.79 (d, J=8.16 Hz, 1H), 7.91 (br t, J=6.39 Hz, 1H), 8.60 (br d, J=7.72 Hz, 1H), 8.68-8.78 (m, 1H), 8.87 (s, 1H), 8.94 (br d, J=5.51 Hz, 1H), 9.10 (s, 1H), 9.14 (s, 1H), 9.35 (s, 1H), 9.51 (s, 1H); ESIMS found for C₃₂H₂₃N₇O m/z 522.1 (M+1).

N,N-Dimethyl-1-(5-(3-(4-(pyridin-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methanamine 153

¹H NMR (400 MHz, METHANOL-d₄) δ ppm 2.98 (br s, 6H), 4.71 (br s, 2H), 7.37-7.47 (m, 1H), 7.54 (br d, J=7.28 Hz, 1H), 7.75 (d, J=7.94 Hz, 1H), 8.05 (br d, J=0.66 Hz, 1H), 8.64 (br dd, J=3.42, 2.31 Hz, 1H), 8.73-8.82 (m, 1H), 8.83 (br s, 1H), 8.94 (br d, J=1.10 Hz, 1H), 9.00-9.10 (m, 3H), 9.56 (br s, 1H), 9.85 (br s, 1H); ESIMS found for C₂₇H₂₃N₇ m/z 446.1 (M+1).

N-(5-(3-(4-(Pyridin-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl) pyridin-3-yl)pentanamide 159

¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.94 (br t, J=7.28 Hz, 3H), 1.39 (td, J=14.88, 7.72 Hz, 2H), 1.61-1.72 (m, 2H), 2.42 (br t, J=7.39 Hz, 2H), 7.25-7.33 (m, 1H), 7.35-7.42 (m, 1H), 7.59 (br d, J=3.31 Hz, 1H), 7.61 (br d, J=2.65 Hz, 1H), 7.78 (s, 1H), 7.92-8.01 (m, 1H), 8.07 (br d, J=7.94 Hz, 1H), 8.61 (s, 1H), 8.74 (br d, J=1.54 Hz, 1H), 8.84-8.89 (m, 1H), 8.91 (br s, 1H), 9.09 (br d, J=1.32 Hz, 1H), 9.25 (s, 1H), 10.25 (s, 1H), 11.93 (br s, 1H), 14.07 (s, 1H); ESIMS found for C₂₉H₂₅N₇O m/z 488.1 (M+1).

N-(5-(3-(4-(Pyridin-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl) pyridin-3-yl)cyclohexanecarboxamide 163

¹H NMR (400 MHz, METHANOL-d₄) δ ppm 1.27-1.49 (m, 3H), 1.50-1.65 (m, 2H), 1.73-1.82 (m, 1H), 1.84-1.93 (m, 2H), 1.93-2.03 (m, 2H), 2.47-2.60 (m, 1H), 7.40-7.49 (m, 1H), 7.55 (d, J=7.06 Hz, 2H), 7.80 (d, J=7.94 Hz, 1H), 8.03-8.12 (m, 1H), 8.67 (br d, J=8.16 Hz, 1H), 8.83 (br t, J=7.39 Hz, 1H), 8.89 (s, 1H), 9.02 (br d, J=5.51 Hz, 1H), 9.15 (s, 1H), 9.19 (s, 1H), 9.35 (s, 1H), 9.41 (s, 1H); ESIMS found for C₃₁H₂₇N₇O m/z 514.2 (M+1).

3-Methyl-N-(5-(3-(4-(piperidin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)butanamide 170

¹H NMR (400 MHz, METHANOL-d₄) δ ppm 1.07 (d, J=6.62 Hz, 6H), 1.79-1.95 (m, 1H), 1.96-2.07 (m, 1H), 2.08-2.19 (m, 2H), 2.26 (tt, J=13.75, 6.64 Hz, 1H), 2.42 (d, J=7.06 Hz, 2H), 2.49-2.65 (m, 2H), 3.84-4.02 (m, 4H), 7.27-7.37 (m, 1H), 7.44 (d, J=7.94 Hz, 1H), 7.65 (d, J=8.16 Hz, 1H), 8.07 (s, 1H), 9.02 (d, J=1.10 Hz, 1H), 9.18 (d, J=1.10 Hz, 1H), 9.34 (d, J=2.21 Hz, 1H), 9.42 (t, J=1.98 Hz, 1H), 9.47 (d, J=1.54 Hz, 1H); ESIMS found for C₂₉H₃₁N₇O m/z 494.2 (M+1).

N-((5-(3-(4-(Piperidin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl) pyridin-3-yl)methyl)ethanamine 174

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.32 (t, J=7.28 Hz, 3H), 1.74-1.87 (m, 2H), 1.89-2.03 (m, 2H), 3.06-3.15 (m, 2H), 3.71-3.99 (m, 4H), 4.35-4.46 (m, 2H), 7.27-7.36 (m, 1H), 7.46-7.59 (m, 1H), 7.60-7.69 (m, 1H), 8.76 (d, J=1.76 Hz, 1H), 9.11-9.19 (m, 1H), 9.24-9.38 (m, 2H), 9.29 (s, 1H), 9.57 (d, J=2.21 Hz, 1H), 12.39 (br s, 1H), 14.26 (br s, 1H); ESIMS found for C₂₇H₂₉N₇ m/z 452.1 (M+1).

N-(5-(3-(4-(Piperidin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl) pyridin-3-yl)pivalamide 176

¹H NMR (400 MHz, METHANOL-d₄) δ ppm 1.42 (s, 9H), 1.79-1.95 (m, 1H), 1.96-2.06 (m, 1H), 2.07-2.18 (m, 2H), 2.57-2.74 (m, 2H), 3.87-4.00 (m, 4H), 7.31-7.41 (m, 1H), 7.46 (d, J=7.28 Hz, 1H), 7.68 (d, J=7.94 Hz, 1H), 8.20 (d, J=0.66 Hz, 1H), 9.17 (d, J=1.10 Hz, 1H), 9.23 (d, J=1.32 Hz, 1H), 9.45 (d, J=2.21 Hz, 1H), 9.47 (d, J=1.76 Hz, 1H), 9.91 (t, J=1.98 Hz, 1H); ESIMS found for C₂₉H₃₁N₇O m/z 494.1 (M+1).

N-Isopropyl-5-(3-(4-(piperidin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-amine 180

¹H NMR (400 MHz, METHANOL-d₄) δ ppm 1.34 (d, J=6.39 Hz, 6H), 1.99-2.18 (m, 4H), 2.55 (br s, 2H), 3.88-3.99 (m, 5H), 7.33-7.40 (m, 1H), 7.42-7.48 (m, 1H), 7.70 (d, J=8.16 Hz, 1H), 8.00-8.06 (m, 1H), 8.13 (d, J=0.88 Hz, 1H), 8.52 (dd, J=2.43, 1.54 Hz, 1H), 8.84 (d, J=0.88 Hz, 1H), 9.09 (d, J=0.88 Hz, 1H), 9.32 (d, J=0.88 Hz, 1H); ESIMS found for C₂₇H₂₉N₇ m/z 452.2 (M+1).

N-(5-(3-(4-(Piperidin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl) pyridin-3-yl)cyclopropanecarboxamide 188

¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.80-1.06 (m, 4H), 1.71-1.90 (m, 4H), 1.96 (ddd, J=12.24, 7.28, 4.96 Hz, 3H), 3.72-3.95 (m, 4H), 7.31 (br t, J=8.05 Hz, 1H), 7.53-7.61 (m, 1H), 7.64 (br d, J=8.38 Hz, 1H), 8.43 (br d, J=1.32 Hz, 1H), 9.15 (d, J=1.98 Hz, 1H), 9.24 (s, 1H), 9.31 (d, J=1.10 Hz, 1H), 9.41 (s, 1H), 9.84 (s, 1H), 11.48 (s, 1H), 12.44 (br s, 1H), 14.41 (br s, 1H); ESIMS found for C₂H₂₇N₇O m/z 478.1 (M+1).

5-(5-((3,3-Difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-3-(4-(piperidin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine 194

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.70-2.04 (m, 4H), 2.55-2.85 (m, 4H), 3.77 (br t, J=7.17 Hz, 4H), 3.87-4.03 (m, 2H), 4.04-4.15 (m, 2H), 4.86 (s, 2H), 7.30 (t, J=8.05 Hz, 1H), 7.66 (d, J=1.98 Hz, 1H), 7.67 (s, 1H), 8.42 (d, J=1.32 Hz, 1H), 9.14 (s, 1H), 9.31 (s, 1H), 9.39 (s, 1H), 9.79 (d, J=1.32 Hz, 1H), 9.91 (s, 1H), 12.48 (br d, J=1.32 Hz, 1H), 14.60 (s, 1H); ESIMS found for C₂₉H₂₉F₂N₇ m/z 514.2 (M+1).

3-(4-(Piperidin-1-yl)-1H-indol-2-yl)-5-(pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridine 196

¹H NMR (400 MHz, METHANOL-d₄) δ ppm 1.68-1.78 (m, 2H), 1.88-2.01 (m, 4H), 3.34 (br s, 4H), 6.72 (d, J=7.28 Hz, 1H), 7.06-7.16 (m, 1H), 7.22 (d, J=8.16 Hz, 1H), 7.25 (s, 1H), 7.37-7.46 (m, 1H), 7.95 (br t, J=7.72 Hz, 1H), 8.39 (br d, J=7.94 Hz, 1H), 8.67 (br d, J=4.19 Hz, 1H), 9.01 (s, 1H), 9.08 (s, 1H); ESIMS found for C₂₄H₂₂N₆ m/z 395.1 (M+1).

5-(3-(4-(4-Methylpiperazin-1-yl)-H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-amine 227

¹H NMR (400 MHz, METHANOL-d₄) δ ppm 3.09 (s, 3H), 3.64-3.87 (m, 6H), 3.93-4.04 (m, 2H), 6.95 (d, J=7.50 Hz, 1H), 7.21 (dt, J=7.99, 3.83 Hz, 2H), 7.41 (d, J=8.38 Hz, 1H), 8.05 (d, =J=1.98 Hz, 1H), 8.56-8.63 (m, 1H), 8.82 (s, 1H), 8.96 (d, J=0.10 Hz, 1H), 9.27 (d, J=1.10 Hz, 1H); ESIMS found for C₂₄H₂₄N₈ m/z 425.1 (M+1).

N-(5-(3-(4-(4-Methylpiperazin-1-yl)-H-indol-2-yl)-H-indol-2-yl)-H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)isobutyramide 233

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.19 (d, J=6.84 Hz, 6H), 2.73-2.83 (m, 1H), 2.92 (br d, J=4.63 Hz, 3H), 3.14-3.28 (m, 2H), 3.41-3.55 (m, 2H), 3.55-3.69 (m, 2H), 3.75-3.89 (m, 2H), 6.61 (br d, J=7.72 Hz, 1H), 7.05-7.14 (m, 1H), 7.23 (br d, J=7.72 Hz, 1H), 7.32 (br s, 1H), 8.90 (s, 1H), 9.13-9.24 (m, 1H), 9.28 (s, 1H), 9.34 (br s, 1H), 9.47 (br d, J=0.88 Hz, 1H), 10.62 (br s, 1H), 11.10 (br s, 1H), 11.89 (br s, 1H), 14.23 (br s, 1H); ESIMS found for C₂₈H₃₀N₈O m/z 495.2 (M+1).

N-(5-(3-(4-(4-Methylpiperazin-1-yl)-H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-2-phenylacetamide 234

¹H NMR (400 MHz, DMSO-d₆) δ ppm 2.21-2.32 (m, 3H), 2.63 (br s, 4H), 3.21 (br s, 4H), 3.73 (s, 2H), 6.51 (br d, J=7.50 Hz, 1H), 7.04 (br t, J=7.72 Hz, 2H), 7.09-7.18 (m, 2H), 7.22-7.31 (m, 1H), 7.31-7.43 (m, 3H), 8.66 (br d, J=0.88 Hz, 1H), 8.80 (d, J=2.43 Hz, 1H), 8.86 (br d, J=1.98 Hz, 1H), 9.13 (d, J=1.98 Hz, 1H), 9.21 (d, J=1.10 Hz, 1H), 10.54 (s, 1H), 11.67 (s, 1H), 13.98 (br s, 1H); ESIMS found for C₃₂H₃₀N₈O m/z 543.2 (M+1).

N,N-Dimethyl-1-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methanamine 237

¹H NMR (400 MHz, METHANOL-d₄) δ ppm 3.65 (d, J=4.63 Hz, 6H), 3.72 (d, J=4.41 Hz, 3H), 4.01-4.14 (m, 2H), 4.24-4.52 (m, 4H), 4.63 (br d, J=13.23 Hz, 2H), 5.40 (br d, J=5.07 Hz, 2H), 7.43 (d, J=7.72 Hz, 1H), 7.90 (t, J=7.83 Hz, 1H), 8.07 (d, J=7.94 Hz, 1H), 8.23 (d, J=1.10 Hz, 1H), 9.75 (d, J=1.54 Hz, 1H), 9.87 (s, 1H), 10.09 (d, J=0.88 Hz, 1H), 10.28 (br d, J=0.66 Hz, 1H), 10.45 (d, J=1.98 Hz, 1H); ESIMS found for C₂₇H₃₀N₈ m/z 467.2 (M+1).

N-(5-(3-(4-(4-Methylpiperazin-1-yl)-H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)pentanamide 243

¹H NMR (400 MHz, METHANOL-d₄) δ ppm 1.00 (t, J=7.39 Hz, 3H), 1.40-1.53 (m, 2H), 1.71-1.81 (m, 2H), 2.45 (s, 3H), 2.46-2.50 (m, 2H), 2.84 (br d, J=3.53 Hz, 4H), 3.32-3.39 (m, 4H), 6.64 (d, J=7.28 Hz, 1H), 7.11 (t, J=7.72 Hz, 1H), 7.17-7.25 (m, 2H), 8.58 (d, J=1.32 Hz, 1H), 8.71 (d, J=2.43 Hz, 1H), 8.89 (t, J=2.09 Hz, 1H), 9.00 (d, J=1.98 Hz, 1H), 9.14 (d, J=1.10 Hz, 1H); ESIMS found for C₂₉H₃₂N₈O m/z 509.1 (M+1).

N-(5-(3-(4-(4-Methylpiperazin-1-yl)-H-indol-2-yl)-H-indol-2-yl)-H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclobutanecarboxamide 245

¹H NMR (400 MHz, METHANOL-d₄) δ ppm 1.97 (qd, J=9.44, 4.96 Hz, 1H), 2.05-2.18 (m, 1H), 2.26-2.38 (m, 2H), 2.38-2.53 (m, 2H), 3.10 (s, 3H), 3.48 (quin, J=8.49 Hz, 1H), 3.67-3.88 (m, 6H), 3.98 (br d, J=11.03 Hz, 2H), 6.96 (br d, J=7.72 Hz, 1H), 7.16-7.25 (m, 1H), 7.41 (d, J=8.16 Hz, 1H), 8.97 (s, 1H), 9.21 (d, J=0.88 Hz, 1H), 9.40 (d, J=1.76 Hz, 1H), 9.41-9.43 (m, 1H), 9.44 (s, 1H); ESIMS found for C₂₉H₃₀N₈O m/z 507.2 (M+1).

3-(4-(4-Methylpiperazin-1-yl)-1H-indol-2-yl)-5-(pyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridine 251

¹H NMR (400 MHz, DMSO-d₆) δ ppm 2.95 (br d, J=4.85 Hz, 3H), 3.04-3.16 (m, 2H), 3.56-3.67 (m, 2H), 3.80-3.91 (m, 2H), 6.58 (br d, J=7.94 Hz, 1H), 7.03-7.14 (m, 1H), 7.21 (br d, J=7.94 Hz, 1H), 7.33 (br d, J=1.98 Hz, 1H), 8.85 (br d, J=1.10 Hz, 1H), 9.25 (s, 1H), 9.28 (d, J=1.32 Hz, 1H), 9.62 (s, 2H), 11.81 (br s, 1H), 14.13 (br s, 1H); ESIMS found for C₂₃H₂₂N₈ m/z 411.2 (M+1).

N-(5-(3-(1H-Indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-3-methylbutanamide 254

¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.99 (d, J=6.62 Hz, 6H), 2.10-2.22 (m, 1H), 2.35 (d, J=7.06 Hz, 2H), 7.01-7.09 (m, 1H), 7.16 (td, J=7.50, 1.10 Hz, 1H), 7.45-7.56 (m, 2H), 7.65 (d, J=8.16 Hz, 1H), 8.94 (s, 1H), 9.22 (s, 1H), 9.25 (br s, 1H), 9.28 (d, J=1.10 Hz, 1H), 9.51 (s, 1H), 11.00 (br d, J=1.54 Hz, 1H), 11.78 (d, J=1.32 Hz, 1H), 14.20 (br s, 1H); ESIMS found for C₂₄H₂₂N₆O m/z 411.0 (M+1).

3-(1H-Indol-2-yl)-5-(pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine 256

¹H NMR (400 MHz, DMSO-d₆) δ ppm 6.99-7.11 (m, 1H), 7.12-7.22 (m, 1H), 7.50 (d, J=7.72 Hz, 1H), 7.56 (d, J=1.54 Hz, 1H), 7.65 (d, J=7.72 Hz, 1H), 8.16 (br dd, J=8.16, 5.51 Hz, 1H), 8.92 (br d, J=5.51 Hz, 1H), 9.03 (d, J=0.88 Hz, 1H), 9.29 (d, J=1.10 Hz, 1H), 9.39 (br d, J=7.72 Hz, 1H), 9.74 (d, J=1.98 Hz, 1H), 11.80 (s, 1H), 14.23 (br s, 1H); ESIMS found for C₁₉H₁₃N₅ m/z 312.1 (M+1).

N-(5-(3-(1H-Indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl) benzamide 263

¹H NMR (400 MHz, DMSO-d₆) δ ppm 7.06 (t, J=7.50 Hz, 1H), 7.12-7.22 (m, 1H), 7.50 (d, J=8.38 Hz, 1H), 7.52 (d, J=1.98 Hz, 1H), 7.58-7.74 (m, 4H), 8.10 (d, J=1.54 Hz, 1H), 8.12 (s, 1H), 8.93 (s, 1H), 9.29 (d, J=1.10 Hz, 1H), 9.34 (d, J=1.98 Hz, 1H), 9.45 (s, 1H), 9.51 (s, 1H), 11.11 (s, 1H), 11.79 (d, J=0.66 Hz, 1H), 14.19 (br s, 1H); ESIMS found for C₂₆H₁₈N₆O m/z 431.1 (M+1).

3-(1H-Indol-2-yl)-5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo [3,4-c]pyridine 266

¹H NMR (400 MHz, METHANOL-d₄) δ ppm 1.89 (dt, J=6.28, 3.25 Hz, 4H), 2.65-2.77 (m, 4H), 3.86 (s, 2H), 7.01-7.11 (m, 1H), 7.17 (ddd, J=8.21, 7.11, 1.21 Hz, 1H), 7.30 (d, J=0.66 Hz, 1H), 7.44-7.53 (m, 1H), 7.66 (d, J=7.72 Hz, 1H), 8.55 (s, 1H), 8.60 (t, J=1.87 Hz, 1H), 8.65 (d, J=1.32 Hz, 1H), 9.13 (d, J=1.32 Hz, 1H), 9.25 (s, 1H); ESIMS found for C₂₄H₂₂N₆ m/z 395.0 (M+1).

N-(5-(3-(1H-Indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-3,3-dimethylbutanamide 268

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.07 (d, J=0.66 Hz, 9H), 2.28 (s, 2H), 7.05 (br t, J=7.39 Hz, 1H), 7.15 (br t, J=7.50 Hz, 1H), 7.44-7.53 (m, 2H), 7.63 (br d, J=7.94 Hz, 1H), 8.23 (br s, 1H), 8.72 (s, 1H), 8.83 (s, 1H), 9.17 (s, 1H), 9.23 (s, 1H), 10.15 (s, 1H), 11.70 (br s, 1H), 14.00 (br s, 1H); ESIMS found for C₂₅H₂₄N₆O m/z 425.2 (M+1).

N-(5-(3-(1H-Indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl) cyclohexanecarboxamide 275

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.16-1.37 (m, 3H), 1.40-1.54 (m, 2H), 1.63-1.73 (m, 1H), 1.75-1.92 (m, 4H), 2.34-2.44 (m, 1H), 7.01-7.09 (m, 1H), 7.15 (t, J=7.04 Hz, 1H), 7.42-7.53 (m, 2H), 7.63 (d, J=7.43 Hz, 1H), 8.70 (s, 1H), 8.78-8.88 (m, 2H), 9.15 (d, J=1.57 Hz, 1H), 9.22 (d, J=0.78 Hz, 1H), 10.17 (s, 1H), 11.72 (br d, J=1.96 Hz, 1H), 14.02 (s, 1H); ESIMS found for C₂₆H₂₄N₆O m/z 437.1 (M+1).

3-(4-(Furan-3-yl)-1H-indol-2-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine 323

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.41 (br d, J=4.19 Hz, 2H), 1.54 (quin, J=5.24 Hz, 4H), 2.45 (br s, 4H), 3.64 (s, 2H), 7.10-7.14 (m, 1H), 7.16-7.24 (m, 1H), 7.25-7.30 (m, 1H), 7.45 (d, J=7.94 Hz, 1H), 7.48 (d, J=0.66 Hz, 1H), 7.79-7.86 (m, 1H), 8.15 (s, 1H), 8.48 (s, 1H), 8.53 (d, J=1.54 Hz, 1H), 8.55 (s, 1H), 8.78 (s, 1H), 9.24 (s, 1H), 9.35 (d, J=1.76 Hz, 1H), 11.88 (s, 1H), 14.05 (br s, 1H); ESIMS found for C₂₉H₂₆N₆O m/z 475.1 (M+1).

3-(4-(Furan-3-yl)-1H-indol-2-yl)-5-(pyridin-4-yl)-1H-pyrazolo[3,4-c]pyridine 326

¹H NMR (400 MHz, DMSO-d₆) δ ppm 7.13 (d, J=1.10 Hz, 1H), 7.16-7.25 (m, 1H), 7.25-7.34 (m, 1H), 7.48 (d, J=7.94 Hz, 1H), 7.57 (d, J=1.10 Hz, 1H), 7.84 (t, J=1.54 Hz, 1H), 8.56 (s, 1H), 8.89-9.00 (m, 2H), 9.03 (d, J=6.84 Hz, 2H), 9.28 (s, 1H), 9.35 (d, J=0.88 Hz, 1H), 12.02 (s, 1H), 14.48 (br s, 1H); ESIMS found for C₂₃H₁₅N₅O m/z 378.1 (M+1).

N-(5-(3-(4-(Thiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl) pyridin-3-yl)propionamide 337

¹H NMR (400 MHz, METHANOL-d₄) δ ppm 1.14-1.28 (m, 3H), 2.50 (q, J=7.35 Hz, 2H), 7.17-7.25 (m, 2H), 7.25-7.32 (m, 1H), 7.41-7.50 (m, 2H), 7.54 (br d, J=7.94 Hz, 1H), 7.60 (br d, J=3.31 Hz, 1H), 7.67-7.73 (m, 1H), 8.56 (s, 1H), 9.06 (br s, 1H), 9.09 (br s, 1H), 9.11 (br s, 1H); ESIMS found for C₂₆H₂₀N₆O_(S) m/z 465.0 (M+1).

N,N-Dimethyl-5-(3-(4-(thiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-amine 343

¹H NMR (400 MHz, METHANOL-d₄) δ ppm 3.12 (s, 6H), 6.91-6.99 (m, 1H), 7.14-7.24 (m, 1H), 7.31-7.39 (m, 2H), 7.42 (d, J=8.38 Hz, 1H), 7.60 (d, J=3.97 Hz, 1H), 7.86-7.90 (m, 1H), 7.92 (d, J=−3.75 Hz, 1H), 8.09 (d, J=3.09 Hz, 1H), 8.53 (d, J=1.10 Hz, 1H), 8.55 (d, J=1.76 Hz, 1H), 9.12 (s, 1H); ESIMS found for C₂₅H₂₀N₆S m/z 437.0 (M+1).

N-(5-(3-(4-(Thiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl) pyridin-3-yl)butyramide 353

¹H NMR (400 MHz, METHANOL-d₄) δ ppm 1.05 (t, J=7.39 Hz, 3H), 1.72-1.87 (m, 2H), 2.45 (t, J=−7.39 Hz, 2H), 6.95 (d, J=2.87 Hz, 1H), 7.18 (br t, J=7.83 Hz, 1H), 7.29-7.40 (m, 2H), 7.42 (br d, J=8.16 Hz, 1H), 7.60 (d, J=3.97 Hz, 1H), 7.90 (br d, J=3.53 Hz, 1H), 8.53 (s, 1H), 8.78 (br s, 1H), 8.80 (br s, 1H), 9.00 (br s, 1H), 9.13 (s, 1H); ESIMS found for C₂₇H₂₂N₆OS m/z 479.0 (M+1).

N-Benzyl-1-(5-(3-(4-(thiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methanamine 360

¹H NMR (400 MHz, DMSO-d₆) δ ppm 3.78 (s, 2H), 3.85 (br s, 2H), 6.89 (br s, 1H), 7.13-7.27 (m, 2H), 7.29-7.36 (m, 2H), 7.39 (br d, J=7.28 Hz, 2H), 7.45 (br d, J=7.50 Hz, 1H), 7.51 (br s, 1H), 7.65 (br dd, J=1.98, 1.32 Hz, 1H), 8.10-8.23 (m, 1H), 8.11-8.15 (m, 1H), 8.56 (br s, 2H), 8.70 (s, 1H), 9.22 (br s, 1H), 9.33 (br s, 1H), 11.40 (br d, J=1.10 Hz, 1H), 13.87 (br s, 1H); ESIMS found for C₃₁H₂₄N₆S m/z 513.1 (M+1).

N¹-(3-(2-(5-(5-Aminopyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)-5-fluorophenyl)-N²,N²-dimethylethane-1,2-diamine 451

¹H NMR (400 MHz, DMSO-d₆) δ ppm 2.82 (s, 6H), 3.23-3.34 (m, 2H), 3.57 (t, J=6.28 Hz, 2H), 6.53 (dt, J=11.85, 2.12 Hz, 1H), 6.72 (br dd, J=9.81, 1.87 Hz, 1H), 6.98 (s, 1H), 7.09-7.17 (m, 1H), 7.21-7.29 (m, 1H), 7.39 (d, J=1.32 Hz, 1H), 7.56 (d, J=7.94 Hz, 1H), 8.03 (d, J=2.43 Hz, 1H), 8.47-8.55 (m, 1H), 8.86 (d, J=1.10 Hz, 1H), 8.98 (s, 1H), 9.26 (d, J=1.32 Hz, 1H), 12.06 (d, J=1.98 Hz, 1H), 14.31 (br s, 1H); ESIMS found for C₂₉H₂₇FN₈ m/z 507.2 (M+1).

N¹-(3-(2-(5-(5-((Ethylamino)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)-5-fluorophenyl)-N²,N²-dimethylethane-1,2-diamine 454

¹H NMR (400 MHz, METHANOL-d₄) δ ppm 1.35 (t, 0.1-7.17 Hz, 3H), 2.79 (s, 6H), 3.15 (q, J=7.28 Hz, 2H), 3.22 (br t, J=5.95 Hz, 2H), 3.55 (br t, J=6.17 Hz, 2H), 4.31 (s, 2H), 6.48 (br d, J=11.03 Hz, 1H), 6.81 (br d, J=10.36 Hz, 1H), 6.88 (s, 1H), 7.14 (d, J=7.28 Hz, 1H), 7.26 (t, J=7.61 Hz, 1H), 7.30 (s, 1H), 7.51 (br d, J=8.16 Hz, 1H), 8.56 (s, 1H), 8.66 (s, 2H), 9.16 (s, 1H), 9.31 (s, 1H); ESIMS found for C₃₂H₃₃FN₈ m/z 549.2 (M+1).

N-(5-(3-(4-(3-((2-(Dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)pivalamide 456

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.31 (s, 9H), 2.82 (s, 6H), 3.25-3.36 (m, 2H), 3.51-3.61 (m, 2H), 6.48-6.58 (m, 1H), 6.68-6.78 (m, 1H), 6.98 (s, 1H), 7.15 (d, J=7.28 Hz, 1H), 7.19-7.30 (m, 1H), 7.42 (d, J=1.32 Hz, 1H), 7.56 (d, J=8.16 Hz, 1H), 8.96 (s, 1H), 9.29 (d, J=1.10 Hz, 2H), 9.41-9.50 (m, 1H), 9.54 (s, 1H), 10.32 (br s, 1H), 12.04 (d, J=1.76 Hz, 1H), 14.32 (br s, 1H); ESIMS found for C₃₄H₃₅FN₈O m/z 591.2 (M+1).

N-(5-(3-(4-(3-((2-(Dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-2-phenylacetamide 458

¹H NMR (400 MHz, METHANOL-d₄) δ ppm 2.88 (s, 6H), 2.84-2.96 (m, 2H), 3.55 (br t, J=5.84 Hz, 2H), 3.76 (s, 2H), 6.40-6.47 (m, 1H), 6.79 (br d, J=8.16 Hz, 1H), 6.87 (s, 1H), 7.09 (br d, J=7.28 Hz, 1H), 7.20 (br t, J=7.72 Hz, 1H), 7.24-7.39 (m, 5H), 7.47 (br d, J=7.94 Hz, 1H), 8.66 (s, 2H), 9.06-9.15 (m, 2H), 9.18 (br s, 1H), 9.23 (br s, 1H); ESIMS found for C₃₇H₃₃FN₈O m/z 625.1 (M+1).

N¹-(3-(2-(5-(5-((Dimethylamino)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)-5-fluorophenyl)-N²,N²-dimethylethane-1,2-diamine 461

¹H NMR (400 MHz, METHANOL-d₄) δ ppm 2.96 (s, 6H), 3.00 (s, 6H), 3.42 (t, J=5.95 Hz, 2H), 3.59-3.68 (m, 2H), 4.63 (s, 2H), 6.53 (dt, J=11.30, 2.18 Hz, 1H), 6.82-6.89 (m, 1H), 6.91-6.99 (m, 1H), 7.16 (dd, J=7.28, 0.88 Hz, 1H), 7.27 (dd, J=8.16, 7.28 Hz, 1H), 7.53-7.61 (m, 1H), 8.83 (s, 1H), 8.86-8.97 (m, 2H), 9.18-9.31 (m, 2H), 9.56 (s, 1H); ESIMS found for C₃₂H₃₃FN₈ m/z 549.2 (M+1).

N-(5-(3-(4-(3-((2-(Dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide 468

¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.87-0.99 (m, 4H), 1.87-2.00 (m, 1H), 2.82 (s, 6H), 3.25-3.35 (m, 2H), 3.51-3.59 (m, 2H), 6.53 (dt, J=1.74, 2.07 Hz, 1H), 6.68-6.78 (m, 1H), 6.98 (d, J=1.32 Hz, 1H), 7.14 (dd, J=7.28, 0.88 Hz, 1H), 7.21-7.30 (m, 1H), 7.41 (d, J=1.32 Hz, 1H), 7.55 (d, J=8.16 Hz, 1H), 8.90 (s, 1H), 9.14 (d, J=1.98 Hz, 1H), 9.20 (s, 1H), 9.29 (d, J=1.32 Hz, 1H), 9.45 (s, 1H), 11.30-11.38 (m, 1H), 12.03 (d, J=1.98 Hz, 1H), 14.30 (br s, 1H); ESIMS found for C₃₃H₃₁FN₈O m/z 575.1 (M+1).

N¹-(3-Fluoro-5-(2-(5-(pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)phenyl)-N²,N²-dimethylethane-1,2-diamine 476

¹H NMR (400 MHz, DMSO-d₆) δ ppm 2.81 (br s, 6H), 3.29 (br s, 2H), 3.57 (br t, J=6.28 Hz, 2H), 6.54 (br d, J=11.91 Hz, 1H), 6.74 (br d, J=9.70 Hz, 1H), 6.98 (s, 1H), 7.15 (d, J=7.28 Hz, 1H), 7.25 (t, J=7.72 Hz, 1H), 7.42 (s, 1H), 7.57 (br d, J=7.94 Hz, 1H), 7.77-7.91 (m, 1H), 8.41-8.54 (m, 1H), 8.85 (br d, J=5.29 Hz, 1H), 8.92 (br d, J=7.50 Hz, 1H), 9.33 (s, 2H), 12.12 (br s, 1H), 14.57 (br s, 1H); ESIMS found for C₂₉H₂₆FN₇ m/z 492.1 (M+1).

N-(3-Fluoro-5-(2-(5-(4-methylpyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)benzyl)methanesulfonamide 481

¹H NMR (400 MHz, DMSO-d₆) δ ppm 2.63 (s, 3H), 2.81 (s, 3H), 4.27 (br d, J=6.17 Hz, 2H), 7.14-7.21 (m, 2H), 7.23-7.31 (m, 1H), 7.35 (d, J=1.32 Hz, 1H), 7.41 (br d, J=9.92 Hz, 1H), 7.54 (d, J=7.94 Hz, 1H), 7.65-7.74 (m, 2H), 8.00 (br d, J=6.61 Hz, 1H), 8.48 (d, J=1.10 Hz, 1H), 8.77-8.85 (m, 1H), 9.02 (s, 1H), 9.28 (d, J=1.32 Hz, 1H), 12.03 (d, J=2.21 Hz, 1H), 14.24 (br s, 1H); ESIMS found for C₂₈H₂₃FN₆O₂S m/z 527.1 (M+1).

N-(5-(3-(4-(3-Fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)benzamide 487

¹H NMR (400 MHz, DMSO-d₆) δ ppm 2.90 (s, 3H), 4.34 (d, J=6.17 Hz, 2H), 7.19 (br d, J=7.28 Hz, 2H), 7.24-7.32 (m, 1H), 7.42 (d, J=1.54 Hz, 1H), 7.47 (br d, J=9.70 Hz, 1H), 7.51-7.68 (m, 4H), 7.68-7.78 (m, 2H), 8.00-8.11 (m, 2H), 8.72 (s, 1H), 9.02 (s, 1H), 9.05 (br d, J=2.21 Hz, 1H), 9.19 (d, J=1.76 Hz, 1H), 9.27 (d, J=0.66 Hz, 1H), 10.62 (s, 1H), 11.98 (br d, J=1.76 Hz, 1H), 14.10 (s, 1H); ESIMS found for C₃₄H₂₆FN₇O₃S m/z 632.3 (M+1).

N-(3-Fluoro-5-(2-(5-(5-(isopropylamino)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)benzyl)methanesulfonamide 488

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.23 (d, J=6.17 Hz, 6H), 2.89 (s, 3H), 4.34 (br d, J=6.17 Hz, 2H), 7.06 (br s, 1H), 7.14-7.25 (m, 2H), 7.25-7.32 (m, 1H), 7.42-7.52 (m, 2H), 7.56 (br d, J=8.16 Hz, 1H), 7.69 (br s, 1H), 7.71-7.80 (m, 1H), 8.04 (br d, J=2.21 Hz, 1H), 8.39 (br s, 1H), 8.79 (br d, J=4.85 Hz, 2H), 9.26 (s, 1H), 12.03 (br s, 1H), 14.23 (br s, 1H); ESIMS found for C₃₀H₂₈FN₇O₂S m/z 570.2 (M+1).

N-(5-(3-(4-(3-Fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclohexanecarboxamide 499

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.19-1.38 (m, 3H), 1.40-1.53 (m, 2H), 1.63-1.73 (m, 1H), 1.73-1.84 (m, 2H), 1.85-1.94 (m, 2H), 2.38-2.48 (m, 1H), 2.89 (s, 2H), 4.32-4.40 (m, 2H), 7.13-7.25 (m, 2H), 7.25-7.33 (m, 1H), 7.42-7.52 (m, 2H), 7.57 (d, J=8.16 Hz, 1H), 7.72 (s, 1H), 7.77 (br t, J=6.39 Hz, 1H), 8.84 (d, J=1.10 Hz, 1H), 9.15 (br s, 1H), 9.19 (br s, 1H), 9.29 (d, J=1.10 Hz, 1H), 9.38 (br d, J=1.32 Hz, 1H), 10.80 (br s, 1H), 12.06 (d, J=1.54 Hz, 1H), 14.27 (br s, 1H); ESIMS found for C₃₄H₃₂FN₇O₃S m/z 638.2 (M+1).

N-(3-(2-(5-(5-(((Cyclopentylmethyl)amino)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)-5-fluorobenzyl)methanesulfonamide 501

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.19-1.35 (m, 2H), 1.44-1.69 (m, 4H), 1.73-1.87 (m, 2H), 2.22 (dt, J=15.10, 7.66 Hz, 1H), 2.91 (s, 3H), 2.93-3.05 (m, 2H), 4.32-4.42 (m, 2H), 7.11-7.25 (m, 2H), 7.25-7.33 (m, 1H), 7.38-7.51 (m, 2H), 7.59 (br d, J=7.94 Hz, 1H), 7.72 (s, 1H), 7.74-7.82 (m, 1H), 8.85 (s, 1H), 9.01 (br s, 1H), 9.12 (br s, 1H), 9.27 (br d, J=1.10 Hz, 1H), 9.55 (br d, J=1.76 Hz, 1H), 12.01 (br d, J=1.32 Hz, 1H), 14.21 (br s, 1H); ESIMS found for C₃₄H₃₄FN₇O₂S m/z 624.2 (M+1).

N-(3-(2-(5-(5-((3,3-Difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)-5-fluorobenzyl)methanesulfonamide 502

¹H NMR (400 MHz, DMSO-d₆) δ ppm 2.54-2.65 (m, 2H), 2.90 (s, 3H), 3.54 (br s, 2H), 3.83 (br s, 2H), 4.36 (br d, J=5.73 Hz, 2H), 4.61 (br s, 2H), 7.16-7.25 (m, 2H), 7.25-7.33 (m, 1H), 7.42-7.53 (m, 2H), 7.59 (d, J=7.94 Hz, 1H), 7.73 (s, 1H), 7.80 (br t, J=6.28 Hz, 1H), 8.94 (br s, 1H), 8.98 (br s, 1H), 9.24 (br s, 1H), 9.29 (d, J=1.10 Hz, 1H), 9.65 (d, J=1.54 Hz, 1H), 12.06 (br d, J=1.32 Hz, 1H), 14.33 (br s, 1H); ESIMS found for C₃₂H₂₈F₃N₇O₂S m/z 632.2 (M+1).

N-(3-Fluoro-5-(2-(5-(pyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)benzyl)methanesulfonamide 503

¹H NMR (400 MHz, DMSO-d₆) δ ppm 2.94 (s, 3H), 4.36 (br d, F=5.95 Hz, 2H), 7.15-7.24 (m, 2H), 7.24-7.31 (m, 1H), 7.42-7.51 (m, 2H), 7.56 (d, J=7.94 Hz, 1H), 7.70-7.81 (m, 2H), 8.83 (d, J=1.10 Hz, 1H), 9.22 (s, 1H), 9.28 (d, J=1.10 Hz, 1H), 9.57 (s, 2H), 11.97 (br d, J=1.76 Hz, 1H), 14.16 (br s, 1H); ESIMS found for C₂₆H₂₀FN₇O₂S m/z 514.1 (M+1).

5-(3-(1H-Pyrrolo[3,2-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl) pyridin-3-amine 507

¹H NMR (400 MHz, DMSO-d₆) δ ppm 6.67 (br s, 2H), 7.69 (br dd, J=7.94, 5.73 Hz, 1H), 7.77 (br d, J=1.10 Hz, 1H), 8.06 (br d, J=2.43 Hz, 1H), 8.52 (br s, 1H), 8.57 (br d, J=7.94 Hz, 1H), 8.66 (br d, J=5.51 Hz, 1H), 9.02 (s, 1H), 9.08 (s, 1H), 9.36 (br d, J=0.88 Hz, 1H), 13.60 (br s, 1H), 14.86 (br s, 1H); ESIMS found for C₁₈H₁₃N₇ m/z 328.0 (M+1).

1-(5-(3-(1H-Pyrrolo[3,2-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl) pyridin-3-yl)-N-(cyclopentylmethyl)methanamine 529

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.21-1.35 (m, 2H), 1.47-1.67 (m, 4H), 1.76-1.89 (m, 2H), 2.25-2.32 (m, 1H), 2.94-3.04 (m, 2H), 4.39 (br t, J=5.62 Hz, 2H), 7.71 (dd, J=8.16, 5.95 Hz, 1H), 7.86 (d, J=1.32 Hz, 1H), 8.60 (d, J=8.16 Hz, 1H), 8.63-8.69 (m, 1H), 8.87 (d, J=1.76 Hz, 1H), 9.16 (s, 1H), 9.24 (br s, 1H), 9.37 (d, J=1.10 Hz, 1H), 9.60 (d, J=1.99 Hz, 1H), 13.57 (br s, 1H), 14.85 (br s, 1H); ESIMS found for C₂₅H₂₅N₇ m/z 424.1 (M+1).

5-(5-(Benzyloxy)pyridin-3-yl)-3-(4-(3-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine 546

¹H NMR (400 MHz, DMSO-d₆) ppm 5.38 (s, 2H), 7.12-7.22 (m, 2H), 7.27 (t, J=7.45 Hz, 1H), 7.38 (br d, J=6.58 Hz, 1H), 7.40-7.47 (m, 2H), 7.48 (s, 1H), 7.52-7.63 (m, 5H), 7.68 (d, J=8.33 Hz, 1H), 8.48 (s, 1H), 8.51 (s, 1H), 8.80 (s, 1H), 9.12 (s, 1H), 9.25 (s, 1H), 12.00 (d, J=2.19 Hz, 1H), 14.15 (br s, 1H); ESIMS found for C₃₂H₂₂FN₅O m/z 512.0 (M+1).

3-(4-(2-Fluorophenyl)-1H-indol-2-yl)-5-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-c]pyridine 567

¹H NMR (400 MHz, DMSO-d₆) δ ppm 7.11 (br d, J=2.63 Hz, 2H), 7.26 (t, J=7.67 Hz, 1H), 7.35-7.44 (m, 2H), 7.46-7.53 (m, 1H), 7.56 (d, J=7.89 Hz, 1H), 7.66-7.75 (m, 1H), 8.33 (s, 2H), 8.40 (br s, 1H), 9.17 (s, 1H), 11.92 (s, 1H), 14.16 (br s, 1H); ESIMS found for C₂₃H₁₅FN₆ m/z 395.0 (M+1).

N,N-Dimethyl-2-((5-(3-(4-(pyridin-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)oxy)ethan-1-amine 591

¹H NMR (400 MHz, DMSO-d₆) δ ppm 2.90 (br s, 6H), 3.65 (br s, 2H), 4.75 (br s, 2H), 7.37 (br d, J=3.07 Hz, 2H), 7.64 (s, 1H), 7.73 (dd, J=5.04, 3.73 Hz, 1H), 8.16-8.24 (m, 1H), 8.61 (br s, 1H), 8.77 (br s, 1H), 8.95-9.02 (m, 2H), 9.07 (s, 1H), 9.29 (br s, 1H), 9.30 (br s, 1H), 9.35 (s, 1H), 12.37 (br s, 1H), 14.41 (br s, 1H); ESIMS found for C₂₈H₂₅N₇O m/z 476.2 (M+1).

5-(1-Methyl-1H-pyrazol-4-yl)-3-(4-(pyridin-4-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine 600

¹H NMR (400 MHz, DMSO-d₆) δ ppm 3.94 (br s, 3H), 7.37-7.48 (m, 1H), 7.51-7.62 (m, 2H), 7.74-7.83 (m, 1H), 8.29 (br s, 1H), 8.53 (br d, J=7.94 Hz, 4H), 9.01 (br d, J=4.41 Hz, 2H), 9.21 (br s, 1H), 12.37 (br s, 1H), 14.43 (br s, 1H); ESIMS found for C₂₃H₁₇N₇ m/z 392.1 (M+1).

2-(Piperidin-4-yl)-N-(5-(3-(4-(pyridin-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)acetamide 621

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.44-1.61 (m, 2H), 1.81-1.94 (m, 2H), 2.07-2.20 (m, 1H), 2.81-2.96 (m, 2H), 3.21-3.31 (m, 2H), 3.99-4.08 (m, 2H), 7.42 (br t, J=7.28 Hz, 1H), 7.61 (br d, J=7.06 Hz, 1H), 7.68 (br s, 1H), 7.82 (br d, J=7.72 Hz, 1H), 8.00 (br s, 1H), 8.53 (br d, J=7.94 Hz, 1H), 8.65 (br t, J=7.83 Hz, 1H), 8.95-9.04 (m, 1H), 9.06 (br s, 1H), 9.18 (br s, 1H), 9.30 (s, 1H), 9.39 (br s, 1H), 9.56 (br s, 1H), 11.47 (br s, 1H), 12.43 (br s, 1H), 14.47 (br s, 1H); ESIMS found for C₃₁H₂₈N₈O m/z 529.2 (M+1).

5-(5-(Cyclohexyloxy)pyridin-3-yl)-3-(4-(piperidin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine 635

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.25-1.40 (m, 2H), 1.48-1.62 (m, 4H), 1.67-2.14 (m, 8H), 2.55-2.70 (m, 2H), 3.68-3.88 (m, 4H), 5.13 (br d, J=3.31 Hz, 1H), 7.26-7.36 (m, 1H), 7.58 (br d, J=5.51 Hz, 1H), 7.61-7.70 (m, 1H), 8.54 (br s, 1H), 8.63 (br s, 1H), 8.94 (br s, 1H), 9.29 (br s, 1H), 9.30 (br s, 1H), 9.42 (br s, 1H), 12.44 (br s, 1H), 14.41 (br s, 1H); ESIMS found for C₃₀H₃₂N₆O m/z 493.2 (M+1).

5-(1,2-Dimethyl-1H-imidazol-5-yl)-3-(1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine 681

¹H NMR (400 MHz, DMSO-d₆) δ ppm 2.70 (s, 3H), 3.98 (s, 3H), 7.01-7.09 (m, 1H), 7.13-7.20 (m, 1H), 7.36 (br d, J=1.54 Hz, 1H), 7.48 (br d, J=7.50 Hz, 1H), 7.61 (br d, J=7.72 Hz, 1H), 8.18 (s, 1H), 8.57 (br d, J=0.10 Hz, 1H), 9.26 (d, J=1.10 Hz, 1H), 11.77 (br s, 1H), 14.18 (br s, 1H), 14.44 (br s, 1H); ESIMS found for C₁₉H₁₆N₆ m/z 329.0 (M+1).

3-(4-(Furan-3-yl)-1H-indol-2-yl)-5-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-c]pyridine 711

¹H NMR (400 MHz, DMSO-d₆) δ ppm 7.14 (s, 1H), 7.17-7.25 (m, 1H), 7.28 (d, J=7.45 Hz, 1H), 7.45 (d, J=7.89 Hz, 1H), 7.48 (s, 1H), 7.84 (s, 1H), 8.53 (s, 2H), 8.56 (s, 1H), 8.72 (s, 1H), 9.30 (s, 1H), 11.97 (s, 1H), 14.50 (br s, 1H); ESIMS found for C₂₁H₁₄N₆O m/z 367.0 (M+1).

5-(Piperidin-4-yl)-3-(4-(thiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine 725

¹H NMR (400 MHz, DMSO-d₆) δ ppm 2.04-2.21 (m, 4H), 2.99-3.13 (m, 2H), 3.22-3.32 (m, 1H), 3.38-3.48 (m, 2H), 6.88 (br s, 1H), 7.19 (br t, J=7.89 Hz, 1H), 7.38 (d, J=7.45 Hz, 1H), 7.45 (d, J=7.89 Hz, 1H), 7.52 (br d, J=2.63 Hz, 1H), 7.65 (d, J=3.95 Hz, 1H), 7.93 (d, J=3.95 Hz, 1H), 8.08 (s, 1H), 9.20 (br s, 1H), 11.45 (br s, 1H), 14.11 (br s, 1H); ESIMS found for C₂₃H₂₁N₅S m/z 400.1 (M+1).

5-(3-(4-(3-((2-(Dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-ol 817

¹H NMR (400 MHz, DMSO-d₆) δ ppm 2.82 (br s, 6H), 3.30 (br d, J=1.10 Hz, 2H), 3.56 (br s, 2H), 6.53 (br d, J=11.91 Hz, 1H), 6.73 (br d, J=9.70 Hz, 1H), 6.98 (br s, 1H), 7.11-7.18 (m, 1H), 7.18-7.29 (m, 1H), 7.44 (br s, 1H), 7.51-7.61 (m, 1H), 8.45 (br s, 1H), 8.77 (br s, 1H), 8.96 (br s, 1H), 9.28 (br d, J=0.88 Hz, 2H), 10.38 (br s, 1H), 11.95 (br s, 1H), 12.03 (br s, 1H), 14.32 (br s, 1H); ESIMS found for C₂₉H₂₆FN₇O m/z 508.1 (M+1).

5-(1-Methyl-1H-pyrazol-4-yl)-3-(1H-pyrrolo[3,2-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridine 1022

¹H NMR (400 MHz, DMSO-d₆) δ ppm 3.93 (s, 3H), 7.65 (d, J=1.32 Hz, 1H), 7.68 (dd, J=8.16, 5.95 Hz, 1H), 8.21 (s, 1H), 8.41 (s, 1H), 8.56 (br t, J=3.97 Hz, 2H), 8.64 (d, J=5.51 Hz, 1H), 9.19 (d, J=0.88 Hz, 1H), 13.50 (br s, 1H), 14.63 (br s, 1H); ESIMS found for C₁₇H₁₃N₇ m/z 316.0 (M+1).

5-(5-(Cyclohexyloxy)pyridin-3-yl)-3-(1H-pyrrolo[3,2-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridine 1025

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.27-1.39 (m, 2H), 1.41-1.63 (m, 4H), 1.72-1.82 (m, 2H), 2.01 (ddd, J=7.55, 4.69, 2.98 Hz, 2H), 4.65-4.74 (m, 1H), 7.69 (br dd, J=8.27, 5.84 Hz, 1H), 7.80 (br d, J=1.54 Hz, 1H), 8.39 (br s, 1H), 8.46 (br d, J=1.76 Hz, 1H), 8.54 (br d, J=8.16 Hz, 1H), 8.64-8.71 (m, 1H), 8.96 (s, 1H), 9.14 (br d, 0.1=1.32 Hz, 1H), 9.36 (br d, 0.1-1.32 Hz, 1H), 13.48 (br s, 1H), 14.72 (br s, 1H); ESIMS found for C₂₄H₂₂N₆O m/z 411.1 (M+1).

2-((5-(3-(1H-Pyrrolo[3,2-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl) pyridin-3-yl)oxy)-N,N-dimethylethan-1-amine 1029

¹H NMR (400 MHz, DMSO-d₆) δ ppm 2.91 (d, J=4.63 Hz, 6H), 3.61 (br dd, J=9.48, 4.41 Hz, 2H), 4.63-4.71 (m, 2H), 7.70 (br dd, J=8.16, 5.73 Hz, 1H), 7.77 (br d, J=1.32 Hz, 1H), 8.51 (s, 2H), 8.61 (br d, J=8.16 Hz, 1H), 8.64-8.70 (m, 1H), 9.10 (s, 1H), 9.26 (s, 1H), 9.36 (br d, J=1.10 Hz, 1H), 13.66 (br d, J=0.88 Hz, 1H), 14.79 (br s, 1H); ESIMS found for C₂₂H₂₁N₇O m/z 400.2 (M+1).

Example 2

The screening assay for Wnt activity is described as follows. Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) with a lentiviral construct that includes a Wnt-responsive promoter driving expression of the firefly luciferase gene.

SW480 colon carcinoma cells were transduced with a lentiviral vector expressing luciferase with a human Sp5 promoter consisting of a sequence of eight TCF/LEF binding sites. SW480 cells stably expressing the Sp5-Luc reporter gene and a hygromycin resistance gene were selected by treatment with 150 μg/mL of hygromycin for 7 days. These stably transduced SW480 cells were expanded in cell culture and used for all further screening activities. Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. Serial dilution (1:3, 10-point dose-response curves starting from 10 μM) and compound transfer was performed using the ECHO 550 (Labcyte, Sunnyvale, Calif.) into 384-well white solid bottom assay plates (Greiner Bio-One) with appropriate DMSO backfill for a final DMSO concentration of 0.1%. For Sp5-Luc reporter gene assays, the cells were plated at 4,000 cells/well in 384-well plates with medium containing 1% fetal bovine serum and incubated overnight at 37° C. and 5% CO₂. Following incubation, 20 gil of BrightGlo luminescence reagent (Promega) was added to each well of the 384-well assay plates. The plates were placed on an orbital shaker for 2 min and then luminescence was quantified using the Envision (Perkin Elmer) plate reader. Readings were normalized to DMSO only treated cells, and normalized activities were utilized for EC₅₀ calculations using the dose-response log (inhibitor) vs. response-variable slope (four parameters) nonlinear regression feature available in GraphPad Prism 5.0 (or Dotmatics). For EC₅₀ of >10 μM, the percent inhibition at 10 μM is provided.

Table 2 shows the measured activity for representative compounds of Formula I as described herein.

TABLE 2 Compound EC₅₀ (μM) 1 0.570 5 0.590 11 >10 (50.2%) 13 1.350 16 1.970 21 1.512 26 1.030 28 2.245 30 1.536 34 0.382 36 0.872 38 4.310 42 1.843 51 >10 (32.6%) 55 4.139 59 0.296 60 0.740 65 >10 (35.8%) 68 0.494 71 2.094 72 1.705 75 >10 (11.1%) 76 0.940 85 0.305 88 0.260 93 0.275 95 0.400 98 1.198 104 0.336 110 0.137 114 0.469 117 >10 (43.1%) 120 0.194 124 0.108 128 >10 (46.5%) 133 0.401 139 1.233 140 0.485 143 0.255 145 0.567 150 1.417 153 0.711 159 3.481 163 0.550 170 1.333 174 0.553 176 3.039 180 0.362 188 2.417 194 1.827 196 3.417 227 1.159 233 0.700 234 1.036 237 3.405 243 1.052 245 1.970 251 1.518 254 0.154 256 0.185 263 0.199 266 0.390 268 0.615 275 0.635 323 2.768 326 0.157 337 0.911 343 1.129 353 4.911 360 1.781 451 0.448 454 1.258 456 0.386 458 3.590 461 1.314 468 1.314 476 3.754 481 0.195 487 0.800 488 0.157 499 1.763 501 1.335 502 0.253 503 0.560 507 0.248 529 2.308 546 0.421 567 0.203 591 2.739 600 0.027 621 >10 (46.2%) 635 3.840 681 0.754 711 0.203 725 >10 (25.9%) 817 0.407 1022 0.047 1025 0.171 1029 3.063

Example 3

Representative compounds were screened using the following assay procedure to assess the effect on cell viability as described below.

Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. Serial dilution (1:3, 8-point dose-response curves from 10 μM to 0.0045 μM) and compound transfer was performed using the ECHO 550 (Labcyte, Sunnyvale, Calif.) into 96-well clear bottom, black-walled plates (Corning-Costar).

Approximately 2×103 SW480 colon cancer cells were seeded into each well and allowed to incubate in the presence or absence of compound for four days at 37° C./5% CO₂. Eight replicates of DMSO-treated cells served as controls and cells treated with compound were performed in duplicate.

After incubation, 20 μL of CellTiter-Blue (Promega) was added to each well allowed to incubate for approximately 3 hours. This reagent was a buffered solution which contains resazurin, metabolically active cells were able to reduce rezarurin (blue) into resorufin (pink) which was highly fluorescent. This measured fluorescence was used as a readout for cell viability.

After incubation, the plates were read at Ex 560 nm Em 590 nm (Cytation 3, BioTek). Dose-response curves were generated and EC₅₀ concentration values were calculated using non-linear regression curve fit in the GraphPad Prism (San Diego, Calif.) or Dotmatics' Studies Software (Bishops Stortford, UK). For EC₅₀ of >10 μM, the percent inhibition at 10 μM is provided.

Table 3 shows the activity of representative compounds of Formula I as provided herein.

TABLE 3 Compound EC₅₀ (μM) 1 4.069 5 6.843 11 5.418 13 4.931 16 3.923 21 >10 (11.5%) 26 3.948 28 3.531 30 >10 (28.3%) 34 0.805 36 5.957 38 4.323 42 1.081 51 9.617 55 >10 (13.6%) 59 1.303 60 0.909 65 5.054 68 1.612 71 1.656 72 4.428 75 >10 (10.7%) 76 6.553 85 1.155 88 1.086 93 0.305 95 1.395 98 7.217 104 1.466 110 1.067 114 6.981 117 >10 (16.6%) 120 >10 (32.2%) 124 5.827 128 >10 (14.0%) 133 >10 (45.9%) 139 >10 (15.5%) 140 0.370 143 1.922 145 0.814 150 2.973 153 2.060 159 2.809 163 0.938 170 4.654 174 1.083 176 7.136 180 1.732 188 >10 (25.3%) 194 6.214 196 6.056 227 2.611 233 1.950 234 3.133 237 3.797 243 2.135 245 >10 (64.6%) 251 1.693 254 1.273 256 2.246 263 4.923 266 1.636 268 >10 (4.5%)  275 >10 (35.4%) 323 2.341 326 0.103 337 3.417 343 0.696 353 4.011 360 3.466 451 0.659 454 1.476 456 0.437 458 4.552 461 0.964 468 1.980 476 2.855 481 1.934 487 >10 (45.4%) 488 0.688 499 4.539 501 2.249 502 0.882 503 4.000 507 1.232 529 >10 (0%)   546 0.365 567 >10 (46.1%) 591 2.779 600 >10 (45.1%) 621 >10 (29.3%) 635 >10 (26.8%) 681 1.521 711 >10 (45.1%) 725 >10 (8.1%)  817 1.073 1022 2.557 1025 1.431 1029 >10 (17.1%)

Example 4

Representative compounds were screened using primary human fibroblasts (derived from IPF patients) treated with TGF-β1 to determine their ability to inhibit the fibrotic process.

Human Fibroblast Cell Culture:

Primary human fibroblasts derived from IPF patients (LL29 cells) [¹Xiaoqiu Liu, et. al., “Fibrotic Lung Fibroblasts Show Blunted Inhibition by cAMP Due to Deficient cAMP Response Element-Binding Protein Phosphorylation”, Journal of Pharmacology and Experimental Therapeutics (2005), 315(2), 678-687; ²Watts, K. L., et. al., “RhoA signaling modulates cyclin D1 expression in human lung fibroblasts; implications for idiopathic pulmonary fibrosis”, Respiratory Research (2006), 7(1), 88] were obtained from American Type Culture Collection (ATCC) and expanded in F12 medium supplemented with 15% Fetal Bovine Serum and Penicillin/Streptomycin.

Compound Screening:

Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. Serial dilution (1:2, 11-point dose-response curves from 10 μM to 1.87 nM) and compound transfer was performed using the ECHO 550 (Labcyte, Sunnyvale, Calif.) into 384-well clear bottom assay plates (Greiner Bio-One) with appropriate DMSO backfill for a final DMSO concentration of 0.1%. LL29 cells are plated at 1,500 cells/well in 80 μL/well F12 medium supplemented with 1% Fetal Bovine Serum. One hour after addition of the cells, TGF-β1 (Peprotech; 20 ng/mL) was added to the plates to induce fibrosis (ref. 1 and 2 above). Wells treated with TGF-β1 and containing DMSO were used as controls. Cells were incubated at 37° C. and 5% CO₂ for 4 days. Following incubation for 4 days, SYTOX green nucleic acid stain (Life Technologies [Thermo Fisher Scientific]) was added to the wells at a final concentration of 1 μM and incubated at room temperature for 30 min. Cells were then fixed using 4% formaldehyde (Electron Microscopy Sciences), washed 3 times with PBS followed by blocking and permeabilization using 3% Bovine Serum Albumin (BSA; Sigma) and 0.3% Triton X-100 (Sigma) in PBS. Cells were then stained with antibody specific to α-smooth muscle actin (αSMA; Abcam) (ref. 1 and 2 above) in 3% Bovine Serum Albumin (BSA; Sigma) and 0.3% Triton X-100 (Sigma) in PBS, and incubated overnight at 4° C. Cells were then washed 3 times with PBS, followed by incubation with Alexa Flor-647 conjugated secondary antibody (Life Technologies [Thermo Fisher Scientific]) and DAPI at room temperature for 1 hour. Cells were then washed 3 times with PBS and plates were sealed for imaging. αSMA staining was imaged by excitation at 630 nm and emission at 665 nm and quantified using the Compartmental Analysis program on the CellInsight CX5 (Thermo Scientific). Dead or apoptotic cells were excluded from analysis based on positive SYTOX green staining. % of total cells positive for αSMA were counted in each well and normalized to the average of 11 wells treated with TGF-β1 on the same plate using Dotmatics' Studies Software. The normalized averages (fold change over untreated) of 3 replicate wells for each compound concentration were used to create dose-responses curves and EC₅₀ values were calculated using non-linear regression curve fit in the Dotmatics' Studies Software. For EC₅₀ of >10 μM, the percent inhibition at 10 μM is provided.

Table 4 shows the activity of representative compounds of Formula I as provided herein.

TABLE 4 Compound EC₅₀ (μM) 1 0.529 5 0.605 11 0.873 13 2.204 16 0.640 21 1.699 26 0.092 28 1.182 30 2.280 34 0.029 36 1.011 38 0.659 42 0.078 51 0.809 55 2.661 59 0.144 60 0.090 65 1.114 68 0.215 71 0.157 72 0.701 75 2.029 76 0.307 85 0.553 88 0.305 93 0.298 95 0.166 98 1.609 104 0.189 110 0.081 114 0.033 117 1.044 120 1.030 124 0.138 128 >10 (23.7%) 133 0.391 139 0.238 140 0.319 143 0.098 145 0.223 150 0.531 153 0.461 159 0.269 163 0.081 170 0.902 174 0.650 176 0.700 180 0.267 188 1.371 194 0.694 196 1.160 227 1.912 233 >10 (74.5%) 234 1.253 237 7.318 243 1.010 245 4.606 251 1.691 254 0.139 256 0.051 263 0.065 266 0.143 268 9.985 275 3.270 323 0.261 326 1.388 337 0.387 343 0.134 353 0.056 360 0.373 451 0.046 454 0.583 456 0.444 458 2.844 461 1.183 468 3.513 476 0.582 481 0.712 487 5.014 488 0.182 499 4.787 501 0.463 502 0.028 503 >10 (0%)   507 >10 (0%)   529 >10 (0%)   546 0.234 567 0.027 591 2.189 600 0.013 621 3.144 635 1.318 681 0.292 711 0.125 725 >10 (4.5%)  817 0.519 1022 >10 (44.5%) 1025 0.584 1029 1.716

Example 5

Representative compounds were screened using primary human mesenchymal stem cells (hMSCs) to determine their ability to induce chondrogenesis (process by which cartilage is developed).

Human Mesenchymal Stem Cell Culture:

Primary human mesenchymal stem cells (hMSCs) were purchased from Lonza (Walkersville, Md.) and expanded in Mesenchymal Stem Cell Growth Media (Lonza). Cells between passage 3 and 6 were used for the experiments.

Compound Screening:

Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. Serial dilution (1:3, 6-point dose-response curves from 2700 nM to 10 nM) and compound transfer was performed using the ECHO 550 (Labcyte, Sunnyvale, Calif.) into 96-well clear bottom assay plates (Greiner Bio-One) with appropriate DMSO backfill for a final DMSO concentration of 0.03%. hMSCs were plated at 20,000 cells/well in 250 μL/well Incomplete Chondrogenic Induction Medium (Lonza; DMEM, dexamethasone, ascorbate, insulin-transferrin-selenium [ITS supplement], gentamycin-amphotericin [GA-1000], sodium pyruvate, proline and L-glutamine). TGF-β3 (10 ng/mL) was used as a positive control for differentiation while negative control wells were treated with 75 nL DMSO for normalization and calculating EC₅₀ values. Cells were incubated at 37° C. and 5% CO₂ for 6 days. To image chondrogenic nodules, the cells were fixed using 4% formaldehyde (Electron Microscopy Sciences), and stained with 2 μg/mL Rhodamine B (Sigma-Aldrich) and 20 μM Nile Red (Sigma-Aldrich) [Johnson K., et. al, A Stem Cell-Based Approach to Cartilage Repair, Science, (2012), 336(6082), 717-721]. The nodules imaged (4 images per well at 4× magnification) by excitation at 531 nm and emission at 625 nm and quantified using the CellInsight CX5 (Thermo Scientific). Number of nodules in each well was normalized to the average of 3 DMSO treated wells on the same plate using Excel (Microsoft Inc.). The normalized averages (fold change over DMSO) of 3 replicate wells for each compound concentration were calculated. Due to solubility limitations of some of the compounds, curve fitting was incomplete leading to inaccurate EC₅₀ determinations.

Using TGF-β3 as a positive control, the concentration of representative compounds required to induce 50% levels of chondrogenesis is reported. In addition, the maximum activity of each compound and the respective dose that each compound reached maximum chondrogenesis activity is reported. Table 5 shows the activity of representative compounds as provided herein.

TABLE 5 Conc Max. (nM) of Activity as 50% Conc (nM) of % TGF-β3 TGF-β3 Compound Max. activity activity activity 34 2700 268 900 42 2700 164 300 59 300 94 30 71 2700 18 NA 85 2700 101 2700 88 2700 141 30 93 10 201 10 95 100 236 100 98 2700 22 NA 104 100 308 100 143 300 118 300 145 2700 90 30 153 2700 75 30 159 900 84 900 233 10 36 NA 263 2700 122 2700 266 2700 138 2700 323 2700 85 2700 451 100 180 100 454 2700 294 30 456 30 87 10 461 2700 52 2700 476 900 89 10 481 2700 152 900 503 2700 102 900 591 2700 36 NA 600 300 138 300 621 2700 57 2700 817 10 66 10

Example 6

Representative compounds were screened using the following assay procedure to determine their ability to inhibit IL-6 and therefore demonstrate their anti-inflammatory properties.

Human Monocyte Cell Culture:

Human monocyte cell line (THP-1 cells; Catalog # TIB-202, ATCC, Manassas, Va.) were cultured in Roswell Park Memorial Institute (RPMI) 1640 Medium (Catalog #21870-100, Buffalo, N.Y.) with 1% L-glutamine, 1% HEPES, 1% Sodium Pyruvate, 2% Sodium Bicarbonate supplemented with 100 units/mL penicillin, 50 μg/mL streptomycin, 2-mercaptoethanol (0.05 mM) [basal medium] and 10% fetal bovine serum (Catalog #16140089, Life Technologies, Carlsbad, Calif.) at 37° C. and 5% CO₂.

Compound Screening:

THP-1 cells were cultured in basal media with 1% FBS for 24 hours before the start of the assay. Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. Serial dilution (1:3, 10-point dose-response curves starting from 10 μM) and compound transfer was performed using the ECHO 550 (Labcyte, Sunnyvale, Calif.) into 384-well white low volume assay plates (Greiner Bio-One) with appropriate DMSO backfill for a final DMSO concentration of 0.1%. THP-1 cells were plated at 5000 cells/well in the 384-well plates and incubated at 37° C. for 2 h. 500 ng/mL of LPS was added after 2 hours and cells were incubated for another 22 hours at 37° C. Plates were spun in a centrifuge for 1 minute at 10,000 rpm and a mixture of anti-IL6 XL665, and anti-IL6 Cryptate diluted in reconstitution buffer (Cisbio Inc.) was added to each well. Following incubation for 3 hrs at room temperature, Homogeneous Time-Resolved Fluorescence (HTRF) was measured using the Envision (Perkin Elmer) at 665 nm and 620 nM. The ratio of fluorescence at 665 nm to 620 nm was used as a readout for IL6 quantification. All samples were processed in duplicate. Readings were normalized to DMSO treated cells and normalized activities were utilized for EC₅₀ calculations using the dose-response log (inhibitor) vs. response-variable slope (four parameters) nonlinear regression feature available in GraphPad Prism 5.0 (or Dotmatics). For EC₅₀ of >10 μM, the percent inhibition at 10 μM is provided.

Table 6 shows the activity of representative compounds of Formula I as provided herein.

TABLE 6 Compound EC₅₀ (μM) 1 2.915 5 >10 (30.7%) 11 3.213 13 7.515 16 1.873 21 >10 (0%)   26 3.094 28 3.600 30 5.127 34 0.399 36 1.631 38 >10 (29.4%) 42 3.808 51 >10 (6.7%)  55 9.588 59 0.968 60 2.568 65 >10 (30.1%) 68 3.103 71 7.660 72 3.207 75 0.003 76 >10 (11.1%) 85 0.074 88 0.109 93 0.181 95 0.727 98 1.522 104 0.226 110 0.422 114 1.077 117 >10 (53.0%) 120 2.496 124 3.353 128 >10 (0%)   133 0.251 139 >10 (3.0%)  140 0.481 143 0.549 145 2.833 150 2.024 153 0.989 159 1.560 163 2.493 170 4.286 174 0.167 176 8.892 180 1.002 188 4.963 194 >10 (0%)   196 8.778 227 1.079 233 0.753 234 1.937 237 3.610 243 3.233 245 0.967 251 1.078 254 0.200 256 0.056 263 1.186 266 0.424 268 >10 (25.1%) 275 0.092 323 3.486 326 5.077 337 7.116 343 7.754 353 1.889 360 1.432 451 0.091 454 0.856 456 0.286 458 3.299 461 0.657 468 0.866 476 1.561 481 1.176 487 >10 (28.8%) 488 0.526 499 1.785 501 1.029 502 0.481 503 2.982 507 0.404 529 0.999 546 3.991 567 0.438 591 1.460 600 0.044 621 1.654 635 >10 (0%)   681 0.954 711 >10 (0%)   725 >10 (45.4%) 817 0.232 1022 0.344 1025 0.353 1029 2.449 

1.-58. (canceled)
 59. A compound, or a pharmaceutically acceptable salt thereof, of Formula I:

wherein: R¹ and R⁴ are independently selected from the group consisting of H and halide; R³ is selected from the group consisting of -heteroaryl optionally substituted with 1-4 R⁶ and -heterocyclyl optionally substituted with 1-10 R⁷; X is CR⁵ or N; R⁵ is selected from the group consisting of H, -heteroaryl optionally substituted with 1-4 R⁸, -heterocyclyl optionally substituted with 1-10 R⁹, and -aryl optionally substituted with 1-5 R¹⁰; each R⁶ is independently selected from the group consisting of halide, —(C₁₋₆ alkyl), —(C₂₋₆ alkenyl), —(C₂₋₆ alkynyl), —(C₁₋₄ alkylene)_(p)heterocyclyl optionally substituted with 1-10 R¹¹, —(C₂₋₄ alkenylene)_(p)heterocyclyl optionally substituted with 1-10 R¹¹, —(C₂₋₄ alkynylene)_(p)heterocyclyl optionally substituted with 1-10 R¹¹, —(C₁₋₄ alkylene)_(p)carbocyclyl optionally substituted with 1-12 R¹², —(C₂₋₄ alkenylene)_(p)carbocyclyl optionally substituted with 1-12 R¹², —(C₂₋₄ alkynylene)_(p)carbocyclyl optionally substituted with 1-12 R¹², —(C₁₋₄ alkylene)_(p)aryl optionally substituted with 1-5 R¹³, —(C₂₋₄ alkenylene)_(p)aryl optionally substituted with 1-5 R¹³, —(C₂₋₄ alkynylene)_(p)aryl optionally substituted with 1-5 R¹³, —NHC(═O)R¹⁴, —NR¹⁵R¹⁶, —(C₁₋₆ alkylene)NR¹⁷R¹⁸, —(C₂₋₆ alkenylene)NR¹⁷R¹⁸, —(C₂₋₆ alkynylene)NR¹⁷R¹⁸, and —(C₁₋₄ alkylene)_(p)OR²⁴; each R⁷ is independently selected from the group consisting of —(C₁₋₄ alkyl), —(C₂₋₄ alkenyl), —(C₂₋₄ alkynyl), halide, —CF₃, and —CN; each R⁸ is independently selected from the group consisting of —(C₁₋₆ alkyl), —(C₂₋₆ alkenyl), —(C₂₋₆ s alkynyl), halide, —CF₃, —OCH₃, —CN, and —C(═O)R¹⁹; each R⁹ is independently selected from the group consisting of —(C₁₋₆ alkyl), —(C₂₋₆ alkenyl), —(C₂₋₆ alkynyl), halide, —CF₃, —CN, and —OCH₃; each R¹⁰ is independently selected from the group consisting of —(C₁₋₆ alkyl), —(C₂₋₆ alkenyl), —(C₂₋₆ alkynyl), halide, —CF₃, —CN, —(C₁₋₆ alkylene)_(p)NHSO₂R¹⁹, —(C₂₋₆ alkenylene)NHSO₂R¹⁹, —(C₂₋₆ alkynylene)₉NHSO₂R¹⁹, —NR¹⁵(C₁₋₆ alkylene)NR¹⁵R¹⁶, —NR¹⁵(C₂₋₆ alkenylene)NR¹⁵R¹⁶, —NR¹⁵(C₂₋₆ alkynylene)NR¹⁵R¹⁶, —(C₁₋₆ alkylene)₉NR¹⁵R¹⁶, —(C₂₋₆ alkenylene)_(p)NR¹⁵R¹⁶, —(C₂₋₆ alkynylene)₉NR¹⁵R¹⁶, and —OR²⁷; each R¹¹ is independently selected from the group consisting of amino, —(C₁₋₄ alkyl), —(C₂₋₄ alkenyl), —(C₂₋₄ alkynyl), halide, —CF₃, and —CN; each R¹² is independently selected from the group consisting of —(C₁₋₄ alkyl), —(C₂₋₄ alkenyl), —(C₂₋₄ alkynyl), halide, —CF₃, and —CN; each R¹³ is independently selected from the group consisting of —(C₁₋₄ alkyl), —(C₂₋₄ alkenyl), —(C₂₋₄ alkynyl), halide, —CF₃, and —CN; each R¹⁴ is independently selected from the group consisting of —(C₁₋₉ alkyl), —(C₁₋₄ haloalkyl), —(C₂₋₉ alkenyl), —(C₂₋₉ alkynyl), -heteroaryl optionally substituted with 1-4 R²⁰, -aryl optionally substituted with 1-5 R²¹, —CH₂aryl optionally substituted with 1-5 R²¹, -carbocyclyl optionally substituted with 1-12 R²², —CH₂carbocyclyl optionally substituted with 1-12 R²², —(C₁₋₄ alkylene)_(p)NR²⁵R²⁶, —(C₂₋₄ alkenylene)_(p)NR²⁵R²⁶, —(C₂₋₄ alkynylene)_(p)NR²⁵R²⁶, -heterocyclyl optionally substituted with 1-10 R²³, and —CH₂heterocyclyl optionally substituted with 1-10 R²³; each R¹⁵ is independently selected from the group consisting of H, —(C₁₋₆ alkyl), —(C₂₋₆ alkenyl), and —(C₂₋₆ alkynyl); each R¹⁶ is independently selected from the group consisting of H, —(C₁₋₆ alkyl), —(C₂₋₆ alkenyl), —(C₂₋₆ alkynyl), —CH₂aryl optionally substituted with 1-5 R²¹, and —CH₂carbocyclyl optionally substituted with 1-12 R²²; each R¹⁷ is independently selected from the group consisting of H, —(C₁₋₆ alkyl), —(C₂₋₆ alkenyl), and —(C₂₋₆ alkynyl); each R¹⁸ is independently selected from the group consisting of H, —(C₁₋₆ alkyl), —(C₂₋₆ alkenyl), —(C₂₋₆ alkynyl), —CH₂aryl optionally substituted with 1-5 R²¹, and —CH₂carbocyclyl optionally substituted with 1-12 R²²; each R¹⁹ is independently selected from the group consisting of —(C₁₋₆ alkyl), —(C₂₋₆ alkenyl), and —(C₂₋₆ alkynyl); each R²⁰ is independently selected from the group consisting of —(C₁₋₄ alkyl), —(C₂₋₄ alkenyl), —(C₂₋₄ alkynyl), halide, —CF₃, and —CN; each R²¹ is independently selected from the group consisting of —(C₁₋₄ alkyl), —(C₂₋₄ alkenyl), —(C₂₋₄ alkynyl), halide, —CF₃, and —CN; each R²² is independently selected from the group consisting of —(C₁₋₄ alkyl), —(C₂₋₄ alkenyl), —(C₂₋₄ alkynyl), halide, —CF₃, and —CN; each R²³ is independently selected from the group consisting of —(C₁₋₄ alkyl), —(C₂₋₄ alkenyl), —(C₂₋₄ alkynyl), halide, —CF₃, and —CN; R²⁴ is selected from the group consisting of H, —(C₁₋₆ alkyl), —(C₂₋₆ alkenyl), —(C₂₋₆ alkynyl), —(C₁₋₄ alkylene)_(p)heterocyclyl optionally substituted with 1-10 R²³, —(C₂₋₄ alkenylene)_(p)heterocyclyl optionally substituted with 1-10 R²³, —(C₂₋₄ alkynylene)_(p)heterocyclyl optionally substituted with 1-10 R²³, —(C₁₋₄ alkylene))carbocyclyl optionally substituted with 1-12 R²², —(C₂₋₄ alkenylene)_(p)carbocyclyl optionally substituted with 1-12 R²², —(C₂₋₄ alkynylene)_(p)carbocyclyl optionally substituted with 1-12 R²², —(C₁₋₄ alkylene)_(p)aryl optionally substituted with 1-5 R²¹, —(C₂₋₄ alkenylene)_(p)aryl optionally substituted with 1-5 R²¹, —(C₂₋₄ alkynylene)_(p)aryl optionally substituted with 1-5 R²¹, —(C₁₋₆ alkylene)_(p)NR²⁵R²⁶, —(C₂₋₄ alkenylene)_(p)NR²⁵R²⁶, and —(C₂₋₄ alkynylene)_(p)NR²⁵R²⁶; each R²⁵ is independently selected from the group consisting of H, —(C₁₋₆ alkyl), —(C₂₋₆ alkenyl), and —(C₂₋₆ alkynyl); each R²⁶ is independently selected from the group consisting of H, —(C₁₋₆ alkyl), —(C₂₋₆ alkenyl), and —(C₂₋₆ alkynyl); R²⁷ is selected from the group consisting of H, —(C₁₋₆ alkyl), —(C₂₋₆ alkenyl), —(C₂₋₆ alkynyl), —(C₁₋₄ alkylene)_(p)heterocyclyl optionally substituted with 1-10 R²³, —(C₂₋₄ alkenylene)_(p)heterocyclyl optionally substituted with 1-10 R²³, —(C₂₋₄ alkynylene)_(p)heterocyclyl optionally substituted with 1-10 R²³, —(C₁₋₆ alkylene)_(p)NR²⁵R²⁶, —(C₂₋₆ alkenylene)_(p)NR²⁵R²⁶, and —(C₂₋₆ alkynylene)_(p)NR²⁵R²⁶; and each p is independently an integer of 0 or
 1. 60. The compound of claim 59, wherein R¹ and R⁴ are H.
 61. The compound of claim 60, wherein X is CR⁵.
 62. The compound of claim 61, wherein R³ is -pyridin-3-yl optionally substituted with 1 R⁶.
 63. The compound of claim 61, wherein R³ is -pyrimidin-5-yl optionally substituted with 1 R⁶.
 64. The compound of claim 61, wherein R³ is -pyrazolyl optionally substituted with 1 R⁶.
 65. The compound of claim 61, wherein R³ is -imidazolyl substituted with 1-2 R⁶.
 66. The compound of claim 62, wherein R⁶ is selected from the group consisting of —(C₁₋₃ alkyl), —CH₂heterocyclyl optionally substituted with 1-2 R¹¹, —NHC(═O)R¹⁴, —NR¹⁵R¹⁶, —CH₂NR¹⁷R¹⁸, and —OR²⁴.
 67. The compound of claim 64, wherein R⁶ is —(C₁₋₃ alkyl).
 68. The compound of claim 65, wherein R⁶ is —(C₁₋₃ alkyl).
 69. The compound of claim 66, wherein R¹⁴ is selected from the group consisting of —(C₁₋₅ alkyl), -phenyl optionally substituted with 1-2 R²¹, —CH₂phenyl optionally substituted with 1-2 R²¹, and -carbocyclyl optionally substituted with 1-2 R²².
 70. The compound of claim 66, wherein R¹⁵ and R¹⁶ are independently selected from H and —(C₁₋₃ alkyl).
 71. The compound of claim 66, wherein R¹⁷ and R¹⁸ are independently selected from H and —(C₁₋₃ alkyl).
 72. The compound of claim 66, wherein R²⁴ is selected from the group consisting of H, —(C₁₋₃ alkyl), -heterocyclyl optionally substituted with 1-2 R²³, —(CH₂)heterocyclyl optionally substituted with 1-2 R²³, —(CH₂CH₂)heterocyclyl optionally substituted with 1-2 R²³, -carbocyclyl optionally substituted with 1-2 R²², —(CH₂)aryl optionally substituted with 1-2 R²¹, and —(CH₂CH₂)N(C₁₋₂ alkyl)₂.
 73. The compound of claim 61, wherein R⁵ is -phenyl optionally substituted with 1-2 R¹⁰.
 74. The compound of claim 73, wherein R⁵ is substituted with 1 R¹⁰, and wherein R¹⁰ is halide.
 75. The compound of claim 73, wherein R⁵ is substituted with 2 R¹⁰, and wherein one R¹⁰ is halide and one R¹⁰ is —CH₂NHSO₂R¹⁹.
 76. The compound of claim 73, wherein R⁵ is substituted with 2 R¹⁰, and wherein one R¹⁰ is halide and one R¹⁰ is —NHCH₂CH₂NR¹⁵R¹⁶.
 77. The compound of claim 61, wherein R⁵ is selected from the group consisting of -pyridinyl optionally substituted with 1-2 R⁸, -imidazolyl optionally substituted with 1-2 R⁸, -furanyl optionally substituted with 1-2 R⁸, and -thiophenyl optionally substituted with 1-2 R⁸.
 78. The compound of claim 77, wherein R⁸ is selected from the group consisting of halide, —(C₁₋₃ alkyl), and —C(═O)R¹⁹, and R¹⁹ is —(C₁₋₂ alkyl).
 79. The compound of claim 61, wherein R⁵ is selected from the group consisting of -piperidinyl optionally substituted with 1-2 R⁹ and -piperazinyl optionally substituted with 1-2 R⁹.
 80. The compound of claim 59, wherein the compound of Formula I is selected from the group consisting of: N-(5-(3-(4-(3-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)propionamide [1]; N-(5-(3-(4-(3-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-3-methylbutanamide [2]; 5-(3-(4-(3-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-amine [3]; 3-(4-(3-fluorophenyl)-1H-indol-2-yl)-5-(pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [4]; 3-(4-(3-fluorophenyl)-1H-indol-2-yl)-5-(4-methylpyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [5]; N-((5-(3-(4-(3-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methyl)ethanamine [6]; 5-(3-(4-(3-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)-N,N-dimethylpyridin-3-amine [7]; N-(5-(3-(4-(3-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)pivalamide [8]; N-(5-(3-(4-(3-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)isobutyramide [9]; N-(5-(3-(4-(3-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-2-phenylacetamide [10]; N-(5-(3-(4-(3-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)benzamide [11]; 5-(3-(4-(3-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)-N-isopropylpyridin-3-amine [12]; 1-(5-(3-(4-(3-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-N,N-dimethylmethanamine [13]; 3-(4-(3-fluorophenyl)-1H-indol-2-yl)-5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [14]; 3-(4-(3-fluorophenyl)-1H-indol-2-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [15]; N-(5-(3-(4-(3-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-3,3-dimethylbutanamide [16]; N-(5-(3-(4-(3-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)butyramide [17]; 3-(4-(3-fluorophenyl)-1H-indol-2-yl)-5-(pyridin-4-yl)-1H-pyrazolo[3,4-c]pyridine [18]; N-(5-(3-(4-(3-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)pentanamide [19]; N-(5-(3-(4-(3-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide [20]; N-(5-(3-(4-(3-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclobutanecarboxamide [21]; N-(5-(3-(4-(3-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclopentanecarboxamide [22]; N-(5-(3-(4-(3-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclohexanecarboxamide [23]; N-benzyl-1-(5-(3-(4-(3-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methanamine [24]; 1-cyclopentyl-N-((5-(3-(4-(3-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methyl)methanamine [125]; 5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-3-(4-(3-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [26]; 3-(4-(3-fluorophenyl)-1H-indol-2-yl)-5-(pyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridine [27]; 3-(4-(3-fluorophenyl)-1H-indol-2-yl)-5-(pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridine [28]; N-(5-(3-(4-(4-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)propionamide [29]; N-(5-(3-(4-(4-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-3-methylbutanamide [30]; 5-(3-(4-(4-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-amine [31]; 3-(4-(4-fluorophenyl)-1H-indol-2-yl)-5-(pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [32]; 3-(4-(4-fluorophenyl)-1H-indol-2-yl)-5-(4-methylpyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [33]; N-((5-(3-(4-(4-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methyl)ethanamine [34]; 5-(3-(4-(4-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)-N,N-dimethylpyridin-3-amine [35]; N-(5-(3-(4-(4-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)pivalamide [36]; N-(5-(3-(4-(4-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)isobutyramide [37]; N-(5-(3-(4-(4-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-2-phenylacetamide [38]; N-(5-(3-(4-(4-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)benzamide [39]; 5-(3-(4-(4-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)-N-isopropylpyridin-3-amine [40]; 1-(5-(3-(4-(4-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-N,N-dimethylmethanamine [41]; 3-(4-(4-fluorophenyl)-1H-indol-2-yl)-5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [42]; 3-(4-(4-fluorophenyl)-1H-indol-2-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [43]; N-(5-(3-(4-(4-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-3,3-dimethylbutanamide [44]; N-(5-(3-(4-(4-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)butyramide [45]; 3-(4-(4-fluorophenyl)-1H-indol-2-yl)-5-(pyridin-4-yl)-1H-pyrazolo[3,4-c]pyridine [46]; N-(5-(3-(4-(4-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)pentanamide [47]; N-(5-(3-(4-(4-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide [48]; N-(5-(3-(4-(4-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclobutanecarboxamide [49]; N-(5-(3-(4-(4-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclopentanecarboxamide [50]; N-(5-(3-(4-(4-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclohexanecarboxamide [51]; N-benzyl-1-(5-(3-(4-(4-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methanamine [52]; 1-cyclopentyl-N-((5-(3-(4-(4-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methyl)methanamine [53]; 5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-3-(4-(4-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [54]; 3-(4-(4-fluorophenyl)-1H-indol-2-yl)-5-(pyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridine [55]; 3-(4-(4-fluorophenyl)-1H-indol-2-yl)-5-(pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridine [56]; N-(5-(3-(4-(2-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)propionamide [57]; N-(5-(3-(4-(2-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-3-methylbutanamide [58]; 5-(3-(4-(2-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-amine [59]; 3-(4-(2-fluorophenyl)-1H-indol-2-yl)-5-(pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [60]; 3-(4-(2-fluorophenyl)-1H-indol-2-yl)-5-(4-methylpyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [61]; N-((5-(3-(4-(2-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methyl)ethanamine [62]; 5-(3-(4-(2-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)-N,N-dimethylpyridin-3-amine [63]; N-(5-(3-(4-(2-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)pivalamide [64]; N-(5-(3-(4-(2-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)isobutyramide [65]; N-(5-(3-(4-(2-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-2-phenylacetamide [66]; N-(5-(3-(4-(2-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)benzamide [67]; 5-(3-(4-(2-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)-N-isopropylpyridin-3-amine [68]; 1-(5-(3-(4-(2-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-N,N-dimethylmethanamine [69]; 3-(4-(2-fluorophenyl)-1H-indol-2-yl)-5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [70]; 3-(4-(2-fluorophenyl)-1H-indol-2-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [71]; N-(5-(3-(4-(2-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-3,3-dimethylbutanamide [72]; N-(5-(3-(4-(2-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)butyramide [73]; 3-(4-(2-fluorophenyl)-1H-indol-2-yl)-5-(pyridin-4-yl)-1H-pyrazolo[3,4-c]pyridine [74]; N-(5-(3-(4-(2-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)pentanamide [75]; N-(5-(3-(4-(2-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide [76]; N-(5-(3-(4-(2-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclobutanecarboxamide [77]; N-(5-(3-(4-(2-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclopentanecarboxamide [78]; N-(5-(3-(4-(2-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclohexanecarboxamide [79]; N-benzyl-1-(5-(3-(4-(2-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methanamine [80]; 1-cyclopentyl-N-((5-(3-(4-(2-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methyl)methanamine [81]; 5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-3-(4-(2-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [82]; 3-(4-(2-fluorophenyl)-1H-indol-2-yl)-5-(pyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridine [83]; 3-(4-(2-fluorophenyl)-1H-indol-2-yl)-5-(pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridine [84]; N-(5-(3-(4-(pyridin-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)propionamide [85]; 3-methyl-N-(5-(3-(4-(pyridin-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)butanamide [86]; 5-(3-(4-(pyridin-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-amine [87]; 5-(pyridin-3-yl)-3-(4-(pyridin-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [88]; 5-(4-methylpyridin-3-yl)-3-(4-(pyridin-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [89]; N-((5-(3-(4-(pyridin-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methyl)ethanamine [90]; N,N-dimethyl-5-(3-(4-(pyridin-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-amine [91]; N-(5-(3-(4-(pyridin-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)pivalamide [92]; N-(5-(3-(4-(pyridin-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)isobutyramide [93]; 2-phenyl-N-(5-(3-(4-(pyridin-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)acetamide [94]; N-(5-(3-(4-(pyridin-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)benzamide [95]; N-isopropyl-5-(3-(4-(pyridin-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-amine [96]; N,N-dimethyl-1-(5-(3-(4-(pyridin-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methanamine [97]; 3-(4-(pyridin-3-yl)-1H-indol-2-yl)-5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin [98]; 5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-3-(4-(pyridin-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [99]; 3,3-dimethyl-N-(5-(3-(4-(pyridin-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)butanamide [100]; N-(5-(3-(4-(pyridin-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)butyramide [101]; 3-(4-(pyridin-3-yl)-1H-indol-2-yl)-5-(pyridin-4-yl)-1H-pyrazolo[3,4-c]pyridine [102]; N-(5-(3-(4-(pyridin-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)pentanamide [103]; N-(5-(3-(4-(pyridin-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide [104]; N-(5-(3-(4-(pyridin-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclobutanecarboxamide [105]; N-(5-(3-(4-(pyridin-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclopentanecarboxamide [106]; N-(5-(3-(4-(pyridin-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclohexanecarboxamide [107]; N-benzyl-1-(5-(3-(4-(pyridin-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methanamine [108]; 1-cyclopentyl-N-((5-(3-(4-(pyridin-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methyl)methanamine [109]; 5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-3-(4-(pyridin-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [110]; 3-(4-(pyridin-3-yl)-1H-indol-2-yl)-5-(pyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridine [111]; 5-(pyridin-2-yl)-3-(4-(pyridin-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [112]; N-(5-(3-(4-(pyridin-4-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)propionamide [113]; 3-methyl-N-(5-(3-(4-(pyridin-4-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)butanamide [114]; 5-(3-(4-(pyridin-4-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-amine [115]; 5-(pyridin-3-yl)-3-(4-(pyridin-4-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [116]; 5-(4-methylpyridin-3-yl)-3-(4-(pyridin-4-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [117]; N-((5-(3-(4-(pyridin-4-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methyl)ethanamine [118]; N,N-dimethyl-5-(3-(4-(pyridin-4-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-amine [119]; N-(5-(3-(4-(pyridin-4-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)pivalamide [120]; N-(5-(3-(4-(pyridin-4-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)isobutyramide [121]; 2-phenyl-N-(5-(3-(4-(pyridin-4-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)acetamide [122]; N-(5-(3-(4-(pyridin-4-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)benzamide [123]; N-isopropyl-5-(3-(4-(pyridin-4-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-amine [124]; N,N-dimethyl-1-(5-(3-(4-(pyridin-4-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methanamine [125]; 3-(4-(pyridin-4-yl)-1H-indol-2-yl)-5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin [126]; 5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-3-(4-(pyridin-4-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [127]; 3,3-dimethyl-N-(5-(3-(4-(pyridin-4-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)butanamide [128]; N-(5-(3-(4-(pyridin-4-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)butyramide [129]; 5-(pyridin-4-yl)-3-(4-(pyridin-4-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [130]; N-(5-(3-(4-(pyridin-4-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)pentanamide [131]; N-(5-(3-(4-(pyridin-4-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide [132]; N-(5-(3-(4-(pyridin-4-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclobutanecarboxamide [133]; N-(5-(3-(4-(pyridin-4-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclopentanecarboxamide [134]; N-(5-(3-(4-(pyridin-4-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclohexanecarboxamide [135]; N-benzyl-1-(5-(3-(4-(pyridin-4-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methanamine [136]; 1-cyclopentyl-N-((5-(3-(4-(pyridin-4-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methyl)methanamine [137]; 5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-3-(4-(pyridin-4-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [138]; 3-(4-(pyridin-4-yl)-1H-indol-2-yl)-5-(pyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridine [139]; 5-(pyridin-2-yl)-3-(4-(pyridin-4-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [140]; N-(5-(3-(4-(pyridin-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)propionamide [141]; 3-methyl-N-(5-(3-(4-(pyridin-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)butanamide [142]; 5-(3-(4-(pyridin-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-amine [143]; 3-(4-(pyridin-2-yl)-1H-indol-2-yl)-5-(pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [144]; 5-methylpyridin-3-yl)-3-(4-(pyridin-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [145]; N-((5-(3-(4-(pyridin-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methyl)ethanamine [146]; N,N-dimethyl-5-(3-(4-(pyridin-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-amine [147]; N-(5-(3-(4-(pyridin-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)pivalamide [148]; N-(5-(3-(4-(pyridin-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)isobutyramide [149]; 2-phenyl-N-(5-(3-(4-(pyridin-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)acetamide [150]; N-(5-(3-(4-(pyridin-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)benzamide [151]; N-isopropyl-5-(3-(4-(pyridin-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-amine [152]; N,N-dimethyl-1-(5-(3-(4-(pyridin-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methanamine [153]; 3-(4-(pyridin-2-yl)-1H-indol-2-yl)-5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin [154]; 5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-3-(4-(pyridin-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [155]; 3,3-dimethyl-N-(5-(3-(4-(pyridin-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)butanamide [156]; N-(5-(3-(4-(pyridin-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)butyramide [157]; 3-(4-(pyridin-2-yl)-1H-indol-2-yl)-5-(pyridin-4-yl)-1H-pyrazolo[3,4-c]pyridine [158]; N-(5-(3-(4-(pyridin-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)pentanamide [159]; N-(5-(3-(4-(pyridin-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide [160]; N-(5-(3-(4-(pyridin-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclobutanecarboxamide [161]; N-(5-(3-(4-(pyridin-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclopentanecarboxamide [162]; N-(5-(3-(4-(pyridin-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclohexanecarboxamide [163]; N-benzyl-1-(5-(3-(4-(pyridin-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methanamine [164]; 1-cyclopentyl-N-((5-(3-(4-(pyridin-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methyl)methanamine [165]; 5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-3-(4-(pyridin-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [166]; 3-(4-(pyridin-2-yl)-1H-indol-2-yl)-5-(pyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridine [167]; 5-(pyridin-2-yl)-3-(4-(pyridin-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [168]; N-(5-(3-(4-(piperidin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)propionamide [169]; 3-methyl-N-(5-(3-(4-(piperidin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)butanamide [170]; 5-(3-(4-(piperidin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-amine [171]; 3-(4-(piperidin-1-yl)-1H-indol-2-yl)-5-(pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [172]; 5-(4-methylpyridin-3-yl)-3-(4-(piperidin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [173]; N-((5-(3-(4-(piperidin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methyl)ethanamine [174]; N,N-dimethyl-5-(3-(4-(piperidin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-amine [175]; N-(5-(3-(4-(piperidin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)pivalamide [176]; N-(5-(3-(4-(piperidin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)isobutyramide [177]; 2-phenyl-N-(5-(3-(4-(piperidin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)acetamide [178]; N-(5-(3-(4-(piperidin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)benzamide [179]; N-isopropyl-5-(3-(4-(piperidin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-amine [180]; N,N-dimethyl-1-(5-(3-(4-(piperidin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methanamine [181]; 3-(4-(piperidin-1-yl)-1H-indol-2-yl)-5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [182]; 3-(4-(piperidin-1-yl)-1H-indol-2-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [183]; 3,3-dimethyl-N-(5-(3-(4-(piperidin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)butanamide [184]; N-(5-(3-(4-(piperidin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)butyramide [185]; 3-(4-(piperidin-1-yl)-1H-indol-2-yl)-5-(pyridin-4-yl)-1H-pyrazolo[3,4-c]pyridine [186]; N-(5-(3-(4-(piperidin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)pentanamide [187]; N-(5-(3-(4-(piperidin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide [188]; N-(5-(3-(4-(piperidin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclobutanecarboxamide [189]; N-(5-(3-(4-(piperidin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclopentanecarboxamide [190]; N-(5-(3-(4-(piperidin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclohexanecarboxamide [191]; N-benzyl-1-(5-(3-(4-(piperidin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methanamine [192]; 1-cyclopentyl-N-((5-(3-(4-(piperidin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methyl)methanamine [193]; 5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-3-(4-(piperidin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [194]; 3-(4-(piperidin-1-yl)-1H-indol-2-yl)-5-(pyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridine [195]; 3-(4-(piperidin-1-yl)-1H-indol-2-yl)-5-(pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridine [196]; N-(5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)propionamide [197]; 3-methyl-N-(5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)butanamide [198]; 5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-amine [199]; 3-(4-(4-methyl-1H-imidazol-1-yl)-1H-indol-2-yl)-5-(pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [200]; 3-(4-(4-methyl-1H-imidazol-1-yl)-1H-indol-2-yl)-5-(4-methylpyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [201]; N-((5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methyl)ethanamine [202]; N,N-dimethyl-5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-amine [203]; N-(5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)pivalamide [204]; N-(5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)isobutyramide [205]; N-(5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-2-phenylacetamide [206]; N-(5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)benzamide [207]; N-isopropyl-5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-amine [208]; N,N-dimethyl-1-(5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methanamine [209]; 3-(4-(4-methyl-1H-imidazol-1-yl)-1H-indol-2-yl)-5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [210]; 3-(4-(4-methyl-1H-imidazol-1-yl)-1H-indol-2-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [211]; 3,3-dimethyl-N-(5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)butanamide [212]; N-(5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)butyramide [213]; 3-(4-(4-methyl-1H-imidazol-1-yl)-1H-indol-2-yl)-5-(pyridin-4-yl)-1H-pyrazolo[3,4-c]pyridine [214]; N-(5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)pentanamide [215]; N-(5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide [216]; N-(5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclobutanecarboxamide [217]; N-(5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclopentanecarboxamide [218]; N-(5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclohexanecarboxamide [219]; N-benzyl-1-(5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methanamine [220]; 1-cyclopentyl-N-((5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methyl)methanamine [221]; 5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-3-(4-(4-methyl-1H-imidazol-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [222]; 3-(4-(4-methyl-1H-imidazol-1-yl)-1H-indol-2-yl)-5-(pyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridine [223]; 3-(4-(4-methyl-1H-imidazol-1-yl)-1H-indol-2-yl)-5-(pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridine [224]; N-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)propionamide [225]; 3-methyl-N-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)butanamide [226]; 5-(3-(4-(4-methylpiperazin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-amine [227]; 3-(4-(4-methylpiperazin-1-yl)-1H-indol-2-yl)-5-(pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [228]; 3-(4-(4-methylpiperazin-1-yl)-1H-indol-2-yl)-5-(4-methylpyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [229]; N-((5-(3-(4-(4-methylpiperazin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methyl)ethanamine [230]; N,N-dimethyl-5-(3-(4-(4-methylpiperazin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-amine [231]; N-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)pivalamide [232]; N-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)isobutyramide [233]; N-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-2-phenylacetamide [234]; N-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)benzamide [235]; N-isopropyl-5-(3-(4-(4-methylpiperazin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-amine [236]; N,N-dimethyl-1-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methanamine [237]; 3-(4-(4-methylpiperazin-1-yl)-1H-indol-2-yl)-5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [238]; 3-(4-(4-methylpiperazin-1-yl)-1H-indol-2-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [239]; 3,3-dimethyl-N-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)butanamide [240]; N-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)butyramide [241]; 3-(4-(4-methylpiperazin-1-yl)-1H-indol-2-yl)-5-(pyridin-4-yl)-1H-pyrazolo[3,4-c]pyridine [242]; N-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)pentanamide [243]; N-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide [244]; N-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclobutanecarboxamide [245]; N-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclopentanecarboxamide [246]; N-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclohexanecarboxamide [247]; N-benzyl-1-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methanamine [248]; 1-cyclopentyl-N-((5-(3-(4-(4-methylpiperazin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methyl)methanamine [249]; 5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-3-(4-(4-methylpiperazin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [250]; 3-(4-(4-methylpiperazin-1-yl)-1H-indol-2-yl)-5-(pyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridine [251]; 3-(4-(4-methylpiperazin-1-yl)-1H-indol-2-yl)-5-(pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridine [252]; N-(5-(3-(1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)propionamide [253]; N-(5-(3-(1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-3-methylbutanamide [254]; 5-(3-(1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-amine [255]; 3-(1H-indol-2-yl)-5-(pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [256]; 3-(1H-indol-2-yl)-5-(4-methylpyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [257]; N-((5-(3-(1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methyl)ethanamine [258]; 5-(3-(1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)-N,N-dimethylpyridin-3-amine [259]; N-(5-(3-(1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)pivalamide [260]; N-(5-(3-(1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)isobutyramide [261]; N-(5-(3-(1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-2-phenylacetamide [262]; N-(5-(3-(1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)benzamide [263]; 5-(3-(1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)-N-isopropylpyridin-3-amine [264]; 1-(5-(3-(1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-N,N-dimethylmethanamine [265]; 3-(1H-indol-2-yl)-5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [266]; 3-(1H-indol-2-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [267]; N-(5-(3-(1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-3,3-dimethylbutanamide [268]; N-(5-(3-(1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)butyramide [269]; 3<(1H-indol-2-yl)-5-(pyridin-4-yl)-1H-pyrazolo[3,4-c]pyridine [270]; N-(5-(3-(1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)pentanamide [271]; N-(5-(3-(1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide [272]; N-(5-(3-(1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclobutanecarboxamide [273]; N-(5-(3-(1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclopentanecarboxamide [274]; N-(5-(3-(1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclohexanecarboxamide [275]; 1-(5-(3-(1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-N-benzylmethanamine [276]; 1-(5-(3-(1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-N-(cyclopentylmethyl)methanamine [277]; 5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-3-(1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin [278]; 3-(1H-indol-2-yl)-5-(pyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridine [279]; 3-(1H-indol-2-yl)-5-(pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridine [280]; N-(5-(3-(4-(thiophen-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)propionamide [281]; 3-methyl-N-(5-(3-(4-(thiophen-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)butanamide [282]; 5-(3-(4-(thiophen-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-amine [283]; 5-(pyridin-3-yl)-3-(4-(thiophen-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [284]; 5-(4-methylpyridin-3-yl)-3-(4-(thiophen-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [285]; N-((5-(3-(4-(thiophen-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methyl)ethanamine [286]; N,N-dimethyl-5-(3-(4-(thiophen-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-amine [287]; N-(5-(3-(4-(thiophen-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)pivalamide [288]; N-(5-(3-(4-(thiophen-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)isobutyramide [289]; 2-phenyl-N-(5-(3-(4-(thiophen-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)acetamide [290]; N-(5-(3-(4-(thiophen-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)benzamide [291]; N-isopropyl-5-(3-(4-(thiophen-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-amine [292]; N,N-dimethyl-1-(5-(3-(4-(thiophen-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methanamine [293]; 5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-3-(4-(thiophen-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [294]; 5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-3-(4-(thiophen-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin [295]; 3,3-dimethyl-N-(5-(3-(4-(thiophen-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)butanamide [296]; N-(5-(3-(4-(thiophen-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)butyramide [297]; 5-(pyridin-4-yl)-3-(4-(thiophen-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [298]; N-(5-(3-(4-(thiophen-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)pentanamide [299]; N-(5-(3-(4-(thiophen-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide [300]; N-(5-(3-(4-(thiophen-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclobutanecarboxamide [301]; N-(5-(3-(4-(thiophen-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclopentanecarboxamide [302]; N-(5-(3-(4-(thiophen-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclohexanecarboxamide [303]; N-benzyl-1-(5-(3-(4-(thiophen-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methanamine [304]; 1-cyclopentyl-N-((5-(3-(4-(thiophen-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methyl)methanamine [305]; 5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-3-(4-(thiophen-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [306]; 5-(pyrimidin-5-yl)-3-(4-(thiophen-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [307]; 5-(pyridin-2-yl)-3-(4-(thiophen-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [308]; N-(5-(3-(4-(furan-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)propionamide [309]; N-(5-(3-(4-(furan-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-3-methylbutanamide [310]; 5-(3-(4-(furan-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-amine [311]; 3-(4-(furan-3-yl)-1H-indol-2-yl)-5-(pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [312]; 3-(4-(furan-3-yl)-1H-indol-2-yl)-5-(4-methylpyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [313]; N-((5-(3-(4-(furan-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methyl)ethanamine [314]; 5-(3-(4-(furan-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)-N,N-dimethylpyridin-3-amine [315]; N-(5-(3-(4-(furan-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)pivalamide [316]; N-(5-(3-(4-(furan-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)isobutyramide [317]; N-(5-(3-(4-(furan-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-2-phenylacetamide [318]; N-(5-(3-(4-(furan-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)benzamide [319]; 5-(3-(4-(furan-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)-N-isopropylpyridin-3-amine [320]; 1-(5-(3-(4-(furan-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-N,N-dimethylmethanamine [321]; 3-(4-(furan-3-yl)-1H-indol-2-yl)-5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [322]; 3-(4-(furan-3-yl)-1H-indol-2-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [323]; N-(5-(3-(4-(furan-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-3,3-dimethylbutanamide [324]; N-(5-(3-(4-(furan-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)butyramide [325]; 3-(4-(furan-3-yl)-1H-indol-2-yl)-5-(pyridin-4-yl)-1H-pyrazolo[3,4-c]pyridine [326]; N-(5-(3-(4-(furan-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)pentanamide [327]; N-(5-(3-(4-(furan-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide [328]; N-(5-(3-(4-(furan-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclobutanecarboxamide [329]; N-(5-(3-(4-(furan-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclopentanecarboxamide [330]; N-(5-(3-(4-(furan-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclohexanecarboxamide [331]; N-benzyl-1-(5-(3-(4-(furan-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methanamine [332]; 1-cyclopentyl-N-((5-(3-(4-(furan-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methyl)methanamine [333]; 5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-3-(4-(furan-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [334]; 3-(4-(furan-3-yl)-1H-indol-2-yl)-5-(pyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridine [335]; 3-(4-(furan-3-yl)-1H-indol-2-yl)-5-(pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridine [336]; N-(5-(3-(4-(thiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)propionamide [337]; 3-methyl-N-(5-(3-(4-(thiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)butanamide [338]; 5-(3-(4-(thiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-amine [339]; 5-(pyridin-3-yl)-3-(4-(thiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [340]; 5-(4-methylpyridin-3-yl)-3-(4-(thiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [341]; N-((5-(3-(4-(thiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methyl)ethanamine [342]; N,N-dimethyl-5-(3-(4-(thiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-amine [343]; N-(5-(3-(4-(thiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)pivalamide [344]; N-(5-(3-(4-(thiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)isobutyramide [345]; 2-phenyl-N-(5-(3-(4-(thiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)acetamide [346]; N-(5-(3-(4-(thiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)benzamide [347]; N-isopropyl-5-(3-(4-(thiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-amine [348]; N,N-dimethyl-1-(5-(3-(4-(thiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methanamine [349]; 5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-3-(4-(thiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [350]; 5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-3-(4-(thiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin [351]; 3,3-dimethyl-N-(5-(3-(4-(thiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)butanamide [352]; N-(5-(3-(4-(thiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)butyramide [353]; 5-(pyridin-4-yl)-3-(4-(thiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [354]; N-(5-(3-(4-(thiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)pentanamide [355]; N-(5-(3-(4-(thiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide [356]; N-(5-(3-(4-(thiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclobutanecarboxamide [357]; N-(5-(3-(4-(thiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclopentanecarboxamide [358]; N-(5-(3-(4-(thiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclohexanecarboxamide [359]; N-benzyl-1-(5-(3-(4-(thiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methanamine [360]; 1-cyclopentyl-N-((5-(3-(4-(thiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methyl)methanamine [361]; 5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-3-(4-(thiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [362]; 5-(pyrimidin-5-yl)-3-(4-(thiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [363]; 5-(pyridin-2-yl)-3-(4-(thiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [364]; N-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)propionamide [365]; N-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-3-methylbutanamide [366]; 5-(3-(4-(5-fluorothiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-amine [367]; 3-(4-(5-fluorothiophen-2-yl)-1H-indol-2-yl)-5-(pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [368]; 3-(4-(5-fluorothiophen-2-yl)-1H-indol-2-yl)-5-(4-methylpyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [369]; N-((5-(3-(4-(5-fluorothiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methyl)ethanamine [370]; 5-(3-(4-(5-fluorothiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)-N,N-dimethylpyridin-3-amine [371]; N-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)pivalamide [372]; N-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)isobutyramide [373]; N-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-2-phenylacetamide [374]; N-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)benzamide [375]; 5-(3-(4-(5-fluorothiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)-N-isopropylpyridin-3-amine [376]; 1-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-N,N-dimethylmethanamine [377]; 3-(4-(5-fluorothiophen-2-yl)-1H-indol-2-yl)-5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [378]; 3-(4-(5-fluorothiophen-2-yl)-1H-indol-2-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [379]; N-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-3,3-dimethylbutanamide [380]; N-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)butyramide [381]; 3-(4-(5-fluorothiophen-2-yl)-1H-indol-2-yl)-5-(pyridin-4-yl)-1H-pyrazolo[3,4-c]pyridine [382]; N-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)pentanamide [383]; N-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide [384]; N-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclobutanecarboxamide [385]; N-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclopentanecarboxamide [386]; N-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclohexanecarboxamide [387]; N-benzyl-1-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methanamine [388]; 1-cyclopentyl-N-((5-(3-(4-(5-fluorothiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methyl)methanamine [389]; 5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-3-(4-(5-fluorothiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [390]; 3-(4-(5-fluorothiophen-2-yl)-1H-indol-2-yl)-5-(pyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridine [391]; 3-(4-(5-fluorothiophen-2-yl)-1H-indol-2-yl)-5-(pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridine [392]; N-(5-(3-(4-(5-methylthiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)propionamide [393]; 3-methyl-N-(5-(3-(4-(5-methylthiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)butanamide [394]; 5-(3-(4-(5-methylthiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-amine [395]; 3-(4-(5-methylthiophen-2-yl)-1H-indol-2-yl)-5-(pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [3%]; 5-(4-methylpyridin-3-yl)-3-(4-(5-methylthiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [397]; N-((5-(3-(4-(5-methylthiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methyl)ethanamine [398]; N,N-dimethyl-5-(3-(4-(5-methylthiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-amine [399]; N-(5-(3-(4-(5-methylthiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)pivalamide [400]; N-(5-(3-(4-(5-methylthiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)isobutyramide [401]; N-(5-(3-(4-(5-methylthiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-2-phenylacetamide [402]; N-(5-(3-(4-(5-methylthiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)benzamide [403]; N-isopropyl-5-(3-(4-(5-methylthiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-amine [404]; N,N-dimethyl-1-(5-(3-(4-(5-methylthiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methanamine [405]; 3-(4-(5-methylthiophen-2-yl)-1H-indol-2-yl)-5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [406]; 3-(4-(5-methylthiophen-2-yl)-1H-indol-2-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [407]; 3,3-dimethyl-N-(5-(3-(4-(5-methylthiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)butanamide [408]; N-(5-(3-(4-(5-methylthiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)butyramide [409]; 3-(4-(5-methylthiophen-2-yl)-1H-indol-2-yl)-5-(pyridin-4-yl)-1H-pyrazolo[3,4-c]pyridine [410]; N-(5-(3-(4-(5-methylthiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)pentanamide [411]; N-(5-(3-(4-(5-methylthiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide [412]; N-(5-(3-(4-(5-methylthiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclobutanecarboxamide [413]; N-(5-(3-(4-(5-methylthiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclopentanecarboxamide [414]; N-(5-(3-(4-(5-methylthiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclohexanecarboxamide [415]; N-benzyl-1-(5-(3-(4-(5-methylthiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methanamine [416]; 1-cyclopentyl-N-((5-(3-(4-(5-methylthiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methyl)methanamine [417]; 5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-3-(4-(5-methylthiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [418]; 3-(4-(5-methylthiophen-2-yl)-1H-indol-2-yl)-5-(pyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridine [419]; 3-(4-(5-methylthiophen-2-yl)-1H-indol-2-yl)-5-(pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridine [420]; N-(5-(3-(4-(5-acetylthiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)propionamide [421]; N-(5-(3-(4-(5-acetylthiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-3-methylbutanamide [422]; 1-(5-(2-(5-(5-aminopyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)thiophen-2-yl)ethan-1-one [423]; 1-(5-(2-(5-(pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)thiophen-2-yl)ethan-1-one [424]; 1-(5-(2-(5-(4-methylpyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)thiophen-2-yl)ethan-1-one [425]; 1-(5-(2-(5-(5-((ethylamino)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)thiophen-2-yl)ethan-1-one [426]; 1-(5-(2-(5-(5-(dimethylamino)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)thiophen-2-yl)ethan-1-one [427]; N-(5-(3-(4-(5-acetylthiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)pivalamide [428]; N-(5-(3-(4-(5-acetylthiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)isobutyramide [429]; N-(5-(3-(4-(5-acetylthiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-2-phenylacetamide [430]; N-(5-(3-(4-(5-acetylthiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)benzamide [431]; 1-(5-(2-(5-(5-(isopropylamino)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)thiophen-2-yl)ethan-1-one [432]; 1-(5-(2-(5-(5-((dimethylamino)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)thiophen-2-yl)ethan-1-one [433]; 1-(5-(2-(5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)thiophen-2-yl)ethan-1-one [434]; 1-(5-(2-(5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)thiophen-2-yl)ethan-1-one [435]; N-(5-(3-(4-(5-acetylthiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-3,3-dimethylbutanamide [436]; N-(5-(3-(4-(5-acetylthiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)butyramide [437]; 1-(5-(2-(5-(pyridin-4-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)thiophen-2-yl)ethan-1-one [438]; N-(5-(3-(4-(5-acetylthiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)pentanamide [439]; N-(5-(3-(4-(5-acetylthiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide [440]; N-(5-(3-(4-(5-acetylthiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclobutanecarboxamide [441]; N-(5-(3-(4-(5-acetylthiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclopentanecarboxamide [442]; N-(5-(3-(4-(5-acetylthiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclohexanecarboxamide [443]; 1-(5-(2-(5-(5-((benzylamino)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)thiophen-2-yl)ethan-1-one [444]; 1-(5-(2-(5-(5-(((cyclopentylmethyl)amino)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)thiophen-2-yl)ethan-1-one [445]; 1-(5-(2-(5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)thiophen-2-yl)ethan-1-one [446]; 1-(5-(2-(5-(pyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)thiophen-2-yl)ethan-1-one [447]; 1-(5-(2-(5-(pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)thiophen-2-yl)ethan-1-one [448]; N-(5-(3-(4-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)propionamide [449]; N-(5-(3-(4-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-3-methylbutanamide [450]; N¹-(3-(2-(5-(5-aminopyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)-5-fluorophenyl)-N²,N²-dimethylethane-1,2-diamine [451]; N¹-(3-fluoro-5-(2-(5-(pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)phenyl)-N²,N²-dimethylethane-1,2-diamine [452]; N¹-(3-fluoro-5-(2-(5-(4-methylpyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)phenyl)-N²,N²-dimethylethane-1,2-diamine [453]; N¹-(3-(2-(5-(5-((ethylamino)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)-5-fluorophenyl)-N²,N²-dimethylethane-1,2-diamine [454]; N¹-(3-(2-(5-(5-(dimethylamino)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)-5-fluorophenyl)-N²,N²-dimethylethane-1,2-diamine [455]; N-(5-(3-(4-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)pivalamide [456]; N-(5-(3-(4-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)isobutyramide [457]; N-(5-(3-(4-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-2-phenylacetamide [458]; N-(5-(3-(4-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)benzamide [459]; N¹-(3-fluoro-5-(2-(5-(5-(isopropylamino)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)phenyl)-N²,N²-dimethylethane-1,2-diamine [460]; N¹-(3-(2-(5-(5-((dimethylamino)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)-5-fluorophenyl)-N²,N²-dimethylethane-1,2-diamine [461]; N¹-(3-fluoro-5-(2-(5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)phenyl)-N²,N²-dimethylethane-1,2-diamine [462]; N¹-(3-fluoro-5-(2-(5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)phenyl)-N²,N²-dimethylethane-1,2-diamine [463]; N-(5-(3-(4-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-3,3-dimethylbutanamide [464]; N-(5-(3-(4-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)butyramide [465]; N¹-(3-fluoro-5-(2-(5-(pyridin-4-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)phenyl)-N²,N²-dimethylethane-1,2-diamine [466]; N-(5-(3-(4-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)pentanamide [467]; N-(5-(3-(4-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide [468]; N-(5-(3-(4-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclobutanecarboxamide [469]; N-(5-(3-(4-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclopentanecarboxamide [470]; N-(5-(3-(4-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclohexanecarboxamide [471]; N¹-(3-(2-(5-(5-((benzylamino)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)-5-fluorophenyl)-N²,N²-dimethylethane-1,2-diamine [472]; N¹-(3-(2-(5-(5-(((cyclopentylmethyl)amino)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)-5-fluorophenyl)-N²,N²-dimethylethane-1,2-diamine [473]; N¹-(3-(2-(5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)-5-fluorophenyl)-N²,N²-dimethylethane-1,2-diamine [474]; N¹-(3-fluoro-5-(2-(5-(pyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)phenyl)-N²,N²-dimethylethane-1,2-diamine [475]; N¹-(3-fluoro-5-(2-(5-(pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)phenyl)-N²,N²-dimethylethane-1,2-diamine [476]; N-(5-(3-(4-(3-fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)propionamide [477]; N-(5-(3-(4-(3-fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-3-methylbutanamide [478]; N-(3-(2-(5-(5-aminopyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)-5-fluorobenzyl)methanesulfonamide [479]; N-(3-fluoro-5-(2-(5-(pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)benzyl)methanesulfonamide [480]; N-(3-fluoro-5-(2-(5-(4-methylpyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)benzyl)methanesulfonamide [481]; N-(3-(2-(5-(5-((ethylamino)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)-5-fluorobenzyl)methanesulfonamide [482]; N-(3-(2-(5-(5-(dimethylamino)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)-5-fluorobenzyl)methanesulfonamide [483]; N-(5-(3-(4-(3-fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)pivalamide [484]; N-(5-(3-(4-(3-fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)isobutyramide [485]; N-(5-(3-(4-(3-fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-2-phenylacetamide [486]; N-(5-(3-(4-(3-fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)benzamide [487]; N-(3-fluoro-5-(2-(5-(5-(isopropylamino)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)benzyl)methanesulfonamide [488]; N-(3-(2-(5-(5-((dimethylamino)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)-5-fluorobenzyl)methanesulfonamide [489]; N-(3-fluoro-5-(2-(5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)benzyl)methanesulfonamide [490]; N-(3-fluoro-5-(2-(5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)benzyl)methanesulfonamide [491]; N-(5-(3-(4-(3-fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-3,3-dimethylbutanamide [492]; N-(5-(3-(4-(3-fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)butyramide [493]; N-(3-fluoro-5-(2-(5-(pyridin-4-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)benzyl)methanesulfonamide [494]; N-(5-(3-(4-(3-fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)pentanamide [495]; N-(5-(3-(4-(3-fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide [496]; N-(5-(3-(4-(3-fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclobutanecarboxamide [497]; N-(5-(3-(4-(3-fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclopentanecarboxamide [498]; N-(5-(3-(4-(3-fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclohexanecarboxamide [499]; N-(3-(2-(5-(5-((benzylamino)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)-5-fluorobenzyl)methanesulfonamide [500]; N-(3-(2-(5-(5-(((cyclopentylmethyl)amino)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)-5-fluorobenzyl)methanesulfonamide [501]; N-(3-(2-(5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)-5-fluorobenzyl)methanesulfonamide [502]; N-(3-fluoro-5-(2-(5-(pyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)benzyl)methanesulfonamide [503]; N-(3-fluoro-5-(2-(5-(pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)benzyl)methanesulfonamide [504]; N-(5-(3-(1H-pyrrolo[3,2-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)propionamide [505]; N-(5-(3-(1H-pyrrolo[3,2-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-3-methylbutanamide [506]; 5-(3-(1H-pyrrolo[3,2-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-amine [507]; 5-(pyridin-3-yl)-3-(1H-pyrrolo[3,2-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridine [508]; 5-(4-methylpyridin-3-yl)-3-(1H-pyrrolo[3,2-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridine [509]; N-((5-(3-(1H-pyrrolo[3,2-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methyl)ethanamine [510]; 5-(3-(1H-pyrrolo[3,2-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)-N,N-dimethylpyridin-3-amine [511]; N-(5-(3-(1H-pyrrolo[3,2-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)pivalamide [512]; N-(5-(3-(1H-pyrrolo[3,2-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)isobutyramide [513]; N-(5-(3-(1H-pyrrolo[3,2-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-2-phenylacetamide [514]; N-(5-(3-(1H-pyrrolo[3,2-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)benzamide [515]; 5-(3-(1H-pyrrolo[3,2-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)-N-isopropylpyridin-3-amine [516]; 1-(5-(3-(1H-pyrrolo [3,2-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-N,N-dimethylmethanamine [517]; 5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-3-(1H-pyrrolo[3,2-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridine [518]; 5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-3-(1H-pyrrolo[3,2-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridine [519]; N-(5-(3-(1H-pyrrolo[3,2-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-3,3-dimethylbutanamide [520]; N-(5-(3-(1H-pyrrolo[3,2-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)butyramide [521]; 5-(pyridin-4-yl)-3-(1H-pyrrolo[3,2-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridine [522]; N-(5-(3-(1H-pyrrolo[3,2-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)pentanamide [523]; N-(5-(3-(1H-pyrrolo[3,2-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide [524]; N-(5-(3-(1H-pyrrolo[3,2-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclobutanecarboxamide [525]; N-(5-(3-(1H-pyrrolo[3,2-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclopentanecarboxamide [526]; N-(5-(3-(1H-pyrrolo[3,2-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclohexanecarboxamide [527]; 1-(5-(3-(1H-pyrrolo [3,2-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-N-benzylmethanamine [528]; 1-(5-(3-(1H-pyrrolo [3,2-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-N-(cyclopentylmethyl)methanamine [529]; 5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-3-(1H-pyrrolo [3,2-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridine [530]; 5-(pyrimidin-5-yl)-3-(1H-pyrrolo[3,2-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridine [531]; 5-(pyridin-2-yl)-3-(1H-pyrrolo[3,2-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridine [532]; 3-(4-(3-fluorophenyl)-1H-indol-2-yl)-5-(piperidin-4-yl)-1H-pyrazolo[3,4-c]pyridine [533]; 3-(4-(3-fluorophenyl)-1H-indol-2-yl)-5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrazolo[3,4-c]pyridin [534]; 3-(4-(3-fluorophenyl)-1H-indol-2-yl)-5-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-c]pyridine [535]; 3-(4-(3-fluorophenyl)-1H-indol-2-yl)-5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-c]pyridine [536]; 5-(1,2-dimethyl-1H-imidazol-5-yl)-3-(4-(3-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [537]; 1-(6-(3-(4-(3-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyrazin-2-yl)azetidin-3-amine [538]; 5-(5-(cyclohexyloxy)pyridin-3-yl)-3-(4-(3-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [539]; 3-(4-(3-fluorophenyl)-1H-indol-2-yl)-5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [540]; N-(5-(3-(4-(3-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-2-(piperidin-4-yl)acetamide [541]; 3-(4-(3-fluorophenyl)-1H-indol-2-yl)-5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [542]; 2-((5-(3-(4-(3-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)oxy)-N,N-dimethylethan-1-amine [543]; 3-(4-(3-fluorophenyl)-1H-indol-2-yl)-5-(5-methoxypyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [544]; 5-(3-(4-(3-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-ol [545]; 5-(5-(benzyloxy)pyridin-3-yl)-3-(4-(3-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [546]; 2-cyclohexyl-N-(5-(3-(4-(3-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)acetamide [547]; 3-(4-(3-fluorophenyl)-1H-indol-2-yl)-5-(pyrazin-2-yl)-1H-pyrazolo[3,4-c]pyridine [548]; 3-(4-(4-fluorophenyl)-1H-indol-2-yl)-5-(piperidin-4-yl)-1H-pyrazolo[3,4-c]pyridine [549]; 3-(4-(4-fluorophenyl)-1H-indol-2-yl)-5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrazolo[3,4-c]pyridin [550]; 3-(4-(4-fluorophenyl)-1H-indol-2-yl)-5-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-c]pyridine [551]; 3-(4-(4-fluorophenyl)-1H-indol-2-yl)-5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-c]pyridine [552]; 5-(1,2-dimethyl-1H-imidazol-5-yl)-3-(4-(4-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [553]; 1-(6-(3-(4-(4-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyrazin-2-yl)azetidin-3-amine [554]; 5-(5-(cyclohexyloxy)pyridin-3-yl)-3-(4-(4-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [555]; 3-(4-(4-fluorophenyl)-1H-indol-2-yl)-5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [556]; N-(5-(3-(4-(4-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-2-(piperidin-4-yl)acetamide [557]; 3-(4-(4-fluorophenyl)-1H-indol-2-yl)-5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [558]; 2-((5-(3-(4-(4-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)oxy)-N,N-dimethylethan-1-amine [559]; 3-(4-(4-fluorophenyl)-1H-indol-2-yl)-5-(5-methoxypyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [560]; 5-(3-(4-(4-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-ol [561]; 5-(5-(benzyloxy)pyridin-3-yl)-3-(4-(4-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [562]; 2-cyclohexyl-N-(5-(3-(4-(4-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)acetamide [563]; 3-(4-(4-fluorophenyl)-1H-indol-2-yl)-5-(pyrazin-2-yl)-1H-pyrazolo[3,4-c]pyridine [564]; 3-(4-(2-fluorophenyl)-1H-indol-2-yl)-5-(piperidin-4-yl)-1H-pyrazolo[3,4-c]pyridine [565]; 3-(4-(2-fluorophenyl)-1H-indol-2-yl)-5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrazolo[3,4-c]pyridin [566]; 3-(4-(2-fluorophenyl)-1H-indol-2-yl)-5-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-c]pyridine [567]; 3-(4-(2-fluorophenyl)-1H-indol-2-yl)-5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-c]pyridine [568]; 5-(1,2-dimethyl-1H-imidazol-5-yl)-3-(4-(2-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [569]; 1-(6-(3-(4-(2-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyrazin-2-yl)azetidin-3-amine [570]; 5-(5-(cyclohexyloxy)pyridin-3-yl)-3-(4-(2-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [571]; 3-(4-(2-fluorophenyl)-1H-indol-2-yl)-5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [572]; N-(5-(3-(4-(2-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-2-(piperidin-4-yl)acetamide [573]; 3-(4-(2-fluorophenyl)-1H-indol-2-yl)-5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [574]; 2-((5-(3-(4-(2-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)oxy)-N,N-dimethylethan-1-amine [575]; 3-(4-(2-fluorophenyl)-1H-indol-2-yl)-5-(5-methoxypyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [576]; 5-(3-(4-(2-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-ol [577]; 5-(5-(benzyloxy)pyridin-3-yl)-3-(4-(2-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [578]; 2-cyclohexyl-N-(5-(3-(4-(2-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)acetamide [579]; 3-(4-(2-fluorophenyl)-1H-indol-2-yl)-5-(pyrazin-2-yl)-1H-pyrazolo[3,4-c]pyridine [580]; 5-(piperidin-4-yl)-3-(4-(pyridin-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [581]; 3-(4-(pyridin-3-yl)-1H-indol-2-yl)-5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrazolo[3,4-c]pyridine [582]; 5-(1H-pyrazol-4-yl)-3-(4-(pyridin-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [583]; 5-(1-methyl-1H-pyrazol-4-yl)-3-(4-(pyridin-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [584]; 5-(1,2-dimethyl-1H-imidazol-5-yl)-3-(4-(pyridin-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [585]; 1-(6-(3-(4-(pyridin-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyrazin-2-yl)azetidin-3-amine [586]; 5-(5-(cyclohexyloxy)pyridin-3-yl)-3-(4-(pyridin-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [587]; 5-(5-(piperidin-4-yloxy)pyridin-3-yl)-3-(4-(pyridin-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [588]; 2-(piperidin-4-yl)-N-(5-(3-(4-(pyridin-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)acetamide [589]; 3-(4-(pyridin-3-yl)-1H-indol-2-yl)-5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [590]; N,N-dimethyl-2-((5-(3-(4-(pyridin-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)oxy)ethan-1-amine [591]; 5-(5-methoxypyridin-3-yl)-3-(4-(pyridin-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [592]; 5-(3-(4-(pyridin-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-ol [593]; 5-(5-(benzyloxy)pyridin-3-yl)-3-(4-(pyridin-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [594]; 2-cyclohexyl-N-(5-(3-(4-(pyridin-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)acetamide [595]; 5-(pyrazin-2-yl)-3-(4-(pyridin-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [596]; 5-(piperidin-4-yl)-3-(4-(pyridin-4-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [597]; 3-(4-(pyridin-4-yl)-1H-indol-2-yl)-5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrazolo[3,4-c]pyridine [598]; 5-(1H-pyrazol-4-yl)-3-(4-(pyridin-4-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [599]; 5-(1-methyl-1H-pyrazol-4-yl)-3-(4-(pyridin-4-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [600]; 5-(1,2-dimethyl-1H-imidazol-5-yl)-3-(4-(pyridin-4-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [601]; 1-(6-(3-(4-(pyridin-4-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyrazin-2-yl)azetidin-3-amine [602]; 5-(5-(cyclohexyloxy)pyridin-3-yl)-3-(4-(pyridin-4-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [603]; 5-(5-(piperidin-4-yloxy)pyridin-3-yl)-3-(4-(pyridin-4-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [604]; 2-(piperidin-4-yl)-N-(5-(3-(4-(pyridin-4-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)acetamide [605]; 3-(4-(pyridin-4-yl)-1H-indol-2-yl)-5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [606]; N,N-dimethyl-2-((5-(3-(4-(pyridin-4-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)oxy)ethan-1-amine [607]; 5-(5-methoxypyridin-3-yl)-3-(4-(pyridin-4-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [608]; 5-(3-(4-(pyridin-4-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-ol [609]; 5-(5-(benzyloxy)pyridin-3-yl)-3-(4-(pyridin-4-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [610]; 2-cyclohexyl-N-(5-(3-(4-(pyridin-4-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)acetamide [611]; 5-(pyrazin-2-yl)-3-(4-(pyridin-4-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [612]; 5-(piperidin-4-yl)-3-(4-(pyridin-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [613]; 3-(4-(pyridin-2-yl)-1H-indol-2-yl)-5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrazolo[3,4-c]pyridine [614]; 5-(1H-pyrazol-4-yl)-3-(4-(pyridin-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [615]; 5-(1-methyl-1H-pyrazol-4-yl)-3-(4-(pyridin-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [616]; 5-(1,2-dimethyl-1H-imidazol-5-yl)-3-(4-(pyridin-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [617]; 1-(6-(3-(4-(pyridin-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyrazin-2-yl)azetidin-3-amine [618]; 5-(5-(cyclohexyloxy)pyridin-3-yl)-3-(4-(pyridin-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [619]; 5-(5-(piperidin-4-yloxy)pyridin-3-yl)-3-(4-(pyridin-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [620]; 2-(piperidin-4-yl)-N-(5-(3-(4-(pyridin-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)acetamide [621]; 3-(4-(pyridin-2-yl)-1H-indol-2-yl)-5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [622]; N,N-dimethyl-2-((5-(3-(4-(pyridin-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)oxy)ethan-1-amine [623]; 5-(5-methoxypyridin-3-yl)-3-(4-(pyridin-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [624]; 5-(3-(4-(pyridin-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-ol [625]; 5-(5-(benzyloxy)pyridin-3-yl)-3-(4-(pyridin-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [626]; 2-cyclohexyl-N-(5-(3-(4-(pyridin-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)acetamide [627]; 5-(pyrazin-2-yl)-3-(4-(pyridin-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [628]; 3-(4-(piperidin-1-yl)-1H-indol-2-yl)-5-(piperidin-4-yl)-1H-pyrazolo[3,4-c]pyridine [629]; 3-(4-(piperidin-1-yl)-1H-indol-2-yl)-5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrazolo[3,4-c]pyridine [630]; 3-(4-(piperidin-1-yl)-1H-indol-2-yl)-5-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-c]pyridine [631]; 5-(1-methyl-1H-pyrazol-4-yl)-3-(4-(piperidin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [632]; 5-(1,2-dimethyl-1H-imidazol-5-yl)-3-(4-(piperidin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [633]; 1-(6-(3-(4-(piperidin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyrazin-2-yl)azetidin-3-amine [634]; 5-(5-(cyclohexyloxy)pyridin-3-yl)-3-(4-(piperidin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [635]; 3-(4-(piperidin-1-yl)-1H-indol-2-yl)-5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [636]; N-(5-(3-(4-(piperidin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-2-(piperidin-4-yl)acetamide [637]; 3-(4-(piperidin-1-yl)-1H-indol-2-yl)-5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [638]; N,N-dimethyl-2-((5-(3-(4-(piperidin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)oxy)ethan-1-amine [639]; 5-(5-methoxypyridin-3-yl)-3-(4-(piperidin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [640]; 5-(3-(4-(piperidin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-ol [641]; 5-(5-(benzyloxy)pyridin-3-yl)-3-(4-(piperidin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [642]; 2-cyclohexyl-N-(5-(3-(4-(piperidin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)acetamide [643]; 3-(4-(piperidin-1-yl)-1H-indol-2-yl)-5-(pyrazin-2-yl)-1H-pyrazolo[3,4-c]pyridine [644]; 3-(4-(4-methyl-1H-imidazol-1-yl)-1H-indol-2-yl)-5-(piperidin-4-yl)-1H-pyrazolo[3,4-c]pyridine [645]; 3-(4-(4-methyl-1H-imidazol-1-yl)-1H-indol-2-yl)-5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrazolo[3,4-c]pyridine [646]; 3-(4-(4-methyl-1H-imidazol-1-yl)-1H-indol-2-yl)-5-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-c]pyridine [647]; 3-(4-(4-methyl-1H-imidazol-1-yl)-1H-indol-2-yl)-5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-c]pyridine [648]; 5-(1,2-dimethyl-1H-imidazol-5-yl)-3-(4-(4-methyl-1H-imidazol-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [649]; 1-(6-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyrazin-2-yl)azetidin-3-amine [650]; 5-(5-(cyclohexyloxy)pyridin-3-yl)-3-(4-(4-methyl-1H-imidazol-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [651]; 3-(4-(4-methyl-1H-imidazol-1-yl)-1H-indol-2-yl)-5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [652]; N-(5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-2-(piperidin-4-yl)acetamide [653]; 3-(4-(4-methyl-1H-imidazol-1-yl)-1H-indol-2-yl)-5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [654]; N,N-dimethyl-2-((5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)oxy)ethan-1-amine [655]; 5-(5-methoxypyridin-3-yl)-3-(4-(4-methyl-1H-imidazol-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [656]; 5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-ol [657]; 5-(5-(benzyloxy)pyridin-3-yl)-3-(4-(4-methyl-1H-imidazol-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [658]; 2-cyclohexyl-N-(5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)acetamide [659]; 3-(4-(4-methyl-1H-imidazol-1-yl)-1H-indol-2-yl)-5-(pyrazin-2-yl)-1H-pyrazolo[3,4-c]pyridine [660]; 3-(4-(4-methylpiperazin-1-yl)-1H-indol-2-yl)-5-(piperidin-4-yl)-1H-pyrazolo[3,4-c]pyridine [661]; 3-(4-(4-methylpiperazin-1-yl)-1H-indol-2-yl)-5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrazolo[3,4-c]pyridine [662]; 3-(4-(4-methylpiperazin-1-yl)-1H-indol-2-yl)-5-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-c]pyridine [663]; 5-(1-methyl-1H-pyrazol-4-yl)-3-(4-(4-methylpiperazin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [664]; 5-(1,2-dimethyl-1H-imidazol-5-yl)-3-(4-(4-methylpiperazin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [665]; 1-(6-(3-(4-(4-methylpiperazin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyrazin-2-yl)azetidin-3-amine [666]; 5-(5-(cyclohexyloxy)pyridin-3-yl)-3-(4-(4-methylpiperazin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [667]; 3-(4-(4-methylpiperazin-1-yl)-1H-indol-2-yl)-5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [668]; N-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-2-(piperidin-4-yl)acetamide [669]; 3-(4-(4-methylpiperazin-1-yl)-1H-indol-2-yl)-5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [670]; N,N-dimethyl-2-((5-(3-(4-(4-methylpiperazin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)oxy)ethan-1-amine [671]; 5-(5-methoxypyridin-3-yl)-3-(4-(4-methylpiperazin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [672]; 5-(3-(4-(4-methylpiperazin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-ol [673]; 5-(5-(benzyloxy)pyridin-3-yl)-3-(4-(4-methylpiperazin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [674]; 2-cyclohexyl-N-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)acetamide [675]; 3-(4-(4-methylpiperazin-1-yl)-1H-indol-2-yl)-5-(pyrazin-2-yl)-1H-pyrazolo[3,4-c]pyridine [676]; 3-(1H-indol-2-yl)-5-(piperidin-4-yl)-1H-pyrazolo[3,4-c]pyridine [677]; 3-(1H-indol-2-yl)-5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrazolo[3,4-c]pyridine [678]; 3-(1H-indol-2-yl)-5-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-c]pyridine [679]; 3-(1H-indol-2-yl)-5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-c]pyridine [680]; 5-(1,2-dimethyl-1H-imidazol-5-yl)-3-(1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [681]; 1-(6-(3-(1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyrazin-2-yl)azetidin-3-amine [682]; 5-(5-(cyclohexyloxy)pyridin-3-yl)-3-(1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [683]; 3-(1H-indol-2-yl)-5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [684]; N-(5-(3-(1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-2-(piperidin-4-yl)acetamide [685]; 3-(1H-indol-2-yl)-5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [686]; 2-((5-(3-(1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)oxy)-N,N-dimethylethan-1-amine [687]; 3-(1H-indol-2-yl)-5-(5-methoxypyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [688]; 5-(3-(1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-ol [689]; 5-(5-(benzyloxy)pyridin-3-yl)-3-(1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [690]; N-(5-(3-(1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-2-cyclohexylacetamide [691]; 3-(1H-indol-2-yl)-5-(pyrazin-2-yl)-1H-pyrazolo[3,4-c]pyridine [692]; 5-(piperidin-4-yl)-3-(4-(thiophen-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [693]; 5-(1,2,3,6-tetrahydropyridin-4-yl)-3-(4-(thiophen-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [694]; 5-(1H-pyrazol-4-yl)-3-(4-(thiophen-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [695]; 5-(1-methyl-1H-pyrazol-4-yl)-3-(4-(thiophen-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [696]; 5-(1,2-dimethyl-1H-imidazol-5-yl)-3-(4-(thiophen-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [697]; 1-(6-(3-(4-(thiophen-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyrazin-2-yl)azetidin-3-amine [698]; 5-(5-(cyclohexyloxy)pyridin-3-yl)-3-(4-(thiophen-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [699]; 5-(5-(piperidin-4-yloxy)pyridin-3-yl)-3-(4-(thiophen-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [700]; 2-(piperidin-4-yl)-N-(5-(3-(4-(thiophen-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)acetamide [701]; 5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-3-(4-(thiophen-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [702]; N,N-dimethyl-2-((5-(3-(4-(thiophen-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)oxy)ethan-1-amine [703]; 5-(5-methoxypyridin-3-yl)-3-(4-(thiophen-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [704]; 5-(3-(4-(thiophen-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-ol [705]; 5-(5-(benzyloxy)pyridin-3-yl)-3-(4-(thiophen-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [706]; 2-cyclohexyl-N-(5-(3-(4-(thiophen-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)acetamide [707]; 5-(pyrazin-2-yl)-3-(4-(thiophen-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [708]; 3-(4-(furan-3-yl)-1H-indol-2-yl)-5-(piperidin-4-yl)-1H-pyrazolo[3,4-c]pyridine [709]; 3-(4-(furan-3-yl)-1H-indol-2-yl)-5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrazolo[3,4-c]pyridine [710]; 3-(4-(furan-3-yl)-1H-indol-2-yl)-5-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-c]pyridine [711]; 3-(4-(furan-3-yl)-1H-indol-2-yl)-5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-c]pyridine [712]; 5-(1,2-dimethyl-1H-imidazol-5-yl)-3-(4-(furan-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [713]; 1-(6-(3-(4-(furan-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyrazin-2-yl)azetidin-3-amine [714]; 5-(5-(cyclohexyloxy)pyridin-3-yl)-3-(4-(furan-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [715]; 3-(4-(furan-3-yl)-1H-indol-2-yl)-5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [716]; N-(5-(3-(4-(furan-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-2-(piperidin-4-yl)acetamide [717]; 3-(4-(furan-3-yl)-1H-indol-2-yl)-5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [718]; 2-((5-(3-(4-(furan-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)oxy)-N,N-dimethylethan-1-amine [719]; 3-(4-(furan-3-yl)-1H-indol-2-yl)-5-(5-methoxypyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [720]; 5-(3-(4-(furan-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-ol [721]; 5-(5-(benzyloxy)pyridin-3-yl)-3-(4-(furan-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [722]; 2-cyclohexyl-N-(5-(3-(4-(furan-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)acetamide [723]; 3-(4-(furan-3-yl)-1H-indol-2-yl)-5-(pyrazin-2-yl)-1H-pyrazolo[3,4-c]pyridine [724]; 5-(piperidin-4-yl)-3-(4-(thiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [725]; 5-(1,2,3,6-tetrahydropyridin-4-yl)-3-(4-(thiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [726]; 5-(1H-pyrazol-4-yl)-3-(4-(thiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [727]; 5-(1-methyl-1H-pyrazol-4-yl)-3-(4-(thiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [728]; 5-(1,2-dimethyl-1H-imidazol-5-yl)-3-(4-(thiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [729]; 1-(6-(3-(4-(thiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyrazin-2-yl)azetidin-3-amine [730]; 5-(5-(cyclohexyloxy)pyridin-3-yl)-3-(4-(thiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [731]; 5-(5-(piperidin-4-yloxy)pyridin-3-yl)-3-(4-(thiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [732]; 2-(piperidin-4-yl)-N-(5-(3-(4-(thiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)acetamide [733]; 5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-3-(4-(thiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [734]; N,N-dimethyl-2-((5-(3-(4-(thiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)oxy)ethan-1-amine [735]; 5-(5-methoxypyridin-3-yl)-3-(4-(thiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [736]; 5-(3-(4-(thiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-ol [737]; 5-(5-(benzyloxy)pyridin-3-yl)-3-(4-(thiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [738]; 2-cyclohexyl-N-(5-(3-(4-(thiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)acetamide [739]; 5-(pyrazin-2-yl)-3-(4-(thiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [740]; 3-(4-(5-fluorothiophen-2-yl)-1H-indol-2-yl)-5-(piperidin-4-yl)-1H-pyrazolo[3,4-c]pyridine [741]; 3-(4-(5-fluorothiophen-2-yl)-1H-indol-2-yl)-5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrazolo[3,4-c]pyridine [742]; 3-(4-(5-fluorothiophen-2-yl)-1H-indol-2-yl)-5-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-c]pyridine [743]; 3-(4-(5-fluorothiophen-2-yl)-1H-indol-2-yl)-5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-c]pyridine [744]; 5-(1,2-dimethyl-1H-imidazol-5-yl)-3-(4-(5-fluorothiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [745]; 1-(6-(3-(4-(5-fluorothiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyrazin-2-yl)azetidin-3-amine [746]; 5-(5-(cyclohexyloxy)pyridin-3-yl)-3-(4-(5-fluorothiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [747]; 3-(4-(5-fluorothiophen-2-yl)-1H-indol-2-yl)-5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [748]; N-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-2-(piperidin-4-yl)acetamide [749]; 3-(4-(5-fluorothiophen-2-yl)-1H-indol-2-yl)-5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [750]; 2-((5-(3-(4-(5-fluorothiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)oxy)-N,N-dimethylethan-1-amine [751]; 3-(4-(5-fluorothiophen-2-yl)-1H-indol-2-yl)-5-(5-methoxypyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [752]; 5-(3-(4-(5-fluorothiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-ol [753]; 5-(5-(benzyloxy)pyridin-3-yl)-3-(4-(5-fluorothiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [754]; 2-cyclohexyl-N-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)acetamide [755]; 3-(4-(5-fluorothiophen-2-yl)-1H-indol-2-yl)-5-(pyrazin-2-yl)-1H-pyrazolo[3,4-c]pyridine [756]; 3-(4-(5-methylthiophen-2-yl)-1H-indol-2-yl)-5-(piperidin-4-yl)-1H-pyrazolo[3,4-c]pyridine [757]; 3-(4-(5-methylthiophen-2-yl)-1H-indol-2-yl)-5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrazolo[3,4-c]pyridine [758]; 3-(4-(5-methylthiophen-2-yl)-1H-indol-2-yl)-5-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-c]pyridine [759]; 5-(1-methyl-1H-pyrazol-4-yl)-3-(4-(5-methylthiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [760]; 5-(1,2-dimethyl-1H-imidazol-5-yl)-3-(4-(5-methylthiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [761]; 1-(6-(3-(4-(5-methylthiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyrazin-2-yl)azetidin-3-amine [762]; 5-(5-(cyclohexyloxy)pyridin-3-yl)-3-(4-(5-methylthiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [763]; 3-(4-(5-methylthiophen-2-yl)-1H-indol-2-yl)-5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [764]; N-(5-(3-(4-(5-methylthiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-2-(piperidin-4-yl)acetamide [765]; 3-(4-(5-methylthiophen-2-yl)-1H-indol-2-yl)-5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [766]; N,N-dimethyl-2-((5-(3-(4-(5-methylthiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)oxy)ethan-1-amine [767]; 5-(5-methoxypyridin-3-yl)-3-(4-(5-methylthiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin [768]; 5-(3-(4-(5-methylthiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-ol [769]; 5-(5-(benzyloxy)pyridin-3-yl)-3-(4-(5-methylthiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [770]; 2-cyclohexyl-N-(5-(3-(4-(5-methylthiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)acetamide [771]; 3-(4-(5-methylthiophen-2-yl)-1H-indol-2-yl)-5-(pyrazin-2-yl)-1H-pyrazolo[3,4-c]pyridine [772]; 1-(5-(2-(5-(piperidin-4-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)thiophen-2-yl)ethan-1-one [773]; 1-(5-(2-(5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)thiophen-2-yl)ethan-1-one [774]; 1-(5-(2-(5-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)thiophen-2-yl)ethan-1-one [775]; 1-(5-(2-(5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)thiophen-2-yl)ethan-1-one [776]; 1-(5-(2-(5-(1,2-dimethyl-1H-imidazol-5-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)thiophen-2-yl)ethan-1-one [777]; 1-(5-(2-(5-(6-(3-aminoazetidin-1-yl)pyrazin-2-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)thiophen-2-yl)ethan-1-one [778]; 1-(5-(2-(5-(5-(cyclohexyloxy)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)thiophen-2-yl)ethan-1-one [779]; 1-(5-(2-(5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)thiophen-2-yl)ethan-1-one [780]; N-(5-(3-(4-(5-acetylthiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-2-(piperidin-4-yl)acetamide [781]; 1-(5-(2-(5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)thiophen-2-yl)ethan-1-one [782]; 1-(5-(2-(5-(5-(2-(dimethylamino)ethoxy)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)thiophen-2-yl)ethan-1-one [783]; 1-(5-(2-(5-(5-methoxypyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)thiophen-2-yl)ethan-1-one [784]; 1-(5-(2-(5-(5-hydroxypyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)thiophen-2-yl)ethan-1-one [785]; 1-(5-(2-(5-(5-(benzyloxy)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)thiophen-2-yl)ethan-1-one [786]; N-(5-(3-(4-(5-acetylthiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-2-cyclohexylacetamide [787]; 1-(5-(2-(5-(pyrazin-2-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)thiophen-2-yl)ethan-1-one [788]; N-(3-fluoro-5-(2-(5-(piperidin-4-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)benzyl)methanesulfonamide [789]; N-(3-fluoro-5-(2-(5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)benzyl)methanesulfonamide [790]; N-(3-(2-(5-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)-5-fluorobenzyl)methanesulfonamide [791]; N-(3-fluoro-5-(2-(5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)benzyl)methanesulfonamide [792]; N-(3-(2-(5-(1,2-dimethyl-1H-imidazol-5-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)-5-fluorobenzyl)methanesulfonamide [793]; N-(3-(2-(5-(6-(3-aminoazetidin-1-yl)pyrazin-2-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)-5-fluorobenzyl)methanesulfonamide [794]; N-(3-(2-(5-(5-(cyclohexyloxy)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)-5-fluorobenzyl)methanesulfonamide [795]; N-(3-fluoro-5-(2-(5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)benzyl)methanesulfonamide [796]; N-(5-(3-(4-(3-fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-2-(piperidin-4-yl)acetamide [797]; N-(3-fluoro-5-(2-(5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)benzyl)methanesulfonamide [798]; N-(3-(2-(5-(5-(2-(dimethylamino)ethoxy)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)-5-fluorobenzyl)methanesulfonamide [799]; N-(3-fluoro-5-(2-(5-(5-methoxypyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)benzyl)methanesulfonamide [800]; N-(3-fluoro-5-(2-(5-(5-hydroxypyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)benzyl)methanesulfonamide [801]; N-(3-(2-(5-(5-(benzyloxy)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)-5-fluorobenzyl)methanesulfonamide [802]; 2-cyclohexyl-N-(5-(3-(4-(3-fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)acetamide [803]; N-(3-fluoro-5-(2-(5-(pyrazin-2-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)benzyl)methanesulfonamide [804]; N¹-(3-fluoro-5-(2-(5-(piperidin-4-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)phenyl)-N²,N²-dimethylethane-1,2-diamine [805]; N¹-(3-fluoro-5-(2-(5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)phenyl)-N²,N²-dimethylethane-1,2-diamine [806]; N¹-(3-(2-(5-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)-5-fluorophenyl)-N²,N²-dimethylethane-1,2-diamine [807]; N¹-(3-fluoro-5-(2-(5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)phenyl)-N²,N²-dimethylethane-1,2-diamine [808]; N¹-(3-(2-(5-(1,2-dimethyl-1H-imidazol-5-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)-5-fluorophenyl)-N²,N²-dimethylethane-1,2-diamine [809]; N¹-(3-(2-(5-(6-(3-aminoazetidin-1-yl)pyrazin-2-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)-5-fluorophenyl)-N²,N²-dimethylethane-1,2-diamine [810]; N¹-(3-(2-(5-(5-(cyclohexyloxy)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)-5-fluorophenyl)-N²,N²-dimethylethane-1,2-diamine [811]; N¹-(3-fluoro-5-(2-(5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)phenyl)-N²,N²-dimethylethane-1,2-diamine [812]; N-(5-(3-(4-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-2-(piperidin-4-yl)acetamide [813]; N¹-(3-fluoro-5-(2-(5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)phenyl)-N²,N²-dimethylethane-1,2-diamine [814]; N¹-(3-(2-(5-(5-(2-(dimethylamino)ethoxy)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)-5-fluorophenyl)-N²,N²-dimethylethane-1,2-diamine [815]; N¹-(3-fluoro-5-(2-(5-(5-methoxypyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)phenyl)-N²,N²-dimethylethane-1,2-diamine [816]; 5-(3-(4-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-ol [817]; N¹-(3-(2-(5-(5-(benzyloxy)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)-5-fluorophenyl)-N²,N²-dimethylethane-1,2-diamine [818]; 2-cyclohexyl-N-(5-(3-(4-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)acetamide [819]; N¹-(3-fluoro-5-(2-(5-(pyrazin-2-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)phenyl)-N²,N²-dimethylethane-1,2-diamine [820]; N-(5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)propionamide [821]; N-(5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-3-methylbutanamide [822]; 5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-amine [823]; 2-(3-fluoro-5-(2-(5-(pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)phenoxy)-N,N-dimethylethan-1-amine [824]; 2-(3-fluoro-5-(2-(5-(4-methylpyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)phenoxy)-N,N-dimethylethan-1-amine [825]; 2-(3-(2-(5-(5-((ethylamino)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)-5-fluorophenoxy)-N,N-dimethylethan-1-amine [826]; 5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)-N,N-dimethylpyridin-3-amine [827]; N-(5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)pivalamide [828]; N-(5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)isobutyramide [829]; N-(5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-2-phenylacetamide [830]; N-(5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)benzamide [831]; 5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)-N-isopropylpyridin-3-amine [832]; 2-(3-(2-(5-(5-((dimethylamino)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)-5-fluorophenoxy)-N,N-dimethylethan-1-amine [833]; 2-(3-fluoro-5-(2-(5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)phenoxy)-N,N-dimethylethan-1-amine [834]; 2-(3-fluoro-5-(2-(5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)phenoxy)-N,N-dimethylethan-1-amine [835]; N-(5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-3,3-dimethylbutanamide [836]; N-(5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)butyramide [837]; N-(5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)pentanamide [838]; N-(5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide [839]; N-(5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclobutanecarboxamide [840]; N-(5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclopentanecarboxamide [841]; N-(5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclohexanecarboxamide [842]; 2-(3-(2-(5-(5-((benzylamino)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)-5-fluorophenoxy)-N,N-dimethylethan-1-amine [843]; 2-(3-(2-(5-(5-(((cyclopentylmethyl)amino)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)-5-fluorophenoxy)-N,N-dimethylethan-1-amine [844]; 2-(3-(2-(5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)-5-fluorophenoxy)-N,N-dimethylethan-1-amine [845]; 2-(3-fluoro-5-(2-(5-(pyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)phenoxy)-N,N-dimethylethan-1-amine [846]; 2-(3-fluoro-5-(2-(5-(pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)phenoxy)-N,N-dimethylethan-1-amine [847]; 2-(3-fluoro-5-(2-(5-(piperidin-4-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)phenoxy)-N,N-dimethylethan-1-amine [848]; 2-(3-fluoro-5-(2-(5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)phenoxy)-N,N-dimethylethan-1-amine [849]; 2-(3-(2-(5-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)-5-fluorophenoxy)-N,N-dimethylethan-1-amine [850]; 2-(3-fluoro-5-(2-(5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)phenoxy)-N,N-dimethylethan-1-amine [851]; 2-(3-(2-(5-(1,2-dimethyl-1H-imidazol-5-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)-5-fluorophenoxy)-N,N-dimethylethan-1-amine [852]; 1-(6-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyrazin-2-yl)azetidin-3-amine [853]; 2-(3-(2-(5-(5-(cyclohexyloxy)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)-5-fluorophenoxy)-N,N-dimethylethan-1-amine [854]; 2-(3-fluoro-5-(2-(5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)phenoxy)-N,N-dimethylethan-1-amine [855]; N-(5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-2-(piperidin-4-yl)acetamide [856]; 2-(3-fluoro-5-(2-(5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)phenoxy)-N,N-dimethylethan-1-amine [857]; 2-((5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)oxy)-N,N-dimethylethan-1-amine [858]; 2-(3-fluoro-5-(2-(5-(5-methoxypyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)phenoxy)-N,N-dimethylethan-1-amine [859]; 5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-ol [860]; 2-(3-(2-(5-(5-(benzyloxy)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)-5-fluorophenoxy)-N,N-dimethylethan-1-amine [861]; 2-cyclohexyl-N-(5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)acetamide [862]; 2-(3-fluoro-5-(2-(5-(pyridin-4-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)phenoxy)-N,N-dimethylethan-1-amine [863]; 2-(3-fluoro-5-(2-(5-(pyrazin-2-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)phenoxy)-N,N-dimethylethan-1-amine [864]; N-(5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)propionamide [865]; N-(5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-3-methylbutanamide [866]; 5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-amine [867]; 3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-indol-2-yl)-5-(pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [868]; 3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-indol-2-yl)-5-(4-methylpyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [869]; N-((5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methyl)ethanamine [870]; 5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)-N,N-dimethylpyridin-3-amine [871]; N-(5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)pivalamide [872]; N-(5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)isobutyramide [873]; N-(5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-2-phenylacetamide [874]; N-(5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)benzamide [875]; 5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)-N-isopropylpyridin-3-amine [876]; 1-(5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-N,N-dimethylmethanamine [877]; 3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-indol-2-yl)-5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [878]; 3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-indol-2-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [879]; N-(5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-3,3-dimethylbutanamide [880]; N-(5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)butyramide [881]; N-(5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)pentanamide [882]; N-(5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide [883]; N-(5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclobutanecarboxamide [884]; N-(5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclopentanecarboxamide [885]; N-(5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclohexanecarboxamide [886]; N-benzyl-1-(5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methanamine [887]; 1-cyclopentyl-N-((5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methyl)methanamine [888]; 5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [889]; 3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-indol-2-yl)-5-(pyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridine [890]; 3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-indol-2-yl)-5-(pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridine [891]; 3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-indol-2-yl)-5-(piperidin-4-yl)-1H-pyrazolo[3,4-c]pyridine [892]; 3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-indol-2-yl)-5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrazolo[3,4-c]pyridine [893]; 3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-indol-2-yl)-5-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-c]pyridine [894]; 3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-indol-2-yl)-5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-c]pyridine [895]; 5-(1,2-dimethyl-1H-imidazol-5-yl)-3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [896]; 1-(6-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyrazin-2-yl)azetidin-3-amine [897]; 5-(5-(cyclohexyloxy)pyridin-3-yl)-3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [898]; 3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-indol-2-yl)-5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [899]; N-(5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-2-(piperidin-4-yl)acetamide [900]; 3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-indol-2-yl)-5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [901]; 2-((5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)oxy)-N,N-dimethylethan-1-amine [902]; 3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-indol-2-yl)-5-(5-methoxypyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [903]; 5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-ol [904]; 5-(5-(benzyloxy)pyridin-3-yl)-3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [905]; 2-cyclohexyl-N-(5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)acetamide [906]; 3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-indol-2-yl)-5-(pyridin-4-yl)-1H-pyrazolo[3,4-c]pyridine [907]; 3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-indol-2-yl)-5-(pyrazin-2-yl)-1H-pyrazolo[3,4-c]pyridine [908]; N-(5-(3-(4-(3-fluoro-5-hydroxyphenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)propionamide [909]; N-(5-(3-(4-(3-fluoro-5-hydroxyphenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-3-methylbutanamide [910]; 3-(2-(5-(5-aminopyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)-5-fluorophenol [911]; 3-fluoro-5-(2-(5-(pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)phenol [912]; 3-fluoro-5-(2-(5-(4-methylpyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)phenol [913]; 3-(2-(5-(5-((ethylamino)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)-5-fluorophenol [914]; 3-(2-(5-(5-(dimethylamino)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)-5-fluorophenol [915]; N-(5-(3-(4-(3-fluoro-5-hydroxyphenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)pivalamide [916]; N-(5-(3-(4-(3-fluoro-5-hydroxyphenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)isobutyramide [917]; N-(5-(3-(4-(3-fluoro-5-hydroxyphenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-2-phenylacetamide [918]; N-(5-(3-(4-(3-fluoro-5-hydroxyphenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)benzamide [919]; 3-fluoro-5-(2-(5-(5-(isopropylamino)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)phenol [920]; 3-(2-(5-(5-((dimethylamino)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)-5-fluorophenol [921]; 3-fluoro-5-(2-(5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)phenol [922]; 3-fluoro-5-(2-(5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)phenol [923]; N-(5-(3-(4-(3-fluoro-5-hydroxyphenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-3,3-dimethylbutanamide [924]; N-(5-(3-(4-(3-fluoro-5-hydroxyphenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)butyramide [925]; N-(5-(3-(4-(3-fluoro-5-hydroxyphenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)pentanamide [926]; N-(5-(3-(4-(3-fluoro-5-hydroxyphenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide [927]; N-(5-(3-(4-(3-fluoro-5-hydroxyphenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclobutanecarboxamide [928]; N-(5-(3-(4-(3-fluoro-5-hydroxyphenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclopentanecarboxamide [929]; N-(5-(3-(4-(3-fluoro-5-hydroxyphenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclohexanecarboxamide [930]; 3-(2-(5-(5-((benzylamino)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)-5-fluorophenol [931]; 3-(2-(5-(5-(((cyclopentylmethyl)amino)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)-5-fluorophenol [932]; 3-(2-(5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)-5-fluorophenol [933]; 3-fluoro-5-(2-(5-(pyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)phenol [934]; 3-fluoro-5-(2-(5-(pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)phenol [935]; 3-fluoro-5-(2-(5-(piperidin-4-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)phenol [936]; 3-fluoro-5-(2-(5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)phenol [937]; 3-(2-(5-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)-5-fluorophenol [938]; 3-fluoro-5-(2-(5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)phenol [939]; 3-(2-(5-(1,2-dimethyl-1H-imidazol-5-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)-5-fluorophenol [940]; 3-(2-(5-(6-(3-aminoazetidin-1-yl)pyrazin-2-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)-5-fluorophenol [941]; 3-(2-(5-(5-(cyclohexyloxy)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)-5-fluorophenol [942]; 3-fluoro-5-(2-(5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)phenol [943]; N-(5-(3-(4-(3-fluoro-5-hydroxyphenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-2-(piperidin-4-yl)acetamide [944]; 3-fluoro-5-(2-(5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)phenol [945]; 3-(2-(5-(5-(2-(dimethylamino)ethoxy)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)-5-fluorophenol [946]; 3-fluoro-5-(2-(5-(5-methoxypyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)phenol [947]; 5-(3-(4-(3-fluoro-5-hydroxyphenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-ol [948]; 3-(2-(5-(5-(benzyloxy)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)-5-fluorophenol [949]; 2-cyclohexyl-N-(5-(3-(4-(3-fluoro-5-hydroxyphenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)acetamide [950]; 3-fluoro-5-(2-(5-(pyridin-4-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)phenol [951]; 3-fluoro-5-(2-(5-(pyrazin-2-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)-1H-indol-4-yl)phenol [952]; N-(5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)propionamide [953]; N-(5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-3-methylbutanamide [954]; 5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-amine [955]; 3-(4-(3-fluoro-5-methoxyphenyl)-1H-indol-2-yl)-5-(pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [956]; 3-(4-(3-fluoro-5-methoxyphenyl)-1H-indol-2-yl)-5-(4-methylpyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [957]; N-((5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methyl)ethanamine [958]; 5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)-N,N-dimethylpyridin-3-amine [959]; N-(5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)pivalamide [960]; N-(5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)isobutyramide [961]; N-(5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-2-phenylacetamide [962]; N-(5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)benzamide [963]; 5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)-N-isopropylpyridin-3-amine [964]; 1-(5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-N,N-dimethylmethanamine [965]; 3-(4-(3-fluoro-5-methoxyphenyl)-1H-indol-2-yl)-5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [966]; 3-(4-(3-fluoro-5-methoxyphenyl)-1H-indol-2-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [967]; N-(5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-3,3-dimethylbutanamide [968]; N-(5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)butyramide [969]; N-(5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)pentanamide [970]; N-(5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclopropanecarboxamide [971]; N-(5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclobutanecarboxamide [972]; N-(5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclopentanecarboxamide [973]; N-(5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)cyclohexanecarboxamide [974]; N-benzyl-1-(5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methanamine [975]; 1-cyclopentyl-N-((5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)methyl)methanamine [976]; 5-(5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-3-(4-(3-fluoro-5-methoxyphenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [977]; 3-(4-(3-fluoro-5-methoxyphenyl)-1H-indol-2-yl)-5-(pyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridine [978]; 3-(4-(3-fluoro-5-methoxyphenyl)-1H-indol-2-yl)-5-(pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridine [979]; 3-(4-(3-fluoro-5-methoxyphenyl)-1H-indol-2-yl)-5-(piperidin-4-yl)-1H-pyrazolo[3,4-c]pyridine [980]; 3-(4-(3-fluoro-5-methoxyphenyl)-1H-indol-2-yl)-5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrazolo[3,4-c]pyridine [981]; 3-(4-(3-fluoro-5-methoxyphenyl)-1H-indol-2-yl)-5-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-c]pyridine [982]; 3-(4-(3-fluoro-5-methoxyphenyl)-1H-indol-2-yl)-5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-c]pyridine [983]; 5-(1,2-dimethyl-1H-imidazol-5-yl)-3-(4-(3-fluoro-5-methoxyphenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [984]; 1-(6-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyrazin-2-yl)azetidin-3-amine [985]; 5-(5-(cyclohexyloxy)pyridin-3-yl)-3-(4-(3-fluoro-5-methoxyphenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [986]; 3-(4-(3-fluoro-5-methoxyphenyl)-1H-indol-2-yl)-5-(5-(piperidin-4-yloxy)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [987]; N-(5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-2-(piperidin-4-yl)acetamide [988]; 3-(4-(3-fluoro-5-methoxyphenyl)-1H-indol-2-yl)-5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [989]; 2-((5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)oxy)-N,N-dimethylethan-1-amine [990]; 3-(4-(3-fluoro-5-methoxyphenyl)-1H-indol-2-yl)-5-(5-methoxypyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine [991]; 5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-ol [992]; 5-(5-(benzyloxy)pyridin-3-yl)-3-(4-(3-fluoro-5-methoxyphenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridine [993]; 2-cyclohexyl-N-(5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)acetamide [994]; 3-(4-(3-fluoro-5-methoxyphenyl)-1H-indol-2-yl)-5-(pyridin-4-yl)-1H-pyrazolo[3,4-c]pyridine [995]; 3-(4-(3-fluoro-5-methoxyphenyl)-1H-indol-2-yl)-5-(pyrazin-2-yl)-1H-pyrazolo[3,4-c]pyridine [996]; 2-methylamino)-N-(5-(3-(4-(3-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)acetamide [997]; 2-methylamino)-N-(5-(3-(4-(4-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)acetamide [998]; 2-methylamino)-N-(5-(3-(4-(2-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)acetamide [999]; 2-(dimethylamino)-N-(5-(3-(4-(pyridin-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)acetamide [1000]; 2-(dimethylamino)-N-(5-(3-(4-(pyridin-4-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)acetamide [1001]; 2-(dimethylamino)-N-(5-(3-(4-(pyridin-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)acetamide [1002]; 2-(dimethylamino)-N-(5-(3-(4-(piperidin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)acetamide [1003]; 2-(dimethylamino)-N-(5-(3-(4-(4-methyl-1H-imidazol-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)acetamide [1004]; 2-(dimethylamino)-N-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)acetamide [1005]; N-(5-(3-(1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-2-(dimethylamino)acetamide [1006]; 2-(dimethylamino)-N-(5-(3-(4-(thiophen-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)acetamide [1007]; 2-(dimethylamino)-N-(5-(3-(4-(furan-3-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)acetamide [1008]; 2-(dimethylamino)-N-(5-(3-(4-(thiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)acetamide [1009]; 2-(dimethylamino)-N-(5-(3-(4-(5-fluorothiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)acetamide [1010]; 2-(dimethylamino)-N-(5-(3-(4-(5-methylthiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)acetamide [1011]; N-(5-(3-(4-(5-acetylthiophen-2-yl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-2-(dimethylamino)acetamide [1012]; 2-(dimethylamino)-N-(5-(3-(4-(3-fluoro-5-(methylsulfonamidomethyl)phenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)acetamide [1013]; 2-(dimethylamino)-N-(5-(3-(4-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)acetamide [1014]; 2-(dimethylamino)-N-(5-(3-(4-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)acetamide [1015]; 2-(dimethylamino)-N-(5-(3-(4-(3-fluoro-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)acetamide [1016]; 2-(dimethylamino)-N-(5-(3-(4-(3-fluoro-5-hydroxyphenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)acetamide [1017]; 2-(dimethylamino)-N-(5-(3-(4-(3-fluoro-5-methoxyphenyl)-1H-indol-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)acetamide [1018]; 5-(piperidin-4-yl)-3-(1H-pyrrolo[3,2-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridine [1019]; 3-(1H-pyrrolo[3,2-b]pyridin-2-yl)-5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrazolo[3,4-c]pyridine [1020]; 5-(1H-pyrazol-4-yl)-3-(1H-pyrrolo[3,2-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridine [1021]; 5-(1-methyl-1H-pyrazol-4-yl)-3-(1H-pyrrolo[3,2-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridine [1022]; 5-(1,2-dimethyl-1H-imidazol-5-yl)-3-(1H-pyrrolo[3,2-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridine [1023]; 1-(6-(3-(1H-pyrrolo[3,2-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyrazin-2-yl)azetidin-3-amine [1024]; 5-(5-(cyclohexyloxy)pyridin-3-yl)-3-(1H-pyrrolo[3,2-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridine [1025]; 5-(5-(piperidin-4-yloxy)pyridin-3-yl)-3-(1H-pyrrolo[3,2-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridine [1026]; N-(5-(3-(1H-pyrrolo[3,2-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-2-(piperidin-4-yl)acetamide [1027]; 5-(5-(2-(pyrrolidin-1-yl)ethoxy)pyridin-3-yl)-3-(1H-pyrrolo[3,2-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridine [1028]; 2-((5-(3-(1H-pyrrolo[3,2-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)oxy)-N,N-dimethylethan-1-amine [1029]; 5-(5-methoxypyridin-3-yl)-3-(1H-pyrrolo[3,2-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridine [1030]; 5-(3-(1H-pyrrolo[3,2-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-ol [1031]; 5-(5-(benzyloxy)pyridin-3-yl)-3-(1H-pyrrolo[3,2-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridine [1032]; N-(5-(3-(1H-pyrrolo[3,2-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-2-cyclohexylacetamide [1033]; 5-(pyridin-4-yl)-3-(1H-pyrrolo[3,2-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridine [1034]; 5-(pyridin-2-yl)-3-(1H-pyrrolo[3,2-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridine [1035]; 5-(pyrazin-2-yl)-3-(1H-pyrrolo[3,2-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridine [1036]; and N-(5-(3-(1H-pyrrolo[3,2-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yl)-2-(dimethylamino)acetamide [1037]; or a pharmaceutically acceptable salt thereof.
 81. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 59, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
 82. A method of treating or ameliorating in a patient a disorder or disease selected from the group consisting of: cancer, pulmonary fibrosis, idiopathic pulmonary fibrosis (IPF), degenerative disc disease, bone/osteoporotic fractures, bone or cartilage disease, and osteoarthritis, the method comprising administering to the patient a therapeutically effective amount of a compound according to claim 59, or a pharmaceutically acceptable salt thereof. 